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Abstract
Tuberculosis (TB), an infection caused by human pathogen Mycobacterium tuberculosis, continues to
kill millions each year and is as prevalent as it was in the pre-antimicrobial era. With the emergence
of continuously-evolving multi-drug resistant strains (MDR) and the implications of the HIV epidemic,
it is crucial that new drugs with better efficacy and affordable cost are developed to treat TB. With
this in mind, the first part of this thesis discusses the synthesis of libraries of derivatives of pyridine
carboxamidrazones, along with cyclised (1,2,4-triazole and 1,2,4-oxadiazole) and fluorinated analogues.
Microbiological screening against M. tuberculosis was carried out at the TAACF, NIAID and IDRI (USA).
This confirmed the earlier findings that 2-pyridyl-substituted carboxamidrazones were more active than
the 4-pyridyl-substituted carboxamidrazones. Another important observation was that upon cyclisation
of these carboxamidrazones, a small number of the triazoles retained their activity while in most of the
remaining compounds the activity was diminished. This might be attributed to the significant increase
in logP value caused by cyclisation of these linear carboxamidrazones, resulting in high lipophilicity and
decreased permeability. Another reason might be that the rigidity conferred upon the compound due
to cyclisation, results in failure of the compound to fit into the active site of the putative target enzyme.
In order to investigate the potential change to the compounds’ metabolism in the organism and/or host,
the most active compounds were selected and a fluorine atom was introduced in the pyridine ring. The
microbiological results shows a drastic improvement in the activity of the fluorinated carboxamidrazone
amides as compared to their non fluorinated counterpart. This improvement in the activity could possibly
be the result of the increased cell permeability caused by the fluorine.
In a subsidiary strand, a selection of long-chain α, β-unsaturated carboxylic esters, α-keto, β-hydroxy
carboxylic esters and β-keto, α-hydroxy carboxylic esters, structurally similar to mycolic acids, were
synthesised. The microbiological data revealed that one of the open chain compound was active against
the Mycobacterium tuberculosis H37Rv strain and some resistant isolates. The possible compound
activity could be its potential to disrupt mycobacterial cell wall synthesis by interfering with the FAS-II
2
pathway.
Keywords : Mycobacterium tuberculosis, carboxamidrazone, cyclisation, fluorination, Horner-Wadsworth-
Emmons modification to Wittig’s reaction.
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Chapter 1
Introduction
"I have no business to live this life if I cannot eradicate this scourge from mankind" -Robert
Koch (1882)
Ever since the human history is recorded Tuberculosis (TB) has been a curse to mankind. TB is a
highly contagious, air-borne disease. The TB bacilli upon entering the lungs trigger the immune system
and get trapped in granulomas. It is a chronic granulomatous disease mainly affecting the respiratory
tract, however, sometimes it may also affect the lymphatic, uro-genital, or nervous system or even the
gastrointestinal tract in some critical cases (Raviglione et al. (1995)). TB is caused by theMycobacterium
tuberculosis. The early detection of TB is difficult since no symptoms are usually observed in initial
stages. However in the later stage of the disease cough is the most common symptom. The other
symptoms include low blood pressure, dyspnea, tachycardia and cyanosis.
TB accounts for numerous deaths each year. In the recent times followed by AIDS, TB is reported to
be one of the major reasons for the deaths. The World Health Organization (WHO) and the Centres
for Disease Control and Prevention (CDCP) have predicted 3.5 million deaths each year in the early
decades of 2000. Figures stated in the WHO reports suggests that about one third of the population is
already infected by TB with about 8 million more people developing active disease each year. It is esti-
mated that about two million people die each year due to TB. However about 90 − 95% of the infections
remain asymptomatic as they are contained by the immune system. The TB bacillus is opportunistic
and can stay dormant for years in a healthy body. The chances of developing active TB increase in
these patients if the immune system is weakened, for example by an HIV infection or treatment with
immuno-suppressants like in the case of the organ transplants also indirectly contribute to developing
22
TB (Comstock (2000)).
The continued high burden of fighting TB in the developing countries has less to do with a biomedical
understanding of the disease and treatment and more to do with the failure to understand the social
conditions of the disease. The inequality in TB occurrence around the world highlights the importance
of understanding the disease within social, cultural and historical contexts of these populations. In all the
developing countries social determinants of health including poor housing conditions, unemployment,
and inferior health care experiences are involved in contributing to the high disparity of disease (Reading
& Wien (2009)). Some other reasons are minimal exposure to sun light and excessive exposure to
ultraviolet light.
1.1 Evolutionary history of tuberculosis and its discovery
Terms like consumption, phthisis, scrofula, Pott’s disease, tabes, bronchitis, inflammation of lungs,
hectic fever, gastric fever, lupus and the white plague observed in ancient literature refer to TB. TB
is also called Koch’s disease, named after a German scientist Robert Koch (1843 − 1910), who in 1882
first discovered M. tuberculosis, the bacterium which causes TB in humans and mammals.
The TB bacterium has co-evolved with humans for several thousands or perhaps millions of years
(Rothschild et al. (2001), Hershkovitz et al. (2008)). Although it is still unclear how humans were infected,
a popular belief suggests that the TB originated in the bovine and then transferred to the humans through
domestication of these animals. However recent studies have found that the M. tuberculosis complex
(MTBC) obtained from the animals and humans did not match and suggests that it originated from a
common ancestor. Hershkovitz et al. (2008) discovered the 9,000 years old Neolithic era human skeletal
remains infected with TB. The evidence of TB has also been found in Egyptian mummies dating from
2400 − 3000 BC (Zink et al. (2003)).The oldest known fossil remains showing signs of TB infection are
500,000 years old Homo erectus skeleton in Turkey (Kappelman et al. (2008)).
Although the mention of TB has been observed in ancient literature of Hippocrates and Aristotle in the
early 400 BC, it was the Roman doctor, Caelius Aurelianus who made the first accurate description of
the disease making detailed observations of his patients in the 5th century AD. In early 18th century
the English physician Benjamin Marten (c.1690 − 1756) wrote a book ‘A New Theory of Consumptions’
in 1720 in which he correlated the ‘phthisis’ a greek term for the disease consumption as it was then
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called with the ‘animalcules’ that lived in the lungs and caused lesions. He also proposed a theory that
‘phthisis’ was the highly contagious disease as opposed to it being hereditary which was a popular belief
back then (Doetsch (1978)).
The term ‘tuberculosis’ was coined by the German scientist Johann Lukas Schönlein (1793 − 1864) in
1839 who thought of TB as cancer like tumour. The word tuberculosis was derived from tubercles a
word introduced by an English physician Richard Morton (1637 − 1698) to describe the lesions of the
disease ‘consumption’. In 1843 Philipp Klencke (1813− 1881) carried out an experiment to demonstrate
the contagiousness of TB, whereby a rabbit was injected with a tubercle material and it contracted the
disease and subsequently died. The ‘animalcule’ described by Marten was not discovered until 1882,
when Robert Koch isolated a bacillus within tubercles. He developed a tuberculin skin test, from the
extracts of tuberculin from the dead M. tuberculosis cells, which was used to identify the TB patients, a
work for which he received a Nobel Prize in 1905 (Herzog (1998)).
1.2 TB epidemiology
The World Health Organization (WHO) presented a Global Tuberculosis Report in 2012. On a positive
note, the Millennium Development Goal (MDG) target to arrest the TB epidemic by the year 2015 has
already been achieved. The development of new cases of TB have gone down to 2.2% between 2010
to 2011. The last few decades since 1990’s, the mortality rate has decreased by 41% and the worldwide
target of 50% reduction in mortality rate by 2015 is on track. However the global TB burden remains
gigantic. In 2011, approximately 8.7 million new cases of TB were reported of which 13% were co-
infected with HIV and 1.4 million people died from TB. TB continues to remain one of the top reasons
for death among women, with 500,000 deaths in 2011 (WHO (2013)).
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The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health
Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines
on maps represent approximate border lines for which there may not yet be full agreement.
Figure 1.1: Tuberculosis epidemiology in 2011: World map of prevalence of all forms of TB per 100,000
inhabitants (WHO (2013))
The report also suggests that the African and European regions are not on track to reduce the mortality
rate to 50% of the 1990’s by 2015. While the mortality and incidence rates are falling, the multidrug-
resistant TB (MDR-TB) cases are increasing. About 19% i.e. one among every five TB patient is
estimated to have MDR-TB. The countries like India and China where the largest number of TB cases
are observed the number is less than one in ten, however this figure is expected to go up in next three
years (WHO (2013)). Of the top fifteen countries with highest TB incidences, thirteen are in Africa, of
which most are sub-Saharan (see Fig. 1.1). The developing countries face huge problems with regard
to affording large quantities of antibiotics and logistically dispensing the drugs due to huge number of
incidences of TB.
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Figure 1.2: Cases of tuberculosis worldwide, 1840 − 2010. Graph showing the decline in mortality due
to M. tuberculosis infection from 1840 to today and enlarged version showing the graph of TB cases
reported between 1980 to 2005 (McKeown et al. (1966), WHO (2009))
.
The global threat caused by TB was once again brought forward in late 1980s after about a period of
two decades due to HIV (see Fig. 1.2). The 2009 WHO report estimated that of total TB cases reported
about 14.8% were coincident with HIV infection and majority of the incidences occurred in Africa. Since
the probability of TB infection is greatly increased in immuno-compromised people, HIV added a new
dimension to the TB epidemic. One such research has shown an interesting observation between TB
and HIV. The M. tuberculosis bacteria modifies chemokine and cytokine concentrations, as well as their
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receptors, in such a way that it not only permits but also boosts viral replication (Hanna et al. (2005),
Toossi (2003)).
WHO in 2004 first recommended collaborative TB/HIV activities to combat the disease. This implemen-
tation of collaborative TB/HIV activities saved an estimated 1.3 million lives between 2005 and the end
of 2011. In 2011 the number of TB patients tested for HIV went up from 3% in 2004 to 69% in the African
Region. Globally, 48% of the TB patients known to be HIV positive were started on antiretroviral therapy
(ART) in 2011. To meet WHO’s recommendation all TB patients living with HIV are promptly started on
ART.
1.3 Mechanisms of disease and immunological response
1.3.1 Overview of TB disease
TB disease primarily affects the lungs and about 75% of the cases reported are pulmonary. In about
15 − 20% of active cases, the infection spreads outside the respiratory organs, causing other kinds of
TB. These are collectively denoted as ‘extrapulmonary tuberculosis’. It is usually observed in immuno-
suppressed persons and young children. Most commonly it is observed in the lymphatic system, pleura,
bones and joints (most often the spine), the nervous system, liver and spleen. In some rare cases the
TB is dispersed widely throughout the body and it called as ‘Miliary TB’.
The symptoms of TB do not appear until the infection reaches the lungs. Unlike the other bacteria
M. tubeculosis has a slower replication process and hence the symptoms precipitate years after the
individual was infected by the disease. The symptoms of active TB are not very specific and depend
on the localization of the disease. The most evident symptom is in the lungs (pulmonary TB), but can
affect other organs such as the lymph nodes, the spine, the pleura, bones, abdomen or meninges
(extrapulmonary TB). The most common symptoms for pulmonary TB include productive cough (for
more than 2 weeks), weight loss, fever (night sweats), heamoptysis and breathlessness (Miller et al.
(2000)). In addition to this, symptoms can occur that are not related to the site of infection, for instance
haematological abnormalities such as anaemia, as well as electrolyte imbalance and psychological
effects (Chung & Hubbard (1969), Ebrahim et al. (1995), Sukhova (Sukhova)).
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1.3.2 Diagnosing TB
An accurate and speedy detection of TB is required to halt the spread of disease and start the treatment
immediately. This is especially important in cases of the patients who have TB coincident with the HIV
infection. Since this disease is more prevalent in third world countries, cost effectiveness is an important
factor to be considered while developing diagnostic equipments. The present methods to detect TB are
tuberculin skin test, chest X-ray and/or microscopy, culturing and biopsy of the affected tissue. Another
technique is using sputum smear test which is based on Ziehl-Neelsen staining technique and direct
microscopy (Kim et al. (1984), Toman & Frieden (2004)). The use of this test is strongly advocated
by WHO as it is cheap and a quick method. However this method is less sensitive as compared with
culturing which can detect active disease from as few as 10 cells. The culturing method generates
more data such as drug resistance and can also be used to detect extra-pulmonary disease, however
its major drawback is the extensive time required for the cultures to grow (about 3-6 weeks).
1.3.3 M. tuberculosis infection
A person with active pulmonary TB expels infectious aerosol droplets when he coughs, spits or sneezes.
With each sneeze or bout of cough about 40,000 droplets are released which can remain in the air for
up to several hours hence increasing the chances of infection. The infectious dose of TB is very low
hence fewer than 10 bacteria can cause infection thus further adding to the problem.
People who are in close or prolonged contact like family or the caretakers of the patient, are more prone
to infection. Statistics suggest that each person with active untreated disease can infect about 10 − 15
other people each year (Organizationet al. (2011)). Healthcare professionals, medical practitioners and
laboratory scientists who are in close contact with the organism are also at high risk. The chances of TB
infection is greatly increased in patients with HIV infections because of the compromised cell-mediated
immune system which is essential for the defence against TB. Other factors include use of immuno-
suppressant drugs for the treatment of illnesses like diabetes, anti-cancer therapy etc. which can also
increase the risk of infection. Young children and elderly people are also susceptible to TB owing to the
underdeveloped or weaker immune system.
TB infection is developed by the ingestion of M. tuberculosis cells in the form of droplets in air which
are engulfed by the macrophages that reach the alveoli. This triggers a series of events where due to
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replication of the tubercle bacilli additional macrophages are brought into the area. This mass forms an
early tubercle (see Fig. 1.3). After a few weeks many macrophages die and release the bacilli forming
a caseous centre in the tubercle. In another few weeks a large cystic tubercle is formed which has an
enlarged air filled caseous centre where the bacilli multiply extracellularly. This tubercle is surrounded
by the infected macrophages and lymphocytes. When the tubercle matures it ruptures into a bronchiole
and spills the bacilli which spreads the pathogen throughout the respiratory and other systems.
Blood capillary
Alveolar walls
Ingested tubercule
bacillus
Alveolar macrophage
Bronchiole
Inﬁltrating macrophage
(not activated)
Early tubercule
Tubercule bacilli
Caseous center
Activated
macrophages
Lymphocyte
Outer layer of
mature tubercule
Tuberculous cavity
Tubercule bacilli
Rupture of
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Interior of alveolus
Interior of
alveolus
Figure 1.3: The mechanism of TB infection of macrophages in the broader view of tubercle formation in
the lung. Adapted from Ben (2006).
1.3.4 Other mycobacteria causing the disease
The other pathogenic members of the M. tuberculosis complex causing TB are Mycobacterium bovis,
Mycobacterium africanum, Mycobacterium microti and Mycobacterium pinnipedii. The M. bovis cause
TB in amimals, especially cattle, buffalo, and some wild animals like lion and baboon. M. microti causes
TB in small mammals. M. africanum was isolated from ancient human remains in equatorial Africa.
The Mycobacterium pinnipedii primarily infects seals. The other mycobacteria include Mycobacterium
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avium complex (the avium tubercle bacillus), Mycobacterium kansasii, Mycobacterium marinum which
cause granulomatous skin disease in humans, Mycobacterium fortuitum and Mycobacterium chelonae.
Most of these mycobacteria cause TB or TB like diseases and are opportunistic in nature affecting the
immuno-deficient people like young children, elderly people and those suffering from AIDS.
There are some other pathogenic mycobacteria which cause non tubercular diseases like Mycobac-
terium leprae which cause leprosy, Mycobacterium ulcerans which cause Buruli ulcers and Mycobac-
terium avium paratuberculosis which cause Crohn’s disease.
1.4 The mycobacterial cell wall
1.4.1 General structure and functions
M. tuberculosis is a rod-shaped aerobic bacterium. Although M. tuberculosis does not fit into conven-
tional Gram-positive or Gram-negative classification as its cell wall is resistant to Gram-staining tech-
niques due to high lipid content, they are still classified as acid-fast Gram-positive bacteria due to their
lack of an outer cell membrane (Wheeler & Ratledge (1994)). The primary function of this cell wall is
to provide a permeability barrier for both the host’s immune system and the anti-TB drugs (Brennan &
Nikaido (1995)). It also acts as a protective shell around the bacterium that helps the bacteria to survive
the cluttered environment inside infected macrophages (Takayama et al. (2005), Wang et al. (2000)).
The unique cell wall of mycobacteria confers a characteristic acid-fast staining property to the bacte-
ria. Additionally, the cell wall also interacts with the host cell causing immune modulation and virulence
(Bhatt et al. (2007), Cox et al. (1999), Kan-Sutton et al. (2009)). It is believed that the close interaction
of the complex high molecular weight lipids and polysaccharides within the cell wall renders the M. tu-
berculosis its characteristic pathogenesis (Minnikin et al. (2002)). The cell envelope consists of upper
and lower segment. Beyond the membrane is a thin layer of peptidoglycan (PG) which is covalently
linked to arabinogalactan (AG), which is in turn attached to mycolic acids with their long meromycolate
and short α-chains. This complex structure is termed as the cell wall core the mycolyl-arabinogalactan-
peptidoglycan (mAGP) complex and forms the lower segment. The upper segment is composed of free
lipids interspersed with proteins and carbohydrates (Crick et al. (2001)) (see Fig. 1.4).
The bio-synthetic pathways in the synthesis of cell wall have been an attractive target for quite a long
time for many anti-mycobacterial drugs like Isoniazid (INH) targets the enoyl-ACP reductase (InhA) in
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fatty acid synthesis − II (FAS-II) pathway in mycolic acid bio-synthesis (Rozwarski et al. (1998), White
et al. (2005)), Ethambutol (EMB) targets an arabinosyltransferase in arabinan biosynthesis (Belanger
et al. (1996), Telenti et al. (1997)). A good understanding of the structure and bio-synthesis of the cell
wall will not only enable the scientist to develop newer anti-mycobacterial drug targets but also help to
puzzle out the mycobacterium and the host cell interaction.
Figure 1.4: The mycobacterial cell wall: structure and sites of drug action. The cell wall primarily consists
of peptidoglycan layer (yellow & brown hexagons) which are in turn connected to the arabinogalactans
(blue pentagons) by the galactan linkers (orange lines) These arabinogalactans are attached directly
to the mycolic acids (red flagella like structures). The surface free lipids (green ovals) is made up of
complexes like sulfatides, diacyltrehalose, phthiocerol dimycocerosates and polyacyltrehalose which
are attached to the mycolic acids. The figure also dipicts the site of action of some of the known anti-
mycobacterial drugs. Assembled from Chatterjee (1997) and Crellin et al. (2013)
1.4.2 Peptidoglycan-arabinogalactan
The principle part of the mycobacterial cell wall is composed of an insoluble cross-linked peptido-
glycan layer (see Fig. 1.4) (Alderwick et al. (2007)). The PG layer consists of β-(1,4) linked N-
acetylglucosamine (NAG), N-acetylmuramic acid (NAM) residues, and a tetra-peptide chain. These
tetra-peptide chains form a three dimensional mesh like structure (Madigan (2005)). The bio-synthetic
pathway of the PG is well delineated in Escherichia coli and it is believed that the biosynthetic process
is similar between these two species (Goffin & Ghuysen (2002), van Heijenoort (2001)). The PG is not
grappled into the cell membrane but is covalently bound to the arabinogalactan layer; a branched poly-
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mer of arabinose and galactose, with a unique linker which forms a disaccharide bridge between the
NAG end of PG and galactose containing non-reducing end of AG (McNeil et al. (1990)). The growth and
the survival of mycobacteria depends heavily on the AG biosynthesis. The AG is situated right above
the PG layer (see Fig. 1.4) and is formed of approximately 30 β-D-galactofuranose residues which is
further elaborated by the arabinan chains (Alderwick et al. (2007)). Almost two third of these chains are
esterified by the mycolic acids (Daffe et al. (1990)). This entire sandwich model of PG and AG esterified
with mycolic acid is together known as mycolyl-arabinogalactan-peptidoglycan (mAGP) complex.
1.4.3 Mycolic acids and their biosynthesis
The cell wall in mycobacteria is unusual in that it consists of 60% lipids. In the early 1990s, scien-
tists while isolating materials from the cell wall of M. tuberculosis, came across a mixture of many high
molecular weight hydroxyl acids. The wax − like mass was then termed ‘mycolic acid’ by Anderson
& Chargaff (1929). Though it has no direct relation to the anti-fungal agents, however it was named
so, due to its structure which has long chains that appears like flagella. It was predicted that mycolic
acid was mixture of lipids containing long chain molecules, liberating hexacosanoic acid following py-
rolytic cleavage (Barry lll et al. (1998)). Due to the lack of sophisticated analytical equipment, the exact
structure was not known, however, the approximate empirical formula was suggested as C88H172O4 or
C88H176O4. The once predicted as a single component mass, has now been identified as a component
made up of over 500 closely related structures (Barry lll et al. (1998)). This astounding number reflects
the biological importance in the cell wall of M. tuberculosis.
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Figure 1.5: Structures of the main mycolic acids of M. tuberculosis H37Rv. The mero chain is longer
than the alpha chain. Assembled from Barry lll et al. (1998)
Mycolic acids (MA) are defined as β-hydroxy fatty acids with a long α-alkyl side chain. MA obtained
from M. tuberculosis can be further divided into three classes: α-MA, methoxy-MA and keto-MA (see
Fig. 1.5). The nomenclature of these mycolates have been assigned on the positioning of the oxygen
function in the mero chain (see Fig. 1.6) (Asselineau et al. (1998), Minnikin (1982)). The term ‘α’ has
been assigned to the acid that lacks the oxygen function in addition to the 3-OH acid units. The α-MA
consists of two cyclopropane groups in the mero chain: one is positioned in the proximal end (closer
to the hydroxyl group) and other at the distal end (away from the hydroxyl group). Both the methoxy
and keto MA have a cis- or trans-cyclopropane ring in the proximal end, however a methoxy MA have
α-methyl-β-methoxy group at the distal end while keto MA has α-methyl-β-keto group at the distal end
(see Fig. 1.5). When the methoxy and keto MA are in a trans position they have a methyl branch
adjacent to the cyclopropane ring (Minnikin & Polgar (1967a), Minnikin & Polgar (1967b)).
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Figure 1.6: Mycolic acids subclasses fromM. tuberculosis H37Rv. Assembled from Barry lll et al. (1998)
Mycolic acids occur as a mixture of various chain lengths. These acids are formed as a result of com-
bination of various fragments in the meromycolate chains like the cis- and trans- orientations of the
cyclopropane group and the fragments like α-methyl-β-methoxy, α-methyl-β-keto, cis-alkene, α-methyl-
trans-alkene, and α-methyl-trans-epoxy (Minnikin (1982)). A very little is known about the absolute
stereo-chemistry of these compounds. However some evidence suggests that the hydroxyl group as-
sumes R,R configuration and the α-methyl-β-methoxy at the distal end from the hydroxyl group assumes
S,S configuration (see Fig. 1.7 (Daffe et al. (1991), Dubnau et al. (2000))).
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Figure 1.7: The stereochemistry of the hydroxyl group and the α-methyl-β-methoxy group
Different mycobacteria contain different sets of MA. The α-MA and α
′
-MA, with either cis- or trans-
configuration with either one or two double bond and epoxy-MA (in M. smegmatis and M. fortuitum)
(Lacave et al. (1987), Daffé et al. (1981)) to wax esters, ω-carboxy-MA, ω-1-methoxy-MA (Luquin et al.
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(1990)) were isolated from other mycobacteria. The structure of the MA is closely related to the functions
of these lipids; a small change in the structure can alter the entire functioning of the bacilli (Dubnau
et al. (2000)). For example the cyclopropane ring is responsible for the cord formation which are toxic to
humans (Minnikin et al. (2002)). The cis orientation of the cyclopropane ring encourages rapid growth
of the bacteria in the macrophages (Rao et al. (2005)), while the trans orientation causes suppressive
effects on the M. tuberculosis induced inflammation and virulence (Rao et al. (2006)).
To synthesize these lipids mycobacteria employ two fatty acid synthases (FAS) namely FAS-I and FAS-
II. FAS-I are multienzyme complexes found in the advanced prokaryotes and eukaryotes, and FAS-II is
a disaggregated synthetase generally found in plants and bacteria (Raman et al. (2005))
FAS-I
Figure 1.8: The reaction sequence in FAS I: In step 1 the acetyl-CoA and malonyl-CoA covalently binds
to the FAS-I enzyme. In step 3, β-ketoacyl-CoA synthase (elongase) condenses a long-chain acyl-CoA
with two carbons from malonyl-CoA to form β-ketoacyl-CoA. The next step involves a three step reac-
tions β-keto reduction, dehydration and enoyl reduction which produces the saturated butyryl-S-FAS-I
molecule. Repeating these four steps for 9 and 12 cycles leads to C20- and C26-chains respectively,
which are the main precursors of FAS-II. Assembled from Barry lll et al. (1998)
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The synthesis of mycolic acid is initiated in the cell wall through the FAS I system where a multienzyme
system causes elongation of the chain by two carbon atoms. The repetition of the four steps gives the
desired long chain compounds. As step 1 acetyl-CoA and malonyl-CoA are converted to complexes
acetyl-S-Enz and malonyl-S-Enz. In the step 2, condensation of these complexes takes place and a
β-ketoacyl-C4-S-Enz is obtained, which after reduction, dehydration and enoyl reduction gives a butyryl-
S-Enz. After repeating these steps several times C20 and C26 fatty acids are formed (see Fig. 1.8).
Barry lll et al. (1998) proposed that from this step the FAS II system is actively involved in the mycolic
acid formation. A very long acid of α, methoxy and keto mycolic acids are synthesized. The C26
fatty acids i.e. hexacosanoyl −CoA produced in FAS-I become short α-alkyl chain and methyl carboxyl
segments in all the three α, methoxy and keto mycolic acids. These are called merosegments. Barry lll
et al. (1998) defined meroacids as long α-alkyl chains of mycolic acids which are released in the form
of meroaldehydes on pyrolytic cleavage.
FAS-II
Figure 1.9: The reaction sequence in FAS II: In step 1 the acetyl-CoA binds covalently to the FabH (FAS-
II enzyme) active site cysteine. The next step involves decarboxylation of the malonyl-CoA, leaving a
reactive carbon atom. The final step reaction is condensation of the malonyl-CoA with the fatty acyl
chain and the β-ketoacyl-AcpM product is released. This reaction is catalysed by FabH. Assembled
from Barry lll et al. (1998)
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Followed by the FAS I, FAS II reactions take place where the malonyl-S-CoA is converted to malonyl-
S-acyl carrier protein i.e. malonyl-S-ACP by the enzyme malonyl-CoA:ACP transacylase (FabD). The
R-CO-S-ACP is converted to R-CHO-CH2-CO-S-ACP in presence of two enzymes, β-ketoacyl ACP
synthase (KasA/KasB) which is further reduced by the β-ketoacyl ACP reductase to R-CHOH-CH2-CO-
S-ACP. The third step is dehydration. R-CHOH-CH2-CO-S-ACP is converted to R-CH=CH-CO-S-ACP
(trans position) by β-hydroxyacyl ACP dehydrase. Step 4 is reduction. The product is then reduced
to R-CH2-CH2-CO-S-ACP by 2-trans enoyl ACP reductase (InhA) (see Fig. 1.9). In this step a chain
elongation takes place and then product is two carbons longer. This β-ketoacyl-AcpM product is again
taken to be the part of reaction one and after several repetitions of all the steps a long chain compound
is obtained. Claisen condensation: this is the last step and involves the final assembly of the mycolic
acid in M. tuberculosis (see Fig. 1.10).
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Figure 1.10: An overview of mycolic acid synthesis. Assembled from Barry lll et al. (1998) and van
Roermund et al. (1998)
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Mycolic acid functions
The fundamental function of the mycolic acids, like all the fatty acids is to give a rigid shape to the cell,
protection from external forces and a basic barrier function. In addition to this, mycolic acids provide
resistance to chemicals causing dehydration or damage and thus improving its adeptness in surviving
in unfavourable environment (Barry lll et al. (1998)). It is almost impermeable to hydrophilic compounds
and has very low permeability to hydrophobic compounds thus negating the use of common antibiotics
(Barry lll et al. (1998)).
Site of inhibition
Many of the present first line anti tuberculosis agents like Isoniazid, Pyrazinamide etc act on the mycolic
acid pathways. Thus for many years scientists have considered the mycolic acid synthetic pathway of
significant important potential site of inhibition. Many publications suggest that the in the first step of FAS
II of mycolic acid synthesis there is uptake of long chain analogs of mycolic acids with the interrupter
group present at the carboxyl end. This results into termination of the further synthesis of mycolic acid
pathway. Thus it acts as an inhibitor.
Qureshi et al. (1994) suggests that (Z)-tetracos-5-enoic acid (1) is the key intermediate in the mycolic
acid pathway; it stimulates α-mycolic acid synthesis. The cyclopropene analog of (Z)-tetracos-5-enoic
fatty acid (2) was found to inhibit α-mycolate synthesis in M. smegmatis (see Fig. 1.11).
(1) (2)
(Z)-tetracos-5-enoic acid Cyclopropane analogue of (Z)- tetracos-5-enoic acid
(CH2)3CO2CH3H3C(H2C)17H3C(H2C)17 (CH2)3COOH
Figure 1.11: Example showing that a small change in the structure can alter the entire biosynthetic
pathway.
Based on the above arguments, a study was carried out in Aston university, where long chain 2-hydroxy-
3-oxocarboxylic esters were synthesized which are structurally similar to the mycolic acids. This is
discussed in detail in Chapter 5.
38
1.4.4 Intercalation of free-outer lipids
As shown in the Fig. 1.4, the mycobacterial cell envelope is intercalated with various free glycolipids that
are attached to the mAGP complex. This lipid rich outer layer is composed of complex lipids that have
multiple methyl branched-fatty acids esterified to their backbone and various large molecules based on
trehalose and phthiocerol like phthiocerol dimycocerosate (PDIM), phenolic glycolipid (PGL), mycolic
acid containing lipids (TMM, TDM and GMM) and other kinds of complex lipids, such as glycopepti-
dolipids (GPLs) and lipooligosaccharides (LOSs).
Phthiocerol dimycocerosate (PDIM)
The PDIM is formed by esterification of long-chain phthiocerol or phthiodiolone with multiple methyl
branched fatty acids like mycocerosic acids (Minnikin et al. (2002)). This lipid plays an important role
in the early stages of the M. tuberculosis infection with macrophages. It also participates in receptor-
dependent phagocytosis, phagosome acidification arrest, protecting the bacilli from reactive nitrogen
intermediates and host cell membranes modification (Astarie-Dequeker et al. (2009), Rousseau et al.
(2004)).
Phenolic glycolipid (PGL)
The PGL and PDIM are structurally similar molecules with the only difference being that the PGL has
a glycosylated phenolic moiety at the end of the phthiocerol chain. PGL was generally observed in
slow growing pathogenic mycobacteria such as M. kansasii, M. gastri, M. ulcerans, M. leprae, M.
marinum and M. tuberculosis (Daffé & Lanéelle (1988)) and was classified under the class mycoside
(Gastambide-Odier et al. (1967)). PGL is reported to posses several immuno-modulatory properties
(Prasad et al. (1987), Vachula et al. (1989)) like the release of pro-inflammatory chemokines and cy-
tokines (Reed et al. (2004)). Collins et al. (2005) carried out an experiment which demonstrates that
decrease in the production of PGL decreases the virulence of the M. bovis in a Guinea pig infection
model.
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Mycolic acid containing lipids
Somemycolates can be extracted as free lipids; these lipids are covalently bound to trehalose or glucose
to form trehalose monomycolate (TMM), trehalose 6,6"-dimycolate (TDM) and glucose monomycolate
(GMM). GMM is synthesized by using the glucose from the host cell and can be an indicator of infection
(Enomoto et al. (2005), Moody et al. (1997)). The TDM also known as the cord factor, is responsible for
the convoluted growth of the M. tuberculosis as well as its virulence (Ryll et al. (2001)). The TDM also
induces the release of chemokines and cytokines which contributes to its immuno-modulatory properties
(Lima et al. (2001)). The other functions of TDM include enabling the bacterium to enter the host cell
macrophages (Yasuda (1999)) and inducing the formation of granulomas (Behling et al. (1993), Borders
et al. (2005)). TMM, a precursor of TDM, is responsible for the transport of mycolic acid to the cell wall
AG (Katsube et al. (2007), Belisle et al. (1997))and then gets converted to TDM before being ejected
from the cytoplasm (Takayama et al. (2005)).
Sulfolipid (SL)
SL is composed of trehalose 2-sulfate core modified with 4 fatty acyl substituents and is found in some
virulent strains of M. tuberculosis (Goren et al. (1976)). The exact function of this glyco-lipid is still
unclear; it has been experimentally demonstrated that loss of SL has no impact on the bacilli replication
(Kumar et al. (2007)).
Glycopeptidolipids (GPLs)
GPLs are a principle constituent in the outer layer cell wall of several species of mycobacteria. All
the mycobacteria share a common structure of fatty acyl-tetrapeptide (FATP) and the pathogenicity of
the mycobacteria is determined by the glycosylations of FATP (Chatterjee & Khoo (2001), Patterson
et al. (2000)). A recent study has shown that GPLs participate in receptor-dependent phagocytosis of
Mycobacterium by macrophages (Villeneuve et al. (2005)).
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Lipooligosaccharides (LOS’s)
LOSs are highly antigenic glycoconjugates present on the cell surface and are used as targets for
serotyping. They are usually found in following members of the M. tuberculosis class M. kansasii, M.
gastri, M. marinum and M. Canetti (Burguière et al. (2005), Daffe et al. (1991)). The biosynthesis and
role of LOSs is still unclear.
1.5 Control of TB
The TB treatment has come long way since treating the unknown deadly disease to the patient specific
chemotherapy. The use of drugs like sulphonamide and penicillins for the treatment of the infectious
diseases had been around for a while, but these drugs were ineffective against TB bacteria. However
after years of research Selman A. Waksman in 1944 successfully isolated an antibiotic streptomycin
from Streptomyces griseus, the first anti-TB drug. A discovery for which he was awarded the Nobel
prize in medicine in 1952. Although this drug had serious side-effects and within a few months of use
had developed resistance against mutant strains, it proved that M. tuberculosis was no bacteriological
exception and paved a way for further research in TB chemotherapy. The present day TB control involves
two way attack through the use of vaccines and anti-TB drugs.
1.5.1 Vaccines
Currently only one vaccine against TB is available: Bacille Calmette-Guérin also called BCG vaccine;
it is an attenuated live vaccine obtained from Mycobacterium bovis. In the early 1900s a French bac-
teriologist Albert Calmette along with Camille Guérin observed that under specific laboratory conditions
and specific culture media the virulence of Mycobacterium bovis strain, which caused bovine TB, was
reduced. An intensive research involving in vitro passaging of this strain and trials on different animal
models were carried out for about 13 years, before they did the first human trial in 1921, which showed
positive results (Behr (2002)). This BCG strain was then distributed around the world to various labo-
ratories, where addition of different strains to the vaccines resulted in continued evolution of BCG. The
present day vaccine dose not represent a single strain but a group of sub-strains. In 1974 the organ-
isations like WHO, UNICEF and GAVI started a collaborative project called Expanded Programme on
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Immunization. The project aimed to immunise every child across the world against fatal disease TB
by 1990 (UNICEF 2010). The BCG vaccine has a highly variable efficacy, it reduces the risk of TB by
about 50% in new borns and children (Colditz et al. (1995)). However its efficiency in adults ranges from
0-83% (Brewer (2000)).
This limited protection by BCG has encouraged the development of newer vaccines. Based on our
current understanding of M. tuberculosis infection, and the use of specific genetic tools two main ap-
proaches are considered for development of new vaccines (i) boosting the BCG vaccination by express-
ing recombinant M. tuberculosis antigenic protein (known as recombinant BCG, rBCG) (Reed et al.
(2009), Tchilian, Desel, Forbes, Bandermann, Sander, Hill & McShane (Tchilian et al.)) and (ii) creating
attenuated strains ofM. tuberculosis by deleting the genes resposible for replication or virulence (Aguilar
et al. (2007), Waters et al. (2007)). Currently two rBCG candidates are in phase 1 clinical trials (Walker
et al. (2010), Horwitz (2005)).
1.5.2 WHO initiatives
TB is generally treated with a combination of different drugs as a mono-drug therapy results into re-
sistance to the drugs (Wang et al. (2006)). The standard TB treatment involves chemotherapy using
isoniazid (INH), rifampicin (RMP), pyrazinamide (PZA) and ethambutol (EMB) for two months then it
is followed up by INH and RMP for next four months. In the case of latent TB, WHO recommends a
follow up by INH and RMP for two months after the standard treatment (Organizationet al. (2010)).
However the long duration of the course results in poor patient compliance, which is one of causes of
drug resistance.
To overcome this problem, in 1991, the WHO introduced DOTS an acronym for Directly Observed
Therapy Short-course and this scheme is adopted by many countries. In addition to DOTS the WHO
also started a ‘Stop TB’ campaign in 2006 (Organizationet al. (2010)). The six main aims of this
campaign for 2006-2015 to promote the advantages of DOTS and create awareness about MDR. To
reduce the prevalence of TB by 50% of the total cases observed in 1990. According to WHO the
prevalence between the year 1990 to 2007 has dropped from 300 to 206 per 100,000 population. The
target for 2050 is to reduce this to 1 case per million per year (WHO (2009)).
Even the short course like DOTS requires a minimum six months strict regimen of chemotherapy with
a various combination of first line and second line drugs (see 1.5.3). In the DOTS treatment, a com-
42
plete patient profiling is done right from the screening for the disease to the chemotherapy and to the
monitored outcome (Obermeyer et al. (2008)). The present DOTS treatment involves a daily course
of rifampicin, isoniazid, ethambutol, pyrazinamide and (in some cases) streptomycin for the first two
months and then isoniazid and rifampicin thrice a week for four months (Cox et al. (2006)). Should the
bacteria cell develop resistance to one or more drugs, the medication course is altered as needed by
changing drugs and extending the period of treatment (see Table. 1.1) (Campbell & Bah-Sow (2006)).
The major problem with this scheme is the long duration of the treatment. The initial few weeks of
the treatment reduce the symptoms and cause many patients to discontinue the DOTS course. This
non-completion of course not only causes the TB to relapse but also result in drug resistance.
Rifampicin-resistant TB Isoniazid-resistant TB Multidrug-resistant TB
Isoniazid 18 months Rifampicin 12 months Five drugs initially (Ri-
fampicin, isoniazid, etham-
butol, pyrazinamide and
streptomycin) for 12 months
Ethambutol and/ or pyrazi-
namide 18 months
Ethambutol or pyrazinamide
12 months
then three drugs (Iso-
niazid, ethambutol and
pyrazinamide) for 18 − 24
months
Table 1.1: Common treatment regimens for patients suffering from drug-resistant tuberculosis.
1.5.3 Currently-used drugs
In 1947, the introduction of Streptomycin as anti-tubercular agent has seen significant progress in TB
chemotherapy. Later in 1952 the discovery of isoniazid enhanced its therapeutic potential to the fullest.
The early 1960s were marked for introducing ethambutol and rifampin. Later the discovery of pyrazi-
namide completely changed the strategy of the chemotherapy. The recent additions to these drugs are
fluoroquinolones, macrolides, and rifampin congeners.
According to the WHO guideline the anti-TB drugs can in classified in three broad classes based on their
mechanism of action, side-effects and clinical utility. The first line agents (essential drugs), they have
the most efficacies and least toxicity: isoniazid (INH), rifampin (RMP), pyrazinamide (PZA), etham-
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butol (EMB) and streptomycin (STM). The second line agents (reserved drugs) include six different
classes like aminoglycosides (e.g. amikacin (AMK), kanamycin (KM)), polypeptides (e.g. viomycin,
capreomycin), fluoroquinolones (e.g. ciprofloxacin, levofloxacin), thioamides (e.g. ethionamide), cy-
closerine, p-aminosalicylic acid. These compounds generally have fewer efficacies and more toxicity or
both as compared to the first line agents. These agents are rarely used as a single drug in treatment
and are mostly used in combination with the first line agents. The last class of compounds, the third
line agents, comprise of rifabutin and macrolides. These compounds have very less efficacy or the
effectiveness is yet to be proven.
The M. tuberculosis cell is unique and involves large number of genes in lipid synthesis, the enzymes
employed in these pathways provide an excellent drug target. The most common drugs include those
that disrupt the DNA replication, translation and cell wall lipid synthesis. Table. 1.2 list the commonly
used TB drugs and their mechanisms of action.
Drugs Mechanisms of Action
Isoniazid Inhibition of cell wall mycolic acid synthesis; effects on
DNA, lipids, carbohydrates and NAD metabolism
Rifampin Inhibition of RNA synthesis
Pyrazinamide Disruption of membrane transport and energy depletion
Ethambutol Inhibition of cell wall arabinogalactan synthesis
Streptomycin Inhibition of protein synthesis
Kanamycin Inhibition of protein synthesis
Quinolones Inhibition of DNA synthesis
Ethionamide Inhibition of mycolic acid synthesis
PAS Inhibition of folic acid and iron metabolism
Cycloserine Inhibition of peptidoglycan synthesis
Table 1.2: Commonly used TB drugs and their mechanisms.
Nicotinamides.
The nicotinamide discovery was made in the year 1912. However its antitubercular activity was not
discovered till early 1950’s. The French scientist, Chorine in 1945, first reported the antitubercular
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activity of nicotinamide. However it was later discovered that the tuberculostatic activity observed was
not due to the nicotinic acid and the anti-tubercular activity was not related to vitamin function. Thus the
nicotinic acid itself was never used but its clinically active analogs were created, which form the basis of
today’s chemotherapy.
Isoniazid
After extensive research, Fox in 1952, first isolated an intermediate product, hydrazide of isonicotinic
acid (Isoniazid), which was the most active compound known (Fox & Gibas (1952)). INH is an essential
component of every drug therapy unless the bacterium has become resistant or the patient is intolerant
to the drug. The exact mechanism of action is unknown however it is primarily tuberculocidal. It acts
on both intra and extra cellular bacilli. INH is a prodrug and is activated by the mycobacterial KatG,
a catalase peroxidase enzyme, the drug undergoes a series of highly reactive transition states before
oxidising (Suarez et al. (2009)). It is proposed that activated INH might act on the cell wall synthesis
by displacement of the nicotinamide and hence causing an inactive enzyme drug complex which further
triggers changes in protein, lipid and nucleic acid metabolism. Thus causing inhibition of mycolic acid
synthesis and resulting into cell wall rupture.
Pyrazinamide
Pyrazine carboxamide is another active analogue of nicotinamide which was developed in parallel to
INH (Kushner et al. (1952)). It is used along with INH and STM to shorten the DOTS course from one
year to six months. It has a weak tuberculocidal activity and is specifically active against semi-dormant
bacilli in the acidic conditions of phagosome and hence is used to treat intracellular bacterial infections.
Akin to INH, PZA is a prodrug and gets converted to the pyrazinoic acid due to the enzymatic actions
of pyrazinamidase (Zimhony et al. (2007)). This active form of the PZA when accumulated causes
disruptions in membrane potential and eventually leads to cell lysis. It is also believed to have a similar
target to INH i.e. inhibition of mycolic acid bio-synthesis. It acts by preventing the elongation of the fatty
acid C6 to C24/26 in FAS I (Fox & Gibas (1952), Zimhony et al. (2000)). It is used in combination with
other drugs as it develops resistance rapidly.
Ethionamide
Ethionamide (2-ethyl thioisonicotinamide), is a second line agent, most active derivative of nicotinamide
and is used against the drug-resistant TB bacteria (Wang et al. (2007)). It is structurally similar to INH
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and hence it was observed that both the compounds target InhA. Ethionamide is similar to INH in another
way in that it is also a prodrug. A flavin mono-oxygenase, ethA, is identified as the activator gene, that
catalyses the cleavage of a carbon-carbon bond next to carbonyl, thus using a Baeyer-Villiger oxidation
reaction it converts ketones to esters and cyclic ketones to lactones. Winder et al. (1971) established
that ethionamide acts by obstructing the binding of arabino residue to the PG causing disruption in
mycolic acid pathway. It is used when the bacteria develops resistance to the first line agents like INH
and RMP. Ethionamide is known to develop a rapid resistance and hence it is used in combination with
other first or second line drugs.
General SAR of nicotinamides
The pyridine ring is essential in all the above drugs for the activity, replacing the ring with heterocyclic
rings like furan, thiazole, pyrimidine and pyrazine causes loss of activity. The position of hydrazine in
INH, thioamide in ethionamide, and carboxamide in PZA is optimum at 4, moving to 2nd or 3rd position
results in reduced or complete loss of activity (Foye et al. (2008)).
Aminoglycoside antibiotics
Aminoglycosides are produced by soil actinomycetes. This class of compounds are result of deliberate
research against gram-positive bacteria. In 1944, Waksman first introduced streptomycin which was
active against M. tuberculosis in both the in vitro and in vivo studies (Schatz et al. (1944)). Subsequently
many compounds were synthesized like neomycin, gentamycin, tobramycin and paromomycin. But
these drugs were not active against M. tuberculosis.
Streptomycin
Streptomycin is the oldest aminoglycoside antibiotic obtained from Streptomyces griseus. STM was
the first drug clinically available for the treatment of TB and was first used in 1947. It inhibits both
gram-positive and gram-negative bacteria. It was a drug of choice in the past for the treatment of TB.
However large doses were required which gave undesirable side effects like ototoxicity. It mainly acts
on extracellular bacilli, due to poor penetration into the cells. The mechanism of action is transportation
of STM across the cell wall and cytoplasmic membrane, and binding to the P 10 protein of the 30S
ribosomal subunit which causes inhibition of the protein bio-synthesis due to the formation of abnormal
protein. However a recent study has suggested that STM also inhibits the enzymatic polymerisation of
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the amino acids, which is responsible for the bactericidal action (Spotts & Stanier (1961), Foye et al.
(2008)). The aldehyde in the streptose ring when reduced to primary alcohol gives dihydrostreptomycin
which has same activity as STM but the toxicity to auditory branch increases. Conversion of aldehyde
to acids, oxime, semicarbazone, phenylhydrazone results in inactivity (Foye et al. (2008)).
Other aminoglycoside compounds like kanamycin and amikacin are more toxic antibiotics and rarely
used to treat atypical mycobacteria and people who do not respond to the usual therapy.
Salicyclates and benzoates
p-Aminosalicylic acid
Lehmann in 1946 discovered that the salicyclates and benzoates elevate the respiration of tubercle
bacillus and hence it was proposed that these compounds are important for the normal metabolism
of the organisms and hence they can be used as anti-tubercular target. p-Aminosalicylic acid (PASA)
was discovered in an attempt to find compounds that have antitubercular activity. However it was later
observed that PASA shows little effect on the respiration ofM. tuberculosis and hence it established that
the initial hypothesis was flawed (Kobarfard & Kauffman (2003)). It is not active against any bacteria
other than TB, this selectivity could be attributed to the differences in the affinity of folate synthetase
of TB and other bacteria for PASA (Kobarfard & Kauffman (2003), Foye et al. (2008)). It is one of the
least active compounds and acts as a tuberculostatic drug. It is given in rare cases along with other
first line drugs where it delays the resistance to these drugs. It is effective only against the growing
bacilli, thus indicates a mechanism of action similar to that of sulfonamides. The tuberculostatic activity
of the PASA can be reversed by administration of p-aminobenzoic acid. Substitution of the amino group
with hydroxy, alkoxy, tertiary amines or amides causes loss of activity. Conversion of the acid group to
esters, amides or nitrates resulted in inactivity. Conversion of the hydroxyl group to ester or ether results
in loss of activity (Foye et al. (2008)).
Cyclic polypeptides
Capreomycin
It is a cyclic polypeptide and resembles viomycin structurally and pharmacologically. It is effective in vitro
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hence used mostly for treatment of experimental TB. It develops resistance when administered alone,
also cross resistance has been noted with kanamycin, neomycin and viomycin but none is reported with
INH and STM (Georghiou et al. (2012)). The drug shows clinical efficacy along with INH or PASA.
Oxazolidone
Cycloserine
Cycloserine (CYS), (D-4-amino-3-isoxazolidone), was first isolated in 1955 from S. orchidaceus and is
a chemical analogue of D-alanine. This is one of the simplest broad spectrum antibiotic to have anti-
tubercular activity. CYS acts by interfering in several steps of protein synthesis in the M. tuberculosis.
During the early stages of cell wall synthesis L-alanine is converted to D-alanine and then two molecules
of D-alanine are in turn linked together and incorporated into the cell wall. CYS competitively inhibit the
D-alanine incorporation into the cell wall and also inactivates the enzymes which recemise L-alanine,
resulting in its antibiotic property (Prosser & Carvalho (2013), Foye et al. (2008)). Resistance to this
compound is developed slowly and also no cross resistance is observed. Yet this compound is rarely
used in case of resistant bacteria due to the high risk of CNS toxicity. The L-isomer is more active than
the D-isomer. The 4-amino group is essential for the activity. Removing the 4-amino group makes the
compound inactive and converting it to 4-amino-oxy retains the activity (Foye et al. (2008)).
Ethylenediamines
During the screening of compounds for antimycobacterial property N,N’-diisopropylethylenediamine was
found to be active. Subsequently several analogs of this compound were tested against mycobacteria
and (+)-2,2’-(ethylenediimino)di-1-butanol (ethambutol, EMB) was found to be the most active com-
pound.
Ethambutol
Ethambutol is selectively tuberculostatic and clinically as active as STM. It acts prevalently on fast multi-
plying bacteria and atypical mycobacteria. The mechanism of action of this drug is not fully understood,
however few theories have been proposed that it interferes in the RNA synthesis and prevents protein
and DNA synthesis by forming complexes with divalent cations which inhibits the functions of amines
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like spermidine and spermine which are involved in maintaining the integrity of nucleic acids (Tripathi
(2013)). Another theory suggests that it inhibits the arabinogalactan synthesis and thus disrupts the
mycolic acid incorporation in cell wall (Takayama & Kilburn (1989)). Although ethambutol develops a
slow resistance as compared to other first line agents and no cross resistance has been reported, com-
bination therapy is still recommended to prevent resistance from occurring. It is mostly used against the
organisms that are resistant to STM and INH. The distance between the two nitrogen atoms is optimum
for the activity, any alteration to this by addition of carbon, oxygen or sulfur atom results in loss of ac-
tivity. Replacing the alcohol function with phenoxy, thio or amino group renders the compound inactive.
Replacing the sec-butyl group with tert-butyl or hydroxy isopropyl group eliminates the activity. The D-
isomer is 200 to 500 times more active than L-isomer. The ethoxy and methoxy derivatives of EMB have
similar activity as the parent compound when tested in vivo, this is due to the enzymatic dealkylation
action (Foye et al. (2008)).
Rifamycin antibiotics
The Rifamycin antibiotics are highly substituted derivatives of naphthalene, obtained from Streptomyces
mediterranei. This group of compounds have broad spectrum of activity.
Rifampin (Rifampicin, RMP)
Rifampin is a semisynthetic derivative of rifamycin B discovered in 1957 and was clinically available in
Europe in 1966 and was released in US in 1971. It has bactericidal action and acts on both extra and
intracellular organisms. It primarily acts on slow or intermittently dividing bacilli, but generally covers
all the sub-population of TB bacteria including atypical mycobacteria. Its efficacy is similar to INH. It
is thought to interfere selectively with the mycobacterial RNA polymerase and not with the mammalian
RNA, thus inhibiting the DNA dependent RNA synthesis. Mono-drug therapy of RMP develops rapid
resistance due to mutation in the repoB gene (RMP target) (Wehrli (1983), Foye et al. (2008)). No cross
resistance is reported. Modifications on the aliphatic portion of the rifampin molecule results in inactive
compound (Foye et al. (2008)).
Another drug from the rifamycin group is rifabutin. It is structurally similar to RMP and has the same
mechanism of action. It is comparatively less active than RMP and is rarely used in treatment of TB. It
is reported to have only a partial cross resistance (Tripathi (2013)).
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Thiosemicarbazones
During the screening of compounds sulfathiadiazoles an intermediate benzaldehyde thio-semicarbazone
was found to be active against TB. The exact mechanism of action is unknown, however no cross re-
sistance is observed with INH thus indicating that thio-semicarbazones do not act by the same mech-
anisms as INH or sulfonamides. Replacement of the thio-semicarbazone group with a semicarbazone,
hydrazone or oxime yields inactive compounds.
Thioureas
During the screening of some anti-fungal compounds some di-phenylthioureas demonstrated tubercu-
lostatic activity. 4,4’-disubstituted diphenylthioureas were shown to have good activity. The mechanism
of action is unclear, however some evidence suggests that it interferes with protein biosynthesis. The
substitution of electron donating group at para position on both the rings is essential for the activity.
Moving the substitution to the ortho or meta position abolishes the activity. Increased substitution also
reduces the activity. Replacing the phenyl ring by a cyclohexyl ring or replacing the thiourea group with
urea, guanidine, pseudothiourea etc diminishes the activity (Foye et al. (2008)).
Fluoroquinolones
The quinolones class was introduced in the mid 1960s for the treatment of urinary tract or GIT in-
fections, ever since many generations of this class of compound have been synthesized. However
these compounds had limited use due to high risk of resistance, low potency and limited spectrum. A
breakthrough was achieved when a new class of fluorinated quinolones was synthesized. These com-
pounds had better penetrability, broad spectrum, high potency, and slow development of resistance.
The most commonly used drugs from this class are ciprofloxacin, ofloxacin, sparfloxacin, moxifloxacin,
levofloxacin, and lomefloxacin. These compounds interfere with the DNA replication and transcription
processes by inhibiting the bacterial DNA gyrase and topoisomerase IV enzyme (Ginsburg et al. (2003)).
Ciprofloxacin, ofloxacin etc are commonly used in the treatment of TB in combination therapy. Some
third generation fluoroquinolones like temafloxacin, a ciprofloxacin analogue, are used widely in treat-
ment of TB infection and levofloxacin have efficacy similar to EMB against TB bacteria. Another member
of the fourth generation fluoroquinolones used in treatment of TB includes moxifloxacin. However due to
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the broad spectrum, they possess a high risk of resistance and hence are used in combination with the
first line agents (Ginsburg et al. (2003)). Recent studies have shown that the anti bacterial activity of the
compound is attributed to the basic pharmacophore, the quinoline ring system. With the evidence that
suggests that the C-6 fluorine enhances the cell penetration and also improves the DNA gyrase complex
binding. It was observed that the activity of these compounds was greatly affected by the substitution at
C-7. The five or six membered heterocyclic rings increased the activity and piperazinyl ring substitution
demonstrated maximum activity (Foye et al. (2008)).
1.6 Treatment regimen
The TB bacteria usually attacks the lungs, however if the infection goes untreated for a long time, it can
attack other organs like brain, kidney and spine and can be fatal. Both the TB-related conditions like the
latent TB infection (LTBI) and the TB disease are treated using a condition specific regimen.
The treatment of LTBI is essential as it helps in controlling and eliminating the disease. After ensuring
that the risk of developing an active disease is ruled out one of the four suitable regimen as discussed
in Table. 1.3 is recommended by the Centers for Disease Control and Prevention 1.
Drugs Duration Interval Minimum doses
(mg)
Isoniazid 9 months daily 270
twice weekly∗ 76
Isoniazid 6 months daily 180
twice weekly∗ 52
Isoniazid and Rifapen-
tine
3 months once weekly∗ 12
Rifampin 4 months daily 120
∗ Use Directly Observed Therapy (DOT)
Table 1.3: Treatment regimens for Latent TB infection.
2
The treatment of TB disease is more complicated than LTBI and requires an extensive regimen of 6 to
1http://www.cdc.gov/
2http://www.cdc.gov/
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nine months. Once tested positive on the smear test a basic 2 month treatment is recommended with
first line agents (INH, RMP, PZA, EMB) 3. Based on the degree of infection various continuation phases
are used as discussed in table. 1.4.
Preferred Regimen Alternative Regimen Alternative Regimen
Initial Phase Daily INH, RIF,
PZA, and EMB∗ for 56
doses (8 weeks)
Initial Phase Daily INH, RIF,
PZA, and EMB∗ for 14
doses (2 weeks), then twice
weekly for 12 doses (6
weeks)
Initial Phase Thrice-weekly
INH, RIF, PZA, and EMB∗
for 24 doses (8 weeks)
Continuation Phase Daily
INH and RIF for 126 doses
(18 weeks) or Twice-weekly
INH and RIF for 36 doses
(18 weeks)
Continuation Phase Twice-
weekly INH and RIF for 36
doses (18 weeks)
Continuation Phase Thrice-
weekly INH and RIF for 54
doses (18 weeks)
Table 1.4: Basic treatment regimens for TB infection.
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1.7 Drug resistance
According to the 2009 WHO report, out of the total 10.4 million cases of TB nearly 5% were MDR-
TB. Statistics demonstrated that more than half of the cases were new incidences while only 1.9% of
the cases were previously treated for TB. A clear correlation between incidence of MDR-TB and newly
diagnosed disease was observed especially in the high incidence countries like India and China. Due to
the high number of multidrug-resistant (MDR) and extensively drug-resistant cases (XDR) of TB there
is an immense need for new drugs. The worldwide spread of AIDS has added a new aspect to the TB
problem. According to WHO more the 10 million people each year are infected with HIV. These patients
are more prone to develop active TB disease and MAC (Mycobacterium avium complex) infections.
Resistance can be developed by various means such as the target gene undergoing a self-generated
chromosomal mutation, gene over-expression, drug efflux or inactivation mechanisms, and affecting
3http://www.cdc.gov/
4http://www.cdc.gov/
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the drug permeability (Zhang & Yew (2009)). Drug resistant TB strains first arose shortly after the
introduction of STM in 1944, when the mono-drug therapy of STM resulted in relapse of TB due to gene
mutation. The rationale for combination therapy, therefore, is to employ two or three drugs acting on
various targets, as the chances of the cell acquiring mutation at two or three unlinked target genes is less
likely and thus reduces the probability of drug resistance. The process of genetic mutation is accelerated
by mono-drug therapy, poor drug prescription, shortfalls in drug distribution and most importantly patient
drug non-adherence.
With newer publications providing deeper insights of M. tuberculosis H37Rv genome originally isolated
in 1905 has vastly increased the understanding of the organism biology, mechanisms of drug action
and resistance. This paved the way for the development of newer drug leads like 2-aminothiazoles,
oxadiazolylthio, thiadiazolylthio and triazolylthio derivatives (Ananthan et al. (2009)), carboxamidrazones
(Billington et al. (2000)) etc.
1.8 Project aims
Statistics showing an increase in the MDR cases of TB and the reports of continuously evolving resistant
strains, the present chemotherapy is in jeopardy and thus the need for newer, effective and cheap drugs
is as high as it was a century ago. Therefore there are two main aims of this PhD project:
1. To synthesize libraries of analogues and derivatives of carboxamidrazone, a known active com-
pound and its derivatives and its cyclized and fluorinated analogues. And to test for their biological
activity against the M. tuberculosis H37Rv strain.
2. To synthesize target specific compounds like long chain 2-hydroxy-3-oxocarboxylic esters which
are structurally similar to the mycolic acids and might act on the FAS-II mechanism and test for
their biological activity against the M. tuberculosis H37Rv strain.
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Chapter 2
Chemistry and synthesis of heteroaryl
amidrazone compounds
2.1 Introduction
This chapter describes and discusses the generation of a library of heteroaryl compounds and their
analogues to screen for their activity against Mycobacteria especially Mycobacterium tuberculosis. In
the following some of the contributions towards the synthesis of the amidrazone class and its derivatives
are briefly reviewed. The amidrazone compounds have been known for a long time to posses anti-
tubercular activity. Thiele (1892) generated aminoguanidine by reduction of nitroguanidine, a present
day amidrazone class of compound. Numerous scientists have developed the chemistry to make several
new amidrazones (Neilson et al. (1970), Mihina & Herbst (1950), Libman & Slack (1956), Doyle &
Kurzer (1976)). However, its anti tubercular activity was not discovered until the mid 1950s. The high
tuberculostatic activity of carboxyhydrazide of 4-pyridine led to the discovery of many of its analogues.
The next two decades saw further research into the synthesis of hydrazones (Kitaev et al. (1970)),
2-benzimidazolyl derivatives (Vereshchagina et al. (1973)), imidic acid derivatives (Grout (1975)) and
triazolepropionic acids (Buckler et al. (1978)) along with the investigation into their anti inflammatory
and anti tubercular activities.
In the last two decades significant work has been carried out in this area. The Mamolo group in the
1990s has synthesised 2-pyridyl and 4-pyridyl carboxamidrazone compounds and their derivatives.
These compounds were further tested against M. tuberculosis H37Rv and M. tuberculosis isolated
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from human bronchial aspirates (Mamolo et al. (1992), Mamolo et al. (1993), Mamolo & Vio (1996)).
The compounds shown in Fig. 2.1 exhibited some interesting inhibitory activity against some of the M.
tuberculosis organisms that were resistant to isoniazid, rifampicin and ofloxacin.
(3); X=Cl (4); X=Br (6); X=Br(5); X=Cl
X
N
N
N
NH2
N
X
N
N
NH2
N
Figure 2.1: The most active compounds synthesised by Mamolo et al. (1992).
The structure activity relationship studies by Mamolo et al. (1992), Mamolo et al. (1993), Mamolo &
Vio (1996) suggested that it is essential for the amidrazone group to be attached at the 2-position ortho
position of the pyridine ring. It is also suggested that a substituent should be attached to the benzylidene
end as opposed to the pyridine ring, as this combination is optimum for the penetration of the entire
molecule into the highly lipophilic mycobacterial cell membrane. However, the conclusion drawn by
the Mamolo group was based on a small size data set of 21 compounds of N1-benzylideneheteroaryl
carboxamidrazones.
A further investigation in this field was carried out at Aston University by the Rathbone group. A large
library of carboxamidrazones and their derivatives Fig. 2.2 were synthesised using robotic equipments,
which were then subjected to a preliminary testing at Aston University, on M. fortuitum. This organism
was selected since it is much safer and grows faster as compared to M. tuberculosis.
The toxicity levels of the compounds shown in Fig. 2.2 were then tested on the rat liver metabolism
system, human erythrocytes and mononuclear leucocytes using INH as the reference (Coleman et al.
(1999), Coleman et al. (2000), Coleman et al. (2001)). In this study the compounds were incubated in
two ways i) direct and ii) metabolising system controlled. It was observed that the compounds (7), (8),
and (10) were less toxic than INH at same concentration on direct incubations. However compound (9)
exhibited a high level of toxicity towards the human mononuclear leucocytes (Coleman et al. (1999),
Coleman et al. (2000), Coleman et al. (2001)).
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Figure 2.2: List of the most active compounds synthesised by Billington et al. (2000)
Rathbone et al. (2006) took this study further by synthesising a new series of phenolic N1-benzylidene-
pyridinecarboxamidrazones. In this study, many active compounds were synthesised, but the most
active of them all against M. tuberculosis was N1-[3, 5-di-(tert-butyl)-2-hydroxybenzylidene]-pyridine-4-
carboxamidrazone (11) (see Fig. 2.3). It was observed that the compound (11) was active against most
gram positive bacteria, including MRSA strains, and MIC values in the range of 6.50 − 12.99 µM. In
contrast, the compound was found to be completely inactive against gram negative bacteria. However,
compound (11) failed the direct leucocyte toxicity test causing 100% human leucocytes cell lysis.
(11)
N OH
N
N
NH2
Figure 2.3: N1-[3, 5-di-(tert-butyl)-2-hydroxybenzylidene]-pyridine-4-carboxamidrazone
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The compound (11) shown in Fig. 2.3 was used as a lead compound by Khan (2008). Her work involved
mainly synthesis of carboxamidrazone derivatives including amides, ureas, sulphonamides, and methyl
ketimines. The sulphonamides derivatives were difficult to isolate, urea derivatives were generally found
to be inactive, except for the few 4-pyridine-substituted compound derivatives, and methyl ketimines
were also mostly inactive. Amongst all the compound groups, amides were found to be the most active
group against M. tuberculosis. The compound pyridine-2-carboxamidrazone N1[3, 5-di-(tert-butyl)-2-
hydroxybenzoyl] amide (see Fig. 2.4) was found to be of special interest, since it had an MIC value
<20.29 µM causing a 100% inhibition.
(12)
O
NH2
OH
N
H
N
N
Figure 2.4: Pyridine-2-carboxamidrazone N1−[3, 5-di-(tert-butyl)-2-hydroxybenzoyl] amide
Ren (2009), carried out further research using the compound shown in Fig. 2.4 as a lead compound
to synthesis a new series of compounds by modifying the aryl moieties. His work mainly emphasised
amides and imines.
Type I Type II
Type III Type IV
Heteroaryl
Heteroaryl
HeteroarylN
N
H
R
O
NH 2
N
N
H
N
Ar
O
NH 2
N
+
O
–
N
N Ar
NH2
N
N
H
R
O
NH 2
Figure 2.5: General structures of the compounds synthesised by Ren (2009)
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The biological data obtained from Ren’s compounds Type III and IV (see Fig. 2.5) suggested that the
compounds with long alkyl chain substitutions at the benzoyl end were the most active compounds
as shown in Table. 2.1. These results are in agreement with Mamolo et al. (1992) and Billington
et al. (2000), where it is suggested that the increase in the lipophilicity of the molecule increases the
permeability of the bacterial cell wall, thus increasing the activity of the molecule.
Compound Name Compound Structure IC50 µM IC90 µM
N1-(4-Hexylbenzoyl)-pyridine-
2-carboxamidrazone
(13)
N
O
N
H
N
NH2
3.23 4.32
N1-(4-Pentylbenzoyl)-pyridine-
2-carboxamidrazone
(14)
N
O
N
H
N
NH2
2.88 4.50
N1-(4-Heptylbenzoyl)-
pyridine-2-carboxamidrazone
(15)
N
O
N
H
N
NH2
4.58 4.96
N1-(4-Decylbenzoyl)-pyridine-
2-carboxamidrazone
(16)
N
O
N
H
N
NH2
17.75 19.44
N1-(4-(10-Undecenoyl))-
pyridine-2-carboxamidrazone
(17)
N
NH2
O
N
H
N
14.37 23.97
Table 2.1: The list of the most active compounds against M. tuberculosis along with their IC50 and IC90
values synthesised by Ren (2009)
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Sikdar (2010) investigated the carboxamidrazone mostly by modifying the central chain. The pyridyl
moiety was connected with the substituted benzyl moiety using three atoms instead of four to study the
optimum chain length required for the compound activity. However these compounds were found to
have only moderate to low activity.
2.2 Structure activity relationship studies
2.2.1 Imines
(7) (11)
NH2
OH
N
N
N
N
N
NH2
N
Figure 2.6: Two of the most active imines, a: N1-[(E)-[4-(1, 1-dimethylpropyl) phenyl] methyleneamino]
pyridine-2-carboxamidine, b: N1-[(E)-(3, 5-ditert-butyl-2-hydroxy-phenyl) methyleneamino] pyridine-4-
carboxamidine
The compounds (7) and (11) were the most active compounds of the imine series againstM. tuberculosis
with the MIC of 25.98 − 32.47 µM (Billington et al. (2000) (see Fig. 2.6)). The 4-pyridyl substituted
compound (11) was the most active compound with MIC of 6.50 − 12.99 µM. Replacing the 4-pyridine
ring in compound (11) with 2-pyridine, 3-pyridine, 2-pyrazinyl or 2-quinolyl rendered the compound
inactive (Tims (2002)). The tert. butyl groups on the compound (11) were found to be essential for the
activity. Substitution of tert. butyl group with a methyl group caused loss of activity. The introduction
of a halogen group like Iodine in the compound (11) caused the activity to diminish and the compound
was four times less potent (Rathbone et al. (2006)). Replacing the hydroxyl group in (11) with ether
completely abolished the activity. However replacing the hydroxyl group in (11) with acetate slightly
lowered the activity; this anomaly suggested that the acetate derivative might be acting as a pro-drug for
the parent compound. The poly-hydroxylation of compound (11) exhibited moderate activity (Rathbone
et al. (2006)).
Coleman et al. (1999) has shown that the amidrazone nucleus is extremely toxic to the human mononu-
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clear leucocytes. Hence in an attempt to reduce the toxicity a further research was carried out at Aston
University by the Rathbone group, which involved synthesis of urea, sulphonamide, methyl ketimines
and amide derivatives.
2.2.2 Ureas
(18) (19)
NO2
N
N
N
H
N
H
O
NH2
N
N
NH2
N
H
N
H
O
Figure 2.7: Two examples of the urea derivatives, a: 1-[(Z)-[amino (4-pyridyl) methylene] amino]-3-(4-
nitrophenyl) urea, b: 1-[(Z)-[amino (4-pyridyl) methylene] amino]-3-cyclohexyl-urea
The urea derivatives were generally inactive against M. tuberculosis. The 4-pyridyl compounds were
found to be active compared to 2-pyridyl compounds. The methoxy and halogen substitution resulted
in the loss of activity. Nitro group substitution at para position (18) increased the activity, however
substitution at the ortho position caused loss of activity. The substitution of cyclohexane ring at the
benzoyl end (19) caused an increase in activity ((see Fig. 2.7) Khan (2008)). This further supported
the argument that a large alkyl group increased the lipophilicity which was beneficial for the complete
penetration into the bacterial cell and thus increased the activity (Mamolo et al. (1993), Mamolo & Vio
(1996)).
2.2.3 Sulphonamides and N-oxides
The compounds with the sulphonamide nucleus were inactive. The 4-pyridyl-4-N-oxide compounds
were also inactive (Khan (2008)).
2.2.4 Amides
Based on the previous work carried out at Aston university it was observed that the amide derivatives
of carboxamidrazones were the most active compounds against M. tuberculosis. For this study only a
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subset of carboxamidrazone amides with a substituted benzoyl and aliphatic substitutions are consid-
ered. The 2-pyridyl compounds were generally more active as compared to the 4-pyridyl compounds.
Replacing the 2-pyridyl with 3-pyridyl diminished the activity. A large alkyl chain substitution at the ben-
zoyl end enhanced the activity. It was observed that the compounds (13), (14) and (15) containing the
alkyl chain substitution of five to seven carbons on the benzoyl ring was active against M. tuberculosis
(Ren (2009)).
(13) (14)
(15)
N
O
N
H
N
NH2
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NH2
Figure 2.8: List of amides, a: N1-[(Z)-[amino(4-pyridyl) methylene] amino]-4-heptyl-benzamide, b:N1-
(4-Pentylbenzoyl)-pyridine-2-carboxamidrazone, general structures of azobenzoyl amide and general
structure of benzoyloxybenzoyl amide carboxamidrazone
.
2.2.5 General carboxamidrazone amide structure
The five atom carboxamidrazone chain connecting the pyridyl moiety to the benzoyl moiety is essential
for the activity as reducing the chain length caused loss of activity. The 2-pyridyl-substituted carbox-
amidrazone amides were found to be generally more active than the 4-pyridyl or 3-pyridyl substituted
compounds. The alkyl chain substitution at R4 position on the benzoyl ring enhances the activity of
compounds (13), (14) and (15)(Ren (2009)). The tert. butyl groups at R3 and R5 along with a hydroxy
group attached at R2 renders the compound active (12). The hydroxy group at R2 (ortho) position is
essential for the activity. Shifting the hydroxy from R2 to R4 (para) (20) position diminishes the activity
(Sikdar (2010)). Halogens other than iodine like bromine or chlorine causes loss in activity. The pres-
ence of electronegative substitution is favourable for activity, but the compounds were found to be highly
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toxic (Sikdar (2010)).
(13);  R1= 2-Pyridyl
          R4= 6 carbon alkyl chain
(14);  R1= 2-Pyridyl
          R4= 5 carbon alkyl chain
(15);  R1= 2-Pyridyl
          R4= 7 carbon alkyl chain
(12);  R1= 2-Pyridyl
          R3  and R5=  tert. butyl
          R2= OH
(20);  R1= 2-Pyridyl
          R3  and R5=  tert. butyl
          R4= OH
R1
R6
R5
R4
R3
R2
N
N
H
O
NH2
Figure 2.9: General structure of carboxamidrazone amide
2.3 Lead Optimisation
The Fig. 2.10 summarises the previous work carried out at Aston university in the carboxamidrazone
and the changes made to optimise the compound for antimycobacterial activity.
2-Pyridine, 3-Pyridine, 4-Pyridine, 2-
Pyrazinyl, 2-Quinolyl, 4-Pyridyl-4-N-oxides, 
3-Pyridyl-3-N-oxides
Removal of NH2, C-NH2, converting imines into amide, sulphonamide, urea, 
methyl ketimines
Substitutions on the aromatic ring 
Aromatic moeity
Heteroaryl moeity
N
N
NH2
Figure 2.10: Summary of previous work carried out in carboxamidrazone at Aston university.
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2.3.1 Intended variations of the building blocks in synthesis of carboxamidrazone
Compound A
N'-[(alkyl)oxy]pyridyl carboximidamideCarboxamidrazone amide
Compound B
PyridylPyridyl
N
O
O
R
NH2
N
N
H
O
R
NH2
Figure 2.11: General structures of the intended lead compounds to be synthesised
Aryl building block
A library of compounds was synthesised in an attempt to increase the antimycobacterial activity while
decreasing the toxicity of the compounds. To achieve this various building blocks were altered.
In the previous research (Ren (2009)) have synthesised carboxamidrazones with alkyl chains attached
to the benzoyl group and tested them for anti tubercular activity. It was observed that the compounds
with 5 and 6 alkyl chains were the most active compounds followed by the 7 alkyl chain. To take this
research forward a matrix was created where some of the carboxamidrazones missing in the (Ren
(2009)) library were synthesised using different alkyl chain lengths. Table. 2.2 shows the list of various
acid chlorides used to modify the compound A (Fig. 2.11). The acid da was used to study the effect of
cyclic substrate on the activity as opposed to the 6-hexylbenzoyl chloride which has flexible side chain.
Some of the acid chlorides were selected to study the effect absence of a benzoyl ring has on activity.
Some of the acid chlorides selected have an alkoxy group attached to the benzoyl group. Alkyl and
alkoxy both are electron donating groups and are structurally similar and hence were selected for the
present study.
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OCl
O
Cl
O
Cl
aa ab ac
O
Cl
O
Cl
O
Cl
ba bb bc
O
Cl
O
O
OH
O
O
OH
bd ca cb
O
O
OH
O
O
OH
O
O
OH
cc cd ce
O
O
OH O
OH
O
OH
cf da db
Table 2.2: List of acid chlorides and acids used in the synthesis of carboxamidrazone amides
Pyridyl building block
The hydrazine monohydrate on reacting with the cyano pyridines gave subsequent pyridyl carboxam-
idrazones (Tanaka et al. (1994)). Rathbone et al. (2006) have tested the pyridine carboxamidrazone
against Mycobacterium tuberculosis and is known to posses antimicrobial activity. Many amidrazones
like imines, 2, 3 and 4 -pyridyl carboxamidrazones and benzilidines were synthesised to create a library
of compounds in the earlier research (Tims (2002)). However based on previous studies carried out
by Tims (2002), Ren (2009), Sikdar (2010) it was observed that only 2-pyridyl and 4-pyridyl carbox-
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amidrazone were active. Therefore, in the present study only 2 and 4 pyridyl carboxamidrazone were
selected.
In the following sections, the analogues of the lead compounds are listed.
2.3.2 COMPOUND A (Carboxamidrazone amide)
(21); R1= 2-Pyridyl
(22); R1= 4-Pyridyl
Pyridyl
R
N
N
H
R
O
NH2
O
NH
N
NH2
OH
H
H
H H
Figure 2.12: General structures of the Compound A (carboxamidrazone amides)
The carbamidrazone amides were tested at Aston university against E.coli and S.aureaus but failed to
exhibit any activity. Further biological testing of this class of compounds against M. tuberculosis H37Rv
at TAACF, US exhibited some promising results. Five of these compounds were found to be active while
five of them were weakly active Ren (2009). Hence a library of analogues of these compounds was
synthesised to explore this class of compounds.
Compounds (21) and (22) are part of the larger ongoing project at Aston University, ‘Germination to
termination’. The concept is to attach the antimicrobial compound to the bile salt. The bile salt is known
to possess the activity to germinate spores into the fully grown microbes (Sorg & Sonenshein (2008)).
At this point the antimicrobial attached to the bile salt can act on the microbes and cause the lysis of
microbial cells.
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2.3.3 COMPOUND B (N1-[(alkyl)oxy]pyridyl carboximidamide)
R1
NH2
O
RO
N
Figure 2.13: General structure of Compound B
TheN1-[(alkyl)oxy]pyridyl carboximidamide compound is structurally similar to carboxamidrazone amide
and has the same number of atoms in the central chain except that the nitrogen atom adjacent to the
carbonyl group is replaced by oxygen. This class was synthesised to study the effect the increase in
electro-negativity has on the compound’s activity and to investigate the removal of a hydrogen bond
donor at that position.
The biological data from carboxamidrazone amide suggests that compounds having alkyloxy groups
attached to the benzene ring and the alkyl chain attached directly to the carboxyl group do not show
much activity. Hence the substrates ba to bd as listed in Table. 2.2 were omitted while synthesising this
class of compounds.
2.3.4 COMPOUND C (Bis-amide version of carboxamidrazone)
Compound C
	





	


	

amide b
Figure 2.14: General structure of Compound C
The synthesis of bis-amide carboxamidrazone was attempted to introduce a second point of variation in
the molecule to block the amide b with acetate group. The idea behind the synthesis of this compound
was that if both the amide groups could be made reactive, two anti-mycobacterial groups can potentially
be attached on single compound which can attack two resistant strains of bacteria for which at present
a combination therapy is used.
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2.4 Results and Discussion
2.4.1 COMPOUND A (Carboxamidrazone amide)
Scheme A for Compound A
This is a two step reaction sequence. The first step involves preparation of carboxamidrazone. The re-
spective cyanopyridine was reacted with hydrazine in ethanol to give carboxamidrazone (Case (1965)).
These compounds were then reacted with acid chlorides in presence of Hu¨nig’s base to give the desired
product (Khan (2008)).
Et anol
NH2NH2. H2O
Pyridyl carboxamidrazone 
amide
THF/ Acid 
Chloride/ 
Hunig's base
Room temperature
Pyridyl-carboxamidrazone
Compound A
Pyridyl
Pyridyl
PyridylN
NH2
NH2
N
R
O
Cl N
N
H
R
O
NH2
Scheme 2.1: Synthetic scheme A for Compound A
Scheme B for carboxamidrazone amide
A few analogues of carboxamidrazone amides, where the acid chlorides were unavailable, were synthe-
sised from carboxylic acids as shown in Scheme. 2.2.
Pyridyl carboxamidrazone Pyridyl carboxamidrazone amide
CDI/ THF 
Compound A
Pyridyl Pyridyl
R
O
OH
N
NH2
NH2
N
N
H
R
O
NH2
Scheme 2.2: Synthetic scheme B for Compound A
This is a three step reaction sequence. The carboxamidrazone was prepared as discussed in Scheme.
2.1. The solution of required carboxylic acid and N, N’ -carbonyldiimidazole (CDI) were stirred together
in THF which formed an intermediate. This intermediate was then treated with an appropriate solution
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of carboxamidrazone to give the desired product. The crude compound thus obtained was washed with
water and sat. sodium bicarbonate solution. In this reaction the CDI, a coupling agent, promotes the
transacylation reaction in acids.
Scheme C for carboxamidrazone amide
Another set of analogues of carboxamidrazone amides were synthesised from bile acids.
N-methylmorpholine/ 
ethylchlorocarbonate
THF
Pyridyl carboxamidrazone Lithocholic acid
Pyridyl carboxamidrazone amide
Pyridyl
Pyridyl
O
NH
N
NH2
OH
H
H
HH
OH
O
HH
H
H
OH
N
NH2
NH2
+
Scheme 2.3: Synthetic scheme C for Compound A
This was a two step reaction sequence. The carboxamidrazone was prepared as discussed in Scheme.
2.1. This amide was then reacted with the lithocholic acid and N-methylmorpholine and ethylchlorocar-
bonate, in presence of THF to give the desired product.
The analytical data, namely, mass spectrum, NMR, IR were found to be consistent with the proposed
structure. The NH bond suggests the compound formation as it joins the two starting materials. The IR
shows a broad peak in the range of 1665 − 1760 cm−1 representing the carbonyl group. Table. 2.3
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lists the analogues of the final product compound A shown in Scheme. 2.2 synthesised along with their
yields and melting points.
Pyridyl
O
RN
H
N
NH2
Compound
A
Pyridyl R group Yield
(%)
Melting point
(◦C)
(23) 2-Pyridyl 87 230.4− 232.8
(24) 4-Pyridyl 92 177.9− 179.1
(25) 2-Pyridyl 92 195.6− 197.1
(26) 4-Pyridyl 74 150.7− 151.2
(27) 2-Pyridyl 68 149.7− 150.5
(28) 4-Pyridyl 86 201.7− 202.7
(29) 2-Pyridyl 69 228.5− 229.7
(30) 4-Pyridyl 75 218.8− 220.2
(31) 2-Pyridyl 71 224.3− 225.4
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Compound
A
Pyridyl R group Yield
(%)
Melting point
(◦C)
(32) 4-Pyridyl 82 148.2− 149.3
(33) 2-Pyridyl 69 181.5− 183.1
(34) 4-Pyridyl 71 187.1− 189.7
(35) 2-Pyridyl 64 167.1− 168.2
(36) 4-Pyridyl 71 162.8− 166.7
(37) 2-Pyridyl 77 153.5− 154.6
(38) 4-Pyridyl 76 149.4− 151.3
(17) 2-Pyridyl 90 145.2− 147.5
(39) 4-Pyridyl 95 141.3− 144.1
(40) 2-Pyridyl O 69 224.3− 225.3
(41) 4-Pyridyl O 72 207.1− 208.5
(42) 2-Pyridyl O 59 120.5− 121.9
(43) 4-Pyridyl O 64 206.2− 207.1
(44) 2-Pyridyl O 63 224.7− 225.8
(45) 4-Pyridyl O 69 164.1− 165.3
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Compound
A
Pyridyl R group Yield
(%)
Melting point
(◦C)
(46) 2-Pyridyl
O
57 203.3− 204.4
(47) 4-Pyridyl
O
77 177.6− 178.8
(48) 2-Pyridyl
O
68 188.6− 189.7
(49) 4-Pyridyl
O
66 185.0− 186.2
(50) 2-Pyridyl
O
79 165.3− 166.5
(51) 4-Pyridyl
O
87 168.9− 170.1
(21) 2-Pyridyl OH 78 187.8− 189.5
(22) 4-Pyridyl OH 69 187.4− 189.6
Table 2.3: List of analogues of compound A
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2.4.2 COMPOUND B (N1-[(alkyl)oxy]pyridyl carboximidamide)
Scheme A for N1-[(alkyl)oxy]pyridyl carboximidamide
N'-[(alkyl)oxy]pyridyl carboximidamide
Compound B
Ethanol/ 
H2O/ 
NH2-OH. HCl
Aldoxime
THF/ Acid Chloride/ 
Hunig's base
Pyridyl
Pyridyl
PyridylN
OH
NH2
N
R
O
Cl N
O R
O
NH2
Scheme 2.4: Synthetic scheme A for Compound B
This was a two step reaction sequence. The first step involved preparation of an amidoxime. The
respective cyano pyridine was reacted with hydroxylamine in THF to give the respective amidoxime
Hemming (2008). These compounds were then reacted with acid chlorides in the presence of Hu¨nig’s
base to give the desired N1-[(alkyl)oxy]pyridyl carboximidamide.
Scheme B for N1-[(alkyl)oxy]pyridyl carboximidamide
Compound B
N'-[ lkyl)oxy]pyridyl carboximidamideyridyl amidoxime
CDI/ THF 
PyridylPyridyl R OH
O
N
O R
O
NH2
N
OH
NH2
Scheme 2.5: Synthetic scheme B for Compound B
This was also a three step reaction similar to the scheme B for compound A. The only difference is that
pyridine amidoxime was used instead of the carboxamidrazone. The CDI was treated with acids to form
an intermediate which upon reaction with pyridine amidoxime gave the required N1-[(alkyl)oxy]pyridyl
carboximidamide product. The crude product was washed with sodium bicarbonate solution and then
recrystallized using appropriate solvents to give pure product.
The analytical data (mass spectrum, NMR, and IR) all were found to be consistent with the proposed
structure. The IR exhibited strong absorbance in the range of 1665 − 1760 cm−1 typical of the carbonyl
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group. The Table. 2.4 lists the analogues of the compound B synthesised along with their yields and
melting points.
Pyridyl
O
RO
N
NH2
Compound
B
Pyridyl Aryl group Yield
(%)
Melting point
(◦C)
(52) 2-Pyridyl 63 180.8− 181.6
(53) 4-Pyridyl 67 166.8− 167.5
(54) 2-Pyridyl 59 155.3− 156.7
(55) 4-Pyridyl 72 134.3− 135.5
(56) 2-Pyridyl 74 148.2− 149.3
(57) 4-Pyridyl 65 154.1− 154.5
(58) 2-Pyridyl 81 146.3− 147.6
(59) 4-Pyridyl 84 152.1− 153.6
(60) 2-Pyridyl 69 153.3− 154.1
(61) 4-Pyridyl 72 120.3− 121.9
(62) 2-Pyridyl 68 164.2− 165.8
(63) 4-Pyridyl 75 133.7− 135.4
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Compound
B
Pyridyl Aryl group Yield
(%)
Melting point
(◦C)
(64) 2-Pyridyl 82 142.2− 143.4
(65) 4-Pyridyl 74 126.8− 128.3
(66) 2-Pyridyl 67 138.7− 139.2
(67) 4-Pyridyl 73 125.0− 127.2
(68) 2-Pyridyl 67 137.8− 138.5
(69) 4-Pyridyl 69 132.9− 134.1
(70) 2-Pyridyl 71 186.4− 187.8
(71) 4-Pyridyl 74 168.1− 169.4
(72) 2-Pyridyl 76 178.7− 179.6
(73) 4-Pyridyl 81 165.4− 166.3
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Compound
B
Pyridyl Aryl group Yield
(%)
Melting point
(◦C)
(74) 2-Pyridyl
OH
64 179.8− 180.9
(75) 4-Pyridyl
OH
77 176.4− 177.6
Table 2.4: List of analogues of compound B
2.4.3 COMPOUND C (Bis-amide carboxamidrazone)
At a high temperature the amine (b) (see Fig. 2.15) of the carboxamidrazone becomes reactive, as
explained in Chapter 3, where at high temperature a linear carboxamidrazone cyclises. Hence a high
temperature reaction was carried out to attack the (b) amino group with an electrophile eg. an acid
chloride. However the reaction did not work and instead cyclization of carboxamidrazone took over.
(b)
N
NH2
N
N
H
R
O
Figure 2.15: General structure of Compound C
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Scheme 2.6: Synthetic scheme for Compound C
2.4.4 Purity
The 2-pyridine carboxamidrazone starting material for the preparation of carboxamidrazone amide was
clean and did not require further purification and was used as it was. However the 4-pyridine carbox-
amidrazone (4 PY) compound was purified by recrystallizing it from ethanol. The carboxamidrazone
amide products (Compound A) obtained were found to be impure and hence recrystallization was used
to purify them.
Both the 2-pyridine amidoxime and 4- pyridine amidoxime compounds obtained from the reaction were
pure and in crystalline form. They were used in the crude form for the next reaction as no purification
was required. The crude N1-[(alkyl)oxy]pyridyl carboximidamide products (Compound B) obtained from
reaction were found to contain impurities and hence were purified using recrystallization techniques.
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2.4.5 Solubility
It was observed that the yields of 4PY compounds were better than the 2PY compound. This may be
because the solubility of 2PY in THF is higher as compared to 4PY and hence large amounts of product
was precipitated out.
No such discrepancy was observed in the amidoxime compounds. Both the compounds had similar
solubility in THF.
2.4.6 NMR Data
The proton NMR spectra of the carboxamidrazone amides were obtained from d6-DMSO and were con-
sistent with the proposed structures. The characteristic amide singlet peak from the carboxamidrazone
amide compounds was observed in the range of 10− 10.5 ppm. In many spectra an extra set of smaller
peaks were seen in the range of 10 − 10.5 ppm alongside the amide peak and in the range of 7 − 7.5
alongside the protons from the pyridine ring on the NMR spectrum. Together these small peaks ac-
counted for one proton. At a higher temperature (50◦C) the two peaks merge into a single peak. This
phenomenon occurs since the rate of interconversion of the two forms of compound are less than the
frequency of the NMR machine. At high temperature the rate is increased and an average structure is
obtained. Hence at high temperature the two singlets merge into one (see Fig.2.17). Another reason
could be the orientation of the pyridine ring.
A similar phenomenon was observed in some of the N1-[(alkyl)oxy]pyridyl carboximidamide analogues
as well.
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ab
c
d
(39)
N O
N
H
N
NH2
Figure 2.16: Structure of N1-(4-(10-Undecenoyl))-pyridine-4-carboxamidrazone
Figure 2.17: The comparison of partial NMR spectra of compound (39) shows the disappearance of the smaller peak in the nmr spectrum taken at 50◦C.
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2.4.7 Melting point data
The melting points of the compounds showed some anomaly. The anomaly was that the increase in the
molecular weight should increase the melting point due to increase in van der Waal’s attraction. However
it was observed that as the chain length increased the melting point decreased. This phenomenon could
be attributed to two factors, the surface area of the molecule and the organisation of the crystal structure
of the compound.
It is likely that the preferred conformation for the long alkyl chain is to fold up into a spherical shape as
opposed to being a linear structure as shown in the Fig. 2.18. Thus the overall surface area on the
carbon chain which was available for the van der Waals effect might be reduced which in turn could
have reduced the melting point (Morrison & Boyd (1992)).
The other factor is the energy required to break the rigid and solid structure. The compounds with
smaller alkyl chains are packed well in solid phase, forming well organised crystal structures and hence
required more energy to break thus increasing their melting points. However the compounds with larger
alkyl chains may not be not well packed and hence less energy is required to break the loosely packed
crystal structure. Thus decreasing the melting points of the compounds (Boese et al. (1999)).
Figure 2.18: The global minimum version of the linear side chain and cyclised side chain carboxamidra-
zone amide was generated using Cache program and van der Waal’s surface was calculated on the
compounds
2.4.8 Microbiological results
The entire library of Compound A analogues was sent to the Tuberculosis Antimicrobial Acquisition and
Coordinating Facility (TAACF, USA) for screening against Mycobacterium tuberculosis. The library of
Compound A and Compound B analogues was sent to the National Institute of Allergy and Infectious
Diseases (NIAID, USA) for the screening. Both the programs belong to the Southern Research Institute
(SRI, USA) and were set-up to assist the scientists to develop new anti tuberculosis drug candidates.
79
The TAACF, NIAID and SRI have started a new program called high throughput screening (HTS) the
resources can be found on their website 1. This program can screen large compound libraries by the
primary in vitro assays like MTb or against a specific target. It also supports the design and implemen-
tation of in silico systems for predicting drug characteristics like solubility, human intestine absorption,
bioavailability and potential toxicity.
This screening is designed in two stages: first stage involves a parallel MABA and BTG assay on H37Rv
strain to determine the MIC, IC50 and IC90 concentration for the compounds. The compounds which
have MIC values of 32.47 µM or less are further taken to the second stage which involves advanced
anti mycobacterial susceptibility profiling. The second stage involves assays for minimal inhibitory con-
centration (MIC), MBC, LORA, intracellular (macrophage) drug screening, and MTT cell proliferation.
Minimal inhibitory concentration (MIC)
The minimal inhibitory concentration assay is important since it determines the lowest concentration of
drug required to visibly inhibit the growth of micro-organisms.
Minimal Bactericidal Concentration (MBC)
The minimal bactericidal concentration assay helps to determine the compound’s mechanism of action
whether it is bacteriostatic or bactericidal. The bactericidal compound is preferred since it kills the
bacteria and it can potentially reduce the standard treatment regime which is a minimum of six months
for tuberculosis.
Low Oxygen Recovery Assay (LORA)
The LORA assay is an important assay since it can provide an assessment of drug activity against
non-replicating persistent M. tuberculosis.
1http://www.niaid.nih.gov/pages/default.aspx?wt.ac=tnHome
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Intracellular (macrophage) drug screening
The intracellular (macrophage) drug screening evaluates intracellular drug effectiveness. This is impor-
tant since M. tuberculosis can survive inside a macrophage for many days and hence causing treatment
failure and disease relapse. The cytotoxicity control plate assay (MTT proliferation) is performed in par-
allel with this assay where non infected macrophages are used to confirm that the concentrations used
for the assays are non toxic to the macrophages.
Compound name MIC µM IC50 µM IC90 µM
(23) 16.24 14.12 15.33
(25) 32.47 17.11 19.32
(29) 32.47 17.34 19.58
(27) 32.47 26.92 28.02
(40) 32.47 27.54 28.80
(74) 14.94 12.76 14.12
(24) >32.47 − −
(26) >32.47 − −
(28) >32.47 − −
(30) >32.47 − −
(31) >32.47 − −
(32) >32.47 − −
(33) >32.47 − −
(34) >32.47 − −
(35) >32.47 − −
(36) >32.47 − −
(37) >32.47 − −
(38) >32.47 − −
(17) >32.47 − −
(39) >32.47 − −
(41) >32.47 − −
(42) >32.47 − −
(43) >32.47 − −
(44) >32.47 − −
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Compound name MIC µM IC50 µM IC90 µM
(45) >32.47 − −
(46) >32.47 − −
(47) >32.47 − −
(48) >32.47 − −
(49) >32.47 − −
(50) >32.47 − −
(51) >32.47 − −
(52) >32.47 − −
(53) >32.47 − −
(54) >32.47 − −
(55) >32.47 − −
(56) >32.47 − −
(57) >32.47 − −
(58) >32.47 − −
(59) >32.47 − −
(60) >32.47 − −
(61) >32.47 − −
(62) >32.47 − −
(63) >32.47 − −
(64) >32.47 − −
(65) >32.47 − −
(66) >32.47 − −
(67) >32.47 − −
(68) >32.47 − −
(69) >32.47 − −
(70) >32.47 − −
(71) >32.47 − −
(72) >32.47 − −
(73) >32.47 − −
(75) >32.47 − −
Table 2.5: The MIC values and IC50 and IC90 values of the most active compounds
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The compound (74) was found to be the most active compound of the series and hence it was taken to
the second step of screening. The Table. 2.6 presents the data for MIC and MBC values and Table. 2.7
presents data for the macrophage assay.
Compound
name
MIC
H37Rv
µM
%
Inhi-
bitiona
MBC
H37Rv
µM
MIC
INH-
Rb
µM
%
Inhi-
bition
MIC
RMP-
Rc
µM
%
Inhi-
bition
MIC
OFX-
Rd
µM
%
Inhi-
bition
(74) 20.29 69 162.35 5.07 60 20.29 83 20.29 68
Rifampin
(pos con-
trol)
0.16 68 1.27 0.16 64 NAd NA 0.63 66
Isoniazid
(pos con-
trol)
NA NA NA NA NA 0.07 74 NA NA
aPercent inhibition at the MIC concentration
bINH-R = Isoniazid Resistance
cRMP-R = Rifampin Resistance
dNA = Not Applicable: Compound not used in assay.
Table 2.6: The MIC values and IC50 and IC90 values of the most active compound
Compound
name
LORA
(µM)
Macrophage
log reduc-
tion (low
conc.)
Macrophage
log reduc-
tion (mid
conc.)
Macrophage
log reduc-
tion (high
conc.)
MTT%
via-
bility
(low
conc.)
MTT%
via-
bility
(mid
conc.)
MTT%
via-
bility
(high
conc.)
(74) 40.59 0.40 0.44 1.30 1 5 1
Rifampin
(pos con-
trol)
2.54 1.09 1.27 2.11 >100 >100 >100
Table 2.7: The Macrophage assays values and MTT values of the most active compound
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2.4.9 Structure activity relationship
The 2-pyridyl compounds are the more active as compared to the 4-pyridyl compounds. The biological
data obtained from the carboxamidrazone compound shows that the compounds containing 2-hydroxy-
3, 5-di-tert. butylphenyl substituents have maximum activity (Sikdar (2010)). The carboxamidrazone
amides attached to the benzoyl moiety containing an alkyl side chain of 5 to 7 carbons were also found
to be active. This increase in the activity could be related to the increase in the logP value, resulting
in increased lipophilicity of the molecule and hence an improved permeability of the bacterial cell wall,
thus increasing the activity of the molecule.
2.5 Summary and Conclusion
2.5.1 Summary
The Table.2.8 and 2.9 summarises the compounds synthesised in the present study and in the previous
work at Aston University. The compound class synthesised in Table. 2.8 shows a bell shaped activity
curve. The LogP values were calculated using the Accelrys program, which uses ACD/Lab database2.
In the carboxamidrazone amides, those compounds which has a chain length of 5 or 6 carbons attached
to the benzoyl moiety have maximum activity. As the number of carbons in the side chains increases
or decreases the activity is further diminished. The microbiological results are reported only for the
compounds having MIC values of ≤ 32.47 µM. Some of the compounds synthesised earlier by Ren
(2009) were tested by TAACF, USA which did not test the compounds for MIC values. Hence in the
summary table (2.8) the absent values are denoted as hyphen.
2http://accelrys.com/
84
Compound
number
Compound name Pyridyl
group
Aryl group MIC
(µM)
IC50
(µM)
IC90
(µM)
Log P Melting
point (◦C)
Yield
(%)
Reference
(23) N1-(4-Butylbenzoyl)-
pyridine-2-
carboxamidrazone
2-
Pyridyl
16.24 14.12 15.33 3.327 230.4-232.8 87
(14) N1-(4-Pentylbenzoyl)-
pyridine-2-
carboxamidrazone
2-
Pyridyl
- 2.88 4.50 3.723 234.1-235.9 45 Ren (2009)
(13) N1-(4-Hexylbenzoyl)-
pyridine-2-
carboxamidrazone
2-
Pyridyl
- 3.23 4.32 4.119 218.7-220.6 46 Ren (2009)
(15) N1-(4-Heptylbenzoyl)-
pyridine-2-
carboxamidrazone
2-
Pyridyl
- 4.58 4.96 4.516 215.3-216.1 30 Ren (2009)
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Compound
number
Compound name Pyridyl
group
Aryl group MIC
(µM)
IC50
(µM)
IC90
(µM)
Log P Melting
point (◦C)
Yield
(%)
Reference
(25) N1-(4-Octylbenzoyl)-
pyridine-2-
carboxamidrazone
2-
Pyridyl
32.47 17.11 19.32 4.912 195.6-197.1 92
(16) N1-(4-Decylbenzoyl)-
pyridine-2-
carboxamidrazone
2-
Pyridyl
- 17.75 19.44 5.705 201.2-203.2 32 Ren (2009)
(29) N1-(4-Phenylbenzoyl)-
pyridine-2-
carboxamidrazone
2-
Pyridyl
32.47 17.34 19.58 3.355 218.8-220.2 75
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Compound
number
Compound name Pyridyl
group
Aryl group MIC
(µM)
IC50
(µM)
IC90
(µM)
Log P Melting
point (◦C)
Yield
(%)
Reference
(27) N1-(1,2,3,4-
tetrahydronaphthalene)-
pyridine-2-
carboxamidrazone
2-
Pyridyl
32.47 26.92 28.02 2.894 149.7-150.5 68
(31) N1-(2-Phenylbenzoyl)-
pyridine-2-
carboxamidrazone
2-
Pyridyl
>32.47 - - 3.355 224.3 -
225.4
71
(24) N1-(4-Butylbenzoyl)-
pyridine-4-
carboxamidrazone
4-
Pyridyl
>32.47 - - 2.928 177.9 -
179.1
92
(76) N1-(4-Pentylbenzoyl)-
pyridine-4-
carboxamidrazone
4-
Pyridyl
- 57.51 80.82 3.324 201.2-201.8 38 Ren (2009)
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Compound
number
Compound name Pyridyl
group
Aryl group MIC
(µM)
IC50
(µM)
IC90
(µM)
Log P Melting
point (◦C)
Yield
(%)
Reference
(77) N1-(4-Hexylbenzoyl)-
pyridine-4-
carboxamidrazone
4-
Pyridyl
- 38.87 44.88 4.117 187.7-191.0 27 Ren (2009)
(78) N1-(4-Heptylbenzoyl)-
pyridine-4-
carboxamidrazone
4-
Pyridyl
- 24.53 38.01 3.720 182.2-182.8 23 Ren (2009)
(26) N1-(4-Octylbenzoyl)-
pyridine-4-
carboxamidrazone
4-
Pyridyl
>32.47 - - 4.513 150.7-151.2 74
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Compound
number
Compound name Pyridyl
group
Aryl group MIC
(µM)
IC50
(µM)
IC90
(µM)
Log P Melting
point (◦C)
Yield
(%)
Reference
(79) N1-(4-Decylbenzoyl)-
pyridine-4-
carboxamidrazone
4-
Pyridyl
- - - 5.705 191.5-193.9 57
(30) N1-(4-Phenylbenzoyl)-
pyridine-4-
carboxamidrazone
4-
Pyridyl
>32.47 - - 2.956 218.8-220.2 75
(28) N1-(1,2,3,4-
tetrahydronaphthalene)-
pyridine-4-
carboxamidrazone
4-
Pyridyl
>32.47 - - 2.495 20.7-202.7 86
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Compound
number
Compound name Pyridyl
group
Aryl group MIC
(µM)
IC50
(µM)
IC90
(µM)
Log P Melting
point (◦C)
Yield
(%)
Reference
(32) N1-(2-Phenylbenzoyl)-
pyridine-4-
carboxamidrazone
4-
Pyridyl
>32.47 - - 2.956 148.2-149.3 82
Table 2.8: List of the carboxamidrazone amide compounds synthesised at Aston laboratory along with their biological activity.
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This class of compound was found to be generally weakly active to inactive. The previous work by Ren
(2009) in this class suggested that carboxamidrazone amides attached with an alkyl chain containing
more than 10 carbon atoms demonstrated some activity. Hence to investigate this argument a matrix
was created where the carboxamidrazone amides were synthesised varying an alkyl chain moiety. The
alkyl chains varying between 5 to 15 carbon chain lengths were synthesised. The Table. 2.9 confirms
the findings of Ren (2009), that only the carboxamidrazone amides attached to the alkyl chain of 11
carbon atoms, has maximum activity.
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Compound
number
Compound name Pyridyl
group
Aryl group MIC
(µM)
IC50
(µM)
IC90
(µM)
Log P Melting
point (◦C)
Yield
(%)
Reference
(33) N1-(4-Pentenoyl)-pyridine-
2-carboxamidrazone
2-
Pyridyl
>32.47 - - 0.963 191.5-193.9 9 Ren (2009)
(35) N1-(4-Octenoyl)-pyridine-2-
carboxamidrazone
2-
Pyridyl
>32.47 - - 2.367 167.1-168.2 64
(37) N1-(4-Nonanoyl)-pyridine-
2-carboxamidrazone
2-
Pyridyl
>32.47 - - 2.764 153.5-154.6 77
(17) N1-(4-(10-
Undecenoyl))-pyridine-
2-carboxamidrazone
2-
Pyridyl
- 14.37 23.97 3.341 120.9-124.8 9 Ren (2009)
(80) N1-(4-Myristoyl)-pyridine-2-
carboxamidrazone
2-
Pyridyl
- - - 4.745 123.0-125.3 33 Ren (2009)
(81) N1-(4-Palmitoyl)-pyridine-
2-carboxamidrazone
2-
Pyridyl
- - - 5.538 75.9-80.4 40 Ren (2009)
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Compound
number
Compound name Pyridyl
group
Aryl group MIC
(µM)
IC50
(µM)
IC90
(µM)
Log P Melting
point (◦C)
Yield
(%)
Reference
(82) N1-(4-Stearoyl)-pyridine-2-
carboxamidrazone
2-
Pyridyl
- 137.81 151.80 5.538 118.6-121.4 23 Ren (2009)
(34) N1-(4-Pentenoyl)-pyridine-
4-carboxamidrazone
4-
Pyridyl
>32.47 - - 0.564 187.1-189.7 71
(36) N1-(4-Octenoyl)-pyridine-4-
carboxamidrazone
4-
Pyridyl
>32.47 - - 1.968 162.8-166.7 71
(38) N1-(4-Nonanoyl)-pyridine-
4-carboxamidrazone
4-
Pyridyl
>32.47 - - 2.365 149.4-151.3 76
(39) N1-(4-(10-
Undecenoyl))-pyridine-
4-carboxamidrazone
4-
Pyridyl
- 81.95 91.80 2.942 113.0-114.2 4.3 Ren (2009)
(83) N1-(4-Myristoyl)-pyridine-4-
carboxamidrazone
4-
Pyridyl
- - - 4.346 116.8-117.5 40 Ren (2009)
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Compound
number
Compound name Pyridyl
group
Aryl group MIC
(µM)
IC50
(µM)
IC90
(µM)
Log P Melting
point (◦C)
Yield
(%)
Reference
(84) N1-(Lauroyl)-pyridine-4-
carboxamidrazone
4-
Pyridyl
- - - 3.554 121.2-124.4 31 Ren (2009)
Table 2.9: List of the carboxamidrazone amide compounds synthesised at Aston laboratory along with their biological activity.
94
2.5.2 Conclusion
Some of the analogues of compound A and B show weak activity, but no significant activity. This class
of compound has undergone many modifications to yield a compound with high activity and low toxicity.
Further modification can be done to the compound at the benzoyl end and at the centre of the structure.
Chapter. 3 discusses in detail about cyclisation of carboxamidrazone. The introduction of heterocyclic
scaffolds in the centre of the carboxamidrazone causes reduction in the overall entropy penalty for the
binding of the molecule into an active site and thus might increase the binding affinity of the compound.
Another modification involves fluorination of the carboxamidrazone amides as discussed in chapter 4.
The most active carboxamidrazone amides were selected and a fluorine atom was introduced in the
pyridine ring to investigate the potential change to the compound’s metabolism in the organism and/or
host.
The synthesis of the analogues of compound C was not possible due to the low reactivity of amine (b).
However in future if a low temperature reaction can cause increase in reactivity of the amine (b), the
synthesis of compound C can be possible.
Some more carboxamidrazone like imines which are known to posses activity can be reacted with the
lithocholic acid and be tested in future for its activity.
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2.6 EXPERIMENTAL
2.6.1 Chemicals
All the chemicals and solvents were used as supplied. 2-pyridine cyanide, 4 pyridine cyanide, N, N1-
carbonyl di-imidazole, hydrazine, hydroxylamine, Hu¨nig’s base, DMSO, and all the acids and acid chlo-
rides were purchased from Sigma Aldrich. The organic solvents used were purchased from Fisher
Chemicals. An aluminium silica gel 60 F254 plates (Merck) were used for thin layer chromatography
(TLC).
2.6.2 Instrumentation
Proton NMR spectra were obtained on a Bruker AC 250 instrument operation at 250 MHz as solutions
in d6-DMSO or CDCl3 and referenced from δDMSO = 2.50 ppm or δCDCl3 = 7.27 ppm unless otherwise
stated. Infrared spectra were recorded as KBr discs on a Mattson 3000 FTIR spectrophotometer and
neat on Nicolet iS5 RT−IR instrument + ID5 ATR Diamond Sampler holder accessory. (APCI-MS) was
carried out on a Hewlett-Packard 5989B quadruple instrument connected to an electrospray 59987A
unit with an APCI accessory and automatic injecting using a Hewlett-Packard 1100 series autosampler.
Accurate MS was carried out on TOF mass spectra (ESI mode) measured on a Waters LCT Premier
Mass Spectrometer. Some of the compounds were sent to EPSRC Mass Spectrometry Service Cen-
tre at Swansea, the compounds were tested on either of the following machines Thermofisher LTQ
Orbitrap XL, Finnigan MAT 95 XP, Applied Biosystems Voyager DE-STR, Waters Micromass ZQ4000,
Thermofisher DSQ-II, Agilent 5975 GCMS. Melting points were recorded on a Reichert-Jung Thermo
Galen hot stage microscope and were corrected.
96
2.6.3 Preparation of pyridine-2-carboxamidrazone (85)
1
2
a
b
c
d
(85)
NH2
N
NH2N
Figure 2.19: Pyridine-2-carboxamidrazone
2-cyano pyridine (29.99 g, 288.4 mmol) was dissolved in ethanol (90 mL) and to it hydrazine monohy-
drate (60 mL) was added. This reaction mixture was stirred at room temperature for 2 days. The product
was collected by removing excess hydrazine under vacuum. The product was collected by filtration. The
crude product was then washed 3X with petrol ether 40 − 60◦C to give a yellow crystalline compound.
Yield 35.1 g, 89.5%.
Rf value [EtOAc:MeOH (2:1)]: 0.10 (Khan (2008)).
1H NMR (250 MHz, d6-DMSO): 8.48 (m,1H, a), 7.91 (m,1H, d), 7.74 (td, 1H, J= 6.92, 1.8 Hz, b), 7.31
(td,1H, J=4.9, 1.2 Hz, c), 5.24 (bs, 2H, NH2(2)), 5.71 (bs,2H, NH2(1)) ppm.
2.6.4 Preparation of pyridine-4-carboxamidrazone (86)
1
2
a
b
c
d
(86)
NH2
N
NH2
N
Figure 2.20: Pyridine-4-carboxamidrazone
The procedure for the preparation of pyridine-4-carboxamidrazone is same as for pyridine-2-carboxamidrazone.
The time required for completion of the reaction is 14 days. The crude product obtained was purified by
recrystallization from ethanol.
Yield was 33.5 g, 75%.
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Rf value [EtOAc:MeOH (2:1)]: 0.18 (Khan (2008)).
1H NMR (250 MHz, d6-DMSO): 8.51 (d, 2H, J=6.3 Hz, b and d), 7.63 (d, 2H, J=6.3 Hz, a and c), 5.71
(bs,2H, NH2(2)), 5.33 (bs, 2H, NH2(1)) ppm.
2.6.5 Preparation of pyridine-2-amidoxime (87)
a
b
c
d
(87
 

 
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Figure 2.21: Pyridine-2-amidoxime
Hydroxyl ammonium chloride (2.1g, 30 mmol) was dissolved in water (10 mL) and anhydrous sodium
carbonate (1.6g, 15 mmol) was added to this solution and heated up to 60◦C. At this stage 2-cyano
pyridine (3g, 29 mmol) was added to the reaction mixture, followed by ethanol (approx. 6 mL) to dissolve
the cyano pyridine. The temperature of the reaction mixture was raised and maintained at 85◦C for 2
hours. The reaction mixture flask was then cooled to 0◦C and some ice cold water was added to the
reaction mixture. The resulting crude material was collected by filtration to give a white solid.
Yield was 3.1 g ,91%.
Rf value [EtOAc:MeOH (2:1)]: 0.13.
1H NMR (250 MHz, d6-DMSO): 9.89 (s, 1H, OH), 8.56 (ddd, 1H, J = 4.9, 1.7, 1.1 Hz, -a), 8.27 − 7.72
(m, 2H, -b and d), 7.53 − 7.33 (m, 1H, -c), 5.83 (s, 2H, NH2) ppm.
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2.6.6 Preparation of pyridine-4-amidoxime (88)
a
b
c
d
(88
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Figure 2.22: Pyridine-4-amidoxime
Hydroxyl ammonium chloride (2.1g, 30 mmol) was dissolved in water (10 mL) and anhydrous sodium
carbonate (1.6g, 15 mmol) was added to this solution and heated up to 60◦C. At this stage 4-cyano
pyridine (3g, 29 mmol) was added to the reaction mixture, this is an exothermic reaction and the temper-
ature rises to 75◦C and a colourless mass is precipitated out. This reaction mixture is further heated up
to 80◦C and maintained for 0.5 hours. This reaction flask was then cooled on an ice bath for 15 mins.
To this reaction mixture 15 mL of ice cold water was added and a white solid precipitated out which was
collected by filtration. The crude product was washed with ice cold water (3x30 mL). The crude product
obtained was recrystallised from ethanol to obtain transparent needle like crystals.
Yield was 2.5 g ,84%.
Rf value [EtOAc:MeOH (2:1)]: 0.15.
1H NMR (250 MHz, d6-DMSO): 10.03 (s, 1H, OH), 8.57 (dd, J = 4.6, 1.6 Hz, 2H, a and d), 7.63 (dd, J
= 4.6, 1.6 Hz, 2H, b and c), 5.99 (s, 2H, NH2) ppm.
2.6.7 General procedure for carboxamidrazone synthesis from acid chlorides
Heteroaryl carboxamidrazone (1.0 g, 7.35 mmol) was suspended in anhydrous THF (20 mL). To this
solution Hu¨nig’s base (2 mL) was added, followed by acid chloride (1.1 eq). This reaction mixture was
stirred overnight under argon at room temperature. This reaction mixture was added to sat. sodium
bicarbonate solution and the product was collected by filtration. The crude product was further purified
by recrystallization using appropriate solvent systems (Ethyl acetate: Petroleum ether (40-60◦C)).
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2.6.8 General procedure for synthesis of carboxamidrazone from acids
N,N‘-carbonyl-di-imidazole (1.622 g, 10 mmol) and acid (12 mmol, 1 eq) was dissolved in THF (20 mL).
To this reaction mixture appropriate heteroaryl carboxamidrazone (1g, 7.35 mmol) was added and this
reaction mixture was stirred under argon at room temperature overnight. This reaction mixture was
added to sodium bicarbonate solution and the product was collected by filtration. The crude product
was further purified by recrystallization using appropriate solvent systems (Ethyl acetate: Petroleum
ether (40-60◦C)).
N1-(4-Butylbenzoyl)-pyridine-2-carboxamidrazone (23)
a
b
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1H NMR (250 MHz, d6-DMSO): 10.11 (s, 1H, -NH), 8.61 (d, 2H, J = 4.4 Hz, -b and d), 8.18 (d, 1H, J
= 8.1 Hz, - a), 7.99 − 7.74 (overlapping m, 2H, -e and h), 7.50 (m, 1H, -c), 7.31 (d, 2H, J = 8.1 Hz, -f
and g), 6.91 (s, 2H, -NH2), 1.45 (t, 2H, J = 7.5 Hz, -CH2CH2CH2CH3), 1.33 (dq, 4H, J = 14.3, 7.2 Hz,
-CH2CH2CH2CH3), 0.91 (t, 3H, J = 7.3 Hz, -CH2CH2CH2CH3) ppm.
IR (KBr disc) ν: 3341 (N-H), 3340 (N-H), 3303 (N-H), 3120, 3054 (Aromatic C-H), 3022 (Aromatic C-H),
2958 (Alkyl C-H), 2935 (Alkyl C-H), 2849 (Alkyl C-H), 1911, 1665 (C=O), 1634, 1534, 1470, 1443, 1401,
1288 (C-N) cm−1.
Melting point: 230.4 − 232.8 ◦C.
Mass spectrum (APCI+) m/z:Found 296.1625 (M+H)+; calculated for C17H20N4O 296.1637; 4.1 ppm.
Yield: 1.90 g, 87%.
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N1-(4-Butylbenzoyl)-pyridine-4-carboxamidrazone (24)
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1H NMR (250 MHz, d6-DMSO): 10.05 (s, 1H, -NH), 8.65 (d, 2H, J = 5.4 Hz, -b and c), 7.79 (d, 4H, J =
7.9 Hz, -h, a, d and e), 7.30 (d, 2H, J = 8.1 Hz, -f and g), 6.88 (s, 2H, -NH2), 2.65 (t, 2H, J = 7.5 Hz,
-CH2CH2CH2CH3), 1.57 (dd, 2H, J = 15.3, 7.9 Hz, -CH2CH2CH2CH3), 1.32 (dd, 2H, J = 14.8, 7.2 Hz,
-CH2CH2CH2CH3), 0.91 (t, 3H, J = 7.3 Hz, -CH2CH2CH2CH3) ppm.
IR (KBr disc) ν: 3398 (N-H), 3367 (N-H), 3302 (N-H), 3150, 3025 (Aromatic C-H), 2946 (Alkyl C-H),
2919 (Alkyl C-H), 2850 (Alkyl C-H), 1696 (C=O), 1587, 1532, 1494, 1400, 1296 (C-N), 1158 cm−1.
Melting point: 177.9 − 179.1 ◦C.
Mass spectrum (APCI +) m/z: Found 296.1632 (M+H)+; calculated for C17H20N4O 296.1637; 1.6
ppm.
Yield: 2 g, 92%.
N1-(4-Octylbenzoyl)-pyridine-2-carboxamidrazone (25)
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1H NMR (250 MHz, d6-DMSO): 10.11 (s, 1H, -NH), 8.60 (d, 2H, J = 4.4 Hz, b and d), 8.17 (d, 1H, J =
7.7 Hz, - a), 7.80 (d, 3H, J = 8.1 Hz, c, e and h), 7.30 (d, 2H, J = 8.1 Hz, f and g), 6.89 (s, 2H, -NH2),
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2.64 (t, 2H, J = 7.6 Hz, -CH2 (CH2 )6 CH3), 1.59 (s, 2H, -CH2 CH2 (CH2 )5 CH3), 1.27 (overlapping m,
10H, J = 8.9 Hz, -CH2 CH2 (CH2 )5 CH3), 0.86 (t, 3H, J = 6.5 Hz, -CH2 (CH2 )6 CH3) ppm.
IR (KBr disc) ν: 3413 (N-H), 3344 (N-H), 3307 (N-H), 3211, 3022 (Aromatic C-H), 2948 (Alkyl C-H),
2917 (Alkyl C-H), 2843 (Alkyl C-H) , 2357, 2334, 1636 (C=O), 1590, 1539, 1475, 1443, 1337 (C-N),
1149 cm−1.
Melting point: 195.6 − 197.1 ◦C.
Mass spectrum (APCI +) m/z: Found 352.2258 (M+H)+; calculated for C21H28N4O 352.2263; 1.4
ppm.
Yield: 2.38 g, 92%.
N1-(4-Octylbenzoyl)-pyridine-4-carboxamidrazone (26)
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1H NMR (250 MHz, d6-DMSO): 10.04 (s, 1H, -NH), 8.65 (d, 2H, J = 5.7 Hz, -b and c), 7.79 (d, 2H, J
= 8.0 Hz, -e and h), 7.29 (d, 4H, J = 8.1 Hz, -a, d, f and g), 6.87 (s, 2H, -NH2), 2.63 (t, 2H, J = 7.5
Hz, -CH2(CH2)6CH3), 1.59 (s, 2H, -CH2CH2(CH2)5CH3), 1.59 (s, 2H, -CH2CH2CH2(CH2)4CH3), 1.27
(d, 8H, J = 8.7 Hz, -CH2CH2CH2(CH2)4CH3), 0.85 (t, 3H, J = 6.5 Hz, -CH2(CH2)6CH3) ppm.
IR (KBr disc) ν: 3356 (N-H), 3320 (N-H), 3252 (N-H), 3207, 3026 (Aromatic C-H), 2957 (Alkyl C-H),
2915 (Alkyl C-H), 2845 (Alkyl C-H), 1672 (C-C in ring), 1634 (C=O), 1583, 1528, 1500, 1463, 1416,
1291 (C-N), 1189 cm−1.
Melting point: 150.7 − 151.2 ◦C.
Mass spectrum (APCI +) m/z: Found 352.2257 (M+H)+; calculated for C21H28N4O 352.2263; 1.7
ppm.
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Yield: 1.92 g, 74%.
N1-(1,2,3,4-Tetrahydronaphthalene)-pyridine-2-carboxamidrazone (27)
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1H NMR (250 MHz, d6-DMSO): 10.05 (s, 1H, -NH), 8.60 (d, 1H, J = 4.0 Hz, -a), 8.17 (d, 1H, J = 7.9 Hz,
-c), 7.90 (d, 2H, J = 6.8 Hz, -b and d), 7.46 (m, 1H, -k), 7.15 (d, 2H, J = 8.4 Hz, -e and f), 6.91 (s, 2H,
-NH2), 2.78 (d, 6H, J = 4.0 Hz, -g, h and i), 1.76 (s, 2H, -j) ppm.
IR (KBr disc) ν: 3457 (N-H), 3349 (N-H), 3278, 3142, 3014 (Aromatic C-H), 2981, 1666, 1635 (C=O),
1572, 1519, 1475, 1386, 1279 (C-N), 1202, 1114 cm−1.
Melting point: 149.7 − 150.5 ◦C.
Mass spectrum (APCI +) m/z: Found 294.1477 (M+H)+; calculated for C17H18N4O 294.1480; 1.0
ppm.
Yield: 1.47 g, 68%.
N1-(1,2,3,4-Tetrahydronaphthalene)-pyridine-4-carboxamidrazone (28)
a
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1H NMR (250 MHz, d6-DMSO): 10.05 (s, 1H, -NH), 8.60 (d, 1H, J = 4.0 Hz, -b), 8.17 (d, 1H, J = 7.9 Hz,
-c), 7.90 (t, 1H, J = 6.8 Hz, -a), 7.59 (s, 2H, -d), 7.46 (m, 1H, -k), 7.15 (d, 1H, J = 8.4 Hz, -e and f), 6.91
(s, 2H, -NH2), 2.78 (d, 6H, J = 4.0 Hz, -g, h, and i), 1.76 (s, 2H, -j) ppm.
IR (KBr disc) ν: 3467 (N-H), 3357 (N-H), 3204, 3012 (Aromatic C-H), 2931, 2852, 1637 (C=O), 1594,
1545, 1498, 1465, 1407, 1305, 1294, 1265 (C-N), 1191, 1147, 1033 cm−1.
Melting point: 201.7 − 202.7 ◦C.
Mass spectrum (APCI +) m/z: Found 294.1473 (M+H)+; calculated for C17H18N4O 294.1480; 2.3
ppm.
Yield: 1.86 g, 86%.
N1-(4-Phenylbenzoyl)-pyridine-2-carboxamidrazone (29)
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1H NMR (250 MHz, d6-DMSO): 10.23 (s, 1H, -NH), 8.61 (d, 1H, J = 4.6 Hz, -a), 8.20 (d, 1H, J = 8.0 Hz,
-c), 8.16 − 7.68 (overlapping m, 7H, -e, h, f, g, i, k, m), 7.46 (overlapping m, 4H, -b, j, l and d), 6.97 (s,
2H, -NH2) ppm.
IR (KBr disc) ν: 3386 (N-H), 3300 (N-H), 3186 (N-H), 3054 (Aromatic C-H), 3022 (Aromatic C-H), 1798
(C-C in Aromatic ring), 1752 (C=O), 1634, 1579 (C-C in aromatic ring), 1529, 1461, 1397, 1384, 1293
(C-N), 1156 cm−1.
Melting point: 218.8 − 220.2 ◦C.
Mass spectrum (APCI +) m/z: Found 316.1320 (M+H)+; calculated for C19H16N4O 316.1324; 1.2
ppm.
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Yield: 1.74 g, 75%.
N1-(4-Phenylbenzoyl)-pyridine-4-carboxamidrazone (30)
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1H NMR (250 MHz, d6-DMSO): 10.18 (s, 1H, -NH), 8.66 (d, 2H, J = 5.7 Hz, -b and c), 7.99 (d, 2H, J =
8.3 Hz, -f and g), 7.77 (dd, 6H, J = 10.9, 7.7 Hz, -i, m, e, h, a and d), 7.46 (dt, 3H, J = 23.4, 7.1 Hz, -j,
k, and l), 6.94 (s, 2H, -NH2) ppm.
IR (KBr disc) ν: 3449 (N-H), 3367 (N-H), 3312 (N-H), 3179, 3151, 3055 (Aromatic C-H), 3018, 1686,
1645 (C=O), 1590, 1530, 1480, 1397, 1287 (C-N), 1222, 1154 cm−1.
Melting point: 228.5 − 229.7 ◦C.
Mass spectrum (APCI +) m/z: Found 316.1320 (M+H)+; calculated for C19H16N4O 316.1324; 1.5
ppm.
Yield: 1.6 g, 69%.
N1-(2-Phenylbenzoyl)-pyridine-2-carboxamidrazone (31)
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1H NMR (250 MHz, d6-DMSO): 10.13 (s, 1H, -NH), 8.52 (dd, 6H, J = 20.2, 4.8 Hz, -a, c, and g), 8.08
(d, 4H, J = 8.0 Hz, - h, and e), 7.88 (dd, 4H, J = 7.5, 1.7 Hz, -f, and d), 7.85 − 7.14 (overlapping m, 4H,
-m, and i), 6.61 (s, 8H, -l, k, and j), 6.48 (s, 2H, -b), 6.94 (s, 2H, -NH2) ppm.
IR (KBr disc) ν: 3426 (N-H), 3312 (N-H), 3271 (N-H), 3197, 3045 (Aromatic C-H), 3013, 2931, 2848,
1636 (C=O), 1581, 1539, 1461, 1434, 1397, 1300 (C-N), 1241, 1158, 1039 cm−1.
Melting point: 224.3 − 225.4 ◦C.
Mass spectrum (APCI +) m/z: Found 316.1314 (M+H)+; calculated for C19H16N4O 316.1324; 3.1
ppm.
Yield: 1.58 g, 71%.
N1-(2-Phenylbenzoyl)-pyridine-4-carboxamidrazone (32)
a
b
c
d
e
(32)
f
g
h
i
j
k
l
m
N O
N
H
N
NH2
1H NMR (250 MHz, d6-DMSO): 10.29 (s, 1H, -NH), 9.99 (s, 2H, -b and c), 8.64 (d, 2H, J = 5.7 Hz, -g
and h), 7.80 (s, 1H, -e), 7.62 (d, 3H, J = 9.5 Hz,-a, d and f), 7.34 − 7.09 (overlapping m, 2H, -i and m),
6.86 (s, 2H, -l and j), 6.61 (s, 1H, -k), 6.94 (s, 2H, -NH2) ppm.
IR (KBr disc) ν: 3401 (N-H), 3374 (N-H), 3301 (N-H), 3275, 3156, 3036 (Aromatic C-H), 2921, 2692,
2600, 2352, 2122, 1939, 1819, 1773, 1677, 1645 (C=O), 1590, 1539, 1438, 1309, 1254 (C-N), 1154,
1062 cm−1.
Melting point: 148.2 − 149.3 ◦C.
Mass spectrum (APCI +) m/z: Found 316.1315 (M+H)+; calculated for C19H16N4O 316.1324; 2.8
ppm.
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Yield: 1.83 g, 82%.
N1-(4-Pentenoyl)-pyridine-2-carboxamidrazone (33)
a
b
c
d
(33o
pq
r
s
p
q
p
p
1H NMR (250 MHz, d6-DMSO): 9.89 (s, 1H, -NH), 9.77 (s, 1H, -a), 8.56 (s, 1H, -c), 8.15 (m, 1H, -d),
7.86 (d, 1H, J = 7.6 Hz, -b), 6.60 (s, 2H, -NH2), 5.86 (dd, 1H, J = 16.7, 6.5 Hz, -CH2CH2CH=CH2), 5.06
− 4.92 (overlapping m, 2H, -CH2CH2CH=CH2), 3.32 (t, 2H, J = 7.5 Hz, -CH2CH2CH=CH2), 2.72 (q, 2H,
J = 7.5 Hz, -CH2CH2CH=CH2) ppm.
IR (KBr disc) ν: 3409 (N-H), 3340 (N-H), 3277 (N-H), 3227, 3049 (Aromatic C-H), 2995 (Alkyl C-H),
2921 (Alkyl C-H), 2890 (Alkyl C-H), 1652 (C=O) and (C=C), 1607, 1579, 1547, 1475, 1447, 1419, 1338,
1256 (C-N), 1170 cm−1.
Melting point: 181.5 − 183.1 ◦C.
Mass spectrum (APCI +) m/z: Found 218.1164 (M+H)+; calculated for C11H14N4O 218.1167; 1.3
ppm.
Yield: 1.11 g, 69%.
N1-(4-Pentenoyl)-pyridine-4-carboxamidrazone (34)
a
b
c
d
(34)
N O
N
H
N
NH2
107
1H NMR (250 MHz, d6-DMSO): 9.85 (s, 1H, -NH), 9.72 (d, 2H, J = 6.9 Hz, -b and c), 8.62 (t, 1H, J = 4.9
Hz, -a), 7.72 (d, 1H, J = 4.9 Hz, -d), 6.83 (s, 1H, -CH2CH2CH=CH2), 6.60 (s, 2H, -NH2), 6.02 − 5.70
(overlapping m, 2H, J = 6.6 Hz, -CH2CH2CH=CH2), 2.70 (t, 2H, J = 7.5 Hz, -CH2CH2CH=CH2), 2.28 (t,
2H, J = 14.3 Hz, -CH2CH2CH=CH2) ppm.
IR (KBr disc) ν: 3422 (N-H), 3381 (N-H), 3206 (N-H), 3068 (Aromatic C-H), 2921 (Alkyl C-H), 2848
(Alkyl C-H), 2471, 2366, 1709, 1645 (C=C) and (C=O), 1594, 1544, 1484, 1438, 1406, 1378, 1310,
1227 (C-N), 1158,1140 cm−1.
Melting point: 187.1 − 189.7 ◦C.
Mass spectrum (APCI +) m/z: Found 218.1162 (M+H)+; calculated for C11H14N4O 218.1167; 2.2
ppm. Yield: 1.14 g, 71%.
N1-(4-Octenoyl)-pyridine-2-carboxamidrazone (35)
a
b
c
d
(35)
NH2
O
N
H
N
N
1H NMR (250 MHz, d6-DMSO): 9.83 (s, 1H, -NH), 8.57 (s, 1H, -a), 8.06 (t, 1H, J = 7.3 Hz, -c), 7.87 (dd,
1H, J = 10.5, 4.9 Hz, -d), 7.45 (dt, 1H, J = 7.3, 3.6 Hz, -b), 6.61 (d, 2H, J = 7.2 Hz, -NH2), 2.61 (t, 2H, J
= 7.4 Hz, -CH2(CH2)5CH3), 2.16 (t, 2H, J = 18.8, 11.3 Hz, -CH2CH2(CH2)4CH3), 1.58 (t, 6H, J = 6.7 Hz,
-CH2CH2(CH2)3CH2CH3), 1.28 (d, 2H, -CH2(CH2)4CH2CH3), 0.86 (t, 3H, J = 4.9 Hz, -CH2(CH2)5CH3)
ppm.
IR (KBr disc) ν: 3399 (N-H), 3345 (N-H), 3284 (N-H), 3206, 3045 (Aromatic C-H), 2940 (Alkyl C-H),
2931 (Alkyl C-H), 2843 (Alkyl C-H), 1645 (C=O), 1604, 1581, 1553, 1480, 1447, 1392, 1323, 1282,
1227 (C-N), 1176 cm−1.
Melting point: 167.1 − 168.2 ◦C.
Mass spectrum (APCI +) m/z: Found 262.1783 (M+H)+; calculated for C14H22N4O 262.1793; 3.8
108
ppm.
Yield: 1.23 g, 64%.
N1-(4-Octenoyl)-pyridine-4-carboxamidrazone (36)
a
b
c
d
(36)
N O
N
H
N
NH2
1H NMR (250 MHz, d6-DMSO): 9.78 (s, 1H, -NH), 8.61 (d, 2H, J = 4.6 Hz, -b and c), 7.71 (d, 2H,
J = 4.6 Hz, -a and d), 6.58 (d, 2H, -NH2), 2.17 (t, 2H, J = 7.4 Hz, -CH2CH2(CH2)4CH3), 1.57 (t,
2H, -CH2CH2(CH2)4CH3), 1.26 (t, 8H, J = 5.8 Hz, -CH2CH2(CH2)4CH3), 0.86 (t, 3H, J = 5.4 Hz, -
CH2CH2(CH2)4CH3) ppm.
IR (KBr disc) ν: 3426 (N-H), 3385 (N-H), 3293 (N-H), 3220, 3064 (Aromatic C-H), 2921 (Alkyl C-H),
2848 (Alkyl C-H), 2375, 1705, 1645 (C=O), 1599, 1521, 1461, 1397, 1374, 1204 (C-N), 1117 cm−1.
Melting point: 162.8 − 166.7 ◦C.
Mass spectrum (APCI +) m/z: Found 262.1788 (M+H)+; calculated for C14H22N4O 262.1793; 1.9
ppm. Yield: 1.37 g, 71%.
N1-(4-Nonanoyl)-pyridine-2-carboxamidrazone (37)
a
b
c
d
(37)
NH2
O
N
H
N
N
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1H NMR (250 MHz, d6-DMSO): 9.82 (s, 1H, -NH), 9.71 (s, 1H, -a), 8.55 (s, 1H, -c), 7.97 (s, 1H, -
d), 7.84 (s, 1H, -b), 6.59 (d, 2H, J = 7.7 Hz, -NH2), 3.31 (t, 2H, J = 7.5 Hz, -CH2(CH2)6CH3), 2.76
(s, 2H, -CH2CH2(CH2)5CH3), 2.60 (d, 2H, J = 7.4 Hz, -CH2CH2CH2(CH2)4CH3), 2.15 (dd, 2H, J =
18.5, 11.4 Hz, -CH2(CH2)3CH2CH2CH2CH3), 1.58 (s, 2H, -CH2(CH2)4CH2CH2CH3), 1.26 (s, 2H, -
CH2(CH2)5CH2CH3), 0.84 (t, 3H, J = 5.1 Hz, -CH2(CH2)6CH3) ppm.
IR (KBr disc) ν: 3408 (N-H), 3344 (N-H), 3321 (N-H), 3301, 3219, 3050 (Aromatic C-H), 2921 (Alkyl
C-H), 2852 (Alkyl C-H), 1654 (C=O), 1608, 1581, 1558, 1475, 1443, 1392, 1259, 1222 (C-N), 1172,
1144, 1112 cm−1.
Melting point: 153.5 − 154.6 ◦C.
Mass spectrum (APCI +) m/z: Found 276.1946 (M+H)+; calculated for C15H24N4O 276.1950; 1.4
ppm.
Yield: 1.56 g, 77%.
N1-(4-Nonanoyl)-pyridine-4-carboxamidrazone (38)
a
b
c
d
(38)
O
N
H
N
N
NH2
1H NMR (250 MHz, d6-DMSO): 9.78 (t, 1H, -NH), 9.63 (d, 2H, J = 10.5 Hz, -b and c), 8.60 (d, 1H, J =
3.7 Hz, -a), 7.71 (d, 1H, J = 4.6 Hz, -d), 6.58 (s, 2H, -NH2), 2.17 (t, 2H, J = 7.4 Hz, -CH2(CH2)6CH3),
1.56 (d, 2H, -CH2CH2(CH2)5CH3), 1.25 (t, 10H, J = 4.4 Hz, -CH2CH2(CH2)5CH3), 0.85 (t, 3H, J = 4.9
Hz, -CH2(CH2)6CH3) ppm.
IR (KBr disc) ν: 3463 (N-H), 3394 (N-H), 3357 (N-H), 3275, 3219, 3036 (Aromatic C-H), 2949 (Alkyl
C-H), 2917 (Alkyl C-H), 2848 (Alkyl C-H), 1640 (C=O),1585, 1535, 1489, 1457, 1411, 1388, 1333, 1300,
1268 (C-N), 1222, 1190, 1140 cm−1.
Melting point: 149.4 − 151.3 ◦C.
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Mass spectrum (APCI +) m/z: Found 276.1948 (M+H)+; calculated for C15H24N4O 276.1950; 0.7
ppm.
Yield: 1.54 g, 76%.
N1-(4-(10-Undecenoyl))-pyridine-2-carboxamidrazone (17)
a
b
c
d
(17)
NH2
O
N
H
N
N
1H NMR (250 MHz, d6-DMSO) 9.77 (s, 1H, -NH), 8.77 − 8.54 (overlapping m, 2H, -a and c), 7.71
(overlapping m, 2H, J = 4.6 Hz, -b and d), 6.56 (s, 2H, -NH2), 5.77 (ddt, 1H, J = 13.6, 10.3, 5.2
Hz, -CH2(CH2)7CH=CH2), 4.96 (dd, 2H, J = 14.8 Hz, -CH2(CH2)7CH=CH2), 3.30 (t, 2H, J = 7.5 Hz,
-CH2-(CH2)7CH=CH2), 2.77 (s, 2H, -CH2(CH2)6-CH2CH=CH2), 2.73 − 2.43 (overlapping m, 2H, -
CH2CH2(CH2)5-CH2CH=CH2), 2.43 − 1.65 (overlapping m, 10H, -CH2CH2(CH2)5CH2CH=CH2) ppm.
IR (KBr disc) ν: 3418 (N-H), 3341 (N-H), 3286 (N-H), 3222, 3058 (Aromatic C-H), 2913 (Alkyl C-H),
2844 (Alkyl C-H), 2662, 2289, 1647 (C=O), 1584, 1547, 1470, 1438, 1393, 1270 (C-N), 1247, 1170
cm−1.
Melting point: 145.2 − 147.5 ◦C.
Mass spectrum (APCI +) m/z: Found 302.2103 (M+H)+; calculated for C17H26N4O 302.2106; 0.9
ppm.
Yield: 2 g, 90%.
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N1-(4-(10-Undecenoyl))-pyridine-4-carboxamidrazone (39)
a
b
c
d
(39)
N O
N
H
N
NH2
1H NMR (250 MHz, d6-DMSO): 9.80 (s, 1H, -NH), 9.71 (s, 2H, -b and c), 8.55 (s, 2H, -a and d),
6.60 (d, 2H, J = 12.5 Hz, -NH2), 5.78 (ddd, 1H, J = 17.1, 10.4, 4.0 Hz, -CH2(CH2)7CH=CH2), 4.95
(t, 2H, J = 14.9 Hz, -CH2(CH2)7CH=CH2), 3.30 (t, 2H, J = 7.5 Hz, -CH2(CH2)7CH=CH2), 2.77 (s, 2H,
-CH2(CH2)6CH2CH=CH2), 2.69 − 2.36 (overlapping m, 2H, -CH2CH2(CH2)5CH2CH=CH2), 2.08 − 1.91
(overlapping m, 10H, -CH2CH2(CH2)5CH2CH=CH2) ppm.
IR (KBr disc) ν: 3400 (N-H), 3331 (N-H), 3275 (N-H), 3112, 3048 (Aromatic C-H), 2876 (Alkyl C-H),
2823 (Alkyl C-H), 2654, 2278, 1645 (C=O), 1581, 1539, 1468, 1435, 1392, 1267 (C-N), 1235, 1167
cm−1.
Melting point: 141.3 − 144.1 ◦C.
Mass spectrum (APCI +) m/z: Found 302.2102 (M+H)+; calculated for C17H26N4O 302.2106; 1.3
ppm.
Yield: 2.1 g, 95%.
N1-(4-Propyloxybenzoyl)-pyridine-2-carboxamidrazone (40)
a
b
c
d
(40)
e
f
g
h
NH2
O
O
N
H
N
N
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1H NMR (250 MHz, d6-DMSO): 10.04 (s, 1H, -NH), 8.59 (d, 1H, J = 4.7 Hz, -a), 8.17 (d, 2H, J = 8.0 Hz,
-e and h), 7.89 (t, 2H, J = 9.2 Hz, -c and d), 7.50 (m, 1H,-b), 7.01 (d, 2H, J = 8.8 Hz, -f and g), 6.89 (s,
2H, -NH2), 4.00 (t, 2H, J = 6.5 Hz, -OCH2CH2CH3), 2.00 − 1.56 (overlapping m, 2H, -OCH2CH2CH3),
0.99 (t, 3H, J = 7.4 Hz, -OCH2CH2CH3) ppm.
IR (KBr disc) ν: 3413 (N-H), 3330 (N-H), 3298 (N-H), 3206, 3064 (Aromatic C-H), 2958, 2921, 2866,
1668 (C=O), 1631, 1603, 1539, 1502, 1470, 1433, 1396, 1295, 1254 (C-N), 1162, 1112, 1043, 1015
cm−1.
Melting point: 224.3 − 225.3 ◦C.
Mass spectrum (APCI +) m/z: Found 298.1425 (M+H)+; calculated for C16H18N4O2 298.1429; 1.3
ppm.
Yield: 1.51 g, 69%.
N1-(4-Propyloxybenzoyl)-pyridine-4-carboxamidrazone (41)
a
b
c
d
e
t
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v
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1H NMR (250 MHz, d6-DMSO): 9.98 (s, 1H, -NH), 8.65 (d, 2H, J = 5.9 Hz, -b and c), 7.94 − 7.70
(overlapping m, 4H, -a, d, e and h), 7.03 (t, 2H, J = 7.8 Hz, -f and g), 6.86 (s, 2H, -NH2), 4.01 (t, 2H,
J = 6.5 Hz, -OCH2CH2CH3), 1.89 − 1.56 (overlapping m, 2H, -OCH2CH2CH3), 1.00 (t, 3H, J = 7.4 Hz,
-OCH2CH2CH3) ppm.
IR (KBr disc) ν: 3459 (N-H), 3348 (N-H), 3284 (N-H), 3183, 2958 (Aromatic C-H), 2880, 1677 (C=O),
1631, 1617, 1539, 1493, 1466, 1406, 1314, 1286 (C-N), 1240, 1163, 1112, 1062 cm−1.
Melting point: 207.1 − 208.5 ◦C.
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Mass spectrum (APCI +) m/z: Found 298.1421 (M+H)+; calculated for C16H18N4O2 298.1429; 2.0
ppm.
Yield: 1.58 g, 72%.
N1-(4-Butyloxybenzoyl)-pyridine-2-carboxamidrazone (42)
a
b
c
d
(42)
e
f
g
h
NH2
O
O
N
H
N
N
1H NMR (250 MHz, d6-DMSO): 10.04 (s, 1H, -NH), 8.60 (d, 1H, J = 4.6 Hz, -a), 8.17 (d, 2H, J =
8.0 Hz, -e and f), 7.88 (dd, 4H, J = 11.5, 7.2 Hz, -c and d), 7.45 (m, 1H, -b), 7.01 (d, 2H, J = 8.8
Hz, -f and g), 6.90 (s, 2H, -NH2), 4.04 (t, 2H, J = 6.5 Hz, -OCH2(CH2)2CH3), 1.82 − 1.60 (overlap-
ping m, 2H, -OCH2CH2CH2CH3), 1.59 − 1.31 (overlapping m, 2H, -OCH2CH2CH2CH3), 0.93 (t, 3H,
-OCH2(CH2)2CH3) ppm.
IR (KBr disc) ν: 3409 (N-H), 3331 (N-H), 3302 (N-H), 3213, 3054 (Aromatic C-H), 2949, 2858, 1670
(C=O), 1629, 1538, 1501, 1460, 1388, 1270 (C-N), 1238, 1165, 1042 cm−1.
Melting point: 120.5 − 121.9 ◦C.
Mass spectrum (APCI +) m/z: Found 312.1576 (M+H)+; calculated for C17H20N4O2 312.1586; 3.2
ppm.
Yield: 1.35 g, 59%.
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N1-(4-Butyloxybenzoyl)-pyridine-4-carboxamidrazone (43)
a
b
c
d
e
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1H NMR (250 MHz, d6-DMSO): 9.98 (s, 1H, -NH), 8.69 (d, 2H, J = 22.0 Hz, -b and c), 8.63 (s, 2H,
-e and h), 8.35 (d, 2H, J = 19.9 Hz, -a and d), 7.98 − 7.57 (overlapping m, 2H, -f and g), 7.03 −
6.55 (overlapping m, 2H, -NH2), 4.04 (t, 2H,J = 6.5 Hz, -OCH2(CH2)2CH3), 1.86 − 1.60 (overlapping
m, 2H, -OCH2CH2CH2CH3), 1.45 (dq, 2H,J = 14.4, 7.4 Hz, -OCH2CH2CH2CH3), 0.94 (t, 3H, J = 7.3
Hz,-OCH2(CH2)2CH3) ppm.
IR (KBr disc) ν: 3363 (N-H), 3351 (N-H), 3296 (N-H), 3189, 3158, 2945 (Aromatic C-H), 2922, 2863,
2699, 2580, 2357, 2330, 1934, 1898, 1757, 1670 (C=O), 1624, 1606, 1538, 1497, 1456, 1402, 1319,
1256 (C-N), 1169, 1119, 1064, 1019 cm−1.
Melting point: 206.2 − 207.1 ◦C.
Mass spectrum (APCI +) m/z: Found 312.1586 (M+H)+; calculated for C17H20N4O2 312.1586; 2.5
ppm.
Yield: 1.47 g, 64%.
N1-(4-Pentyloxybenzoyl)-pyridine-2-carboxamidrazone (44)
a
b
c
d
(44Ł
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1H NMR (250 MHz, d6-DMSO): 10.03 (s, 1H, -NH), 8.60 (d, 3H, J = 4.5 Hz, -a, e, and h), 8.17 (d, 1H,
J = 8.2 Hz, -c,), 7.86 (d, 2H, J = 8.6 Hz, -d, and b), 7.49 (d, 2H, J = 5.1 Hz, -f, and g), 7.09 − 6.60
(overlapping m, 2H, -NH2), 4.04 (t, 2H, J = 6.5 Hz, -OCH2(CH2)3CH3), 2.59 − 2.41 (overlapping m,
2H, -OCH2CH2(CH2)2CH3), 1.73 (d, J = 7.1 Hz, 2H, -O(CH2)2CH2CH2CH3), 1.38 (d, J = 3.6 Hz, 2H,
-OCH2(CH2)2CH2CH3), 0.90 (t, J = 6.9 Hz, 3H, -OCH2(CH2)3CH3) ppm.
IR (KBr disc) ν: 3417 (N-H), 3330 (N-H), 3302 (N-H), 3215, 3059 (Aromatic C-H), 3027, 2949, 2862,
1897, 1663 (C=O), 1626, 1603, 1535, 1502, 1466, 1434, 1401, 1300, 1254 (C-N), 1167 cm−1.
Melting point: 224.7 − 225.8 ◦C.
Mass spectrum (APCI +) m/z: Found 326.1736 (M+H)+; calculated for C18H22N4O2 326.1742; 1.8
ppm.
Yield: 1.51 g, 63%.
N1-(4-Pentyloxybenzoyl)-pyridine-4-carboxamidrazone (45)
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1H NMR (250 MHz, d6-DMSO): 9.97 (s, 3H, -NH), 8.64 (d, 2H, J = 5.9 Hz, -b, and c), 7.98 − 7.63
(overlapping m, 4H, -a, d, e and h), 7.00 (d, 2H, J = 8.8 Hz, -f, and g), 6.84 (s, 1H, -NH2), 4.04 (t, 2H,
J = 6.5 Hz, OCH2(CH2)3CH3), 1.72 (d, 4H, J = 6.9 Hz, -OCH2(CH2)2CH2CH3 ), 1.38 (d, 2H, J = 3.5 Hz,
-OCH2(CH2)2CH2CH3), 0.90 (t, 3H, J = 7.1 Hz, OCH2(CH2)3CH3) ppm.
IR (KBr disc) ν: 3429 (N-H), 3375 (N-H), 3330 (N-H), 3151, 2953 (Aromatic C-H), 2926, 2857, 2361,
2333, 1667 (C=O), 1621, 1603, 1539, 1498, 1415, 1319, 1254 (C-N), 1167, 1029 cm−1.
Melting point: 164.1 − 165.3 ◦C.
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Mass spectrum (APCI +) m/z: Found 326.1733 (M+H)+; calculated for C18H22N4O2 326.1742; 2.7
ppm.
Yield: 1.66 g, 69%.
N1-(4-Heptyloxybenzoyl)-pyridine-2-carboxamidrazone (46)
a
b
c
d
(46)
e
f
g
h
NH2
O
O
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H
N
N
1H NMR (250 MHz, d6-DMSO): 10.09 (s, 1H, -NH), 8.62 (d, 1H, J = 4.4 Hz, -a), 8.17 (d, 2H, J = 7.8
Hz, -e and h), 7.87 (d, 2H, J = 8.7 Hz, -c and d), 7.12 (d, 1H, J = 8.9 Hz, -b), 7.00 (d, 2H, J = 8.8 Hz,
-f and g), 6.89 (s, 2H, -NH2), 4.03 (t, 2H, J = 6.5 Hz, -OCH2(CH2)5CH3), 1.75 − 1.68 (overlapping m,
2H, -OCH2CH2(CH2)4CH3), 1.33 (d, 8H, J = 25.3 Hz, -OCH2CH2(CH2)4CH3), 0.86 (t, 3H, J = 6.6 Hz,
-OCH2(CH2)5CH3) ppm.
IR (KBr disc) ν: 3399 (N-H), 3339 (N-H), 3302 (N-H), 3220, 3064 (Aromatic C-H), 3031, 2944, 2917,
2871, 2852, 1664 (C=O), 1626, 1594, 1562, 1539, 1502, 1470, 1438, 1401, 1291 (C-N), 1249, 1167,
1112, 1034, 1011 cm−1.
Melting point: 203.3 − 204.4 ◦C.
Mass spectrum (APCI +) m/z: Found 354.2050 (M+H)+; calculated for C20H26N4O2 354.2055; 1.4
ppm.
Yield: 1.49 g, 57%.
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N1-(4-Heptyloxybenzoyl)-pyridine-4-carboxamidrazone (47)
a
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1H NMR (250 MHz, d6-DMSO): 10.07 (s, 1H, -NH), 8.64 (d, J = 5.9 Hz, 2H, -b and c), 7.98 − 7.68
(overlapping m, 4H, -a, d, e and h), 7.12 (d, 2H, J = 8.8 Hz, -f and g), 6.99 (d, 2H, J = 8.8 Hz, -NH2),
4.02 (t, 2H, J = 6.5 Hz, -OCH2(CH2)5CH3), 1.88 − 1.63 (overlapping m, 2H, -OCH2CH2(CH2)4CH3),
1.53 − 1.08 (overlapping m, 8H, -OCH2CH2(CH2)4CH3), 0.87 (t, 3H, J = 6.6 Hz, -OCH2(CH2)5CH3)
ppm.
IR (KBr disc) ν: 3471 (N-H), 3349 (N-H), 3322 (N-H), 3172, 3100, 3086 (Aromatic C-H), 3026, 2917,
2853, 1670 (C=O), 1643, 1597, 1538, 1501, 1497, 1472, 1402, 1292, 1246 (C-N), 1179, 1038 cm−1.
Melting point: 177.6 − 178.8 ◦C.
Mass spectrum (APCI +) m/z: Found 354.2047 (M+H)+; calculated for C20H26N4O2 354.2055; 2.2
ppm.
Yield: 2 g, 77%.
N1-(4-Octyloxybenzoyl)-pyridine-2-carboxamidrazone (48)
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1H NMR (250 MHz, d6-DMSO): 10.09 (s, 1H, -NH), 8.60 (d, 1H, J = 4.3 Hz, -a), 8.18 (d, 2H, J = 9.9 Hz,-e
and h), 8.00− 7.72 (overlapping m, 2H, -c), 7.63 (m, 1H, -d), 7.46 (m, 1H, -b), 7.33− 7.09 (overlapping
m, 2H, -f and g), 7.09 − 6.71 (overlapping m, 2H, -NH2), 4.21 (t, 2H, J = 6.5 Hz, -OCH2(CH2)6CH3),
2.08 (s, 1H, -OCH2CH2(CH2)5CH3), 1.86 − 1.58 (overlapping m, 2H, -OCH2CH2CH2(CH2)4CH3), 1.55
− 1.18 (overlapping m, 16H, -OCH2CH2CH2(CH2)4CH3), 0.85 (d, 3H, J = 6.9 Hz, -OCH2(CH2)6CH3)
ppm.
IR (KBr disc) ν: 3416 (N-H), 3342 (N-H), 3330 (N-H), 3202, 3059 (Aromatic C-H), 3040, 2915, 2845,
1672 (C=O), 1620, 1602, 1565, 1541, 1504, 1463, 1435, 1398, 1291, 1249 (C-N), 1161, 1110, 1017
cm−1.
Melting point: 188.6 − 189.7 ◦C.
Mass spectrum (APCI +) m/z: Found 368.2208 (M+H)+; calculated for C21H28N4O2 368.2212; 1.0
ppm.
Yield: 1.84 g, 68%.
N1-(4-Octyloxybenzoyl)-pyridine-4-carboxamidrazone (49)
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1H NMR (250 MHz, d6-DMSO): 9.99 (s, 1H, -NH), 8.64 (d, 2H, J = 6.0 Hz, -b and c), 7.95 − 7.72
(overlapping m, 4H, -a, d, e and h), 7.00 (d, 2H, J = 8.8 Hz, -f and g), 6.85 (s, 2H, -NH2), 4.04 (t,
3H, J = 6.5 Hz, -OCH2(CH2)6CH3), 1.86 − 1.61 (dq, 2H, J = 14.4, 7.3 Hz, -OCH2CH2(CH2)5CH3), 1.45
(overlapping m, 10H, -OCH2CH2(CH2)5CH3), 0.94 (t, 3H, J = 7.3 Hz, -OCH2(CH2)6CH3) ppm.
IR (KBr disc) ν: 3468 (N-H), 3348 (N-H), 3301 (N-H), 3215, 3187, 3063 (Aromatic C-H), 3031, 2916,
2847, 1659 (C=O), 1640, 1603, 1539, 1502, 1466, 1397, 1300, 1245 (C-N), 1186, 1107, 1034 cm−1.
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Melting point: 185.0 − 186.2 ◦C.
Mass spectrum (APCI +) m/z: Found 368.2202 (M+H)+; calculated for C21H28N4O2 368.2212; 2.7
ppm.
Yield: 1.79 g, 66%.
N1-(4-Decyloxybenzoyl)-pyridine-2-carboxamidrazone (50)
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1H NMR (250 MHz, d6-DMSO): 10.05 (s, 1H, -NH), 8.60 (d, 1H, J = 4.4 Hz, -a), 8.18 (d, J = 8.3 Hz, 2H,
-e and h), 7.84 (dd, 1H, J = 15.8, 8.7 Hz, -c), 7.47 (m, 1H, -d), 7.13 (d, 1H, J = 9.0 Hz, -b), 7.00 (d,
2H, J = 8.8 Hz, -f and g), 6.90 (s, 2H, -NH2), 4.42 (t, 2H, J = 6.5 Hz, -OCH2(CH2)9CH3), 1.75 (dt, 2H, J
= 14.8, 5.6 Hz, -OCH2CH2(CH2)8CH3), 1.54 − 1.01 (overlapping m, 16H, -OCH2CH2(CH2)8CH3), 0.84
(d, 3H, J = 6.8 Hz, -OCH2(CH2)9CH3) ppm.
IR (KBr disc) ν: 3426 (N-H), 3325 (N-H), 3298 (N-H), 3270, 3187, 3068 (Aromatic C-H), 2944, 2921,
2843, 1663 (C=O), 1631, 1603, 1580, 1548, 1507, 1461, 1392, 1433, 1304, 1254 (C-N), 1176, 1112,
1015 cm−1.
Melting point: 165.3 − 166.5 ◦C.
Mass spectrum (APCI +) m/z: Found 396.2520 (M+H)+; calculated for C23H32N4O2 396.2525; 1.2
ppm.
Yield: 2.30 g, 79%.
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N1-(4-Decyloxybenzoyl)-pyridine-4-carboxamidrazone (51)
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1H NMR (250 MHz, d6-DMSO): 10.09 (s, 1H, -NH), 8.65 (d, 4H, J = 5.9 Hz, -b, c, e and h), 8.20 −
7.43 (overlapping m, 4H, -a, d, f and g), 7.38 − 6.45 (overlapping m, 2H, -NH2), 4.10 (t, 2H, J = 6.5 Hz,
-OCH2(CH2)8CH3), 1.72 (dd, 2H, J = 13.9, 6.5 Hz, -OCH2CH2(CH2)7CH3), 1.59 − 1.03 (overlapping m,
14H, -OCH2CH2(CH2)7CH3), 0.87 (t, 3H, J = 6.5 Hz, -OCH2(CH2)8CH3) ppm.
IR (KBr disc) ν: 3445 (N-H), 3300 (N-H), 3181, 3063 (Aromatic C-H), 2926, 2849, 1634 (C=O), 1597,
1533, 1497, 1460, 1393, 1311, 1256 (C-N), 1174, 1115, 1015 cm−1.
Melting point: 168.9 − 170.1 ◦C.
Mass spectrum (APCI +) m/z: Found 396.2518 (M+H)+; calculated for C23H32N4O2 396.2525; 1.7
ppm.
Yield: 2.54 g, 87%.
N1-(4-Pentylbenzoyl)-pyridine-2-carboxamidrazone (14)
(14)
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1H NMR (250 MHz, d6-DMSO): 10.12 (s, 1H, -NH), 8.61 (d, 2H, J = 4.4 Hz, b and d), 8.17 (d, 1H, J =
7.7 Hz, - a), 7.80 (d, 3H, J = 8.1 Hz, c, e and h), 7.30 (d, 2H, J = 8.1 Hz, f and g), 6.91 (s, 2H, -NH2),
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2.64 (t, 2H, J = 7.6 Hz, -CH2 (CH2)3 CH3), 1.59 (s, 2H, -CH2 CH2 (CH2 )2 CH3), 1.27 (overlapping m,
4H, J = 8.9 Hz, -CH2 CH2 (CH2)2 CH3), 0.86 (t, 3H, J = 6.5 Hz, -(CH2)4 CH3) ppm.
IR (KBr disc) ν: 3411 (N-H), 3216, 3031 (Aromatic C-H), 2995 (Alkyl C-H), 2859 (Alkyl C-H), 1637(C=O),
1559, 1474, 1448, 1403, 1313, 1187(C-N) cm−1.
Melting point: 234.1 − 235.9 ◦C.
Yield: 1.58 g, 72%.
N1-(4-Pentylbenzoyl)-pyridine-4-carboxamidrazone (76)
(76)
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1H NMR (250 MHz, d6-DMSO): 10.06 (s, 1H, -NH), 8.65 (d, 2H, J = 5.7 Hz, -b and c), 7.79 (d, 2H, J =
8.0 Hz, -e and h), 7.29 (d, 4H, J = 8.1 Hz, -a, d, f and g), 6.91 (s, 2H, -NH2), 2.64 (t, 2H, J = 7.6 Hz,
-CH2 (CH2)3 CH3), 1.59 (s, 2H, -CH2 CH2 (CH2 )2 CH3), 1.27 (overlapping m, 4H, J = 8.9 Hz, -CH2 CH2
(CH2)2 CH3), 0.86 (t, 3H, J = 6.5 Hz, -(CH2)4 CH3) ppm.
IR (KBr disc) ν: 3349 (N-H), 3166, 3040 (Aromatic C-H), 2956 (Alkyl C-H), 2927 (Alkyl C-H), 1625(C=O),
1598, 1544, 1501, 1411, 1291, 1183(C-N) cm−1.
Melting point: 201.2 − 201.8 ◦C.
Yield: 1.86 g, 76%.
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N1-(4-Hexylbenzoyl)-pyridine-2-carboxamidrazone (13)
(13)
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1H NMR (250 MHz, d6-DMSO): 10.12 (s, 1H, -NH), 8.61 (d, 2H, J = 4.4 Hz, b and d), 8.17 (d, 1H, J =
7.7 Hz, - a), 7.80 (d, 3H, J = 8.1 Hz, c, e and h), 7.30 (d, 2H, J = 8.1 Hz, f and g), 6.91 (s, 2H, -NH2),
2.64 (t, 2H, J = 7.6 Hz, -CH2 (CH2)4 CH3), 1.59 (s, 2H, -CH2 CH2 (CH2 )3 CH3), 1.27 (overlapping m,
6H, J = 8.9 Hz, -CH2 CH2 (CH2)3 CH3), 0.86 (t, 3H, J = 6.5 Hz, -(CH2)5 CH3) ppm.
IR (KBr disc) ν: 3407 (N-H), 3214, 3060 (Aromatic C-H), 2925 (Alkyl C-H), 2857 (Alkyl C-H), 1630(C=O),
1548, 1479, 1448, 1397, 1309, 1187(C-N) cm−1.
Melting point: 218.7 − 220.6 ◦C.
Yield: 2 g, 77%.
N1-(4-Hexylbenzoyl)-pyridine-4-carboxamidrazone (77)
(77)
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1H NMR (250 MHz, d6-DMSO): 10.06 (s, 1H, -NH), 8.65 (d, 2H, J = 5.7 Hz, -b and c), 7.79 (d, 2H, J =
8.0 Hz, -e and h), 7.29 (d, 4H, J = 8.1 Hz, -a, d, f and g), 6.87 (s, 2H, -NH2), 2.64 (t, 2H, J = 7.6 Hz,
-CH2 (CH2)4 CH3), 1.59 (s, 2H, -CH2 CH2 (CH2 )3 CH3), 1.27 (overlapping m, 6H, J = 8.9 Hz, -CH2 CH2
(CH2)3 CH3), 0.86 (t, 3H, J = 6.5 Hz, -(CH2)5 CH3) ppm.
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IR (KBr disc) ν: 3430 (N-H), 3207, 3064 (Aromatic C-H), 2923 (Alkyl C-H), 2856 (Alkyl C-H), 1636
(C=O), 1594, 1552, 1502, 1405, 1301, 1210, 1187 (C-N) cm−1.
Melting point: 187.7 − 191.0 ◦C.
Yield: 1.86 g, 76%.
N1-(4-Heptylbenzoyl)-pyridine-2-carboxamidrazone (15)
(15)
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1H NMR (250 MHz, d6-DMSO): 10.12 (s, 1H, -NH), 8.61 (d, 2H, J = 4.4 Hz, b and d), 8.17 (d, 1H, J =
7.7 Hz, - a), 7.80 (d, 3H, J = 8.1 Hz, c, e and h), 7.30 (d, 2H, J = 8.1 Hz, f and g), 6.91 (s, 2H, -NH2),
2.64 (t, 2H, J = 7.6 Hz, -CH2 (CH2 )5 CH3), 1.59 (s, 2H, -CH2 CH2 (CH2 )4 CH3), 1.27 (overlapping m,
8H, J = 8.9 Hz, -CH2 CH2 (CH2 )4 CH3), 0.86 (t, 3H, J = 6.5 Hz, -(CH2 )6 CH3) ppm.
IR (KBr disc) ν: 3411 (N-H), 3214 (N-H), 3060 (Aromatic C-H), 2927 (Alkyl C-H), 2848 (Alkyl C-H),
1631(C=O), 1548, 1479, 1448, 1397, 1311, 1187(C-N), 1158, 1140 cm−1.
Melting point: 214.9 − 215.8 ◦C. Yield: 1.14 g, 71%.
N1-(4-Heptylbenzoyl)-pyridine-4-carboxamidrazone (81)
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1H NMR (250 MHz, d6-DMSO): 10.04 (s, 1H, -NH), 8.65 (d, 2H, J = 5.7 Hz, -b and c), 7.79 (d, 2H, J =
8.0 Hz, -e and h), 7.29 (d, 4H, J = 8.1 Hz, -a, d, f and g), 6.87 (s, 2H, -NH2), 2.64 (t, 2H, J = 7.6 Hz,
-CH2 (CH2 )5 CH3), 1.59 (s, 2H, -CH2 CH2 (CH2 )4 CH3), 1.27 (overlapping m, 8H, J = 8.9 Hz, -CH2
CH2 (CH2 )4 CH3), 0.86 (t, 3H, J = 6.5 Hz, -(CH2)6 CH3) ppm.
IR (KBr disc) ν: 3417 (N-H), 3320 (N-H), 3252 (N-H), 3204, 3044 (Aromatic C-H), 2957 (Alkyl C-H),
2915 (Alkyl C-H), 2852 (Alkyl C-H), 1640(C=O), 1582, 1558, 1498, 1411, 1295, 1218, 1183(C-N) cm−1.
Melting point: 182.2 − 182.8 ◦C.
Yield: 1.72 g, 70%.
N1-(4-Decylbenzoyl)-pyridine-2-carboxamidrazone (16)
(16)
a
×
1H NMR (250 MHz, d6-DMSO): 10.12 (s, 1H, -NH), 8.61 (d, 2H, J = 4.4 Hz, b and d), 8.17 (d, 1H, J =
7.7 Hz, - a), 7.80 (d, 3H, J = 8.1 Hz, c, e and h), 7.30 (d, 2H, J = 8.1 Hz, f and g), 6.91 (s, 2H, -NH2),
2.64 (t, 2H, J = 7.6 Hz, -CH2 (CH2 )8 CH3), 1.59 (s, 2H, -CH2 CH2 (CH2 )7 CH3), 1.27 (overlapping m,
14H, J = 8.9 Hz, -CH2 CH2 (CH2 )7 CH3), 0.86 (t, 3H, J = 6.5 Hz, -(CH2)9 CH3) ppm.
IR (KBr disc) ν: 3397 (N-H), 3276, 3182, 3056 (Aromatic C-H), 2921 (Alkyl C-H), 2849 (Alkyl C-H),
1629(C=O), 1584, 1540, 1440, 1398, 1295, 1193(C-N) cm−1.
Melting point: 201.2 − 203.2 ◦C.
Yield: 1.14 g, 71%.
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N1-(4-Decylbenzoyl)-pyridine-4-carboxamidrazone (79)
(79)
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1H NMR (250 MHz, d6-DMSO): 10.04 (s, 1H, -NH), 8.65 (d, 2H, J = 5.7 Hz, -b and c), 7.79 (d, 2H, J =
8.0 Hz, -e and h), 7.29 (d, 4H, J = 8.1 Hz, -a, d, f and g), 6.87 (s, 2H, -NH2), 2.64 (t, 2H, J = 7.6 Hz,
-CH2 (CH2 )8 CH3), 1.59 (s, 2H, -CH2 CH2 (CH2 )7 CH3), 1.27 (overlapping m, 14H, J = 8.9 Hz, -CH2
CH2 (CH2 )7 CH3), 0.86 (t, 3H, J = 6.5 Hz, -(CH2)9 CH3) ppm.
IR (KBr disc) ν: 3417 (N-H), 3320 (N-H), 3252 (N-H), 3204, 3044 (Aromatic C-H), 2957 (Alkyl C-H),
2915 (Alkyl C-H), 2852 (Alkyl C-H), 1640(C=O), 1582, 1558, 1498, 1411, 1295, 1218, 1183(C-N) cm−1.
Melting point: 191.5 − 193.9 ◦C.
Yield: 1.49 g, 57%.
N-[(4-Methylbenzoyl)oxy]-2-pyridinecarboximidamide (52)
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1H NMR (250 MHz, d6-DMSO): 8.68 (ddd, 1H, J = 4.8, 1.6, 1.0 Hz, -a), 8.12 (d, 2H, J = 8.2 Hz, -e and
h), 8.07 − 7.85 (overlapping m, 2H, -b and d), 7.57 (ddd, 1H, J = 7.3, 4.8, 1.4 Hz, -c), 7.35 (d, 2H, J =
8.0 Hz, -f and g), 7.07 (s, 2H, -NH2), 2.40 (s, 3H, CH3) ppm.
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IR (KBr disc) ν: 3472 (N-H), 3357 (N-H), 3068 (Aromatic C-H), 3022, 2962, 2902, 2852, 2324, 2168,
1938, 1713, 1621 (C=O), 1575, 1557, 1407, 1433, 1406, 1392, 1373, 1268, 1171, 1079, 1034, 1011
cm−1.
Melting point: 180.8 − 181.6 ◦C.
Mass spectrum (APCI +) m/z: Found 255.1003 (M+H)+; calculated for C14H13N3O2 255.1007; 1.5
ppm.
Yield: 0.51 g, 63%.
N-[(4-Methylbenzoyl)oxy]-4-pyridinecarboximidamide (53)
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1H NMR (250 MHz, d6-DMSO): 8.71 (d, 2H, J = 5.0 Hz,-b and c), 8.10 (d, 2H, J = 8.1 Hz,-e and h), 7.75
(d, 2H, J = 6.0 Hz, -a and d), 7.35 (d, 2H, J = 8.0 Hz, -f and g), 7.16 (s, 2H, -NH2), 2.40 (s, 3H,CH3)
ppm.
IR (KBr disc) ν: 3458 (N-H), 3357 (N-H), 3206 (Aromatic C-H), 3169, 3045, 2912, 2361, 1713, 1626
(C=O), 1539, 1507, 1410, 1304, 1259, 1181, 1093, 1015 cm−1.
Melting point: 166.8 − 167.5 ◦C.
Mass spectrum (APCI +) m/z: Found 255.1000 (M+H)+; calculated for C14H13N3O2 255.1007; 2.7
ppm.
Yield: 0.55 g, 67%.
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N-[(4-Ethylbenzoyl)oxy]-2-pyridinecarboximidamide (54)
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1H NMR (250 MHz, d6-DMSO): 8.68 (ddd, 1H, J = 4.8, 1.6, 1.0 Hz, -a), 8.23 − 8.08 (overlapping m, 2H,
-e and h), 8.08 − 7.89 (overlapping m, 2H, -b and d), 7.57 (ddd, 1H, J = 7.3, 4.8, 1.4 Hz, ), 7.38 (d, 2H,
J = 8.4 Hz, -f and g), 7.06 (s, 2H, -NH2), 2.87 − 2.58 (overlapping m, 2H, -CH2CH3), 1.30 (t, 3H, J =
6.8 Hz, -CH2CH3) ppm.
IR (KBr disc) ν: 3466 (N-H), 3355 (N-H), 3049 (Aromatic C-H), 2961, 2924, 2863, 2367, 1931, 1717,
1629 (C=O), 1583, 1555, 1472, 1411, 1388, 1309, 1263, 1165, 1128, 1082, 1045, 1012 cm−1.
Melting point: 155.3 − 156.7 ◦C.
Mass spectrum (APCI +) m/z: Found 269.1160 (M+H)+; calculated for C15H15N3O2 269.1164; 1.4
ppm.
Yield: 0.58 g, 59%.
N-[(4-Ethylbenzoyl)oxy]-4-pyridinecarboximidamide (55)
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1H NMR (250 MHz, d6-DMSO): 8.70 (d, 2H, J = 5.5 Hz, -b and c), 8.09 (d, 2H, J = 8.1 Hz, -e and h),
7.75 (d, 38H, J = 5.6 Hz, -a and d), 7.38 (d, 2H, J = 8.0 Hz, -f and g), 6.99 (s, 2H, -NH2), 2.72 (q, 2H, J
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= 7.6 Hz, -CH2CH3), 1.31 (t, 3H, J = 6.6 Hz, -CH2CH3) ppm.
IR (KBr disc) ν: 3392 (N-H), 3309 (N-H), 3183, 3030 (Aromatic C-H), 2956, 2924, 2863, 1727, 1634
(C=O), 1601, 1532, 1499, 1453, 1411, 1258, 1253, 1170, 1073, 1008 cm−1.
Melting point: 134.3 − 135.5 ◦C.
Mass spectrum (APCI +) m/z: Found 269.1158 (M+H)+; calculated for C15H15N3O2 269.1164; 2.2
ppm.
Yield: 0.72 g, 72%.
N-[(4-Propylbenzoyl)oxy]-2-pyridinecarboximidamide (56)
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1H NMR (250 MHz, d6-DMSO): 8.68 (ddd, 1H, J = 4.8, 1.6, 1.0 Hz, -a), 8.22 − 8.08 (overlapping m, 2H,
-e and h), 8.08 − 7.86 (overlapping m, 2H, -b and d), 7.57 (ddd, 1H, J = 7.3, 4.8, 1.4 Hz, -c), 7.36 (d,
2H, J = 8.3 Hz, -f and g), 7.06 (s, 2H, -NH2), 2.72 − 2.58 (t, 2H, J = 6.5 Hz, -CH2CH2CH3), 1.79 − 1.47
(overlapping m, 2H, -CH2CH2CH3), 0.90 (t, 3H, J = 7.3 Hz, -CH2CH2CH3) ppm.
IR (KBr disc) ν: 3425 (N-H), 3333 (N-H), 3211, 3026 (Aromatic C-H), 2943, 2911, 2828, 2351, 1717,
1616 (C=O), 1529, 1511, 1460, 1418, 1317, 1253, 1218, 1161, 1089, 1001 cm−1.
Melting point: 161.2 − 162.5 ◦C.
Mass spectrum (APCI +) m/z: Found 283.1315 (M+H)+; calculated for C16H17N3O2 283.1320; 1.7
ppm.
Yield: 0.76 g, 74%.
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N-[(4-Propylbenzoyl)oxy]-4-pyridinecarboximidamide (57)
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1H NMR (250 MHz, d6-DMSO): 8.71 (dd, 2H, J = 4.5, 1.6 Hz, -b and c), 8.11 (d, 2H, J = 8.2 Hz, -e and
h), 7.75 (dd, 2H, J = 4.5, 1.6 Hz, -a and d), 7.36 (d, 2H, J = 8.2 Hz, -f and g), 7.16 (s, 2H, -NH2), 2.69
− 2.61 (overlapping m, 2H, -CH2CH2CH3), 1.79 − 1.46 (overlapping m, 2H, -CH2CH2CH3), 0.91 (t, 3H,
J = 7.3 Hz, -CH2CH2CH3) ppm.
IR (KBr disc) ν: 3449 (N-H), 3348 (N-H), 3215, 3173, 3063 (Aromatic C-H), 3031, 2948, 2921, 2861,
2191, 1906, 1713, 1626 (C=O), 1529, 1456, 1406, 1309, 1272, 1171, 1098, 1020 cm−1.
Melting point: 154.1 − 155.3 ◦C.
Mass spectrum (APCI +) m/z: Found 283.1311 (M+H)+; calculated for C16H17N3O2 283.1320; 3.1
ppm.
Yield: 0.67 g, 65%.
N-[(4-Butylbenzoyl)oxy]-2-pyridinecarboximidamide (58)
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1H NMR (250 MHz, d6-DMSO): 8.68 (d, 1H, J = 4.8 Hz, -a), 8.13 (d, 2H, J = 8.2 Hz, -e and h), 7.97
(ddd, 2H, J = 12.9, 9.4, 4.8 Hz, -b and d), 7.57 (ddd, 1H, J = 7.3, 4.9, 1.2 Hz, -c), 7.36 (d, 2H, J = 8.2
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Hz, -f and g), 7.06 (s, 2H, -NH2), 2.67 (t, 2H, J = 7.6 Hz, -CH2CH2CH2CH3), 1.83 − 1.46 (overlapping
m, 2H, -CH2CH2CH2CH3), 1.44 − 1.20 (overlapping m, 2H, -CH2CH2CH2CH3), 0.90 (t, 3H, J = 7.3 Hz,
-CH2CH2CH2CH3) ppm.
IR (KBr disc) ν: 3463 (N-H), 3348 (N-H), 3045 (Aromatic C-H), 2958, 2916, 2852, 2361, 2333, 1722,
1626 (C=O), 1589, 1557, 1461, 1410, 1392, 1263, 1176, 1084, 1011 cm−1.
Melting point: 146.3 − 147.6 ◦C.
Mass spectrum (APCI +) m/z: Found 297.1472 (M+H)+; calculated for C17H19N3O2 297.1477; 1.6
ppm.
Yield: 0.87 g, 81%.
N-[(4-Butylbenzoyl)oxy]-4-pyridinecarboximidamide (59)
a
b
c
d
e
ø ù
ù
ø
ø
ú
û
1H NMR (250 MHz, d6-DMSO): 8.76 − 8.65 (overlapping m, 2H, -b and c), 8.08 (d, 4H, J = 8.3 Hz, -e
and h), 7.75 (dd, 4H, J = 4.5, 1.6 Hz, -a and d), 7.36 (d, 4H, J = 8.3 Hz, -f and g), 6.98 (s, 2H, -NH2),
2.77 (t, 2H, J = 6.5 Hz, -CH2CH2CH2CH3), 1.72 − 1.49 (overlapping m, 2H, -CH2CH2CH2CH3), 1.48 −
1.10 (overlapping m, 2H, -CH2CH2CH2CH3), 0.92 (t, 3H, J = 7.3 Hz, -CH2CH2CH2CH3) ppm.
IR (KBr disc) ν: 3444 (N-H), 3394 (N-H), 3348, 3173, 3031 (Aromatic C-H), 2958, 2930, 2852, 1713,
1631 (C=O), 1608, 1539, 1465, 1401, 1373, 1309, 1277, 1176, 1075, 1011 cm−1.
Melting point: 152.1 − 153.6 ◦C.
Mass spectrum (APCI +) m/z: Found 297.1469 (M+H)+; calculated for C17H19N3O2 297.1477; 2.6
ppm.
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Yield: 0.90 g, 84%.
N-[(4-Pentylbenzoyl)oxy]-2-pyridinecarboximidamide (60)
a
b
c
d
e
60)
NH2
O
O
N
N
1H NMR (250 MHz, d6-DMSO): 8.88 (m, 1H, -a), 8.13 (d, 2H, J = 8.2 Hz, -e and h), 7.97 (ddd, 2H, J =
12.9, 9.6, 4.8 Hz, -b and d), 7.57 (ddd, 1H, J = 7.3, 4.9, 1.3 Hz, -c), 7.35 (d, 2H, J = 8.3 Hz, -f and g),
7.06 (s, 2H, -NH2), 2.81 − 2.58 (t, 2H, J = 6.5 Hz, -CH2CH2(CH2 )2 CH3), 1.86 − 1.45 (overlapping m,
2H, -CH2CH2(CH2 )2 CH3), 1.39 − 1.18 (overlapping m, 4H, -CH2CH2(CH2 )2 CH3), 0.86 (t, 3H, J = 6.8
Hz, -CH2CH2(CH2 )2 CH3) ppm.
IR (KBr disc) ν: 3462 (N-H), 3337 (N-H), 3054 (Aromatic C-H), 2951, 2919, 2854, 2362, 1810, 1722,
1625 (C=O), 1583, 1555, 1467, 1411, 1379, 1309, 1267, 1179, 1082, 1012 cm−1.
Melting point: 153.3 − 156.7 ◦C.
Mass spectrum (APCI +) m/z: Found 311.1629 (M+H)+; calculated for C18H21N3O2 311.1633; 1.2
ppm.
Yield: 0.77 g, 69%.
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N-[(4-Pentylbenzoyl)oxy]-4-pyridinecarboximidamide (61)
a
b
c
d
e
f
g
h
(
ü ý
ý
ü
üþ
ß
1H NMR (250 MHz, d6-DMSO): 8.70 (d, 2H, J = 5.4 Hz, -b and c), 8.34 − 7.98 (overlapping m, 2H,
-e and h), 7.75 (dd, 2H, J = 4.5, 1.6 Hz, -a and d), 7.36 (d, 2H, J = 8.3 Hz, -f and g), 6.98 (s, 2H,
-NH2), 2.70 (t, 2H, J = 6.5 Hz, -CH2CH2(CH2 )2 CH3), 1.64 (dt, 1H, J = 14.9, 7.3 Hz, -CH2CH2(CH2 )2
CH3), 1.48 − 1.20 (overlapping m, 4H, -CH2CH2(CH2 )2 CH3), 0.88 (t, 3H, J = 8.3, 5.4 Hz,J = 6.8 Hz,
-CH2CH2(CH2 )2 CH3) ppm.
IR (KBr disc) ν: 3448 (N-H), 3346 (N-H), 3030 (Aromatic C-H), 2951, 2928, 2854, 2339, 1722, 1615
(C=O), 1532, 1411, 1309, 1263, 1170, 1110, 1017 cm−1.
Melting point: 120.3 − 121.9 ◦C.
Mass spectrum (APCI +) m/z: Found 311.1624 (M+H)+; calculated for C18H21N3O2 311.1633; 2.8
ppm.
Yield: 0.81 g, 72%.
N-[(4-Hexylbenzoyl)oxy]-2-pyridinecarboximidamide (62)
a
b
c
d
e
f
g
h
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1H NMR (250 MHz, d6-DMSO): 8.68 (ddd, 1H, J = 4.8, 1.7, 1.0 Hz, -a), 8.32 − 8.00 (overlapping m, 2H,
-e and h), 7.99 − 7.86 (overlapping m, 2H, -b and d), 7.56 (ddd, 1H, J = 7.4, 4.8, 1.3 Hz, -c), 7.36 (d,
2H, J = 8.4 Hz, -f and g), 6.89 (s, 2H, -NH2), 2.71 (t, 2H, J = 6.5 Hz, -CH2CH2(CH2 )3CH3), 1.61 (dd,
2H, J = 14.8, 7.2 Hz, -CH2CH2(CH2 )3CH3), 1.33 (d, 6H, J = 10.3 Hz, -CH2CH2(CH2)3CH3), 1.02 (t, 3H,
J = 7.3 Hz, -CH2CH2(CH2 )3CH3) ppm.
IR (KBr disc) ν: 3463 (N-H), 3348 (N-H), 3049 (Aromatic C-H), 2916, 2953, 2847, 2154, 1929, 1718,
1626 (C=O), 1580, 1548, 1502, 1465, 1415, 1387, 1304, 1259, 1171, 1070, 1038, 1011 cm−1.
Melting point: 164.2 − 165.8 ◦C.
Mass spectrum (APCI +) m/z: Found 325.1786 (M+H)+; calculated for C19H23N3O2 325.1790; 1.2
ppm.
Yield: 0.80 g, 68%.
N-[(4-Hexylbenzoyl)oxy]-4-pyridinecarboximidamide (63)
a
b
c
d
e
f
g
h
(63)
N O
O
N
NH2
1H NMR (250 MHz, d6-DMSO): 8.70 (d, 2H, J = 5.1 Hz, -b and c), 8.10 (d, 2H, J = 8.3 Hz, -e and h),
7.75 (dd, 2H, J = 4.6, 1.5 Hz, -a and d), 7.35 (d, 2H, J = 8.3 Hz, -f and g), 7.16 (s, 2H, -NH2), 2.66 (t, J
= 7.6 Hz, 2H, -CH2CH2(CH2 )3CH3), 1.63 (dd, 2H, J = 27.0, 20.5 Hz, -CH2CH2(CH2 )3CH3), 1.29 (dd, J
= 11.4 Hz, 6H, -CH2CH2(CH2)3CH3), 0.84 (t, 3H, J = 6.7 Hz, -CH2CH2(CH2 )3CH3) ppm.
IR (KBr disc) ν: 3443 (N-H), 3346 (N-H), 3207, 3160, 3030 (Aromatic C-H), 2956, 2924, 2849, 1727,
1625 (C=O), 1532, 1499, 1462, 1407, 1305, 1272, 1179, 1110, 1012 cm−1.
Melting point: 133.7 − 135.4 ◦C.
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Mass spectrum (APCI +) m/z: Found 325.1781 (M+H)+; calculated for C19H23N3O2 325.1790; 2.7
ppm.
Yield: 0.88 g, 75%.
N-[(4-Heptylbenzoyl)oxy]-2-pyridinecarboximidamide (64)
a
b
c
d
e
f
g
h
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1H NMR (250 MHz, d6-DMSO): 8.68 (ddd, 1H, J = 4.8, 1.6, 1.0 Hz,-a), 8.36 − 8.01 (overlapping m, 2H,
-e and h), 7.94 (td, 1H, J = 7.7, 1.7 Hz, -c), 7.56 (ddd, 2H, J = 7.4, 4.8, 1.3 Hz,-b and d), 7.36 (d, 2H,
J = 8.3 Hz,-f and g), 6.92 (s, 2H, -NH2), 2.70 (t, 2H, J = 6.5 Hz, -CH2CH2(CH2 )4 CH3), 1.79 − 1.48
(overlapping m, 2H, -CH2CH2(CH2 )4 CH3), 1.29 (dd, 8H, J = 7.3, 3.4 Hz, -CH2CH2(CH2 )4CH3), 0.86
(t, 3H, J = 6.8 Hz, -CH2CH2(CH2 )4 CH3) ppm.
IR (KBr disc) ν: 3472 (N-H), 3366 (N-H), 2958 (Aromatic C-H), 2916, 2856, 2365, 1727, 1631 (C=O),
1580, 1548, 1503, 1461, 1415, 1387, 1309, 1263, 1249, 1181, 1075, 1006 cm−1.
Melting point: 142.2 − 143.4 ◦C.
Mass spectrum (APCI +) m/z: Found 339.1940 (M+H)+; calculated for C20H25N3O2 339.1946; 1.7
ppm.
Yield: 1 g, 82%.
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N-[(4-Heptylbenzoyl)oxy]-4-pyridinecarboximidamide (65)
a
b
c
d
e
f
g
h
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1H NMR (250 MHz, d6-DMSO): 8.70 (d, 2H, J = 6.0 Hz, -b and c), 8.26 − 8.04 (overlapping m, 2H, -e
and h), 7.75 (dd, 2H, J = 4.5, 1.6 Hz, -a and d), 7.35 (d, 2H, J = 8.3 Hz, -f and g), 6.99 (s, 2H, -NH2),
2.70 (t, 2H, J = 6.5 Hz, -CH2CH2(CH2 )4 CH3), 1.85 − 1.47 (overlapping m, 2H, -CH2CH2(CH2 )4 CH3),
1.30 (dd, 8H, J = 7.3, 3.4 Hz, -CH2CH2(CH2 )4CH3), 0.98 (t, 2H, J = 6.8 Hz,-CH2CH2(CH2 )4 CH3) ppm.
IR (KBr disc) ν:3435 (N-H), 3343 (N-H), 3201, 3036 (Aromatic C-H), 2953, 2921, 2838, 2361, 1718,
1617 (C=O), 1539, 1502, 1470, 1419, 1318, 1263, 1208, 1171, 1098, 1011 cm−1.
Melting point: 126.8 − 128.3 ◦C.
Mass spectrum (APCI +) m/z: Found 339.1936 (M+H)+; calculated for C20H25N3O2 339.1946; 2.9
ppm.
Yield: 0.90 g, 74%.
N-[(4-Octylbenzoyl)oxy]-2-pyridinecarboximidamide (66)
a
b
c
d
e
f
g
h
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1H NMR (250 MHz, d6-DMSO): 8.68 (ddd, 1H, J = 4.8, 1.6, 1.0 Hz, -a), 8.22 − 8.00 (overlapping m, 2H,
-e and h), 8.00 − 7.86 (overlapping m, 2H, -b and d), 7.56 (ddd, 1H, J = 7.4, 4.8, 1.3 Hz, -c), 7.35 (d,
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2H, J = 8.3 Hz, -f and g), 6.90 (s, 2H, -NH2), 2.68 (t, 2H, J = 6.5 Hz, -CH2CH2(CH2)5CH3), 1.72 − 1.51
(overlapping m, 2H, -CH2CH2(CH2 )5CH3), 1.28 (dd, 10H, J = 8.0, 4.0 Hz, -CH2CH2(CH2)5CH3), 0.86
(t, 3H, J = 6.7 Hz, -CH2CH2(CH2)5CH3) ppm.
IR (KBr disc) ν: 3476 (N-H), 3371 (N-H), 2962 (Aromatic C-H), 2925, 2843, 1718, 1626 (C=O), 1580,
1562, 1502, 1474, 1406, 1387, 1250, 1181, 1070, 1038 cm−1.
Melting point: 138.7 − 139.2 ◦C.
Mass spectrum (APCI +) m/z: Found 353.2099 (M+H)+; calculated for C21H27N3O2 353.2103; 1.1
ppm.
Yield: 0.85 g, 67%.
N-[(4-Octylbenzoyl)oxy]-4-pyridinecarboximidamide (67)
a
b
c
d
e
f
g
h
(67)
N O
O
N
NH2
1H NMR (250 MHz, d6-DMSO): 8.95 − 8.51 (overlapping m, 2H, -b and c), 8.08 (d, 2H, J = 8.3 Hz, -e
and h), 7.75 (dd, 2H, J = 4.5, 1.7 Hz, -a and d), 7.35 (d, 2H, J = 8.4 Hz, -f and g), 6.99 (s, 1H, -NH2),
2.70 (t, 2H, J = 6.5 Hz, -CH2CH2(CH2)5CH3), 1.85 − 1.48 (overlapping m, 2H, -CH2CH2(CH2)5CH3),
1.28 (d, 10H, J = 7.3 Hz, -CH2CH2(CH2)5CH3), 0.87 (t, 3H, J = 6.6 Hz, -CH2CH2(CH2)5CH3) ppm.
IR (KBr disc) ν: 3444 (N-H), 3339 (N-H), 3045 (Aromatic C-H), 2958, 2921, 2847, 2356, 1718, 1621
(C=O), 1529, 1497, 1461, 1410, 1314, 1263, 1167, 1098, 1006 cm−1.
Melting point: 125.0 − 127.2 ◦C.
Mass spectrum (APCI +) m/z: Found 353.2093 (M+H)+; calculated for C21H27N3O2 353.2103; 2.8
ppm.
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Yield: 0.93 g, 73%.
N-[(4-Decylbenzoyl)oxy]-2-pyridinecarboximidamide (68)
a
b
c
d
e
f
g
h
(68)
NH2
O
O
N
N
1H NMR (250 MHz, d6-DMSO): 8.74 − 8.60 (overlapping m, 1H, -a), 8.17 − 8.01 (overlapping m, 2H,
-e and h), 7.99 − 7.86 (overlapping m, 2H, -b and d), 7.56 (ddd, 1H, J = 7.4, 4.8, 1.3 Hz, -c), 7.35
(d, 2H, J = 8.3 Hz, -f and g), 6.89 (s, 2H, -NH2), 2.65 (t, 2H, J = 6.5 Hz, -CH2CH2(CH2)7CH3), 1.62
(m, 2H, -CH2CH2(CH2)7CH3), 1.28 (d, 14H, J = 13.0 Hz, -CH2CH2(CH2)7CH3), 0.86 (t, 3H, J = 6.6 Hz,
-CH2CH2(CH2)7CH3) ppm.
IR (KBr disc) ν: 3467 (N-H), 3371 (N-H), 2953 (Aromatic C-H), 2925, 2847, 1722, 1612 (C=O), 1580,
1562, 1461, 1383, 1268, 1419, 1176, 1089, 1006 cm−1.
Melting point: 137.8 − 138.5 ◦C.
Mass spectrum (APCI +) m/z: Found 381.2410 (M+H)+; calculated for C23H31N3O2 381.2416; 1.5
ppm.
Yield: 0.93 g, 67%.
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N-[(4-Decylbenzoyl)oxy]-4-pyridinecarboximidamide (69)
a
b
c
d
e
f
g
h
(69)
N O
O
N
NH2
1H NMR (250 MHz, d6-DMSO): 8.70 (dd, 2H, J = 4.6, 1.5 Hz, -b and c), 8.10 (d, 2H, J = 8.2 Hz, -e and
h), 7.75 (dd, 2H, J = 4.5, 1.6 Hz, -a and d), 7.35 (d, 2H, J = 8.2 Hz, -f and g), 7.12 (s, 2H, -NH2), 2.67
(t, 2H, J = 7.6 Hz, -CH2CH2(CH2)7CH3)), 1.60 (overlapping m, 2H, -CH2CH2(CH2)7CH3), 1.38 − 1.13
(overlapping m, 14H, -CH2CH2(CH2)7CH3), 0.85 (t, 3H, J = 6.6 Hz, -CH2CH2(CH2)7CH3) ppm.
IR (KBr disc) ν: 3442 (N-H), 3338 (N-H), 3115, 3053 (Aromatic C-H), 3021, 2938, 2911, 2851, 1703,
1616 (C=O), 1519, 1446, 1401, 1309, 1262, 1161, 1089, 1010 cm−1.
Melting point: 122.4 − 123.6 ◦C.
Mass spectrum (APCI +) m/z: Found 381.2407 (M+H)+; calculated for C23H31N3O2 381.2416; 2.3
ppm.
Yield: 0.95 g, 69%.
N-[(4-tert-Butylbenzoyl)oxy]-2-pyridinecarboximidamide (70)
a
b
c
d
e
f
g
h
(70)
NH2
O
O
N
N
1H NMR (250 MHz, d6-DMSO): 8.92 − 8.50 (overlapping m, 1H, -a and c), 8.31 − 8.08 (overlapping m,
1H, -b and d), 8.09 − 7.84 (overlapping m, 2H, -e and h), 7.58 (dd, 2H, J = 9.8, 4.9 Hz, -f and g), 7.06
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(s, 2H, -NH2), 1.41 (s, 9H, tert. butyl) ppm.
IR (KBr disc) ν: 3448 (N-H), 3328 (N-H), 3044 (Aromatic C-H), 2979, 2891, 2864, 2362, 1718, 1630
(C=O), 1583, 1560, 1472, 1439, 1383, 1356, 1272, 1295, 1184, 1156, 1091, 1026 cm−1.
Melting point: 186.4 − 187.8 ◦C.
Mass spectrum (APCI +) m/z: Found 297.1471 (M+H)+; calculated for C17H19N3O2 297.1477; 2.0
ppm.
Yield: 0.76 g, 71%.
N-[(4-tert-Butylbenzoyl)oxy]-4-pyridinecarboximidamide (71)
a
b
c
d
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1H NMR (250 MHz, d6-DMSO): 8.71 (dd, 2H, J = 4.5, 1.6 Hz, -b and c), 8.27 − 8.04 (overlapping m,
2H, -e and h), 7.75 (dd, 1H, J = 4.5, 1.6 Hz, -a and d), 7.56 (d, 1H, J = 8.5 Hz, -f and g), 7.15 (s, 2H,
-NH2), 1.41 (s, 9H, tert. butyl) ppm.
IR (KBr disc) ν: 3500 (N-H), 3454 (N-H), 3302, 3201, 3155, 3036 (Aromatic C-H), 2962, 2893, 2866,
2714, 2365, 1722, 1626 (C=O), 1534, 1451, 1401, 1355, 1272, 1190, 1116, 1089, 1011 cm−1.
Melting point: 168.1 − 169.4 ◦C.
Mass spectrum (APCI +) m/z: Found 297.1468 (M+H)+; calculated for C17H19N3O2 297.1477; 3.0
ppm.
Yield: 0.79 g, 74%.
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N-[(4-Isopropylbenzoyl)oxy]-2-pyridinecarboximidamide (72)
a
b
c
d
e
f
g
h
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
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
1H NMR (250 MHz, d6-DMSO): 8.79 (d, 1H, J = 4.7 Hz, -a), 8.22 − 7.98 (overlapping m, 2H, -e and
h), 7.63 (ddd, 3H, J = 7.4, 4.8, 1.1 Hz, -b , c and d), 7.55 (d, 2H, J = 8.4 Hz, -f and g), 3.01 (dq, 2H, J
= 13.7, 6.9 Hz, -CH2(CH3)2), 1.25 (d, 6H, J = 6.9 Hz, -CH2(CH3)2) ppm.
IR (KBr disc) ν: 3480 (N-H), 3382 (N-H), 3317, 3150, 2955 (Aromatic C-H), 2915, 2853, 1500, 1610
(C=O), 1578, 1531, 1462, 1424, 1417, 1373, 1350, 1323, 1225, 1160, 1115, 1001 cm−1.
Melting point: 139.6 − 140.7 ◦C.
Mass spectrum (APCI +) m/z: Found 283.1314 (M+H)+; calculated for C16H17N3O2 283.1320; 2.1
ppm.
Yield: 0.78 g, 76%.
N-[(4-Isopropylbenzoyl)oxy]-4-pyridinecarboximidamide (73)
a
b
c
d
e
f
g
h
(73)
N O
O
N
NH2
1H NMR (250 MHz, d6-DMSO): 9.22 − 8.65 (overlapping m, 2H, -b and c), 8.11 (d, 2H, J = 8.2 Hz,
-e and h), 7.86 − 7.69 (overlapping m, 2H, -a and d), 7.41 (d, 2H, J = 8.2 Hz, -f and g), 7.16 (s, 2H,
-NH2), 2.99 (dt, 1H, J = 13.6, 6.7 Hz, -CH2(CH3)2), 1.23 (d, 6H, J = 6.9 Hz, -CH2(CH3)2) ppm.
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IR (KBr disc) ν: 3438 (N-H), 3317 (N-H), 3034 (Aromatic C-H), 2969, 2881, 2853, 2352, 1716, 1619
(C=O), 1573, 1550, 1462, 1429, 1373, 1346, 1285, 1262, 1174, 1146, 1081, 1016 cm−1.
Melting point: 135.4 − 136.3 ◦C.
Mass spectrum (APCI +) m/z: Found 283.1309 (M+H)+; calculated for C16H17N3O2 283.1320; 3.8
ppm.
Yield: 0.83 g, 81%.
N-[(3, 5-ditert-butyl-2-hydroxy-phenyl)oxy]-2-pyridinecarboximidamide (74)
a
b
c
d
(74)
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1H NMR (250 MHz, d6-DMSO): 11.55 (s, 1H, −OH), 8.71 (d, 1H, J = 4.0 Hz, -a), 8.23 − 7.86 (overlap-
ping m, 2H, -e and f), 7.58 (ddd, 3H, J = 11.5, 7.5, 1.9 Hz, -b, c and d), 7.16 (s, 2H, -NH2), 1.43 (s,
9H, tert. butyl), 1.27 (s, 9H, tert. butyl) ppm.
IR (KBr disc) ν: 3480 (OH), 3382 (N-H), 3317 (N-H), 3150, 2955 (Aliphatic C-H), 2915, 2856, 1680,
1610 (C=O), 1578, 1531, 1462, 1424, 1417, 1373, 1350, 1323, 1262, 1225, 1160, 1127, 1115, 1107
cm−1.
Melting point: 166.4 − 177.8 ◦C.
Mass spectrum (APCI +) m/z: Found 369.2046 (M+H)+; calculated for C21H27N3O2 369.2052; 1.6
ppm.
Yield: 0.86 g, 64%.
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N-[(3, 5-ditert-butyl-2-hydroxy-phenyl)oxy]-4-pyridinecarboximidamide (75)
e f
a
b
c
d
(75
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1H NMR (250 MHz, d6-DMSO): 11.51 (s, 1H, −OH), 8.85 (d, 2H, J = 5.9 Hz, -b and c), 8.14 (d, 2H, J
= 6.0 Hz, -e and f), 7.58 (ddd, 2H, J = 11.5, 7.5, 1.9 Hz, -a and d), 7.33 (s, 2H, -NH2), 1.43 (s, 9H, tert.
butyl), 1.27 (s, 9H, tert. butyl) ppm.
IR (KBr disc) ν: 3490 (OH), 3392 (N-H), 3327 (N-H), 3160, 2965 (Aromatic C-H), 2905, 2863, 2719,
2367, 1690, 1620 (C=O), 1588, 1541, 1472, 1434, 1407, 1383, 1360, 1332, 1272, 1235, 1170, 1137,
1105 cm−1.
Melting point: 176.4 − 177.6 ◦C.
Mass spectrum (APCI +) m/z: Found 369.2040 (M+H)+; calculated for C21H27N3O2 369.2052; 3.2
ppm.
Yield: 1.03 g, 77%.
2.6.9 General method for preparation of Lithocholic acid derivatives
To a stirred solution of Lithocholic acid (0.5g, 1.35 mmol) in 20mL THF, under argon, N-methyl-morpholine
(0.15 g, 1.35 mmol) was added and the reaction was cooled over the ice bath for 10 mins. To this reac-
tion mixture ethylchloro carbonate (0.15 g, 1.35 mmol) was added over a period of 10 mins, followed by
amine (0.181 g, 1.35 mmol). This reaction mixture was stirred at 30 ◦C for 3 hours. The reaction mixture
is then poured in NaHCO3 sat. solution. The product precipates out and was collected by filtration and
washed with water (3×10mL).
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N-[(Z)-[amino(2-pyridyl)methylene]amino]-4-(8-hydroxy-10a,12a-dimethyl
-1,2,3,4,4a,4b,5,6,6a,7,8,9,10,10b,11,12-hexadecahydrochrysen-1-yl)-2-methyl-butanamide (21)
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1H NMR (250 MHz, d6-DMSO): 10.05 (s, 1H, -NH), 9.81 (s, 1H, -a), 8.56 (d, 1H, J = 4.5 Hz, -c), 8.06
(m, 1H, -d), 7.85 (t, 1H, J = 7.7 Hz, -b), 7.55 − 7.32 (overlapping m, 2H, -NH2), 6.87 (s, 1H, -OH), 6.63
(d, 5H, J = 17.5 Hz, -e and q), 4.47 (s, 4H, -s and u), 4.08 (q, 5H, J = 7.0 Hz, -r, g and h), 2.36 − 2.04
(overlapping m, 3H, -y), 2.04 − -0.26 (overlapping m, 20H, -i, j, k, l, m, n, o, p, t, v, w and x) ppm.
IR (KBr disc) ν: 3421 (OH), 3392 (N-H), 3377, 3327 (N-H), 3310, 3140, 2927, 2955 (Aromatic C-H),
2901, 2861, 2837, 2715, 2347, 1690, 1623 (C=O), 1588, 1541, 1463, 1414, 1407, 1371, 1350, 1332,
1272, 1235, 1170, 1137, 1105 cm−1.
Melting point: 187.8 − 189.5 ◦C.
Mass spectrum (APCI +) m/z: Found 508.3778 (M+H)+; calculated for C31H48N4O2 508.3777; 0.1
ppm.
Yield: 0.54 g, 78%.
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N-[(Z)-[amino(4-pyridyl)methylene]amino]-4-(8-hydroxy-10a,12a-dimethyl
-1,2,3,4,4a,4b,5,6,6a,7,8,9,10,10b,11,12-hexadecahydrochrysen-1-yl)-2-methyl-butanamide (22)
a
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1H NMR (250 MHz, d6-DMSO):9.74 (s, 1H, -NH), 8.60 (d, 2H, J = 4.9 Hz, -b and c), 7.71 (d, 2H, J =
5.5 Hz, -a and d), 6.87 (s, 2H, -NH2), 6.58 (d, 1H, J = 9.7 Hz, -f), 4.42 (s, 1H, -OH), 4.06 (dd, 6H, J =
12.0, 7.0 Hz, -r, l, g and h), 2.18 (s, 2H, -s), 1.93 (s, 2H, -m and n), 1.72 (d, 2H, J = 35.8 Hz, -i and j),
1.35 (s, 2H, -o), 1.28 − 1.04 (overlapping m, 4H, -k and p), 1.05 (s, 1H, -x), 0.98 − 0.76 (overlapping
m, 5H, -t, v and w), 0.61 (s, 3H, -y) ppm.
IR (KBr disc) ν: 3490 (OH), 3365 (N-H), 3346, 3327 (N-H), 3270, 3160, 3079, 2929, 2965 (Aromatic
C-H), 2905, 2863, 2851, 2719, 2401, 2367, 1641, 1610 (C=O), 1556, 1541, 1472, 1414, 1387, 1353,
1332, 1272, 1235, 1160, 1127, 1102 cm−1.
Melting point: 187.4 − 189.6 ◦C.
Mass spectrum (APCI +) m/z: Found 508.3768 (M+H)+; calculated for C31H48N4O2 508.3777; 1.7
ppm.
Yield: 0.47 g, 69%.
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Chapter 3
Cyclisation of carboxamidrazone amides
3.1 Introduction
The compounds that subsume a heterocyclic scaffold continue to gather a special interest due to their
wide spectrum of biological activity. This chapter reviews the literature concerning five membered ring
systems like 1,2,4-triazoles and 1,2,4-oxadiazoles.
Bladin (1885) first named a five membered carbon and nitrogen ring as triazole. His work depends
heavily on Fischer (1878)’s findings, that reaction of phenylhydrazine with cyanogen results in formation
of dicyanophenylhydrazine. Although the structures reported by Bladin (1885) were slightly incorrect, it
formed the basis of the triazole chemistry (Pellizzari 1911). Andreocci (1893) suggested an alternative
name for the ring system as pyrrodiazole, as it is an analogue of the parent structure pyrrole (Levy &
Andreocci (1888)). It was suggested that the numbering of pyrrodiazole should be similar to that of the
pyrrole, but later this was changed and the name triazole was universally accepted (see Fig. 3.1). There
was no significant research carried out in this field between 1925 to 1946.
The 1,2,4-triazoles developed a renewed interest when it was found that they possess agricultural,
industrial and biological activities (Rabea et al. (2006), Labanauskas et al. (2004)), including antibac-
terial (Bayrak et al. (2009), Holla et al. (2000), Shafiee et al. (2002), Sharma et al. (2008), Güler-
man et al. (2001), Papakonstantinou-Garoufalias et al. (2002), Turan-Zitouni et al. (2001)), anti-fungal
(Sharma et al. (2008), Gülerman et al. (2001), Papakonstantinou-Garoufalias et al. (2002), Turan-
Zitouni et al. (2005), Jalilian et al. (2000)), anti-tubercular (Küçükgüzel et al. (2001), Zahajska et al.
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(2004), Foroumadi et al. (2003)), analgesic (Turan-Zitouni et al. (2001), Tozkoparan et al. (2007)), anti-
inflammatory (Tozkoparan et al. (2007), Rabea et al. (2006), Labanauskas et al. (2004)), anticancer
(Shivarama Holla et al. (2003), Duran et al. (2002)), anti-convulsant (Almasirad et al. (2004), Küçükgüzel
et al. (2004)), antiviral (Kritsanida et al. (2002), Abdel-Aal et al. (2008)), insecticidal (Chai et al. (2003)),
and antidepressant (Varvaresou et al. (1998)) properties. The simple and fused ring triazoles emerged
as an important alternative to prepare photographic emulsions, this made it possible to avoid fogging
and also found its use in chemical herbicides. The triazole rings do not occur in nature and are prepared
synthetically.
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Figure 3.1: Two structures for 1,2,4-triazole. A: the widely accepted structure of triazole. B: the structure
of the pyrrodiazole.
Another related and important five membered ring is 1,2,4-oxadiazole. The cyclisation of aldoxime yields
oxadiazole. Tiemann & Krüger (1884) first synthesised 1,2,4-oxadiazoles and named it as ‘oxozimes’.
The early French scientists considered the oxadiazole ring as a furan ring with nitrogen substituting
two carbon atoms in the furan nucleus. They assigned the name furodiazole or furadiazole and the
position of nitrogen was determined by the symbols α and β′, while the early German literature (1800s)
considered the carbon atoms in the nucleus as a part of the substituents. Table. 3.1 Compares the
three nomenclature systems.
Nomenclature N
ON
German Dimethenylazoxim
French α,β′ -furadiazole
IUPAC 1,2,4-oxadiazole
Table 3.1: Comparison of three nomenclature systems.
Most of the oxadiazole analogues were synthesised by Tiemann and group. However their work in-
volved synthesis of 3,5 substituted aromatic compounds. It was Barrans in 1959 who first synthesised
oxadiazoles with aliphatic substituents (Lenaers et al. (1962)). The 1,2,4-oxadiazole on its own and
other mono-substituted oxadiazoles were synthesised in early 1960s (Lenaers et al. (1962), Hellmann
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et al. (1961), Moussebois et al. (1962), Eloy et al. (1961)). The 1,2,4-oxadiazole is also well known for
its biological activity such as anti asthmatics, anti diabetic, anti inflammatory, anti microbial, anti tumoral
and anti mycobacterial.
The following section discusses synthesis of libraries of 1,2,4-triazole and 1,2,4-oxadiazole analogues
by attaching the substituents which are known to possess biological activity.
3.2 Lead optimisation
This study is a continuation of the linear and flexible carboxamidrazone compounds synthesised at
Aston university as discussed in chapter 2. The structure in Fig. 3.2 shows the modifications made in
the original lead compound (see 2.10).
, 
, 
, 
Heteroaryl
moeity
2-Pyridyl, 4-Pyridyl
Substitution of heterocyclic ring system
Aromatic moeity
1.Substitution on the Aromatic ring, 
R= C1 to C10, 
, 
R=C3 to C5 and 
C7, C8 and C10
, 
2.Subtitution of aliphatic carbon chain.
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N
N
N
N
H
R
O
NH 2
N
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Figure 3.2: Summary of the changes made in this study to the original lead compound.
A series of biologically active carboxamidrazone compounds were synthesised at Aston university, which
are linear and flexible. Based on this knowledge some newer carboxamidrazone compounds that are
structurally similar were synthesised by building a heterocyclic scaffold in the centre of the active com-
pound’s structure. To study this effect a small experiment was carried out using the molecular modelling
software ‘Cache’. The linear carboxamidrazone amide and a 1,2,4-triazole (cyclised) were modelled
using Cache and optimised using MOPAC PM3. The linear and cyclised compounds were superim-
posed in the Cache to study the effect of different scaffold ring sizes on the relative orientations of the
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substituents on the scaffold in comparison to the original linear carboxamidrazones. The computational
data revealed that upon cyclisation the structure becomes rigid and all the rings are in the same plane
as opposed to the original carboxamidrazone, which has a benzoyl moiety forming an obtuse angle with
the pyridine ring. This gave an advantage over the linear structure as the structure became rigid (see
Fig. 3.3) and the overall entropy penalty of the compound was decreased, potentially increasing its
binding affinity providing the size and shape constraints imposed by the receptor are met.
a b
c d
Figure 3.3: Superimposed structures of the linear and cyclised compounds; (a) carboxamidrazone
amide; (b) cyclised carboxamidrazone amide; The highlighted atoms were the super-impositioning sites;
(c) superimposed; (d) superimposed side view.
3.2.1 Synthesis of the intended triazoles and oxadiazoles
Choosing the Aryl building block
To synthesise a library of 1,2,4-triazole and 1,2,4-oxadiazole compounds, the aryl groups were selected
based on the knowledge of the previous research carried out at Aston university.
Ren (2009) has shown that the five or six carbon alkyl chain attached at para position of the benzoyl
ring is optimum for the activity. Hence the compounds with chain length of one to eight carbons and
ten carbons were chosen to complete this matrix. Table. 3.2 lists all the acids and acid chlorides
used for synthesis of compound D. Some of the acyclic aliphatic substituents are also used. The past
research suggests that 2,4-ditert-butyl-phenol substituent has biological activity. Hence for this study
the 2,4-ditert-butyl-phenol and its compounds with similar side chains were used. For this study alkoxy
substituted benzoyl groups were also considered, as they are structurally similar to the alkyl substituted
benzoyl group.
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Table 3.2: Acid chlorides and acids used in synthesis of cyclised compounds
Pyridyl building block
Tanaka et al. (1994) and Rathbone et al. (2006) have synthesised various pyridine carboxamidrazones
by reacting cyanopyridines with hydrazine and have tested them against Mycobacterium tuberculosis.
Some of the compounds exhibited antimycobacterial activity. The previous research carried out in Aston
university by Tims (2002), Ren (2009), and Sikdar (2010) has shown that 2- and 4- substituted pyridyl
carboxamidrazones are the most active and stable pyridyl carboxamidrazones (see chapter 2.3.1).
Hence for this study these two pyridyl carboxamidrazones were predominantly used. However other
pyridyl groups used were pyridine-N-oxides. In the following are the lead compounds of this study:
3.2.2 COMPOUND D (1,2,4-triazole compounds)
R
N
N
NH
R
R
N
H
N
N
OH
H H
H
H
Figure 3.4: General structure of 1,2,4-triazole compounds
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This class of compound was synthesised with a view to combine different fragments of known activity
like 2 and 4 substituted pyridyl moieties and a benzoyl moiety with an alkyl or fused ring substitution
along with the 1,2,4-triazole ring system.
The synthesis of the bile acid related compounds discussed in this chapter is a continuation of the work
carried out in chapter 2. This phase two reaction involves cyclisation of the carboxamidrazone amide
fragment attached to a bile acid to the 1,2,4-triazole ring.
3.2.3 COMPOUND E (1,2,4-oxadiazole compounds)
R1
R
N
O
N
Figure 3.5: General structure of Compound B
The 1,2,4-oxadiazole class of compound was selected as it is known to possess antimycobacterial ac-
tivity (Kumar et al. (2011)). A library of compounds was synthesised and tested against Mycobacterium
tuberculosis.
3.2.4 Cyclisation of urea compounds
RN
H
N
N
NH
R
Figure 3.6: General structure of Compound C
This reaction involved cyclisation of the urea carboxamidrazone at high temperature. The linear chain
urea carboxamidrazone compounds were found to be generally inactive as mentioned in chapter 2. In
an attempt to increase the activity, cyclisation was carried out.
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3.2.5 Cyclisation of N-oxide compounds
NH
N
+
O
–
N
N
R
Figure 3.7: General structure of Compound D
This class of compound was synthesised to study the effect N-oxide has on cyclisation chemistry.
3.3 Results and Discussion
3.3.1 COMPOUND D (1,2,4-triazole compounds)
The carboxamidrazone amides were synthesised according to the synthetic pathway depicted in the
Scheme. 2.4.1, in accordance with previously reported procedures. Synthesis of the target compounds
required a single step reaction where the aryl carboxamidrazone amide was heated at reflux in ethylene
glycol for 10-12 hours, as a result carboxamidrazone amide condensed to give 1,2,4, -triazole products
(see Scheme. 3.1).
Some of the analogues of carboxamidrazone amides where acid chlorides were unavailable were pre-
pared from acids as discussed in Scheme. 2.4.1 in chapter 2.
Compound D
el e gl
e amide Pyridyl-1,2,4-triazole
Pyridyl
Pyridyl
N
H
N
N
R
N
N
H
R
O
NH2
Scheme 3.1: Scheme for the synthesis of 1,2,4-triazole compound from condensation of carboxamidra-
zone amide.
The pyridyl carboxamidrazone 3α-hydroxy-5β-cholan-24-oic acid compound was synthesised as dis-
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cussed in the Scheme. 2.4.1 in chapter 2. These carboxamidrazone amides on heating at reflux in
ethylene glycol for 8 hours’ charred. Therefore the reaction time was reduced from 8 to 4 hours with
hourly TLC performed to monitor the progress of the reaction. The compound decomposed at the end of
4 hours and a sticky mass was obtained which did not dissolve in either polar or non-polar solvents. The
compounds also did not separate into different spots on TLC thus ruling out column chromatography as
a method of isolation. The NMR spectrum of the partially soluble portion of the compound in DMSO
showed a number of complex peaks, but no significant structure could be elucidated.
Pyridyl carboxamidrazone amide *+,-.+d com/ound
Pyridyl
Pyridyl
01
2
2
1
2
1 1
1
1
21
2
21
3
0
01
1 1
1
1
Scheme 3.2: Scheme for the attempted synthesis of 1,2,4-triazole compound from condensation of bile
acid related carboxamidrazone amide.
All the compounds were characterised by their melting points and spectral data (1H NMR, IR and MS).
The IR spectrum shows a characteristic peak of 1,2,4, -triazole compound (C=N) at 1640 − 1560 cm−1
(Curtis & Jennings (2008)). The absence of the NH bond in NMR spectrum in the region of 9 to 10
ppm as seen in the parent carboxamidrazone amide NMR spectrum and the absence of the broad
carbonyl peak in IR spectrum in the range of 1665 − 1760 cm−1 suggests the complete conversion
of the carboxamidrazone amide to carboxamidrazone 1,2,4-triazole compound. According to Curtis &
Jennings (2008), the 1,2,4-triazole shows an additional N=N peak at 1570− 1550 cm−1, however it was
observed that the IR spectrum had many smaller insignificant peaks which made it difficult to identify the
compound structure. To confirm whether the structure has an exchangeable hydrogen bond attached to
one of the nitrogens in the ring or to the triazole carbon, an experiment was conducted. A D2O shake
NMR was obtained to see if the peak observed in the range of 5 to 6 ppm disappears. The absence
of the peak confirmed that it was an exchangeable hydrogen bond attached to nitrogen. These results
were in agreement with the results obtained by Nagahara & Takada (1982).
Table. 3.3 lists the analogues of the final product compound D shown in Fig. 3.1 synthesised along with
their yields and melting points.
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RN
N
NH
R
Compound
number
Pyridyl Aryl group Yield
(%)
Melting point
(◦C)
(89) 2-Pyridyl 72.3 143.0− 144.2
(90) 4-Pyridyl 71.2 229.1− 231.3
(91) 2-Pyridyl 64.4 176.9− 178.9
(92) 4-Pyridyl 69.2 219.5− 221.2
(93) 2-Pyridyl 24.4 −
(94) 4-Pyridyl 64 202.2− 203.9
(95) 2-Pyridyl 67.1 148.7− 150.3
(96) 4-Pyridyl 61.3 183.5− 185.2
(97) 2-Pyridyl 73.2 130.4− 131.6
(98) 4-Pyridyl 58.2 171.8− 172.7
(99) 2-Pyridyl 47.2 128.4− 129.5
(100) 4-Pyridyl 49.3 156.1− 157.0
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Compound
number
Pyridyl Aryl group Yield
(%)
Melting point
(◦C)
(101) 2-Pyridyl 57.1 113.0− 114.9
(102) 4-Pyridyl 71 142.8− 144.2
(103) 2-Pyridyl 71.4 121.8− 123.9
(104) 4-Pyridyl 65.2 143.1− 144.6
(105) 2-Pyridyl 75.3 104.8− 105.9
(106) 4-Pyridyl 78.3 154.4− 155.7
(107) 2-Pyridyl 67.2 178.3− 180.7
(108) 4-Pyridyl 64.4 253.9− 255.2
(109) 2-Pyridyl 23.1 −
(110) 4-Pyridyl 65.2 218.2− 219.6
(111) 2-Pyridyl 32 212.5− 213.3
(112) 4-Pyridyl 47.2 277.6− 278.8
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Compound
number
Pyridyl Aryl group Yield
(%)
Melting point
(◦C)
(113) 2-Pyridyl 28.1 −
(114) 4-Pyridyl 37.4 288.1− 292.3
(115) 2-Pyridyl 74.2 217.5− 219.5
(116) 4-Pyridyl 82.3 287.1− 291.3
(117) 2-Pyridyl O 61 157.9− 161.0
(118) 4-Pyridyl 4 58.3 192.4− 193.1
(119) 2-Pyridyl 5 67.2 151.2− 152.6
(120) 4-Pyridyl 6 78.4 177.3− 179.2
(121) 2-Pyridyl 7 63 124.3− 125.9
(122) 2-Pyridyl 8 68 163.3− 164.5
(123) 4-Pyridyl 9 46 154.3− 155.1
157
Compound
number
Pyridyl Aryl group Yield
(%)
Melting point
(◦C)
(124) 4-Pyridyl : 75.4 167.8− 168.5
(125) 2-Pyridyl ; 62.1 181.8− 182.6
(126) 4-Pyridyl < 57.1 143.2− 144.4
(127) 2-Pyridyl 20.3 −
(128) 2-Pyridyl 33.1 49.1 − 50.7
(129) 4-Pyridyl 62.4 104.2− 106.8
(130) 2-Pyridyl 69 65.9 − 67.1
(131) 4-Pyridyl 73.3 101.2− 103.3
(132) 2-Pyridyl 27.2 −
(133) 4-Pyridyl 46.4 87.3 − 88.4
Table 3.3: List of analogues of compound D
3.3.2 COMPOUND E (1,2,4-oxadiazole compounds)
Dry heat
Aldoxime Pyridyl-1,2,4-oxadiazole
Pyridyl
Pyridyl
O
N
N
R
N
O R
O
NH2
Scheme 3.3: Scheme for the synthesis of 1,2,4-oxadiazole compound from condensation of aldoxime.
The dehydration of the acyl derivatives of the aldoximes facilitates the easy formation of 1,2,4-oxadiazole.
Eloy et al. (1961) suggested various methods for dehydration of the aldoximes which involves heating
the compounds in water, dilute NaOH, glacial acetic acid, acetic anhydride, H2SO4 or in a dry state. The
authors observed that if acylation of aldoxime is carried out at 100 ◦C or above, cyclisation occurs (Eloy
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et al. (1961)).
The N’-[(alkyl)oxy]pyridyl carboximidamide (compound B) were synthesised from aldoximes as dis-
cussed in Scheme. 2.4 in chapter 2. The compound B was heated in water at reflux for 4 hours to
allow the dehydration. However the reaction did not go to the completion, although a hint of the product
was observed by TLC. This reaction was optimised by increasing the reaction time to 12 hours and
to the 10 mL solution of aldoxime in water, 5 mL of acetonitrile was added to completely dissolve the
sample, yet the cyclisation was not completed. Similarly, on heating the aldoximes in DMSO at reflux,
the reaction did not go to completion.
The compound B was then subjected to the ethylene glycol reaction as discussed in the Scheme. 3.1.
Ethylene glycol boils at 197.3 ◦C which is much higher than the required temperature to induce cyclisa-
tion in aldoximes and their derivatives. The compound B when heated at reflux in ethylene glycol for 4
hours causes the compound to decompose and char.
The next reaction involved dry heating of the compound B in a borosilicate glass vessel at 150◦C, for 30
mins. The dry powder melted and upon slow cooling to room temperature the desired 1,2,4, -oxadiazole
product precipitated out which was be isolated by recrystallisation techniques (see Scheme. 3.3).
Some analogues of compound B where acid chlorides were unavailable were prepared from acids as
discussed in Scheme. 2.5 in chapter 2.
The analytical data, namely, mass spectrum, NMR, and IR were found to be consistent with the proposed
structure. The IR spectrum shows the characteristic peaks of 1,2,4, oxadiazole compound at (C=N)
at 1598 − 1592 cm−1, (C-O) at 1218 − 1119 cm−1 and (N-O) at 913 − 904 cm−1 as observed by
Hemming (2008). The absence of the broad carbonyl peak in IR spectrum in the range of 1665 −
1760 cm−1 suggests the complete conversion of the aldoxime to 1,2,4-oxadiazole compound. The data
obtained from NMR spectrum suggests that the NH2 peak present in the parent compound was found
to be absent in the product. Table 3.4 lists the analogues of the final product compound E shown in Fig.
3.3 synthesised along with their yields and melting points.
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Compound
number
Pyridyl Aryl group Yield
(%)
Melting point
(◦C)
(134) 2-Pyridyl 75.1 167.8− 168.5
(135) 4-Pyridyl 68.1 181.8− 182.6
(136) 2-Pyridyl 71.3 143.2− 144.4
(137) 4-Pyridyl 47.2 127.8− 129.3
(138) 2-Pyridyl 46.3 154.3− 155.1
(139) 4-Pyridyl 81.8 121.3− 122.9
(140) 2-Pyridyl 63.1 156.3− 157.7
(141) 4-Pyridyl 78 147.3− 148.6
(142) 2-Pyridyl 75.3 165.2− 166.8
(143) 4-Pyridyl 61.7 139.7− 140.2
(144) 2-Pyridyl 57.6 138.8− 139.5
(145) 4-Pyridyl 71.4 135.4− 136.9
(146) 2-Pyridyl 64.2 135.3− 136.5
(147) 4-Pyridyl 68.5 151.6− 152.9
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Compound
number
Pyridyl Aryl group Yield
(%)
Melting point
(◦C)
(148) 2-Pyridyl 58 135.4− 137.3
(149) 4-Pyridyl 49.4 129.4− 130.8
(150) 2-Pyridyl 64.3 156.7− 159.1
(151) 4-Pyridyl 65 156.9− 157.9
(152) 2-Pyridyl 56.2 187.4− 188.8
(153) 4-Pyridyl 65.2 168.1− 169.4
(154) 2-Pyridyl 68.4 154.5− 155.8
(155) 4-Pyridyl 63.4 153.8− 155.2
(156) 2-Pyridyl
OH
59.4 166.8− 170.2
(157) 4-Pyridyl
O=
61.3 176.8− 177.9
Table 3.4: List of analogues of compound E
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3.3.3 Attempted cyclisation of carboxamidrazone urea compounds
(158); Pyr dyl= 4 pyridine 
Pyridyl carboxamidrazone N1 -(4-tolyl) urea 
Pyridyl carboxamidrazone p -toluoyl isocyanate
THF / DMF
Ethylene glycol
Desired product
Major fragment (Pyridyl carboxamidrazone)
Ethylene glycol
Pyridyl
Pyridyl
Pyridyl
Pyridyl
NH
N
N
N
H
NH2
N
NH2
NH2
N
N
H
N
H
O
N C O
N
NH2
NH2
+
Scheme 3.4: Scheme for the cyclisation of urea derivative of carboxamidrazone amides.
The carboxamidrazone urea compounds were generally found to be inactive, hence an attempt was
made to cyclise these compounds in order to increase their activity. Pyridine-4-carboxamidrazone N1-
(4-tolyl)urea was synthesised by reacting 4-pyridyl carboxamidrazone with p-toluoyl isocyanate in DMF
and THF. The crude product was purified by recrystallisation using ethanol. The pure product obtained
was then heated at reflux in ethylene glycol for 8 hours. The product obtained was charred. Hence
the reaction time was reduced from 8 to 3 hours with an hourly TLC check performed to monitor the
completion of the reaction. However at the end of 3 hours the compound disintegrated into fragments,
major fragment identified was the starting material 4-pyridyl carboxamidrazone. At the high tempera-
ture of the attempted cyclisation reactions, the carboxamidrazone urea fragmented to regenerate the
carboxamidrazone.
Another reaction was carried out with fluorine substituted isocyanate to study the effect an electron
withdrawing group has on the cyclisation reaction. However the compound disintegrated and similar
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fragments of starting material were observed as in the previous reaction.
3.3.4 Cyclisation of N-oxide compounds
The N-oxide carboxamidrazone amide was obtained from the Aston university laboratory which was syn-
thesised by Khan (2008). In an attempt to cyclise, the compound was heated at reflux in ethylene glycol.
The crude product obtained contained hints of possibly the desired product along with starting material,
which was observed by two separate but closely placed spots on TLC that could not be separated using
column techniques. Recrystallisation techniques also failed to isolate a single product.
In order to ascertain if the positive charge on the pyridyl nitrogen was the potential reason for the
failure of the carboxamidrazone N-oxide to cyclise, another experiment was conducted in parallel to
this experiment as a control where 4-pyridyl substituted aldoxime compound synthesised was treated
with methyl iodide in DCM. The product obtained was then taken for the next step of cyclisation. As
expected the compound did not cyclise and the starting material was recovered. It was also observed
that 2-pyridyl substituted aldoxime did not react with methyl iodide.
3.3.5 Purity
The 2 and 4 substituted pyridine carboxamidrazones, both the starting materials for the preparation of
linear carboxamidrazone amide were clean and did not require further purification. The crude linear
carboxamidrazone amides were found to posses impurities and the pure compound was isolated by re-
crystallisation techniques. Most of the 1,2,4-triazole compounds obtained by cyclisation of these linear
carboxamidrazones were found to be clean, however some compounds were isolated by recrystallisa-
tion.
Both the 2 and 4 substituted pyridyl aldoxime starting materials for N’-[(alkyl)oxy]pyridyl carboximidamide
were found to be clean and in crystalline form. The aldoxime derivatives were generally pure, however
some of the compounds required purification. The 1,2,4-oxadiazole compounds obtained from cycli-
sation of the linear N’-[(alkyl)oxy]pyridyl carboximidamide were contaminated with some impurities and
were cleaned up using recrystallisation techniques.
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3.3.6 Solubility
The 2-pyridyl and 4-pyridyl carboxamidrazone amides were readily soluble in hot ethylene glycol.
3.3.7 NMR Data
The proton NMR spectra of the 1,2,4-triazole compounds were obtained from d6-DMSO and were con-
sistent with the proposed structures. The characteristic amide singlet peak from the carboxamidrazone
amide compounds which was observed in the range of 10 − 10.5 ppm, was absent indicating com-
pletion of the reaction. In many of the triazole compounds, an extra set of smaller peaks were seen
in the range of 5 − 6 ppm alongside the triazole -NH peak on the NMR spectrum. This is observed
since the compound exists in two forms (see Fig. 3.8). At a higher temperature (50◦C) the two peaks
merge into a single peak. This phenomenon occurs since the rate of interconversion of the two forms of
compound are less than the frequency of the NMR machine. At high temperature the rate is increased
and an average structure is obtained. Hence at high temperature the two singlets merge into one (see
Fig. 3.10).
Pyridyl R
N
H
N
N
N
H
Pyridyl R
N N
Figure 3.8: The two form of 1,2,4-triazole compound
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Figure 3.9: Structure of 2-[5-(4-butoxyphenyl)-1H-1,2,4-triazol-3-yl]pyridine
Figure 3.10: A comparison of NMR spectra representing two forms of 2-[5-(4-butylphenyl)-4H-1,2,4-triazol-3-yl]pyridine.
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3.3.8 Melting point data
The melting points of the compounds show a similar pattern as observed in section 2.4.7 in chapter
2. As the chain length of the benzoyl substituent increases, the melting point increases due to the
organisation of the crystal structure of the molecule and the surface area.
However there are exceptions to this rule, as in the case of (155) which has a higher mp than the (151)
where more rigid tert-butyl group present in the compound (155) may pack better in the crystal than
compound (151) with the longer and more flexible chain.
3.3.9 Microbiological results
The analogues of both the triazoles and oxadiazoles were sent to the National Institute of Allergy and
Infectious Diseases (NIAID, US) for screening against Mycobacterium tuberculosis. As discussed in
2.4.8 in chapter 2 these compound libraries were subjected to high throughput screening (HTS) pro-
cess. This process involves two stages: in the first stage, MABA and BTG assay are carried out in
parallel on H37Rv strain to determine the MIC, IC50 and IC90 concentration for the compounds. The
compounds which have MIC values of 32.47 µM or less are further taken to the second stage which
involves advanced anti mycobacterial susceptibility profiling (see 2.4.8) in chapter 2. The table gives the
results obtained from NIAID.
Compound number Activity MIC (µM) IC50 (µM) IC90 (µM)
(111) Active 16.24 14.71 15.68
(95) Active 32.47 19.38 22.14
(120) Weakly active 32.47 15.81 17.47
(117) Weakly active 32.47 27.08 28.83
(124) Weakly active 32.47 17.27 19.38
(89) Inactive >32.47 − −
(90) Inactive >32.47 − −
(91) Inactive >32.47 − −
(92) Inactive >32.47 − −
(93) Inactive >32.47 − −
(94) Inactive >32.47 − −
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Compound number Activity MIC (µM) IC50 (µM) IC90 (µM)
(96) Inactive >32.47 − −
(97) Inactive >32.47 − −
(98) Inactive >32.47 − −
(99) Inactive >32.47 − −
(100) Inactive >32.47 − −
(101) Inactive >32.47 − −
(102) Inactive >32.47 − −
(103) Inactive >32.47 − −
(104) Inactive >32.47 − −
(105) Inactive >32.47 − −
(106) Inactive >32.47 − −
(107) Inactive >32.47 − −
(108) Inactive >32.47 − −
(109) Inactive >32.47 − −
(110) Inactive >32.47 − −
(112) Inactive >32.47 − −
(113) Inactive >32.47 − −
(114) Inactive >32.47 − −
(115) Inactive >32.47 − −
(116) Inactive >32.47 − −
(118) Inactive >32.47 − −
(119) Inactive >32.47 − −
(121) Inactive >32.47 − −
(122) Inactive >32.47 − −
(123) Inactive >32.47 − −
(125) Inactive >32.47 − −
(126) Inactive >32.47 − −
(127) Inactive >32.47 − −
(128) Inactive >32.47 − −
(129) Inactive >32.47 − −
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Compound number Activity MIC (µM) IC50 (µM) IC90 (µM)
(130) Inactive >32.47 − −
(131) Inactive >32.47 − −
(132) Inactive >32.47 − −
(133) Inactive >32.47 − −
Table 3.5: The IC50 and IC90 values of the triazole compounds when tested against Mycobacterium
tuberculosis at the NIAID
The NIAID calculated the IC50 and IC90 values of the compounds having the MIC value less than or
equal to 32.47 µM.
The table 3.6 gives the microbiological results of oxadiazole compounds obtained from NIAID, US.
Compound number Activity MIC (µM) IC50 (µM) IC90 (µM)
(153) Active 50.00 38.55 45.62
(146) Active 50.00 26.38 47.99
(144) Weakly active 100.00 47.22 59.75
(142) Weakly active 100.00 49.70 72.33
(136) Weakly active 100.00 65.57 93.99
(137) Weakly active 100.00 67.18 89.18
(140) Inactive NA 70.50 >100.00
(150) Inactive NA 23.39 >100.00
(148) Inactive NA 23.38 >100.00
(138) Inactive NA 90.83 >100.00
(134) Inactive NA >100.00 >100.00
(135) Inactive NA >100.00 >100.00
(139) Inactive NA >100.00 >100.00
(141) Inactive NA >100.00 >100.00
(143) Inactive NA >100.00 >100.00
(145) Inactive NA >100.00 >100.00
(147) Inactive NA >100.00 >100.00
(149) Inactive NA >100.00 >100.00
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Compound number Activity MIC (µM) IC50 (µM) IC90 (µM)
(151) Inactive NA >100.00 >100.00
(152) Inactive NA >100.00 >100.00
(154) Inactive NA >100.00 >100.00
(155) Inactive NA >100.00 >100.00
(156) Inactive NA >100.00 >100.00
(157) Inactive NA >100.00 >100.00
Table 3.6: The MIC, IC50 and IC90 values of the oxadiazole compounds when tested against Mycobac-
terium tuberculosis at the NIAID
3.3.10 Structure activity relationship
The 2-pyridyl compounds were generally more active than the 4-pyridyl compounds. Upon cyclisation of
these carboxamidrazones to 1,2,4-triazoles and 1,2,4-oxadiazoles, a small number of the compounds
retained their activity while in most of the remaining compounds the activity was diminished. This might
be attributed to the significant increase in logP value caused by cyclisation of these linear carboxam-
idrazones amides, resulting in high lipophilicity and decreased cell permeability. Another reason might
be that the rigidity conferred upon the compound due to cyclisation, results in failure of the compound
to fit into the active site of the putative target enzyme. A direct correlation between the logP values
and activity could be made based on the concept of ‘sweet spot’ as defined in the molecular mass-logP
space (Hann & Keserü (2012)) (see Fig. 3.11).
The results obtained are in agreement with the Lipinski’s rule of five. The compounds in general passed
the first three rules: molecular weight (MW)< 500, number of hydrogen bond donors (HBD)< 5 and
number of hydrogen bond acceptors (HBA)< 10. But many compounds failed the last octanol-water
partition coefficient (ALOGP) criterion. The compounds which have the least activity have higher logP
values.
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Figure 3.11: MIC value as a function of logP
3.4 Summary and Conclusion
The incorporation of 1,2,4 substituted triazole and oxadiazole rings has not resulted in the desired im-
provement in the activity. For the future work other 5 and 6 membered cyclic structures can be synthe-
sised like 2-aminothiazoles, oxadiazolylthio, thiazolylthio and triazolylthio. Some compounds which are
structurally similar to cyclised carboxamidrazones, with the above mentioned rings have been shown to
posses activity against M. tuberculosis H37Rv strain (Ananthan et al. (2009)).
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3.5 EXPERIMENTAL
3.5.1 Chemicals
All the chemicals and solvents were used as supplied. 2-pyridine cyanide, 4-pyridine cyanide, N, N’-
carbonyl di-imidazole, hydrazine, hydroxylamine, Hu¨nig’s base, DMSO, and all the acids and acid chlo-
rides were purchased from Sigma Aldrich. The organic solvents used were purchased from Fisher
Chemicals. An aluminium silica gel 60 F254 plates (Merck) were used for thin layer chromatography
(TLC).
3.5.2 Instrumentation
Proton NMR spectra were obtained on a Bruker AC 250 instrument operation at 250MHz as solutions
in d6-DMSO or CDCl3 and referenced from δDMSO=2.50ppm or δCDCl3=7.27ppm unless otherwise
stated. Infrared spectra were recorded as KBr discs on a Mattson 3000 FTIR spectrophotometer and
neat on Nicolet iS5 RT−IR instrument + ID5 ATR Diamond Sampler holder accessory. (APCI-MS) was
carried out on a Hewlett-Packard 5989B quadruple instrument connected to an electrospray 59987A
unit with an APCI accessory and automatic injecting using a Hewlett-Packard 1100 series autosampler.
Accurate MS was carried out on TOF mass spectra (ESI mode) measured on a Waters LCT Premier
Mass Spectrometer. Some of the compounds were sent to EPSRC Mass Spectrometry Service Cen-
tre at Swansea, the compounds were tested on either of the following machines Thermofisher LTQ
Orbitrap XL, Finnigan MAT 95 XP, Applied Biosystems Voyager DE-STR, Waters Micromass ZQ4000,
Thermofisher DSQ-II, Agilent 5975 GCMS. Melting points were recorded on a Reichert-Jung Thermo
Galen hot stage microscope and were corrected.
3.5.3 General procedure for synthesis of 1,2,4-triazole from carboxamidrazone amide
The carboxamidrazone amide (0.5 g) was heated in ethylene glycol (4 mL) at reflux for 10-12 hours.
This reaction mixture was then added to ice cold water and crude product was precipitated. The crude
product was further purified by recrystallisation using appropriate solvent systems (water to methanol).
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2-[5-(p-Tolyl)-1H-1,2,4-triazol-3-yl]pyridine (89)
(89)
a
b
c d
e
f
g
h
N
NH
NN
1H NMR (d6-DMSO): 8.71 (d, 1H, J = 4.7 Hz, -a), 8.16 (d, 2H, J = 7.9 Hz, -e and h), 7.99 (d, 2H, J = 8.1
Hz, -b and d), 7.89 (d, J = 8.2 Hz, 3H, -c, f and g), 4.27 (s, 1H, triazole -NH), 2.38 (s, 3H, CH3) ppm.
IR (neat) ν: 3035 (Aromatic C-H), 2919, 2841 (Alkyl C-H), 1713, 1599, 1570 (C=N), 1563 (N=N), 1458,
1411, 1372, 1273, 1178, 1149, 1112, 1021, 1008 cm−1.
Melting point: 143.0 − 144.2 ◦C.
Mass spectrum(APCI +) m/z: Found 236.1053 (M+H)+; calculated for C14H12N4 236.1061; 3.3 ppm.
Yield: 0.37 g, 72.3%.
4-[5-(p-Tolyl)-1H-1,2,4-triazol-3-yl]pyridine (90)
(90)
ab
c d
e
f
g
h
N
N
N
NH
1H NMR (d6-DMSO): 8.71 (dd, 2H, J = 4.5, 1.6 Hz, -b and c), 8.02 − 7.93 (overlapping m, 4H, -a, d, e
and h), 7.37 (d, 2H, J = 7.9 Hz, -f and g), 4.28 (s, 1H, triazole -NH), 2.39 (s, 3H, CH3) ppm.
IR (neat) ν: 3104, 3046 (Aromatic C-H), 2936 (Alkyl C-H), 2877 (Alkyl C-H), 2792, 1643, 1609 (C=N),
1572, 1547 (N=N), 1507, 1456, 1423, 1386, 1334, 1297, 1218, 1190, 1177, 1144, 1085, 1068, 1038,
1019, 1002 cm−1.
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Melting point: 229.1 − 231.3 ◦C.
Mass spectrum(APCI+) m/z: Found 236.1100 (M+H)+; calculated for C14H12N4 236.1061; 16.5 ppm.
Yield: 0.4 g, 71.2%.
2-[5-(4-Ethylphenyl)-1H-1,2,4-triazol-3-yl]pyridine (91)
(91)
a
b
c d
e
f
g
h
N
NH
NN
1H NMR (d6-DMSO): 8.60 (d, 1H, J = 4.7 Hz, -a), 8.27 (d, 2H, J = 7.9 Hz, -e and h), 8.05 (d, 2H, J = 8.1
Hz, -b and d), 7.84 (d, J = 8.2 Hz, 3H, -c, f and g), 4.46 (s, 1H, triazole -NH), 2.64 (q, 2H, J = 7.6 Hz,
-CH2CH3), 1.22 (t, 3H, J = 6.5 Hz, -CH2CH3ppm.
IR (neat) ν: 3028 (Aromatic C-H), 2958 (Alkyl C-H), 1651, 1599 (C=N), 1571, 1554 (N=N), 1478, 1460,
1416, 1372, 1311, 1290, 1180, 1147, 1110, 1062, 1009 cm−1.
Melting point: 176.9 − 178.9 ◦C.
Mass spectrum(APCI +) m/z: Found 250.1198 (M+H)+; calculated for C15H14N4 250.1218; 7.9 ppm.
Yield: 0.33 g, 64.4%.
4-[5-(4-Ethylphenyl)-1H-1,2,4-triazol-3-yl]pyridine (92)
(92)
ab
c d
e
f
g
h
N
N
N
NH
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1H NMR (d6-DMSO): 8.71 (dd, 2H, J = 4.5, 1.6 Hz, -b and c), 8.04 − 7.95 (overlapping m, 4H, -a, d, e
and h), 7.40 (d, 2H, J = 8.4 Hz, -f an g), 4.25 (s, 1H, triazole -NH), 2.70 (q, 2H, J = 7.6 Hz, -CH2CH3),
1.24 (t, 3H, J = 6.5 Hz, -CH2CH3) ppm.
IR (neat) ν: 3105, 3042 (Aromatic C-H), 2961, 2871 (Alkyl C-H), 2759, 1715, 1611 (C=N), 1547 (N=N),
1509, 1446, 1422, 1413, 1385, 1213, 1175, 1139, 1062, 1021, 1003 cm−1.
Melting point: 219.5 − 221.2 ◦C.
Mass spectrum(APCI +) m/z: Found 250.1301 (M+H)+; calculated for C15H14N4 250.1218; 6.7 ppm.
Yield: 0.34 g, 69.2%.
2-[5-(4-Propylphenyl)-1H-1,2,4-triazol-3-yl]pyridine (93)
(93)
a
b
c d
e
f
g
h
N
NH
NN
1H NMR (d6-DMSO): 8.76 (d, 1H, J = 4.7 Hz, -a), 8.42 (d, 2H, J = 7.9 Hz, -e and h), 7.98 (d, 2H, J = 8.1
Hz, -b and d), 7.75 (d, J = 8.2 Hz, 3H, -c, f and g), 4.63 (s, 2H, triazole -NH), 2.64 (t, 2H, J = 6.5 Hz,
-CH2CH2CH3)1.86 (q, 2H, J = 7.6 Hz, -CH2CH2CH3), 1.21 (t, 3H, J = 6.5 Hz, -(CH2)2CH3ppm.
IR (neat) ν: 3043 (Aromatic C-H), 2952, 2862 (Alkyl C-H), 1712, 1597 (C=H), 1571, 1539 (N=N), 1483,
1462, 1415, 1374, 1273, 1179, 1144, 1083, 1021, 1007 cm−1.
Mass spectrum(APCI +) m/z: Found 264.1369 (M+H)+; calculated for C16H16N4 264.1374; 1.8 ppm.
Yield: 0.09 g, 24.4%.
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4-[5-(4-Propylphenyl)-1H-1,2,4-triazol-3-yl]pyridine (94)
(94)
ab
c d
e
f
g
h
N
N
N
NH
1H NMR (d6-DMSO): 8.71 (dd, 2H, J = 4.5, 1.6 Hz, -b and c), 8.02 − 7.94 (overlapping m, 4H, -a,
d, e and h), 7.38 (d, 2H, J = 8.2 Hz, -f and g), 4.27 (s, 1H, triazole -NH), 2.65 (t, 2H, J = 6.5 Hz, -
CH2CH2CH3), 1.65 (dq, 2H, J = 14.7, 7.3 Hz, -CH2CH2CH3), 0.93 (dd, 3H, J = 9.3, 5.4 Hz, -(CH2)2CH3)
ppm.
IR (neat) ν: 3109, 3072, 3030 (Aromatic C-H), 2956, 2929 (Alkyl C-H), 2869 (Alkyl C-H), 2753, 1682,
1645, 1613 (C=N), 1578, 1560 (N=N), 1504, 1487, 1443, 1421, 1391, 1381, 1345, 1305, 1279, 1232,
1174, 1150, 1117, 1086, 1036, 1006 cm−1.
Melting point: 202.2 − 203.9 ◦C.
Mass spectrum(APCI +) m/z: Found 264.1364 (M+H)+; calculated for C16H16N4 264.1374; 3.7 ppm.
Yield: 0.3 g, 64%.
2-[5-(4-Butylphenyl)-1H-1,2,4-triazol-3-yl]pyridine (95)
(95)
a
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1H NMR (d6-DMSO): 8.71 (d, 1H, J = 4.1 Hz, -a), 8.16 (d, 1H, J = 7.9 Hz, -e), 8.05 − 7.96 (overlapping
m, 3H, -h, b, and d), 7.51 (m, 1H, -c), 7.33 (d, 2H, J = 8.2 Hz, -f and g), 5.73 (s, 1H, triazole -NH), 2.64
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(t, 2H, J = 6.5 Hz, -CH2CH2CH2CH3), 1.62 (m, 2H, -CH2CH2CH2CH3), 1.35 (dq, 2H, J = 14.0, 7.2 Hz,
-CH2CH2CH2CH3), 0.93 (t, 3H, J = 7.3 Hz, -CH2CH2CH2CH3) ppm.
IR (neat) ν: 3123, 3068 (Aromatic C-H), 3028 (Aromatic C-H), 2928 (Alkyl C-H), 2854 (Alkyl C-H), 2781,
1600 (C=N), 1571 (N=N), 1555, 1497, 1478, 1461, 1442, 1427, 1416, 1374, 1307, 1288, 1247, 1177,
1150, 1099, 1043, 1021, 1009 cm−1.
Melting point: 148.7 − 150.3 ◦C.
Mass spectrum(APCI +) m/z: Found 278.1525 (M+H)+; calculated for C17H18N4 278.1531; 2.1 ppm.
Yield: 0.29 g, 67.1%.
4-[5-(4-Butylphenyl)-1H-1,2,4-triazol-3-yl]pyridine (96)
(96)
ab
c d
e
f
g
h
N
N
N
NH
1H NMR (d6-DMSO): 8.71 (d, 2H, J = 4.6 Hz, -b and c), 8.07− 7.95 (overlapping m, 4H, -e, h, a and d),
7.38 (d, 2H, J = 8.2 Hz, -f and g), 5.73 (s, 1H, triazole -NH), 2.67 (t, 2H, J = 7.6 Hz, -CH2CH2CH2CH3),
1.60 (dd, 2H, J = 15.2, 7.7 Hz, -CH2CH2CH2CH3), 1.35 (dq, 2H, J = 14.2, 7.2 Hz, -CH2CH2CH2CH3),
0.92 (t, 3H, J = 7.3 Hz, -CH2CH2CH2CH3) ppm.
IR (neat) ν: 3044 (Aromatic C-H), 2959 (Aromatic C-H), 2927 (Alkyl C-H), 2855 (Alkyl C-H), 2541, 1668,
1611 (C=N), 1572 (N=N), 1505, 1446, 1422, 1411, 1384, 1328, 1284, 1214, 1175, 1139, 1098, 1081,
1064, 1022, 1003 cm−1.
Melting point: 183.5 − 185.2 ◦C.
Mass spectrum(APCI +) m/z: Found 278.1520 (M+H)+; calculated for C17H18N4 278.1531; 3.9 ppm.
Yield: 0.32 g, 61.3%.
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2-[5-(4-Pentylphenyl)-1H-1,2,4-triazol-3-yl]pyridine (97)
(97)
a
b
c d
e
f
g
h
N
NH
NN
1H NMR (d6-DMSO): 9.06 (d, 1H, J = 4.4 Hz, -a), 8.76 (d, 1H, J = 8.1 Hz, -e), 8.46 − 8.11 (overlapping
m, 3H, -h, b, and d), 7.61 (m, 1H, -c), 7.12 (d, 2H, J = 8.1 Hz, -f and g), 6.51 (s, 1H, triazole -NH),
1.55 (t, 2H, J = 6.5 Hz, -CH2(CH2)3CH3), 1.33 (dq, 6H, J = 14.3, 7.2 Hz, -CH2(CH2)3CH3), 0.91 (t, 3H,
J = 7.3 Hz, -CH2(CH2)3CH3) ppm.
IR (neat) ν: 3119 (Aromatic C-H), 3031 (Aromatic C-H), 2956 (Aromatic C-H), 2930 (Alkyl C-H), 2850
(Alkyl C-H), 1611 (C=N), 1595, 1567 (N=N), 1475, 1457, 1445, 1429, 1410, 1389, 1358, 1335, 1317,
1283, 1258, 1218, 1202, 1189, 1165, 1115, 1055, 1042, 1028, 1007 cm−1.
Melting point: 130.4 − 131.6 ◦C.
Mass spectrum(APCI +) m/z: Found 292.1682 (M+H)+; calculated for C18H20N4 292.1687; 1.7 ppm.
Yield: 0.33 g, 63%.
4-[5-(4-Pentylphenyl)-1H-1,2,4-triazol-3-yl]pyridine (98)
(98)
ab
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e
f
g
h
N
N
N
NH
1H NMR (d6-DMSO): 8.71 (dd, 2H, J = 4.5, 1.6 Hz, -b aand c), 8.06 − 7.91 (overlapping m, 4H, -a,
d, e and h), 7.37 (d, 2H, J = 8.2 Hz, -f and g), 4.27 (s, 1H, triazole -NH), 2.65 (t, 2H, J = 6.5 Hz,
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-CH2(CH2)3CH3), 2.05 − 1.54 (overlapping m, 2H, -CH2(CH2)2CH2CH3), 1.32 (dd, J = 7.1, 3.8 Hz, 4H,
-CH2(CH2)2CH2CH3), 0.88 (t, 3H, J = 6.8 Hz, -CH2(CH2)3CH3) ppm.
IR (neat) ν: 3106, 3059 (Aromatic C-H), 2952, 2925 (Alkyl C-H), 2849, 1715, 1611 (C=N), 1569 (N=N),
1509, 1474, 1449, 1422, 1409, 1386, 1328, 1290, 1213, 1185, 1139, 1062, 1040, 1023, 1003 cm−1.
Melting point: 171.8 − 172.7 ◦C.
Mass spectrum(APCI +) m/z: Found 292.1689 (M+H)+; calculated for C18H20N4 292.1687; 0.6 ppm.
Yield: 0.29 g, 58%.
2-[5-(4-Hexylphenyl)-1H-1,2,4-triazol-3-yl]pyridine (99)
(99)
a
b
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1H NMR (d6-DMSO): 8.71 (d, 1H, J = 4.4 Hz, -a), 8.16 (d, 1H, J = 7.8 Hz, -e), 8.00 (d, 3H, J = 8.2
Hz, -h, b, and d), 7.57 − 7.47 (m, 1H, -c), 7.32 (d, 2H, J = 8.1 Hz, -f and g), 4.27 (dd, 1H, J =
6.4, 3.8 Hz, triazole -NH), 2.65 (t, 2H, J = 6.5 Hz, -CH2(CH2)4CH3), 1.61 (dd, 2H, J = 15.0, 7.1 Hz,
-CH2CH2(CH2)3CH3), 1.39 − 1.24 (overlapping m, 6H, -CH2CH2(CH2)3CH3), 0.86 (dd, 3H, J = 8.5, 5.5
Hz, -CH2(CH2)4CH3) ppm.
IR (neat) ν: 3029 (Aromatic C-H), 2926, 2849 (Alkyl C-H), 2849, 1715, 1601 (C=N), 1562 (N=N), 1551,
1531, 1478, 1461, 1416, 1374, 1150, 1070, 1009 cm−1.
Melting point: 128.4 − 129.5 ◦C.
Mass spectrum(APCI +) m/z: Found 306.1837 (M+H)+; calculated for C19H22N4 306.1844; 2.2 ppm.
Yield: 0.22 g, 47.2%.
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4-[5-(4-Hexylphenyl)-1H-1,2,4-triazol-3-yl]pyridine (100)
(100)
ab
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h
N
N
N
NH
1H NMR (d6-DMSO): 8.71 (dd, 2H, J = 4.5, 1.6 Hz, -b and c), 8.02 − 7.95 (overlapping m, 4H, -
a, d, e and h), 7.38 (d, 2H, J = 8.3 Hz, -f and g), 4.27 (s, 1H, triazole -NH), 2.65 (t, 2H, J =
6.5 Hz, -CH2(CH2)4CH3), 1.61 (d, 2H, J = 7.4 Hz, -CH2CH2(CH2)3CH3), 1.31 (overlapping m, 6H, -
CH2CH2(CH2)3CH3), 0.92 − 0.83 (t, 3H, J = 6.8 Hz, -CH2(CH2)4CH3) ppm.
IR (neat) ν: 3174, 3150, 3108, 3062 (Aromatic C-H), 2949 (Alkyl C-H), 2927 (Alkyl C-H), 2850 (Alkyl
C-H), 1715, 1644, 1609 (C=N), 1568, 1548 (N=N), 1506, 1448, 1420, 1386, 1328, 1272, 1214, 1186,
1174, 1138, 1062, 1036, cm−1.
Melting point: 156.1 − 157.0 ◦C.
Mass spectrum(APCI +) m/z: Found 306.1833 (M+H)+; calculated for C19H22N4 306.1844; 3.5 ppm.
Yield: 0.21 g, 49.3%.
2-[5-(4-Heptylphenyl)-1H-1,2,4-triazol-3-yl]pyridine (101)
(101)
a
b
c d
e
f
g
h
N
NH
NN
1H NMR (d6-DMSO): 8.71 (d, 1H, J = 4.1 Hz, -a), 8.16 (d, 1H, J = 7.9 Hz, -e), 7.99 (t, 3H, J = 6.7 Hz,
-h, b, and d), 7.52 (m, 1H, -c), 7.32 (d, 2H, J = 8.1 Hz, -f and g), 4.27 (s, 1H, triazole -NH), 2.65 (t, 2H,
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J = 6.5 Hz, -CH2(CH2)5CH3), 1.69 − 1.54 (overlapping m, 2H, -CH2CH2(CH2)4CH3), 1.30 (dd, 8H, J =
7.8, 4.1 Hz, -CH2CH2(CH2)4CH3), 0.87 (t, 3H, J = 6.8 Hz, -CH2(CH2)5CH3) ppm.
IR (neat) ν: 3167, 2921 (Aromatic C-H), 2929 (Alkyl C-H), 2869 (Alkyl C-H), 2850 (Alkyl C-H), 1715,
1644, 1615, 1598 (C=N), 1571, 1554 (N=N), 1482, 1462, 1425, 1373, 1272, 1178, 1143, 1115, 1097,
1049, 1020, 1008 cm−1.
Melting point: 113.0 − 114.9 ◦C.
Mass spectrum(APCI +) m/z: Found 320.2020 (M+H)+; calculated for C20H24N4 320.2000; 6.2 ppm.
Yield: 0.29 g, 57.1%.
4-[5-(4-Heptylphenyl)-1H-1,2,4-triazol-3-yl]pyridine (102)
(102)
ab
c d
e
f
g
h
N
N
N
NH
1H NMR (d6-DMSO): 8.71 (dd, 2H, J = 4.5, 1.6 Hz, -b and c), 8.01 − 7.96 (overlapping m, 4H, -a,
d, e and h), 7.37 (d, 2H, J = 8.3 Hz, -f and g), 4.28 (m, 1H, triazole -NH), 2.65 (t, 2H, J = 6.5 Hz,
-CH2(CH2)5CH3), 1.78 − 1.52 (overlapping m, 2H, -CH2CH2(CH2)4CH3), 1.35 − 1.22 (overlapping m,
8H, -CH2CH2(CH2)4CH3), 0.86 (t, 3H, J = 6.8 Hz, -CH2(CH2)5CH3) ppm.
IR (neat) ν: 3108, 3062 (Aromatic C-H), 2951, 2925 (Alkyl C-H), 2853 (Alkyl C-H), 1609 (C=N), 1568,
1507 (N=N), 1467, 1448, 1420, 1387, 1328, 1280, 1213, 1186, 1173, 1138, 1123, 1062, 1036, 1024,
1001 cm−1.
Melting point: 142.8 − 144.2 ◦C.
Mass spectrum(APCI +) m/z: Found 320.2015 (M+H)+; calculated for C20H24N4 320.2000; 4.6 ppm.
Yield: 0.41 g, 71%.
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2-[5-(4-Octylphenyl)-1H-1,2,4-triazol-3-yl]pyridine (103)
(103)
a
b
c d
e
f
g
h
N
NH
NN
1H NMR (d6-DMSO): 8.71 (d, 1H, J = 4.3 Hz, -a), 8.16 (d, J = 7.9 Hz, 1H, -e), 8.00 (d, 3H, J = 8.1 Hz, -h,
b, and d), 7.51 (m, 1H, -c), 7.32 (d, 2H, J = 8.0 Hz, -f and g), 5.75 (s, 1H, triazole -NH),2.64 (t, 2H, J =
6.5 Hz, -CH2 (CH2 )6 CH2), 1.61 (d, 2H, J = 7.1 Hz, -CH2 CH2 (CH2 )5 CH3), 1.39 − 1.19 (overlapping
m, 10H, -CH2 CH2 (CH2 )5 CH3), 0.90 − 0.82 (t, 3H, J = 7.3 Hz, -CH2 (CH2 )6 CH3) ppm.
IR (neat) ν: 3129, 3071 (Aromatic C-H), 3030 (Aromatic C-H), 2947 (Alkyl C-H), 2918 (Alkyl C-H), 2848
(Alkyl C-H), 2774, 2625, 2531, 2155, 2027, 1900, 1715, 1619, 1600 (C=N), 1571 (N=N), 1555, 1478,
1462, 1428, 1416, 1374, 1313, 1289, 1267, 1178, 1152, 1112, 1099, 1074, 1044, 1010 cm−1.
Melting point: 121.8 − 123.9 ◦C.
Mass spectrum(APCI +) m/z: Found 334.2151 (M+H)+; calculated for C21H26N4 334.2157; 1.7 ppm.
Yield: 0.38 g, 71.4%.
4-[5-(4-Octylphenyl)-1H-1,2,4-triazol-3-yl]pyridine (104)
(104)
ab
c d
e
f
g
h
N
N
N
NH
1H NMR (d6-DMSO): 8.71 (d, 2H, J = 5.1 Hz, -b and c), 8.02 − 7.96 (overlapping m, 4H, -e, h, a and
d), 7.37 (d, 2H, J = 7.9 Hz, -f and g), 5.75 (s, 1H, triazole -NH), 2.68 (t, 2H, J = 6.5 Hz, -CH2 (CH2 )6
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CH2), 1.68 − 1.56 (overlapping m, 2H, -CH2 CH2 (CH2 )5 CH3), 1.38 − 1.19 (overlapping m, 10H, -CH2
CH2 (CH2)5 CH3), 0.90 − 0.82 (t, 3H, J = 7.3 Hz, -CH2 (CH2 )6 CH3) ppm.
IR (neat) ν: 3047 (Aromatic C-H), 2955 (Aromatic C-H), 2918 (Alkyl C-H), 2848 (Alkyl C-H), 2774, 2637,
2534. 2155, 1795, 1612 (C=N), 1571 (N=N), 1510, 1463, 1447, 1421, 1387, 1329, 1277, 1213, 1183,
1173, 1141, 1099, 1064, 1021, 1004 cm−1.
Melting point: 143.1 − 144.6 ◦C.
Mass spectrum(APCI +) m/z: Found 334.2148 (M+H)+; calculated for C21H26N4 334.2157; 2.6 ppm.
Yield: 0.31 g, 65.2%.
2-[5-(4-Decylphenyl)-1H-1,2,4-triazol-3-yl]pyridine (105)
(105)
a
b
c d
e
f
g
h
N
NH
NN
1H NMR (d6-DMSO): 8.60 (d, 1H, J = 4.4 Hz, -a), 8.15 (s, 1H, -e), 7.93 − 7.77 (overlapping m, 3H, -h,
b, and d), 7.47 (m, 1H, -c), 7.29 (d, 2H, J = 8.2 Hz, -f and g), 6.79 (s, 1H, triazole -NH), 2.68 (t, 2H, J
= 6.5 Hz, -CH2(CH2)8CH3), 1.70 − 1.56 (overlapping m, 2H, -CH2CH2(CH2)7CH3), 1.31 (dd, 14H, J =
15.9, 12.4 Hz, -CH2CH2(CH2)7CH3), 0.86 (t, 3H, J = 6.6 Hz, -CH2(CH2)8CH3) ppm.
IR (neat) ν: 3129, 3068, 3030 (Aromatic C-H), 2917 (Alkyl C-H), 2847, 1646, 1615, 1601 (C=N), 1572,
1556 (N=N), 1479, 1462, 1416, 1374, 1269, 1178, 1151, 1113, 1098, 1044, 1010 cm−1.
Melting point: 104.8 − 105.9 ◦C.
Mass spectrum(APCI +) m/z: Found 362.2466 (M+H)+; calculated for C23H30N4 362.2470; 1.1 ppm.
Yield: 0.4 g, 75.3%.
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4-[5-(4-Decylphenyl)-1H-1,2,4-triazol-3-yl]pyridine (106)
(106)
ab
c d
e
f
g
h
N
N
N
NH
1H NMR (d6-DMSO): 8.65 (dd, 2H, J = 4.5, 1.6 Hz, -b and c), 8.09 − 7.96 (overlapping m, 4H, -a,
d, e and h), 7.27 (d, 2H, J = 8.3 Hz, -f and g), 4.32 (m, 1H, triazole -NH), 2.58 (t, 2H, J = 6.5 Hz,
-CH2(CH2)8CH3), 1.65 − 1.51 (overlapping m, 2H, -CH2CH2(CH2)7CH3), 1.26 (dd, 14H, J = 15.9, 12.4
Hz, -CH2CH2(CH2)7CH3), 0.94 (t, 3H, J = 6.6 Hz, -CH2(CH2)8CH3) ppm.
IR (neat) ν: 3058 (Aromatic C-H), 2953, 2918 (Alkyl C-H), 2848, 1719, 1647, 1611 (C=N), 1568 (N=N),
1552, 1537, 1488, 1467, 1451, 1413, 1387, 1369, 1324, 1273, 1180, 1138, 1110, 1078, 1065, 1047,
1021, 1005 cm−1.
Melting point: 154.4 − 155.7 ◦C.
Mass spectrum(APCI +) m/z: Found 362.2463 (M+H)+; calculated for C23H30N4 362.2470; 1.9 ppm.
Yield: 0.42 g, 78.3%.
2-[5-(4-tert-Butylphenyl)-1H-1,2,4-triazol-3-yl]pyridine (107)
(107)
a
b
c d
e
f
g
h
N
NH
NN
1H NMR (d6-DMSO): 8.72 (d, 1H, J = 4.3 Hz, -a), 8.62 (d, 1H, J = 8.1 Hz, -e), 8.46 − 8.11 (overlapping
m, 3H, -h, b, and d), 7.61 (m, 1H, -c), 7.12 (d, 2H, J = 8.1 Hz, -f and g), 6.51 (s, 2H, triazole -NH), 1.34
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(s, 9H, tert. butyl -(CH3)3) ppm.
IR (neat) ν: 3167, 3092, 3062 (Aromatic C-H), 2955, 2907 (Alkyl C-H), 2865 (Alkyl C-H), 1718, 1597
(C=N), 1568 (N=N), 1551, 1480, 1460, 1422, 1369, 1315, 1301, 1267, 1192, 1170, 1138, 1113, 1095,
1050, 1018, 1007 cm−1.
Melting point: 178.3 − 180.7 ◦C.
Mass spectrum(APCI +) m/z: Found 278.1526 (M+H)+; calculated for C17H18N4 278.1531; 1.7 ppm.
Yield: 0.3 g, 67.2%.
4-[5-(4-tert-Butylphenyl)-1H-1,2,4-triazol-3-yl]pyridine (108)
(108)
ab
c d
e
f
g
h
N
N
N
NH
1H NMR (d6-DMSO): 8.90 (d, 2H, J = 5.9 Hz, -b and c), 8.58 (d, 4H, J = 8.3 Hz, -a, d, e and h) 8.30 −
7.63 (overlapping m, 2H, -f and g), 6.51 (m, 1H, triazole -NH), 1.34 (s, 9H, tert. butyl -(CH3)3) ppm.
IR (neat) ν: 3059 (Aromatic C-H), 2965, 2945 (Alkyl C-H), 2878 (Alkyl C-H), 1715, 1611 (C=N), 1585,
1571, 1552 (N=N), 1510, 1472, 1449, 1419, 1385, 1361, 1313, 1292, 1265, 1243, 1212, 1198, 1169,
1142, 1109, 1062, 1044, 1024, 1003 cm−1.
Melting point: 253.9 − 255.2 ◦C.
Mass spectrum(APCI +) m/z: Found 278.1522 (M+H)+; calculated for C17H18N4 278.1531; 3.2 ppm.
Yield: 0.27 g, 64.4%.
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2-[5-(4-Isopropylphenyl)-1H-1,2,4-triazol-3-yl]pyridine (109)
(109)
a
b
c d
e
f
g
h
N
NH
NN
1H NMR (d6-DMSO): 8.96 − 8.49 (d, 1H, J = 4.4 Hz, -a), 8.45 (d, 1H, J = 8.1 Hz, -e), 8.31 − 8.10
(overlapping m, 3H, -h, b, and d), 7.54 (m, 1H, -c), 7.09 (d, 2H, J = 8.1 Hz, -f and g) 4.82 (d, 1H, J =
23.9 Hz, triazole -NH), 2.97 (dtt, 1H, J = 13.7, 6.8, 3.7 Hz, Isopropyl -(CH2), 1.61 (s, 6H, Isopropyl
-(CH3)2) ppm.
IR (neat) ν: 3052 (Aromatic C-H), 2954, 2868 (Alkyl C-H), 1715, 1610 (C=N), 1591, 1572, 1551 (N=N),
1505, 1462, 1416, 1394, 1336, 1310, 1274, 1249, 1182, 1153, 1085, 1038, 1007 cm−1.
Mass spectrum(APCI +) m/z: Found 264.1361 (M+H)+; calculated for C16H16N4 264.1374; 4.9 ppm.
Yield: 0.08 g, 23.1%.
4-[5-(4-Isopropylphenyl)-1H-1,2,4-triazol-3-yl]pyridine (110)
(110)
ab
c d
e
f
g
h
N
N
N
NH
1H NMR (d6-DMSO): 9.03 (d, 2H, J = 5.9 Hz, -b and c), 8.69 (d, 4H, J = 8.3 Hz, -a, d, e and h) 8.46 −
7.78 (overlapping m, 2H, -f and g), 4.82 (d, 1H, J = 23.9 Hz, triazole -NH), 2.94 (dtt, 1H, J = 13.7, 6.8,
3.7 Hz, Isopropyl -(CH2), 1.41 (s, 6H, Isopropyl -(CH3)2) ppm.
IR (neat) ν: 3043 (Aromatic C-H), 2957, 2870 (Alkyl C-H), 1714, 1610 (C=N), 1569 (N=N), 1505, 1446,
1413, 1384, 1362, 1328, 1274, 1212, 1172, 1138, 1084, 1054, 1019, 1003 cm−1.
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Melting point: 218.2 − 219.6 ◦C.
Mass spectrum(APCI +) m/z: Found 264.1358 (M+H)+; calculated for C16H16N4 264.1374; 6.0 ppm.
Yield: 0.31 g, 65.2%.
2-(5-Tetralin-6-yl-1H-1,2,4-triazol-3-yl)pyridine (111)
(111)
i
jk
a
b
c d
e
f g
h
N
NH
NN
1H NMR (d6-DMSO): 8.71 (m, 1H, -a), 7.99 (m, 1H, -c), 7.78 (d, 2H, J = 6.9 Hz, -b and d), 7.22 (d, 1H,
J = 8.5 Hz,triazole -NH), 3.20 (s, 5H, -k, e, f and g ), 2.86 − 2.76 (overlapping m, 2H, -h), 2.50 (d, 2H,
J = 1.9 Hz, -i), 1.79 (t, 2H, J = 3.1 Hz, -j) ppm.
IR (neat) ν: 3175 (Aromatic C-H), 3002 (Aromatic C-H), 2924 (Alkyl C-H), 2854 (Alkyl C-H), 1615, 1597
(C=N), 1581, 1571, 1551 (N=N), 1488, 1468, 1416, 1382, 1336, 1310, 1282, 1247, 1184, 1151, 1127,
1086, 1105, 1044, 1007 cm−1.
Melting point: 212.5 − 213.3 ◦C.
Mass spectrum(APCI +) m/z: Found 276.1369 (M+H)+; calculated for C17H16N4 276.1374; 1.8 ppm.
Yield: 0.16 g, 32%.
4-(5-Tetralin-6-yl-1H-1,2,4-triazol-3-yl)pyridine (112)
(112)
i
jk
ab
c d
e
f g
h
N
NH
N
N
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1H NMR (d6-DMSO): 8.71 (d, 2H, J = 4.3 Hz, -b and c), 8.38 − 7.72 (overlapping m, 2H, -a and d),
6.69 (s, 1H, triazole -NH), 4.28 (s, 3H, -e, f and k), 3.42 (s, 4H, g and h), 2.95 − 2.62 (overlapping m,
2H, i), 1.78 (d, 2H, J = 3.5 Hz, -j) ppm.
IR (neat) ν: 3165,3092 (Aromatic C-H), 3041 (Aromatic C-H), 3017, 2989, 2925 (Alkyl C-H), 2865 (Alkyl
C-H), 2828, 1659 (C=N), 1569 (N=N), 1499, 1457, 1451, 1422, 1396, 1351, 1317, 1281, 1247, 1208,
1190, 1175, 1120, 1007 cm−1.
Melting point: 277.6 − 278.8 ◦C.
Mass spectrum(APCI +) m/z: Found 276.1358 (M+H)+; calculated for C17H16N4 276.1374; 5.7 ppm.
Yield: 0.19 g, 47.2%.
2-[5-(2-Phenylphenyl)-1H-1,2,4-triazol-3-yl]pyridine (113)
(113)
i
j
k
m
a
]
]^
]
]
1H NMR (d6-DMSO): 8.74 (m, 1H, -a), 8.66 (d, 2H, J = 4.7 Hz, -c and d ), 8.01 (td, 1H, J = 7.4, 1.4 Hz,
-h), 7.94 (dd, 3H, J = 6.7, 2.7 Hz, -m, e, and g), 7.86 − 7.69 (overlapping m, 5H, -b, i, k, l and j), 7.53
(m, 1H, -f), 7.13 (m, 1H, triazole -NH) ppm.
IR (neat) ν: 3169, 3132 (Aromatic C-H), 3089 (Aromatic C-H), 3046, 2947 (Alkyl C-H), 2895 (Alkyl C-H),
2837, 1659, 1596 (C=N), 1570 (N=N), 1547, 1485, 1442, 1419, 1366, 1304, 1277, 1244, 1171, 1140,
1119, 1091, 1070, 1045, 1010 cm−1.
Melting point: − ◦C.
Mass spectrum(APCI +) m/z: Found 298.1210 (M+H)+; calculated for C19H14N4 298.1218; 2.6 ppm.
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Yield: 0.08 g, 28.1%.
4-[5-(2-Phenylphenyl)-1H-1,2,4-triazol-3-yl]pyridine (114)
(114)
i
j
k
m
a
_
_`
_
_
1H NMR (d6-DMSO): 8.68 (ddd, J = 12.0, 4.4, 1.6 Hz, 2H, -b and c), 7.96 (td, 2H, J = 7.4, 1.4 Hz, -a
and d), 7.82 (dd, 3H, J = 6.7, 2.7 Hz, -e, m and h), 7.76 − 7.69 (overlapping m, 5H, -f, i, g, k and l),
7.51 (m, 1H, -j), 6.26 (m, 1H, triazole -NH) ppm.
IR (neat) ν: 3169, 3130 (Aromatic C-H), 3079 (Aromatic C-H), 3046, 2951 (Alkyl C-H), 2885 (Alkyl C-H),
2832, 1660, 1576 (C=N), 1575 (N=N), 1550, 1475, 1445, 1421, 1364, 1303, 1267, 1242, 1176, 1138,
1129, 1095, 1060, 1025, 1007 cm−1.
Melting point: 288.1 − 292.3 ◦C.
Mass spectrum(APCI +) m/z: Found 298.1207 (M+H)+; calculated for C19H14N4 298.1218; 3.6 ppm.
Yield: 0.26 g, 37.4%.
2-[5-(4-Phenylphenyl)-1H-1,2,4-triazol-3-yl]pyridine (115)
(115)
i
j
k
m
a
a
a
b
a
a
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1H NMR (d6-DMSO): 8.74 (m, 1H, -a), 8.25 − 8.16 (overlapping m, 4H, -c, e, h and f), 8.02 (m, 1H, -g),
7.82 (d, 2H, J = 8.4 Hz, -i and k), 7.77 − 7.71 (overlapping m, 2H, -m and b), 7.52 (dt, 3H, J = 6.9, 3.2
Hz, -j, l and d), 7.49 − 7.22 (overlapping m, 1H, triazole -NH) ppm.
IR (neat) ν: 3129 (Aromatic C-H), 3065 (Aromatic C-H), 3029 (Aromatic C-H), 2958, 2892 (Alkyl C-H),
2844 (Alkyl C-H), 1682, 1598 (C=N) , 1569 (N=N), 1552, 1479, 1462, 1447, 1427, 1410, 1373, 1332,
1314, 1298, 1248, 1183, 1145, 1109, 1075, 1048, 1011 cm−1.
Melting point: 217.5 − 219.5 ◦C.
Mass spectrum(APCI +) m/z: Found 298.1201 (M+H)+; calculated for C19H14N4 298.1218; 5.7 ppm.
Yield: 0.43 g, 74.2%.
4-[5-(4-Phenylphenyl)-1H-1,2,4-triazol-3-yl]pyridine (116)
(116)
i
j
k
m
a
c
cd
c
c
1H NMR (d6-DMSO): 8.73 (dd, 2H, J = 4.5, 1.5 Hz, -b and c), 8.21 − 8.14 (overlapping m, 2H, -f and
g), 8.02 (dd, 2H, J = 4.5, 1.6 Hz, -i and m), 7.87 (d, 2H, J = 8.5 Hz, -e and h), 7.77 (dd, 1H, J = 5.2,
3.2 Hz, -a), 7.58 (m, 1H, -d), 7.50 (d, 1H, J = 6.0 Hz, -j and k), 7.44 (t, J = 1.3 Hz, 1H, -l), 7.39 (m, 1H,
triazole -NH) ppm.
IR (neat) ν:3031 (Aromatic C-H), 2927 (Alkyl C-H), 2855 (Alkyl C-H), 1652 (C=N), 1611, 1559 (N=N),
1515, 1487, 1438, 1421, 1384, 1213, 1175, 1145, 1709, 1062, 1023, 1006 cm−1.
Melting point: 287.1 − 291.3 ◦C.
Mass spectrum(APCI +) m/z: Found 298.1206 (M+H)+; calculated for C19H14N4 298.1218; 4.0 ppm.
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Yield: 0.44 g, 82.3%.
2-[3-(4-Propoxyphenyl)-1H-1,2,4-triazol-5-yl]pyridine (117)
a
b
c
d
e f
g
h
(ee7)
f
g
g
gh
g
1H NMR (d6-DMSO): 8.71 (d, 1H, J = 4.7 Hz, -a), 8.46 (d, 2H, J = 8.0 Hz, -c and d), 7.71 (t, 2H, J =
9.2 Hz, -e and h), 7.61 − 7.35 (m, 1H,-b), 7.07 (d, 2H, J = 8.8 Hz, -f and g), 6.77 (s, 1H, triazole -NH),
4.01 (t, 2H, J = 6.5 Hz, -OCH2CH2CH3), 2.00 − 1.58 (overlapping m, 2H, -OCH2CH2CH3), 0.76 (t, 3H,
J = 7.4 Hz, -OCH2CH2CH3) ppm.
IR (neat) ν: 3053 (Aromatic C-H), 2967, 2941 (Alkyl C-H), 2838, 1731, 1617, 1600, 1584 (C=N), 1571,
1553 (N=N), 1533, 1461, 1427, 1417, 1389, 1372, 1312, 1300, 1291, 1244, 1169, 1149, 1112, 1100,
1069, 1046, 1008 cm−1.
Melting point: 157.9 − 161.0 ◦C.
Mass spectrum(APCI +) m/z: Found 280.1319 (M+H)+; calculated for C16H16N4O 280.1324; 1.7
ppm.
Yield: 0.3 g, 61%.
4-[3-(4-Propoxyphenyl)-1H-1,2,4-triazol-5-yl]pyridine (118)
a
b
c
d
e f
g
h
(
i
j
j
j
k
j
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1H NMR (d6-DMSO): 8.78 (d, 2H, J = 5.9 Hz, -b and c), 8.47 (s, 2H, -a and d), 8.36− 7.70 (overlapping
m, 2H, -e and h), 7.34 (t, 2H, J = 7.8 Hz, -f and g), 6.89 (s, 1H, triazole -NH), 3.57 (t, 2H, J =
6.5 Hz, -OCH2CH2CH3), 1.95 − 1.56 (overlapping m, 2H, -OCH2CH2CH3), 0.80 (t, 3H, J = 7.4 Hz,
-OCH2CH2CH3) ppm.
IR (neat) ν: 3102 (Aromatic C-H), 3062 (Aromatic C-H), 3040 (Aromatic C-H), 2962, 2937 (Alkyl C-H),
2878 (Alkyl C-H), 2825, 1712, 1678, 1643 (C=N), 1610, 1557 (N=N), 1507, 1451, 1419, 1392, 1281,
1256, 1245, 1212, 1175, 1139, 1115, 1063, 1035, 1012, 1003 cm−1.
Melting point: 192.4 − 193.1 ◦C.
Mass spectrum(APCI +) m/z: Found 280.1316 (M+H)+; calculated for C16H16N4O 280.1324; 2.8
ppm.
Yield: 0.28 g, 58.3%.
2-[3-(4-Butoxyphenyl)-1H-1,2,4-triazol-5-yl]pyridine (119)
a
b
c
d
e f
g
h
( 9)
N
N
NH
N
l
1H NMR (d6-DMSO):8.90 (d, 1H, J = 4.6 Hz, -a), 8.76 (d, 2H, J = 8.0 Hz, -c and d), 7.88 (dd, 1H,
J = 11.5, 7.2 Hz, -b), 7.53 − 7.37 (overlapping m, 2H, -f and g), 7.01 (d, 2H, J = 8.8 Hz, -e and
h), 6.90 (s, 1H, triazole -NH), 4.04 (t, 2H, J = 6.5 Hz, -OCH2(CH2)2CH3), 1.82 − 1.60 (overlap-
ping m, 2H, -OCH2CH2CH2CH3), 1.59 − 1.31 (overlapping m, 2H, -OCH2CH2CH2CH3), 0.90 (t, 3H,
-OCH2(CH2)2CH3) ppm.
IR (neat) ν: 3172, 3101 (Aromatic C-H), 2955 (Alkyl C-H), 2869 (Alkyl C-H), 1682, 1612, 1598 (C=N),
1582, 1573, 1554 (N=N), 1532, 1482, 1460, 1438, 1428, 1396, 1372, 1314, 1268, 1242, 1172, 1143,
1127, 1108, 1098, 1037, 1007 cm−1.
Melting point: 151.2 − 152.6 ◦C.
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Mass spectrum(APCI +) m/z: Found 294.1477 (M+H)+; calculated for C17H18N4O 294.1480; 1.0
ppm.
Yield: 0.33 g, 67.2%.
4-[3-(4-Butoxyphenyl)-1H-1,2,4-triazol-5-yl]pyridine (120)
a
b
c
d
e f
g
h
(
m
n
n
no
n
1H NMR (d6-DMSO): 8.58 (d, 2H, J = 22.0 Hz, -b and c), 8.48 (s, 2H, -a and d), 8.39 (d, 2H, J = 19.9
Hz, -e and h), 7.89 − 7.53 (overlapping m, 2H, -f and g), 6.55 (m, 1H, triazole -NH), 4.02 (t, 2H,J = 6.5
Hz, -OCH2(CH2)2CH3), 1.76 − 1.57 (overlapping m, 2H, -OCH2CH2CH2CH3), 1.41 (dq, 2H,J = 14.4,
7.4 Hz, -OCH2CH2CH2CH3), 0.93 (t, 3H, J = 7.3 Hz,-OCH2(CH2)2CH3) ppm.
IR (neat) ν: 3326, 3165, 3108 (Aromatic C-H), 3068 (Aromatic C-H), 3035, 2953 (Alkyl C-H), 2925
(Alkyl C-H), 2868 (Alkyl C-H), 1612, 1575 (C=N), 1565 (N=N), 1506, 1469, 1451, 1417, 1378, 1302,
1244, 1181, 1141, 1108, 1065, 1040, 1002 cm−1.
Melting point: 177.3 − 179.2 ◦C.
Mass spectrum(APCI +) m/z: Found 294.1472 (M+H)+; calculated for C17H18N4O 294.1480; 2.7
ppm.
Yield: 0.41 g, 78.4%.
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2-[3-(4-Pentoxyphenyl)-1H-1,2,4-triazol-5-yl]pyridine (121)
a
b
c
d
e f
g
h
(
p
q
q
qr
q
1H NMR (d6-DMSO): 8.71 (d, 1H, J = 4.1 Hz, -a), 8.15 (d, 2H, J = 7.8 Hz, -e and h), 8.10 − 7.85
(overlapping m, 2H, -b and d), 7.73 − 7.32 (overlapping m, 3H, -c, f and g), 7.05 (d, 1H, J = 8.8
Hz, triazole -NH), 4.04 (t, 2H, J = 6.5 Hz, -OCH2(CH2)3CH3), 2.59 − 2.41 (overlapping m, 2H, -
OCH2CH2(CH2)2CH3), 1.74 (dd, 2H, J = 13.7, 6.7 Hz, -O(CH2)2CH2CH2CH3), 1.59− 1.23 (overlapping
m, 2H, -OCH2(CH2)2CH2CH3), 1.23 − 0.74 (t, 3H, J = 6.9 Hz, -OCH2(CH2)3CH3) ppm.
IR (neat) ν: 3032 (Aromatic C-H), 2932, 2854 (Alkyl C-H), 1600, 1572 (C=N), 1567 (N=N), 1532, 1459,
1418, 1378, 1313, 1299, 1236, 1177, 1153, 1115, 1060, 1010 cm−1.
Melting point: 124.3 − 125.9 ◦C.
Mass spectrum(APCI +) m/z: Found 308.1632 (M+H)+; calculated for C18H20N4O 308.1637; 1.6
ppm.
Yield: 0.31 g, 63%.
2-[3-(4-Heptoxyphenyl)-1H-1,2,4-triazol-5-yl]pyridine (122)
a
b
c
d
e f
g
h
(
s
t
t
t
u
t
1H NMR (d6-DMSO): 8.80 (d, 1H, J = 4.4 Hz, -a), 8.35 (s, 1H, -e), 7.89− 7.67 (overlapping m, 3H, -h, b,
and d), 7.38 (m, 1H, -c), 7.10 (d, 2H, J = 8.2 Hz, -f and g), 6.12 (d, 2H, J = 8.8 Hz, triazole -NH), 4.47
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(t, 2H, J = 6.5 Hz, -OCH2(CH2)5CH3), 1.89 − 1.69 (overlapping m, 2H, -OCH2CH2(CH2)4CH3), 1.49 −
1.11 (overlapping m, 8H, -OCH2CH2(CH2)4CH3), 0.89 (t, 3H, J = 6.6 Hz, -OCH2(CH2)5CH3) ppm.
IR (neat) ν: cm−1.
Melting point: 163.3 − 164.5 ◦C.
Mass spectrum(APCI +) m/z: Found 336.1938 (M+H)+; calculated for C20H24N4O 336.1950; 3.5
ppm.
Yield: 0.33 g, 68%.
4-[3-(4-Heptoxyphenyl)-1H-1,2,4-triazol-5-yl]pyridine (123)
a
b
c
d
e f
g
h
(
v
w
w
w
x
w
1H NMR (d6-DMSO): 8.61 (d, J = 5.9 Hz, 2H, -b and c), 8.34 − 7.38 (overlapping m, 4H, -a, d, e and
h), 7.35 (d, 2H, J = 8.8 Hz, -f and g), 6.06 (d, 1H, J = 8.8 Hz, triazole -NH), 4.58 (t, 2H, J = 6.5 Hz,
-OCH2(CH2)5CH3), 1.99 − 1.74 (overlapping m, 2H, -OCH2CH2(CH2)4CH3), 1.51 − 1.13 (overlapping
m, 8H, -OCH2CH2(CH2)4CH3), 0.94 (t, 3H, J = 6.6 Hz, -OCH2(CH2)5CH3) ppm.
IR (neat) ν: 3162, 3033 (Aromatic C-H), 2942, 2852 (Alkyl C-H), 1689, 1609 (C=N), 1545 (N=N), 1506,
1455, 420, 1392, 1282, 1251, 1176, 1136, 1074, 1038, 1012 cm−1.
Melting point: 97.3 − 98.2 ◦C.
Mass spectrum(APCI +) m/z: Found 336.1943 (M+H)+; calculated for C20H24N4O 336.1950; 2.0
ppm.
Yield: 0.39 g, 73.2%.
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4-[3-(4-Octoxyphenyl)-1H-1,2,4-triazol-5-yl]pyridine (124)
a
b
c
d
e f
g
h
(
y
z
z
z{
z
1H NMR (d6-DMSO): 9.04 (d, 2H, J = 6.0 Hz, -b and c), 8.34 (s, 2H, -a and d), 7.85− 7.70 (overlapping
m, 4H, -e and h), 7.09 (d, 2H, J = 8.8 Hz, -f and g), 6.42 (s, 1H, triazole -NH), 4.12 (t, 3H, J = 6.5 Hz,
-OCH2(CH2)6CH3), 1.96 − 1.71 (dq, 2H, J = 14.4, 7.3 Hz, -OCH2CH2(CH2)5CH3), 1.38 (overlapping m,
10H, -OCH2CH2(CH2)5CH3), 0.91 (t, 3H, J = 7.3 Hz, -OCH2(CH2)6CH3) ppm.
IR (neat) ν: 3106 (Aromatic C-H), 3057 (Aromatic C-H), 2930, 2854 (Alkyl C-H), 1712, 1608, 1575
(C=N), 1565 (N=N), 1505, 1473, 1453, 1419, 1406, 1391, 1329, 1300, 1280, 1249, 1171, 1136, 1063,
1043, 1016, 1000 cm−1.
Melting point: 141.9 − 143.1 ◦C.
Mass spectrum(APCI +) m/z: Found 350.2099 (M+H)+; calculated for C21H26N4O 350.2106; 1.9
ppm.
Yield: 0.42 g, 75.4%.
2-[3-(4-Decoxyphenyl)-1H-1,2,4-triazol-5-yl]pyridine (125)
a
b
c
d
e f
g
h
(
|
}
}
}
~
}
1H NMR (d6-DMSO): 8.75 (dd, 1H, J = 25.1, 4.7 Hz, -a), 8.49 (d, 2H, J = 8.3 Hz, -c and d), 7.82 (dd,
1H, J = 15.8, 8.7 Hz, -b), 7.39 (m, 1H, -e), 7.12 (d, 1H, J = 9.0 Hz, -h), 7.08 (d, 2H, J = 8.8 Hz, -f and
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g), 6.46 (s, 1H, triazole -NH), 4.04 (t, 2H, J = 6.5 Hz, -OCH2(CH2)9CH3), 1.68 (dt, 2H, J = 14.8, 5.6 Hz,
-OCH2CH2(CH2)8CH3), 1.34 − 1.01 (overlapping m, 16H, -OCH2CH2(CH2)8CH3), 0.83 (d, 3H, J = 6.8
Hz, -OCH2(CH2)9CH3) ppm.
IR (neat) ν: 3175, 3086 (Aromatic C-H), 3047 (Aromatic C-H), 2921 (Alkyl C-H), 2850 (Alkyl C-H), 1711,
1661, 1606 (C=N), 1582 (N=N), 1552, 1532, 1510, 1494, 1462, 1440, 1426, 1392, 1369, 132, 1248,
1166, 1140, 1106, 1074, 1047, 1028, 1007 cm−1.
Melting point: 108.3 − 109.4 ◦C.
Mass spectrum(APCI +) m/z: Found 378.2412 (M+H)+; calculated for C23H30N4O 378.2419; 1.8
ppm.
Yield: 0.31 g, 62.1%.
4-[3-(4-Decoxyphenyl)-1H-1,2,4-triazol-5-yl]pyridine (126)
a
b
c
d
e f
g
h
(





1H NMR (d6-DMSO): 8.70 (d, 2H, J = 5.9 Hz, -b and c), 8.38 (d, 2H, J = 8.3 Hz, -a and d) 8.20 −
7.43 (overlapping m, 4H, -e, h, f and g), 6.74 (m, 1H, triazole -NH), 4.43 − 4.04 (t, 2H, J = 6.4 Hz,
-OCH2(CH2)8CH3), 2.18 (dd, 2H, J = 13.9, 6.5 Hz, -OCH2CH2(CH2)7CH3), 1.57 − 1.03 (overlapping m,
14H, -OCH2CH2(CH2)7CH3), 0.89 (t, 3H, J = 6.5 Hz, -OCH2(CH2)8CH3) ppm.
IR (neat) ν: 3106, 3070 (Aromatic C-H), 3041 (Aromatic C-H), 2944 (Alkyl C-H), 2919 (Alkyl C-H), 2845,
2789, 1614 (C=N), 1574, 1525 (N=N), 1505, 1453, 1422, 1406, 1394, 1298, 1285, 1252, 1211, 1174,
1138, 1114, 1053, 1033, 1021, 1003 cm−1.
Melting point: 125.1 − 125.9 ◦C.
Mass spectrum(APCI +) m/z: Found 378.2407 (M+H)+; calculated for C23H30N4O 378.2419; 3.1
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ppm.
Yield: 0.26 g, 57.1%.
2-(5-But-3-enyl-1H-1,2,4-triazol-3-yl)pyridine (127)
(127)
a
b
c d
N N
N
N
1H NMR (d6-DMSO): 8.65 (d, 1H, J = 4.1 Hz, -a), 8.04 (d, 1H, J = 7.9 Hz, -c), 7.92 (s, 1H, -b), 7.44
(s, 1H, -d), 5.89 (ddt, 1H, J = 16.8, 10.2, 6.4 Hz, -CH2CH2CH=CH2), 5.21 − 4.87 (overlapping m, 2H,
-CH2CH2CH=CH2), 4.28 (s, 1H, triazole -NH), 2.82 (t, 2H, J = 6.5 Hz, -CH2CH2CH=CH2), 2.59 − 2.38
(overlapping m, 2H, -CH2CH2CH=CH2) ppm.
IR (neat) ν: 3055 (Aromatic C-H), 2975 (Aromatic C-H), 2943 (Alkyl C-H), 2897 (Alkyl C-H), 2791 (Alkyl
C-H), 1778, 1638 (C=N), 1593, 1570 (N=N), 1542, 1518, 1459, 1416, 1374, 1340, 1319, 1294, 1278,
1245, 1207, 1174, 1149, 1127, 1119, 1089, 1052, 1016 cm−1.
Mass spectrum(APCI +) m/z: Found 200.1056 (M+H)+; calculated for C11H12N4 200.1061; 2.4 ppm.
Yield: 0.08 g, 20.3%.
2-(3-Heptyl-1H-1,2,4-triazol-5-yl)pyridine (128)
a
b
c
d
(128)
N
NH
N
N
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1H NMR (d6-DMSO): 8.65 (d, 1H, J = 3.4 Hz, -a), 8.03 (d, 1H, J = 7.7 Hz, -c), 7.92 (s, 1H, -b), 7.45
(s, 1H, -d), 4.43 (s, 1H, triazole -NH), 2.70 (t, 2H, J = 6.5 Hz, -CH2CH2(CH2)4CH3), 1.89 − 1.55
(overlapping m, 2H, -CH2CH2(CH2)4CH3), 1.28 (dd, 8H, J = 9.1, 4.4 Hz, -CH2CH2(CH2)4CH3), 0.85 (t,
3H, J = 6.7 Hz, -CH2CH2(CH2)4CH3) ppm.
IR (neat) ν: 3148 (Aromatic C-H), 3107 (Aromatic C-H), 2948 (Alkyl C-H), 2923 (Alkyl C-H), 2847 (Alkyl
C-H), 1665, 1597, 1573, 1556 (N=N), 1448, 1462, 1446, 1427, 1377, 1320, 1293, 1272, 1247, 1207,
1150, 1128, 1092, 1055, 1011 cm−1.
Melting point: 49.1 − 50.7 ◦C.
Mass spectrum(APCI +) m/z: Found 244.1681 (M+H)+; calculated for C14H20N4 244.1687; 2.4 ppm.
Yield: 0.22 g, 33.1%.
4-(3-Heptyl-1H-1,2,4-triazol-5-yl)pyridine (129)
a
b
c
d
(129)
N
NH
N
N
1H NMR (d6-DMSO): 8.65 (d, 2H, J = 4.5 Hz, -b and c), 8.12− 7.73 (overlapping m, 2H, -a and d), 4.43
(s, 1H, triazole -NH), 2.80 (t, 2H, J = 6.5 Hz, -CH2CH2(CH2)4CH3), 1.73 (s, 2H, -CH2CH2(CH2)4CH3),
1.30 (s, 8H, -CH2CH2(CH2)4CH3), 0.85 (s, 3H, -CH2CH2(CH2)4CH3) ppm.
IR (neat) ν: 3219 (Aromatic C-H), 3044 (Aromatic C-H), 2952 (Aromatic C-H), 2923 (Alkyl C-H), 2850
(Alkyl C-H), 1611, 1595 (C=N), 1547 (N=N), 1485, 1467, 1455, 1438, 1416, 1388, 1348, 1325, 1307,
1284, 1258, 1238, 1212, 1193, 1170, 1111, 1061, 1044, 1026, 1000 cm−1.
Melting point: 104.2 − 106.8 ◦C.
Mass spectrum(APCI +) m/z: Found 244.1673 (M+H)+; calculated for C14H20N4 244.1687; 5.7 ppm.
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Yield: 0.31 g, 62.4%.
2-(3-Octyl-1H-1,2,4-triazol-5-yl)pyridine (130)
a
b
c
d
(130)
N
N
N
N
1H NMR (d6-DMSO): 8.65 (d, 1H, J = 4.4 Hz, -a), 8.03 (d, 1H, J = 7.8 Hz, -c), 7.91 (s, 1H, -b), 7.44 (s,
1H, -d), 4.27 (s, 1H, triazole -NH), 2.71 (t, 2H, J = 6.5 Hz, -CH2(CH2)6CH3), 1.70 (dd, 2H, J = 14.4,
7.2 Hz, -CH2CH2(CH2)5CH3), 1.39 − 1.20 (overlapping m, 10H, -CH2CH2(CH2)5CH3), 0.86 (dd, 3H, J
= 9.2, 4.3 Hz, -CH2(CH2)6CH3) ppm.
IR (neat) ν: 3180 (Aromatic C-H), 3106 (Aromatic C-H), 3048 (Aromatic C-H), 2948 (Alkyl C-H), 2919
(Alkyl C-H), 2867 (Alkyl C-H), 2846 (Alkyl C-H), 1667, 1598 (C=N), 1572 (N=N), 1555, 1493, 1480,
1463, 1440, 1423, 1375, 1350, 1314, 1291, 1259, 1244, 1221, 1146, 1131, 1092, 1047, 1019, 1010
cm−1.
Melting point: 65.9 − 67.1 ◦C.
Mass spectrum(APCI +) m/z: Found 258.1852 (M+H)+; calculated for C15H22N4 258.1844; 3.0 ppm.
Yield: 0.33 g, 69%.
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4-(3-Octyl-1H-1,2,4-triazol-5-yl)pyridine (131)
a
b
c
d
(131)
N
NH
N
N
1H NMR (d6-DMSO): 8.64 (d, 2H, J = 5.1 Hz, -b and c), 7.89 (dd, 2H, J = 4.5, 1.6 Hz, -a and d), 4.76
(s, 1H, triazole -NH), 1.71 (t, 2H, J = 6.5 Hz, -CH2(CH2)6CH3), 1.51 (s, 2H, -CH2CH2(CH2)5CH3), 1.28
(d, 10H, J = 11.2 Hz, -CH2CH2(CH2)5CH3), 0.91 − 0.79 (overlapping m, 3H, -CH2(CH2)6CH3) ppm.
IR (neat) ν: 3217 (Aromatic C-H), 3045 (Aromatic C-H), 2956 (Aromatic C-H), 2919 (Alkyl C-H), 2848
(Alkyl C-H), 1595 (C=N), 1559 (N=N), 1496, 1479, 1462, 1412, 1390, 1283, 1262, 1223, 1189, 1111,
1058, 1034, 1002 cm−1.
Melting point: 101.2 − 103.3 ◦C.
Mass spectrum(APCI +) m/z: Found 258.1838 (M+H)+; calculated for C15H22N4 258.1844; 2.3 ppm.
Yield: 0.42 g, 73.2%.
2-(3-Dec-9-enyl-1H-1,2,4-triazol-5-yl)pyridine (132)
a
b
c
d
(13





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1H NMR (d6-DMSO): 8.65 (m, 1H, -a), 8.04 (d, 1H, J = 7.9 Hz, -c), 7.89 (dd, 1H, J = 11.6, 3.8 Hz, -b),
7.44 (m, 1H, -d), 5.77 (ddt, 1H, J = 16.9, 10.1, 6.6 Hz, triazole -NH), 4.96 (m, 1H, -CH2(CH2)7CH=CH2),
4.36 (dd, 2H, J = 16.7, 11.7 Hz, -CH2(CH2)7CH=CH2), 2.71 (t, 2H, J = 7.5 Hz, -CH2-(CH2)7CH=CH2),
1.98 (t, 2H, J = 6.4 Hz, -CH2(CH2)6-CH2CH=CH2), 1.79 − 1.68 (overlapping m, 2H, -CH2CH2(CH2)5-
CH2CH=CH2), 1.41 − 0.99 (overlapping m, 10H, -CH2CH2(CH2)5CH2CH=CH2) ppm.
IR (neat) ν: 3175 (Aromatic C-H), 3073 (Aromatic C-H), 2924 (Alkyl C-H), 2853 (Alkyl C-H), 2322, 1976,
1737, 1639 (C=N), 1595, 1573 (N=N), 1556, 1514, 1464, 1417, 1387, 1324, 1279, 1246, 1177, 1148,
1088, 1043, 1002 cm−1.
Mass spectrum(APCI +) m/z: Found 284.2019 (M+H)+; calculated for C17H24N4 284.2000; 6.6 ppm.
Yield: 0.13 g, 27.2%.
4-(3-Dec-9-enyl-1H-1,2,4-triazol-5-yl)pyridine (133)
a
b
c
d
(133)
N
NH
N
N
1H NMR (d6-DMSO): 8.64 (dd, 2H, J = 4.5, 1.6 Hz, -b and c), 7.89 (dd, 2H, J = 4.5, 1.6 Hz, -a and
d), 5.80 (m, 1H, triazole -NH), 5.08 (m, 1H, -CH2(CH2)7CH=CH2), 4.85 (dd, 2H, J = 16.7, 11.7 Hz,
-CH2(CH2)7CH=CH2), 2.76 (t, 2H, J = 7.5 Hz, -CH2-(CH2)7CH=CH2), 2.08 − 1.93 (overlapping m, 2H,
-CH2(CH2)6-CH2CH=CH2), 1.71 (dd, 2H, J = 14.4, 7.2 Hz, -CH2CH2(CH2)5-CH2CH=CH2), 1.29 (d, 10H,
J = 1.9 Hz, -CH2CH2(CH2)5CH2CH=CH2) ppm.
IR (neat) ν: 3222 (Aromatic C-H), 3047 (Aromatic C-H), 2922 (Alkyl C-H), 2849 (Alkyl C-H), 2555, 1640
(C=N), 1612, 1597, 1580, 1549 (N=N), 1488, 1459, 1488, 1459, 1446, 1427, 1389, 1324, 1283, 1267,
1212, 1172, 1112, 1057, 1037, 1020, 1001 cm−1.
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Melting point: 87.3 − 88.4 ◦C.
Mass spectrum(APCI+) m/z: Found 284.2029 (M+H)+; calculated for C17H24N4 284.2000; 10.2 ppm.
Yield: 0.24 g, 46.4%.
3.5.4 General procedure for synthesis of 1,2,4-oxadiazole from aldoxime
The dry powder of aldoxime (0.2 g) was heated in a borosilicate vial at 150◦C for 30 mins. The dry
powder melted and upon slow cooling to room temperature the crude compound precipitated out. The
crude product was further purified by recrystallisation using water to methanol solvent system.
5-(p-Tolyl)-3-(2-pyridyl)-1,2,4-oxadiazole (134)
(134)
a
b
c d
e
f
g
h
N



1H NMR (d6-DMSO): 8.79 (ddd, 1H, J = 4.8, 1.7, 0.9 Hz, -a), 8.21 − 8.02 (overlapping m, 3H, -b, d and
h), 7.78 (ddd, 1H, J = 7.6, 4.8, 1.3 Hz, -e), 7.60 (d, 2H, J = 8.0 Hz, -f and g), 7.52 (m, 1H, -c), 2.44 (s,
3H, -CH3) ppm.
IR (neat) ν: 3070, 3032 (Aromatic C-H), 2918 (Alkyl C-H), 2851 (Alkyl C-H), 1625, 1608, 1598 (C=N),
1584, 1561, 1520, 1496, 1470, 1438, 1408, 1391, 1359, 1312, 1265, 1209 (C-O), 1180, 1153, 1124,
1083, 1045, 1019, 989, 958, 926, 910 (N-O), 865, 809, 753 cm−1.
Melting point: 167.8 − 168.5 ◦C.
Mass spectrum(APCI +) m/z: Found 237.0897 (M+H)+; calculated for C14H11N3O 237.0902; 2.1
ppm.
Yield: 0.14 g, 75.1%.
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5-(p-Tolyl)-3-(4-pyridyl)-1,2,4-oxadiazole (135)
(135)
ab
c d
e
f
g
h
N
N
N

1H NMR (d6-DMSO): 9.09 − 8.61 (overlapping m, 2H, -b and c), 8.10 (d, 2H, J = 8.2 Hz, -a and d),
8.01 (dd, 2H, J = 4.5, 1.5 Hz, -e and h), 7.49 (d, 2H, J = 8.2 Hz, -f and g), 2.44 (s, 3H, -CH3) ppm.
IR (neat) ν: 3068, 3024 (Aromatic C-H), 2924 (Alkyl C-H), 1704, 1611, 1598 (C=N), 1581, 1561, 1517,
1500, 1458, 1412, 1365, 1300, 1297, 1288, 1271, 1244, 1180, 1136 (C-O), 1109, 1071, 1060, 1032,
1015, 989, 961, 929, 910 (N-O), 872, 835, 826, 749 cm−1.
Melting point: 181.8 − 182.6 ◦C.
Mass spectrum(APCI +) m/z: Found 237.0908 (M+H)+; calculated for C14H11N3O 237.0902; 2.5
ppm.
Yield: 0.09 g, 68.1%.
5-(4-Ethylphenyl)-3-(4-pyridyl)-1,2,4-oxadiazole (136)
(136)
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1H NMR (d6-DMSO): 8.79 (ddd, 1H, J = 4.7, 1.6, 0.9 Hz, -a), 8.40 − 8.23 (overlapping m, 3H, -b, d and
h), 7.80 (m, 1H, -e), 7.61 (d, 2H, J = 8.3 Hz, -f and g), 7.52 (m, 1H, -c), 2.72 (dt, 2H, J = 10.9, 5.5 Hz,
-CH2CH3), 1.25 (t, 3H, J = 7.5 Hz, -CH2CH3) ppm.
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IR (neat) ν: 3049 (Aromatic C-H), 2968, 2878 (Alkyl C-H), 1675, 1611, 1598 (C=N), 1582, 1556, 1513,
1488, 1466, 1420, 1375, 1300, 1275, 1245, 1185 (C-O), 1159, 1125, 1087, 1049, 1012, 986, 965, 931,
910 (N-O), 888, 856, 810, 762 cm−1.
Melting point: 143.2 − 144.4 ◦C.
Mass spectrum(APCI +) m/z: Found 251.1047 (M+H)+; calculated for C15H13N3O 251.1058; 4.3
ppm.
Yield: 0.1 g, 71.3%.
5-(4-Ethylphenyl)-3-(4-pyridyl)-1,2,4-oxadiazole (137)
(137)
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1H NMR (d6-DMSO): 9.00 − 8.78 (overlapping m, 2H, -b and c), 8.15 (t, 2H, J = 6.4 Hz, -a and d),
8.07 − 7.97 (overlapping m, 2H, -e and h), 7.53 (d, 2H, J = 8.3 Hz, -f and g), 2.74 (q, 2H, J = 7.6 Hz,
-CH2CH3), 1.24 (t, 3H, J = 7.6 Hz, -CH2CH3) ppm.
IR (neat) ν: 3041 (Aromatic C-H), 2973, 2929 (Alkyl C-H), 2889 (Alkyl C-H), 1716, 1611, 1598 (C=N),
1588, 1566, 1553, 1520, 1500, 1466, 1423, 1414, 1367, 1277, 1216, 1180 (C-O), 1141, 1123, 1080,
1064, 1056, 1020, 988, 976, 968, 910 (N-O), 844, 833, 779 cm−1.
Melting point: 127.8 − 129.3 ◦C.
Mass spectrum(APCI +) m/z: Found 251.1045 (M+H)+; calculated for C15H13N3O 251.1058; 5.1
ppm.
Yield: 0.08 g, 47.2%.
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5-(4-Propylphenyl)-3-(2-pyridyl)-1,2,4-oxadiazole (138)
(138)
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1H NMR (d6-DMSO): 8.80 (ddd, 1H, J = 4.8, 1.7, 0.9 Hz, -a), 8.38 − 7.92 (overlapping m, 4H, -b, d, e
and h), 7.64 (ddd, 2H, J = 7.6, 4.8, 1.3 Hz, -f and g), 7.50 (d, 1H, J = 8.3 Hz, -c), 2.68 (t, 2H, J = 7.5 Hz,
-CH2CH2CH3), 1.77 − 1.50 (overlapping m, 2H, -CH2CH2CH3), 0.92 (t, 3H, J = 7.3 Hz, -CH2CH2CH3)
ppm.
IR (neat) ν: 3422, 3065, 3032 (Aromatic C-H), 2956, 2921 (Alkyl C-H), 2865 (Alkyl C-H), 1675, 1611,
1598 (C=N), 1578, 1558, 1517, 1493, 1467, 1461, 1414 1362, 1288, 1271, 1186, 1159, 1118 (C-O),
1092, 1048, 1019, 998, 962, 929, 910 (N-O), 867, 849, 808, 761 cm−1.
Melting point: 154.3 − 155.1 ◦C.
Mass spectrum(APCI +) m/z: Found 265.1220 (M+H)+; calculated for C16H15N3O 265.1215; 1.8
ppm.
Yield: 0.07 g, 46.3%.
5-(4-Propylphenyl)-3-(4-pyridyl)-1,2,4-oxadiazole (139)
(139)
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1H NMR (d6-DMSO): 8.80 (ddd, 1H, J = 4.8, 1.7, 0.9 Hz, -b and c), 8.38 − 7.92 (overlapping m, 2H,
-a and d), 7.64 (ddd, 2H, J = 7.6, 4.8, 1.3 Hz, -e and h), 7.50 (d, 2H, J = 8.3 Hz, -f and g), 2.68 (t,
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2H, J = 7.5 Hz, -CH2CH2CH3), 1.77 − 1.50 (overlapping m, 2H, -CH2CH2CH3), 0.92 (t, 3H, J = 7.3 Hz,
-CH2CH2CH3) ppm.
IR (neat) ν: 3041 (Aromatic C-H), 2956, 2930 (Alkyl C-H), 2868 (Alkyl C-H), 1713, 1611, 1598 (C=N),
1584, 1555, 1523, 1501, 1467, 1416, 1368, 1321, 1303, 1271, 1221, 1180 (C-O), 1136, 987, 966, 946,
910 (N-O), 878, 829, 815, 796 cm−1.
Melting point: 121.3 − 122.9 ◦C.
Mass spectrum(APCI +) m/z: Found 265.1228 (M+H)+; calculated for C16H15N3O 265.1215; 4.9
ppm.
Yield: 0.14 g, 81.8%.
5-(4-Butylphenyl)-3-(2-pyridyl)-1,2,4-oxadiazole (140)
(140)
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1H NMR (d6-DMSO): 8.80 (m, 1H, -a), 8.46 − 7.87 (overlapping m, 4H, -b, d, e and h), 7.63 (ddd, 1H, J
= 7.5, 4.8, 1.2 Hz, -c), 7.50 (d, 2H, J = 8.1 Hz, -f and g), 2.71 (t, 2H, J = 7.5 Hz, -CH2(CH2)2CH3), 1.60
(dt, 2H, J = 15.4, 7.6 Hz, -CH2CH2CH2CH3), 1.32 (dq, 2H, J = 14.7, 7.3 Hz, -(CH2)2CH2CH3), 0.91 (t,
3H, J = 7.3 Hz, -(CH2)3CH3) ppm.
IR (neat) ν: 3428, 3044 (Aromatic C-H), 2959, 2930 (Alkyl C-H), 2856 (Alkyl C-H), 1675, 1611, 1598
(C=N), 1581, 1555, 1514, 1493, 1456, 1414, 1367, 1277, 1247, 1186 (C-O), 1156, 1124, 1098, 1048,
1019, 995, 955, 933, 910 (N-O), 865, 839, 803, 761 cm−1.
Melting point: 156.3 − 157.7 ◦C.
Mass spectrum(APCI +) m/z: Found 279.1368 (M+H)+; calculated for C17H17N3O 279.1371; 1.0
ppm.
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Yield: 0.1 g, 63.1%.
5-(4-Butylphenyl)-3-(4-pyridyl)-1,2,4-oxadiazole (141)
(141)
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1H NMR (d6-DMSO): 8.84 (dd, 2H, J = 4.4, 1.6 Hz, -b and c), 8.12 (d, 2H, J = 8.3 Hz, -a and d),
8.02 (dd, 2H, J = 4.4, 1.6 Hz, -e and h), 7.50 (d, 2H, J = 8.3 Hz, -f and g), 2.70 (t, 2H, J = 7.5 Hz,
-CH2(CH2)2CH3), 1.60 (dt, 2H, J = 12.7, 7.4 Hz, -CH2CH2CH2CH3), 1.33 (dq, 2H, J = 14.2, 7.2 Hz,
-(CH2)2CH2CH3), 1.01 − 0.78 (t, 3H, J = 7.3 Hz, -(CH2)3CH3) ppm.
IR (neat) ν: 3050 (Aromatic C-H), 2950 (Alkyl C-H), 2930 (Alkyl C-H), 2865 (Alkyl C-H), 2854 (Alkyl
C-H), 1681, 1611, 1598 (C=N), 1587, 1567, 1552, 1523, 1499, 1488, 1464, 1432, 1367, 1318, 1300,
1262, 1218, 1177, 1139, 1118 (C-O), 1104, 1065, 1022, 986, 965, 931, 910 (N-O), 888, 856, 810, 762
cm−1.
Melting point: 147.3 − 148.6 ◦C.
Mass spectrum(APCI +) m/z: Found 279.1358 (M+H)+; calculated for C17H17N3O 279.1371; 4.6
ppm.
Yield: 0.13 g, 78%.
5-(4-Pentylphenyl)-3-(2-pyridyl)-1,2,4-oxadiazole (142)
(142)
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1H NMR (d6-DMSO): 8.80 (d, 1H, J = 3.9 Hz, -a), 8.11 (ddd, 4H, J = 17.7, 10.9, 7.0 Hz, -b, d, e
and h), 7.64 (dd, 1H, J = 7.5, 4.8 Hz, -c), 7.50 (d, 2H, J = 8.1 Hz, -f and g), 2.70 (t, 2H, J =
7.5 Hz, -CH2(CH2)3CH3), 1.64 (d, 2H, J = 7.1 Hz, -CH2CH2(CH2)2CH3), 1.31 (d, 4H, J = 3.3 Hz, -
(CH2)2(CH2)2CH3), 0.87 (t, 3H, J = 6.6 Hz, -(CH2)4CH3) ppm.
IR (neat) ν: 3109, 3059 (Aromatic C-H), 2941 (Alkyl C-H), 2924 (Alkyl C-H), 2900 (Alkyl C-H), 2865
(Alkyl C-H), 1690, 1611, 1598 (C=N), 1587, 1558, 1514, 1496, 1467, 1452, 1438,1420, 1356, 1311,
1280, 1271, 1247, 1177, 1153, 1142, 1121 (C-O), 1095, 1071, 1045, 1027, 989, 971, 931, 910 (N-O),
872, 854, 811, 763 cm−1.
Melting point: 165.2 − 166.8 ◦C.
Mass spectrum(APCI +) m/z: Found 293.1523 (M+H)+; calculated for C18H19N3O 293.1528; 1.7
ppm.
Yield: 0.12 g, 75.3%.
5-(4-Pentylphenyl)-3-(4-pyridyl)-1,2,4-oxadiazole (143)
(143)
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1H NMR (d6-DMSO): 8.84 (d, 2H, J = 6.0 Hz, -b and c), 8.12 (d, 1H, J = 8.2 Hz, -a and d), 8.02 (dd, 2H, J
= 4.5, 1.6 Hz, -e and h), 7.51 (d, 2H, J = 8.2 Hz, -f and g), 2.69 (t, 2H, J = 7.5 Hz, -CH2(CH2)3CH3), 1.84
− 1.48 (overlapping m, 2H, -CH2CH2(CH2)2CH3), 1.53 − 1.09 (overlapping m, 4H, -(CH2)2(CH2)2CH3),
0.86 (t, 3H, J = 8.8, 4.7 Hz, -(CH2)4CH3) ppm.
IR (neat) ν:3047 (Aromatic C-H), 3024, 2953, 2921 (Alkyl C-H), 2854 (Alkyl C-H), 1716, 1675, 1611,
1598 (C=N), 1567, 1555, 1523, 1502, 1464, 1417, 1369, 1318, 1300, 1271, 1215, 1174, 1142, 1118
(C-O), 1104, 1063, 1039, 1019, 995, 963, 932, 910 (N-O), 845, 811, 755 cm−1.
Melting point: 139.7 − 140.2 ◦C.
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Mass spectrum(APCI +) m/z: Found 293.1531 (M+H)+; calculated for C18H19N3O 293.1528; 1.0
ppm.
Yield: 0.12 g, 61.7%.
5-(4-Hexylphenyl)-3-(2-pyridyl)-1,2,4-oxadiazole (144)
(144)
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1H NMR (d6-DMSO): 8.80 (d, 1H, J = 4.7 Hz, -a), 8.30 − 7.98 (overlapping m, 4H, -b, d, e and h),
7.64 (ddd, 1H, J = 7.5, 4.8, 1.2 Hz, -c), 7.50 (d, 2H, J = 8.2 Hz, -f and g), 2.70 (t, 2H, J = 7.6 Hz,
-CH2(CH2)4CH3), 1.60 (d, 2H, J = 7.3 Hz, -CH2CH2(CH2)3CH3), 1.41 − 1.17 (overlapping m, 6H, -
(CH2)2(CH2)3CH3), 0.87 (t, 3H, J = 6.9 Hz, -(CH2)5CH3) ppm.
IR (neat) ν: 3050 (Aromatic C-H), 2953, 2921 (Alkyl C-H), 2854 (Alkyl C-H), 1672, 1611, 1598 (C=N),
1584, 1558, 1520, 1499, 1461, 1414, 1364, 1279, 1253, 1186, 1148, 1121 (C-O), 1089, 1042, 1016,
989, 963, 931, 910 (N-O), 872, 845, 812, 761 cm−1.
Melting point: 138.8 − 139.5 ◦C.
Mass spectrum(APCI +) m/z: Found 307.1677 (M+H)+; calculated for C19H21N3O 307.1684; 2.2
ppm.
Yield: 0.09 g, 57.6%.
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5-(4-Hexylphenyl)-3-(4-pyridyl)-1,2,4-oxadiazole (145)
(145)
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1H NMR (d6-DMSO): 8.84 (dd, 2H, J = 4.4, 1.6 Hz, -b and c), 8.12 (d, 2H, J = 8.3 Hz, -a and d),
8.02 (dd, 2H, J = 4.4, 1.6 Hz, -e and h), 7.50 (d, 2H, J = 8.3 Hz, -f and g), 2.70 (t, 2H, J = 7.6 Hz,
-CH2(CH2)4CH3), 1.75 − 1.48 (overlapping m, 2H, -CH2CH2(CH2)3CH3), 1.43 − 1.09 (overlapping m,
6H, -(CH2)2(CH2)3CH3), 0.85 (t, 3H, J = 6.9 Hz, -(CH2)5CH3) ppm.
IR (neat) ν: 3167, 3041 (Aromatic C-H), 3024, 2959, 2918 (Alkyl C-H), 2868 (Alkyl C-H), 2848, 2689,
1713, 1611, 1598 (C=N), 1584, 1567, 1555, 1520, 1488, 1464, 1452, 1432, 1414, 1364, 1315, 1303,
1268, 1215, 1177, 1136, 1115 (C-O), 1068, 1060, 1039, 1022, 991, 973, 926, 910 (N-O), 868, 843, 823,
774 cm−1.
Melting point: 135.4 − 136.9 ◦C.
Mass spectrum(APCI +) m/z: Found 307.1692 (M+H)+; calculated for C19H21N3O 307.1684; 2.6
ppm.
Yield: 0.12 g, 71.4%.
5-(4-Heptylphenyl)-3-(2-pyridyl)-1,2,4-oxadiazole (146)
(146)
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1H NMR (d6-DMSO): 8.80 (d, 1H, J = 4.7 Hz,-a ), 8.09 (ddd, 4H, J = 11.1, 9.5, 4.8 Hz, -b, d, e and h),
7.68 (m, 1H, -c), 7.50 (d, 2H, J = 8.2 Hz, -f and g), 2.70 (t, 2H, J = 7.5 Hz, -CH2(CH2)5CH3), 1.62 (t,
2H, J = 7.0 Hz, -CH2CH2(CH2)4CH3), 1.27 (d, 8H, J = 11.5 Hz, -(CH2)2(CH2)4CH3), 0.85 (t, 3H, J = 6.3
Hz, -(CH2)6CH3) ppm.
IR (neat) ν: 3053 (Aromatic C-H), 2953 (Alkyl C-H), 2925 (Alkyl C-H), 2850 (Alkyl C-H), 1681, 1613,
1598 (C=N), 1588, 1553, 1518, 1497, 1463, 1439, 1420, 1365, 1321, 1311, 1299, 1272, 1241, 1178
(C-O), 1145, 1120, 1087, 1041, 1009, 999, 984, 967, 945, 910 (N-O), 888, 856, 809, 766 cm−1.
Melting point: 135.3 − 136.5 ◦C.
Mass spectrum(APCI +) m/z: Found 321.1835 (M+H)+; calculated for C20H23N3O 321.1841; 1.8
ppm.
Yield: 0.13 g, 64.2%.
5-(4-Heptylphenyl)-3-(4-pyridyl)-1,2,4-oxadiazole (147)
(147)
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1H NMR (d6-DMSO): 8.84 (d, 2H, J = 5.0 Hz, -b and c), 8.12 (d, 2H, J = 8.2 Hz, -a and d), 8.02 (d, 2H,
J = 5.9 Hz, -e and h), 7.50 (d, 2H, J = 8.3 Hz, -f and g), 2.70 (t, 2H, J = 7.5 Hz, -CH2(CH2)5CH3), 1.62
(s, 2H, -CH2CH2(CH2)4CH3), 1.28 (dd, 8H, J = 7.7, 4.0 Hz, -(CH2)2(CH2)4CH3), 0.85 (t, 3H, J = 6.7 Hz,
-(CH2)6CH3) ppm.
IR (neat) ν: 3044 (Aromatic C-H), 2956 (Alkyl C-H), 2921 (Alkyl C-H), 2848, 1611, 1598 (C=N), 1584,
1567, 1555, 1517, 1499, 1464, 1426, 1388, 1374, 1362, 1321, 1309, 1271, 1259, 1224, 1180 (C-O),
1136, 1124, 1101, 1074, 1063, 1041, 1025, 993, 968, 933, 910 (N-O), 893, 855, 807, 762 cm−1.
Melting point: 151.6 − 152.9 ◦C.
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Mass spectrum(APCI +) m/z: Found 321.1849 (M+H)+; calculated for C20H23N3O 321.1841; 2.4
ppm.
5-(4-Octylphenyl)-3-(2-pyridyl)-1,2,4-oxadiazole (148)
(148)
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1H NMR (d6-DMSO): 8.80 (d, 1H, J = 4.0 Hz, -a), 8.39 − 7.93 (overlapping m, 4H, -b, d, e and h), 7.64
(dd, 1H, J = 6.9, 5.4 Hz, -c), 7.50 (d, 2H, J = 8.2 Hz, -f and g), 2.70 (t, 2H, J = 7.6 Hz, -CH2(CH2)6CH3),
1.62 (s, 2H, -CH2CH2(CH2)5CH3), 1.41 − 1.09 (overlapping m, 10H, -(CH2)2(CH2)5CH3), 0.85 (t, 3H, J
= 6.5 Hz, -(CH2)7CH3) ppm.
IR (neat) ν: 3053 (Aromatic C-H), 2950 (Alkyl C-H), 2921 (Alkyl C-H), 2848, 1611, 1598 (C=N), 1584,
1558, 1514, 1499, 1473, 1452, 1414, 1378, 1326, 1277, 1244, 1183 (C-O), 1156, 1121, 1095, 1039,
1022, 992, 971, 932, 910 (N-O), 872, 856, 811, 766 cm−1.
Melting point: 135.4 − 137.3 ◦C.
Mass spectrum(APCI +) m/z: Found 335.1990 (M+H)+; calculated for C21H25N3O 335.1997; 2.0
ppm.
Yield: 0.11 g, 58%.
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5-(4-Octylphenyl)-3-(4-pyridyl)-1,2,4-oxadiazole (149)
(149)
ab
c d
e
f
g
h
N
N
N

1H NMR (d6-DMSO): 8.84 (d, 2H, J = 5.8 Hz, -b and c), 8.12 (d, 2H, J = 8.1 Hz, -a and d), 8.02 (d,
2H, J = 6.0 Hz, -e and h), 7.50 (d, 2H, J = 8.1 Hz, -f and g), 2.70 (t, 2H, J = 7.6 Hz, -CH2(CH2)6CH3),
1.88 − 1.50 (overlapping m, 2H, -CH2CH2(CH2)5CH3), 1.48 − 1.04 (overlapping m, 10H, J = 12.0 Hz,
-(CH2)2(CH2)5CH3), 0.83 (t, 3H, J = 6.4 Hz, -(CH2)7CH3) ppm.
IR (neat) ν: 3035 (Aromatic C-H), 3024, 2944 (Alkyl C-H), 2927 (Alkyl C-H), 2845, 1713, 1669, 1611,
1598 (C=N), 1584, 1564, 1552, 1517, 1499, 1464, 1388, 1364, 1306, 1274, 1224, 1177 (C-O), 1139,
1124, 1112, 1077, 1063, 1016, 989, 967, 942, 910 (N-O), 875, 827, 812, 793 cm−1.
Melting point: 129.4 − 130.8 ◦C.
Mass spectrum(APCI +) m/z: Found 335.1205 (M+H)+; calculated for C21H25N3O 335.1997; 3.8
ppm.
Yield: 0.09 g, 49.4%.
5-(4-Decylphenyl)-3-(2-pyridyl)-1,2,4-oxadiazole (150)
(150)
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1H NMR (d6-DMSO): 8.80 (d, 1H, J = 4.1 Hz, -a), 8.38 − 7.93 (overlapping m, 4H, -b, d, e and h),
7.69 (m, 1H, -c), 7.50 (d, 2H, J = 8.3 Hz, -f and g), 2.70 (t, 2H, J = 7.6 Hz, -CH2(CH2)8CH3), 1.78
− 1.44 (overlapping m, 2H, -CH2CH2(CH2)7CH3), 1.42 − 1.13 (overlapping m, 14H, J = 15.3 Hz, -
(CH2)2(CH2)7CH3), 0.84 (t, 3H, J = 6.5 Hz, -(CH2)9CH3) ppm.
IR (neat) ν: 3050 (Aromatic C-H), 2953 (Alkyl C-H), 2918 (Alkyl C-H), 2868 (Alkyl C-H), 2845, 1611,
1598 (C=N), 1581, 1555, 1520, 1499, 1461, 1452, 1441, 1423, 1367, 1417, 1312, 1297, 1288, 1271,
1244, 1183, 1156, 1145, 1115 (C-O), 1098, 1074, 1045, 1016, 992, 967, 939, 910 (N-O), 888, 835, 807,
786 cm−1.
Melting point: 156.7 − 159.1 ◦C.
Mass spectrum(APCI +) m/z: Found 363.2323 (M+H)+; calculated for C23H29N3O 363.2310; 3.5
ppm.
Yield: 0.13 g, 64%.
5-(4-Decylphenyl)-3-(4-pyridyl)-1,2,4-oxadiazole (151)
(151)
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1H NMR (d6-DMSO): 8.84 (t, 2H, J = 6.0 Hz, -b and c), 8.12 (d, 2H, J = 8.2 Hz, -a and d), 8.02 (d,
2H, J = 6.1 Hz, -e and h), 7.50 (d, 2H, J = 8.1 Hz, -f and g), 2.70 (t, 2H, J = 7.6 Hz, -CH2(CH2)8CH3),
1.82 − 1.50 (overlapping m, 2H, -CH2CH2(CH2)7CH3), 1.47 − 1.07 (overlapping m, 14H, J = 14.8 Hz,
-(CH2)2(CH2)7CH3), 0.83 (t, 3H, J = 6.5 Hz, -(CH2)9CH3) ppm.
IR (neat) ν: 3396, 3030 (Aromatic C-H), 2953 (Alkyl C-H), 2878 (Alkyl C-H), 2848 (Alkyl C-H), 1611,
1598 (C=N), 1587, 1567, 1555, 1502, 1489, 1461, 1421, 1342, 1309, 1277, 1224, 1183 (C-O), 1136,
1121, 1077, 1060, 1019, 992, 954, 904 (N-O), 873, 851, 813, 789 cm−1.
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Melting point: 156.9 − 157.9 ◦C.
Mass spectrum(APCI +) m/z: Found 363.2329 (M+H)+; calculated for C23H29N3O 363.2310; 5.2
ppm.
Yield: 0.13 g, 65%.
5-(4-tert-Butylphenyl)-3-(2-pyridyl)-1,2,4-oxadiazole (152)
(152)
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1H NMR (d6-DMSO): 8.80 (ddd, 1H, J = 4.8, 1.7, 0.9 Hz, -a), 8.28 − 8.09 (overlapping m, 3H, -b, d and
h), 8.03 (dd, 1H, J = 7.8, 1.8 Hz, -e), 7.84 − 7.65 (overlapping m, 2H, -f and g), 7.59 (m, 1H, -c), 1.36
(s, 9H, tert. butyl -(CH3)3) ppm.
IR (neat) ν: 3050 (Aromatic C-H), 2953, 2921 (Alkyl C-H), 2865 (Alkyl C-H), 1675, 1611, 1598 (C=N),
1578, 1558, 1514, 1499, 1473, 1452, 1408, 1388, 1326, 1309, 1294, 1265, 1364, 1315, 1303, 1268,
1215 (C-O), 1177, 1136,1083, 1042, 1030, 992, 972, 906 (N-O), 893, 855, 807, 762 cm−1.
Melting point: 187.4 − 188.8 ◦C.
Mass spectrum(APCI +) m/z: Found 279.1379 (M+H)+; calculated for C17H17N3O 279.1371; 2.8
ppm.
Yield: 0.09 g, 56.2%.
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5-(4-tert-Butylphenyl)-3-(4-pyridyl)-1,2,4-oxadiazole (153)
(153)
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1H NMR (d6-DMSO): 8.99 − 8.74 (overlapping m, 2H, -b and c), 8.14 (d, 2H, J = 8.4 Hz, -a and d),
8.03 (m, 1H, -e and h), 7.71 (d, J = 8.4 Hz, 2H, -f and g), 1.34 (s, 9H, tert. butyl -(CH3)3) ppm.
IR (neat) ν: 3044 (Aromatic C-H), 2982, 2956, 2900 (Alkyl C-H), 2865 (Alkyl C-H), 1699, 1678, 1611,
1598 (C=N), 1584, 1549, 1517, 1473, 1458, 1408, 1388, 1326, 1309, 1294, 1265, 1224, 1194, 1145,
1115 (C-O), 1063, 1016, 986, 966, 945, 910 (N-O), 872, 823, 805, 786 cm−1.
Melting point: 168.1 − 169.4 ◦C.
Mass spectrum(APCI +) m/z: Found 279.1383 (M+H)+; calculated for C17H17N3O 279.1371; 4.2
ppm.
Yield: 0.12 g, 65.2%.
5-(4-Isopropylphenyl)-3-(2-pyridyl)-1,2,4-oxadiazole (154)
(154)
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1H NMR (d6-DMSO): 8.85 (d, 1H, J = 4.1 Hz, -a), 8.46 − 7.99 (overlapping m, 4H, -b, d, e and h), 7.68
(m, 1H, -c), 7.47 (d, 2H, J = 8.3 Hz, -f and g), 2.87 (dtt, 1H, J = 13.7, 6.8, 3.7 Hz, Isopropyl -(CH2),
1.51 (s, 6H, Isopropyl -(CH3)2) ppm.
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IR (neat) ν: 3157, 3066 (Aromatic C-H), 2955 (Alkyl C-H), 2882 (Alkyl C-H), 2725, 2631, 2517, 2423,
1906, 1823, 1714, 1675, 1625, 1608, 1598 (C=N), 1541, 1429, 1354, 1245, 1163 (C-O), 1073, 1032,
1027, 972, 932, 910 (N-O), 883, 861, 812, 758 cm−1.
Melting point: 154.5 − 155.8 ◦C.
Mass spectrum(APCI +) m/z: Found 265.1209 (M+H)+; calculated for C16H15N3O 265.1215; 2.2
ppm.
Yield: 0.14 g, 68.4%.
5-(4-Isopropylphenyl)-3-(4-pyridyl)-1,2,4-oxadiazole (155)
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1H NMR (d6-DMSO): 8.80 (t, 2H, J = 6.0 Hz, -b and c), 8.35 (d, 2H, J = 8.2 Hz, -a and d), 8.09 (d, 2H,
J = 6.1 Hz, -e and h), 7.60 (d, 2H, J = 8.1 Hz, -f and g), 2.89 (dtt, 1H, J = 13.7, 6.8, 3.7 Hz, Isopropyl
-(CH2), 1.57 (s, 6H, Isopropyl -(CH3)2) ppm.
IR (neat) ν: 3167, 3076 (Aromatic C-H), 2965 (Alkyl C-H), 2892 (Alkyl C-H), 2745, 2631, 2537, 2443,
1916, 1833, 1725, 1690, 1640, 1611, 1598 (C=N), 1546, 1447, 1379, 1265, 1177 (C-O), 1083, 1042,
1030, 992, 972, 906 (N-O), 893, 862, 802, 778 cm−1.
Melting point: 153.8 − 155.2 ◦C.
Mass spectrum(APCI +) m/z: Found 265.1223 (M+H)+; calculated for C16H15N3O 265.1215; 3.0
ppm.
Yield: 0.11 g, 63.4%.
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2,4-Ditert-butyl-6-[3-(2-pyridyl)-1,2,4-oxadiazol-5-yl]phenol (156)
(156)
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1H NMR (d6-DMSO): 10.94 (s, 1H, -OH), 8.89 (m, 1H, -a), 8.30 (d, 1H, J = 7.8 Hz, -e), 8.07 (td, 1H, J
= 7.8, 1.7 Hz, -d), 7.83 (s, 1H, -c), 7.65 (ddd, 2H, J = 17.5, 8.8, 1.7 Hz, -b and f), 1.45 (overlapping m,
18H, tert. butyl -(CH3)9) ppm.
IR (neat) ν: 3233, 3215, 3156, 3033 (Aromatic C-H), 2966, 2912 (Alkyl C-H), 2875 (Alkyl C-H), 1601,
1598 (C=N), 1565, 1523, 1508, 1477, 1413, 1365, 1333, 1268, 1239, 1224, 1213 (C-O), 1120, 1100,
1062, 1014, 1009, 996, 972, 943, 910 (N-O), 889, 841, 810, 784 cm−1.
Melting point: 166.8 − 170.2 ◦C.
Mass spectrum(APCI +) m/z: Found 351.1939 (M+H)+; calculated for C21H25N3O2 351.1946; 1.9
ppm.
Yield: 0.1 g, 59.4%.
2,4-Ditert-butyl-6-[3-(4-pyridyl)-1,2,4-oxadiazol-5-yl]phenol (157)
(157)
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1H NMR (d6-DMSO): 10.65 (s, 1H, -OH), 8.85 (d, 2H, J = 5.7 Hz, -b and c), 8.28 − 8.08 (overlapping
m, 2H, -a and d), 7.81 (d, 1H, J = 2.3 Hz, -e), 7.61 (d, 1H, J = 2.3 Hz, -f), 1.39 (d, 18H, J = 31.1 Hz,
tert. butyl -(CH3)9) ppm.
IR (neat) ν: 3235, 3205, 3155, 3038 (Aromatic C-H), 2956, 2909 (Alkyl C-H), 2865 (Alkyl C-H), 1609,
1598 (C=N), 1570, 1543, 1517, 1473, 1423, 1375, 1335, 1268, 1247, 1221, 1203 (C-O), 1130, 1101,
1063, 1024, 1001, 928, 909 (N-O), 876, 851, 810, 776 cm−1.
Melting point: 176.8 − 177.9 ◦C.
Mass spectrum(APCI +) m/z: Found 351.1938 (M+H)+; calculated for C21H25N3O2 351.1946; 2.2
ppm.
Yield: 0.12 g, 61.3%.
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Chapter 4
Fluorinated Carboxamidrazone
Derivatives
4.1 Introduction
The element fluorine has been prominent and has interested the scientific community because of its very
particular properties (small size, strong electronegativity, low polarisability) ever since it was discovered
and isolated by Henri Moissan in 1886. The addition of one or more fluorine atoms in an organic com-
pound can cause significant change in the properties and reactivity of the compound without causing
many changes in the steric conformation. This is because the C-F bond length is almost the same as
the length between C-H bond (1.39 and 1.09 respectively). The study of fluorinated organic compounds
has seen a significant increase during the last 10-15 decades due to the unique properties of the fluorine
atom and its resulting applications and potential. Today, the use of compounds with at least one fluorine
atom is found to be common in many fields like agrochemicals (Theodoridis (2006)), electronics (Babu-
dri et al. (2007)) and in separation process of 235U from 238U in nuclear power stations (Gurs (1976)).
However, its the medicinal chemistry field that has seen a major expansion of fluorinated compounds.
Before 1957 there were no fluorinated drugs, the first fluorinated drug synthesised was 5-fluorouracil ,
an anti-tumour drug (Montgomery & Hewson (1957)). This changed the entire scenario in the medicinal
world. As of today, there are over 150 fluorinated drugs in the market representing ∼ 20% of all phar-
maceuticals. Some fluorinated drugs are among the best sellers, such as the anti-depressant fluoxetine
(Prozac), the anti-cholesterol atorvastatin (Lipitor) and the anti-bacterial ciprofloxacin (Ciprobay). Of the
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total 39 new molecular entities approved by the US FDA in 2012 eight compounds contained a fluorine
atom, and so far till August 2013 US FDA had approved 16 compounds of which six are fluorinated
compounds.
The inclusion of fluorine atoms in the drugs has some useful advantages such as metabolic stability,
improved bioavailability, increased binding affinity (BÃu˝hm et al. (2004)). The metabolic stability is the
most important factor determining the bioavailability of the compound. The liver enzymes, especially the
P450 cytochromes, often cause rapid oxidative metabolism of the drug, thus limiting its bioavailability.
This problem is addressed by introducing a C-F group in place of an oxidisable C-H group. Thus in-
creasing the metabolic stability. A classic example of this is Ezetimibe, a cholesterol-absorption inhibitor.
The molecules contain two labile sites (the phenyl rings), which are blocked by the fluorine atom. Thus
preventing the oxidation of the phenyl ring to phenol and dealkylation of the methoxy group (see Fig. 4.1)
(Clader (2004), BÃu˝hm et al. (2004)). The fluorine atom being an electro negative atom has a strong
effect on the nearby atom. Thus substitution of fluorine atom can alter the acidic or basic properties of
the molecule, resulting in change in pKa, another important factor affecting the bioavailibity.
1,4-Bis(4-methoxyphenyl)-3-(3-phenylpropyl)azetidin-2-one Ezetimibe
(158) (159)
OMe
OMe
F
O
N
F
OH
OH
N
O
Figure 4.1: Ezetimibe: an example representing the significant contribution of fluorine substitution on
metabolic stability.
The substitution of a fluorine atom in a molecule can cause change in the preferred molecular confor-
mation. This effect can be explained by the example of a drug fluoxetine. The mechanism of action of
fluoxetine involves selective inhibition of the reuptake of serotonin, thus allowing the neurotransmitter to
activate its specific receptor. The SAR studies shows that the substitution of a trifluoromethyl group in the
para position of the phenolic ring increased the potency for inhibiting 5-HT uptake by 6-fold, compared
to the non-fluorinated parent compound. This could be attributed to the fact that the trifluoromethane
molecule is roughly twice the size of methyl group as shown by the van der Waal’s radius of 1.47 A for
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fluorine thus the steric bulk of the trifluoromethyl group at the para position allows the phenoxy ring to
adopt a conformation which favours binding to the serotonin transporter.
In the following section the fluorination of the carboxamidrazone compounds which are known to pos-
sess biological activity is discussed (see table 2.5).
4.2 Lead optimisation
This study is a subset of the larger project carboxamidrazone amides discussed in chapter 2.
(77); Pyridyl= 4-pyridine(76); Pyridyl= 4-pyridine
(14); Pyridyl= 2-pyridine (13); Pyridyl= 2-pyridine
(12); Pyridyl= 2-pyridine
Pyridyl
Pyridyl
Pyridyl
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N
H
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O
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O OH
Figure 4.2: Active compounds for CF3
Based on the findings in chapter 2, the most active carboxamidrazone amides (Fig. 4.2) were selected
for further optimisation. These candidates were then subjected to various radical based fluorine chem-
istry reactions in an attempt to incorporate the fluorine atom(s) on to the pyridyl ring of the compound
and study its effect on the carboxamidrazone amides (see Fig. 4.3).
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Figure 4.3: Structure of the proposed fluorine containing compounds
4.3 Results and Discussion
4.3.1 Trifluoromethylationof heteroaryl amidrazone compounds using Langlois reagent
The Langlois reagent, i.e. sodium salt of trifluoromethanesulfinic acid, in presence of catalytic metal
is known to initiate a free radical reaction to introduce a trifluoromethyl group onto the electron rich
aromatic compounds (Langlois et al. (1991)). Based on the recent findings of Ji et al. (2011) the trifluo-
romethylation reactions can be carried out in milder conditions by avoiding the use of a metal catalyst,
although it is still debated if the traces of metal elements present in the compound are responsible for
reaction initiation. The authors also demonstrated that the trifluoromethyl group can be introduced in the
electron deficient compounds such as pyridines using excess of reagents. Hence a trifluoromethylation
of heteroaryl amidrazone compounds was attempted using Langlois reagent (see Scheme. 4.1).
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Scheme 4.1: Scheme for the trifluoromethylation of the heteroaryl amidrazone compounds using Lan-
glois reagent. Adapted from Ji et al. (2011)
Following the procedure of (Ji et al. (2011)), 2-pyridyl-4-butylbenzoyl carboxamidrazone was dissolved
in a solution of DMSO and water along with 3 equivalents of sodium trifluromethanesulfinate at 0◦C,
followed by dropwise addition of 5 equivalent of tert-butylhydroperoxide with vigorous stirring. This
reaction mixture was allowed to warm up to room temperature and the progress of the reaction was
monitored with an hourly TLC check. However by the end of 4 hours the reaction did not progress and
the starting material was recovered.
The reaction conditions were varied, where all the steps were followed as mentioned earlier with only
changing the temperature. The reaction mixture instead of warming to room temperature was heated up
to 30◦C and stirred for 4 hours with an hourly TLC check. However the reaction did not progress and the
starting material was recovered. In the next reaction all the steps were followed along with heating up to
30◦C for 4 hours with hourly TLC check, with the only change being degassing of the system and argon
back fill, as is done generally in the radical reaction experiments. Again the reaction did not progress
and the starting material was recovered. The next reaction was performed with the same quantities of
chemicals with degassing of the system and argon back fill, the reaction mixture was heated up to 30◦C
and was stirred for a longer duration of 8 hours with hourly TLC checks. The reaction did not progress
and the starting material was recovered.
In the next set of experiments an excess of reagents were used i.e. two times addition of three equiv-
alent of Sodium trifluromethanesulfinate and 5 equivalents of tert-butylhydroperoxide at the intervals of
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4 hours. This reaction mixture was stirred overnight at 60◦C. The system was degassed and argon
back fill was performed before the start of the experiment. The reaction did not go to completion with
large amount of starting material recovered with some impurity which was identified as the by product
mentioned in the literature (see Scheme. 4.1, Ji et al. (2011)). The next reaction performed was with
the same parameters as in the previous reaction with use of excess of reagents and was stirred for a
longer duration of 5 days. The reaction was stopped since it did not go to completion and the starting
material was recovered with some impurities.
Further optimisation was carried out for this reaction where the reaction mixture was stirred at room
temperature between 20-24◦C for 8 days. The reaction system was degassed followed by the argon
back fill at the start of the experiment and the excess of reagent was added (2 times addition of 3
equivalent Sodium trifluromethanesulfinate and 5 equivalent of tert-butylhydroperoxide) at the intervals
of 24 hours. The reaction was halted after 8 days with the starting material being recovered.
A parallel set of reactions was carried out with the 4-pyridyl-4-butylbenzoyl. Similar results were ob-
tained.
In an attempt to validate the reaction, a controlled experiment was carried out with 4-cyanopyridine. The
reaction system was degassed followed by the argon back fill, excess of reagent was added (two times
addition of 3 equivalents Sodium trifluromethanesulfinate and 5 equivalents of tert-butylhydroperoxide)
at the intervals of 24 hours and stirred at room temperature (20-24◦C) for 2 days. The completion of
reaction was monitored with TLC. At the end of two days, the reaction went to 80 % completion. The
product obtained contained the desired compound (10 %), with some starting material and by product
(see Scheme. 4.1).
Since the yield obtained was low no further optimisation was carried out to this reaction.
4.3.2 Trifluoromethylation of heteroaryl amidrazone compounds by photoredox catal-
ysis method
Nagib & MacMillan (2011) have recently published a mechanism for direct trifluoromethylation of un-
activated arenes and heteroarenes which requires milder experimental conditions like household light
and commercially available photo-catalysts. The proposed mechanism by Nagib & MacMillan (2011)
suggests that the photoredox catalytic cycle is initiated by the excitation of the photo-catalyst in the
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presence of a household bulb. This excited state catalyst acts as a reductant and via single electron
transfer reduces the triflyl chloride to a high energy species, which spontaneously collapses to form CF3
radical. This CF3 radical then selectively attaches with the most electron-rich position of any arene or
heteroarene resulting in the trifluoromethylation of the compound. In the process the catalyst is pro-
moted to the next level where it acts as an oxidant on the trifluoromethylated aromatic system to provide
a cation and there by completing the catalytic cycle. This cation on subsequent deprotonation gives the
required trifluoromethylated aromatic system (see Fig. 4.4). Using this principle a trifluoromethylation
of the heteroaryl amidrazone compounds was attempted. The authors (Nagib & MacMillan (2011) sug-
gested that for the electron deficient species a photo catalyst with longer excited state should be used
along with excess of CF3 source i.e. triflyl chloride ).
Figure 4.4: Proposed mechanism for direct trifluoromethylation of arenes by photoredox catalysis. As-
sembled from Nagib & MacMillan (2011)
A borosilicate tube was equipped with a small stirrer bar, 0.02 equivalent of iridium photocatalyst (Tris[2-
(2,4-difluorophenyl)pyridine]iridium(III), Ir(Fppy)3) and 3 equivalent of phosphate buffer (K2HPO4) and
sealed with a rubber cork. This system was then degassed with alternate vacuum suction and argon
backfill (three times) before injecting the solvent anhydrous acetonitrile and 1 equivalent of 4-pyridyl-
4-octylbenzoyl carboxamidrazone. The resulting reaction mixture was again degassed with alternate
vacuum suction and argon backfill (three times). To this triflyl chloride 4 equivalent was injected and the
tube was placed approximately 2 cm apart from the normal household light (compact fluorescent light
bulb, 600 lumens output) with very slow stirring (< 4000 rpm), to allow more light penetration through
the solution, for 24 hours. The reaction did not yield desired product. The proton and fluorine NMR data
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suggested a mixture of starting material and some compounds with CF3 substituted in multiple positions
as impurities. Isolation of these compounds was difficult as they did not separate on TLC. Based on the
results, the experiment was repeated with the same quantities and the entire reaction system was kept
dry. The reaction did not go to completion and starting material was recovered with impurities.
It was thought that during the work up, the iridium catalyst present in the system carried on the reaction
and multiple substitutions occurred. To address this problem the next experiment was set up under
similar conditions with the same chemical quantities, however the work up was done rapidly and in
the dark. The catalyst was removed by column chromatography and resulting product obtained was
impure. To further optimise this reaction, a new experiment was set up with half the quantities of the
photo-catalyst iridium (0.01 eq) and CF3 source triflyl chloride (2 eq). To check the completion of the
reaction an hourly TLC check was performed. The reaction did not go to completion and after 24 hours
the reaction was stopped and the starting material was recovered along with some impurities after the
work up.
The reaction conditions were also probed using a simpler compound, 4-cyano pyridine, which if fluo-
rinated could be used as precursor to the carboxamidrazone compound. In this experiment the 0.02
eq. of iridium was added to 3 eq. of phosphate buffer and after the degassing and argon backfill (three
times) anhydrous acetonitrile solvent was added along with 1 eq. of 4-cyano pyridine. To this 4 eq. of
triflyl chloride was added after another round of alternate degassing and argon backfill (three times) and
placed approximately 2 cm from light source. After monitoring the experiment with TLC it was observed
that the reaction did not go to completion after 24 hours and hence the reaction was stopped. After the
column chromatography to remove the catalyst, starting material was recovered with impurities. Another
experiment was set with further halving the quantities of the catalyst iridium (0.01 eq) and triflyl chloride
(2 eq) , while the quantities of remaining chemicals remained unchanged. The reaction did not yield the
desired product and starting material along with impurities was obtained.
The previous sets of reactions have seen lowered concentrations of the photo-catalyst and CF3 source
in order to prevent the reaction from undergoing multiple CF3 substitutions. Another attempt was
made by changing the photo-catalyst. In the next experiment, ruthenium catalyst (Dichlorotris(1,10-
phenanthroline)ruthenium(II) hydrate) was used as it has lower lived excited state as compared to irid-
ium. All the chemicals were used in the same quantities 0.01 eq ruthenium, 3 eq phosphate buffer, 1
eq 4-cyano pyridine and 2 eq triflyl chloride along with anhydrous acetonitrile as solvent. The reaction
conditions were same as in the previous experiment. The reaction did not progress after 24 hours and
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the starting material was obtained with some impurities. To make the conditions milder, the quantity
of CF3 source triflyl chloride was further lowered to (1 eq). The reaction did not progress and starting
material was obtained.
As the reaction failed to go to the completion, in the next set of reactions a large amount of the iridium
catalyst (0.04 eq) and triflyl chloride (8 eq) was added. The quantities of phosphate buffer and 4-cyano
pyridine remained constant. The reaction progressed but did not go to the completion. Hence another
reaction was set up with the excess of catalyst (0.04 eq) and triflyl chloride (8 eq) for a longer duration
(3 days). The reaction did not go to completion and starting material was obtained.
It was observed that normal household light (energy saving soft white) has a colour temperature of 2700
to 3000 K and lumen output up to 600 lumens. The literature suggests the use of any fluorescent light.
Hence a white light which has the colour temperature of 6500 K and up to 1900 lumens output was
selected for the next set of experiments due to its intense luminosity (Nagib & MacMillan (2011)). The
chemicals used were 0.02 eq iridium catalyst, 3 eq phosphate buffer, 1 eq 4-cyano pyridine and 4 eq
triflyl chloride along with anhydrous acetonitrile as solvent. The reaction mixture was stirred for 72 hours.
Upon work up the crude product was found to be a mixture of starting material and desired product with
some impurities as evidenced by 19F NMR shifts (see Fig. 4.5).
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Figure 4.5: Fluorine NMR showing the ratio of desired product to impurities.
For the next set two experiments were set up in parellel with the same quantities of chemicals one with
4-cyano pyridine and another with 4-pyridyl-4octylbenzoyl carboxamidrazone and were allowed to stir
for longer period of time (7 days) and were monitored with 19F NMR. In the first experiment with 4-cyano
pyridine the reaction did not go to the completion and the crude product obtained contained a mixture
of the starting material and the desired product with some impurities. The ratio of the desired product
to the starting material was increased (see Fig. 4.6). In the second experiment, it was observed that
the crude product obtained was mixture of the starting material, desired product and cyclised version of
the 4-pyridyl-4-octylbenzoyl carboxamidrazone. The last experiment in this set was set up with 4-cyano
pyridine, all the chemicals were used in the same quantites, the only change in parameters was longer
time (14 days). The reaction did not progress and was stopped. The crude product contained starting
material as a major product.
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Figure 4.6: Fluorine NMR showing increase in the desired product.
The next set of reactions was carried out in a UV chamber as it has higher lumen intensity (4200
lumens) as compared to the household light and white light. The chemical quantities remained same.
The reaction mixture ejected out of the reaction vessel after 24 hours. Hence for next experiment, the
reaction vessel was sealed with paraffin film and reaction was monitored by 19F NMR. After 7 days the
reaction was stopped as it did not progress and starting material was obtained after work up.
In a separate strand the cyclisation of 4-pyridyl-4-octylbenzoyl carboxamidrazone was very interesting
as it offered a possibility of cyclisation of carboxamidrazone compound at lower temperature, which is
in contrast to the methods requiring harsh temperature conditions as discussed in chapter 3. To find
the exact conditions that caused cyclisation, a series of experiments were set up (see Table. 4.1).
It was observed that the cyclisation occurred in the presence of acetonitrile, daylight bulb, catalyst
and triflyl chloride, i.e entry number 14, the presence of the buffer did not affect the reaction. The
column chromatography was performed to isolate the cyclised product, however the yield of the cyclised
compound was much lower (∼ 15 %) as compared to the conventional high temperature reaction.
230
Entry 30◦C Carbox-
amidrazone
Trifluoro-
methyl
source
Acetonitrile K2HPO4 Daylight
bulb
Catalyst
(Iridium,
Ir(Fppy)3)
1 X X X
2 X X X X
3 X X X
4 X X X X
5 X X X X
6 X X X X
7 X X X X
8 X X X X X
9 X X X X
10 X X X X X
11 X X X X
12 X X X X X
13 X X X X X X
14 X X X X X X
Table 4.1: Table of experiments for cyclisation
4.3.3 Trifluoromethylationof heteroaryl amidrazone compounds using the Togni reagent
The direct trifluoromethylation usually requires harsh experimental conditions, and hence cannot be
used for the compounds which have sensitive functionalities in the molecules. The Rupert-Prakash
reagent (Me3SiCF3) has large applications in nucleophilic trifluoromethylation, however the electrophilic
trifluoromethylation methods are considerably less developed. In an attempt to solve this problem An-
tonio Togni and co-workers have recently developed a new hypervalent iodine based reagent, 3,3-
dimethyl-1-(trifluoromethyl)-1,2-benziodoxole, which facilitates direct addition of CF3 group on to the
heteroaryl systems. This reagent is known to be tolerant towards short exposure of moisture without
causing significant alterations to the compound. Although this reagent is shown to react readily with
the electron rich compound, it requires an elevated temperature for the less reactive system. Hence a
trifluoromethylation of 4-cyano pyridine was attempted using Togni reagent at an elevated temperature
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Scheme 4.2: Scheme for the trifluoromethylation of the heteroaryl amidrazone compounds using Togni
reagent
(see Scheme. 4.2).
4-cyano pyridine (0.3 mmol) was dissolved in anhydrous acetonitrile along with (0.6 mmol) of Togni
reagent. The entire system was degassed by alternate vacuum suction and argon backfill (three times).
This reaction mixture was stirred at 80◦C for 96 hours under argon. The reaction was monitored by
19F NMR. The subsequent work up showed a mixture of two products, one with CF3 substitution at 2nd
position on the pyridine ring and other with CF3 substitution at the 3rd position. The mixture could not
be isolated and the yield of the target compound in the mixture was low (9%). Since the yield was low
and isolation of the compounds was not possible, also as discussed in chapter3 at a high temperature
the possibility of cyclisation of the carboxamidrazone increases, this reaction was not taken any further.
4.3.4 Synthesis of fluorinated carboxamidrazone amides
THF/ Acid/ CDI
Fluorinated carboxamidrazone amide
Room temperature
Ethanol
THF/ Acid Chloride/ 
Hunig's base
H2O
R
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N
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Scheme 4.3: Scheme for the synthesis of fluorinated caxboxamidrazone amide.
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The direct trifluoromethylation techniques did not yield the desired product, hence another attempt was
made to synthesise fluorinated carboxamidrazone amides. This reaction was carried out in two steps.
The first step involved preparation of carboxamidrazone. 4-Cyano-2-fluoro pyridine was bought com-
mercially. This compound was then suspended in ethanol and was treated with hydrazine monohydrate
and stirred at room temperature for 14 days. The crude product obtained was recrystallised from ethanol
to obtain the subsequent carboxamidrazone compound. This fluorinated carboxamidrazone was then
reacted with the acid chloride to yield the desired carboxamidrazone amide. Using the similar process
two more cyano pyridines which were bought commercially, namely 2-cyano-5-fluoro pyridine and 2-
cyano-3-fluoro pyridine, were converted to carboxamidrazones and treated with acid chlorides and acid
to yield fluorinated carboxamidrazone amides (see Scheme. 4.3).
Based on the microbiological results of the most active carboxamidrazone amides discussed in chapter
2 the acid chloride and acid substrates used were 4-pentylbenzoyl chloride, 4-hexylbenzoyl chloride and
3,5-ditert-butyl-2-hydroxy benzoic acid.
The 4-cyano-2-fluoro pyridine carboxamidrazone when reacted with the acid chlorides and acid in 1:
1.1 equivalent yielded the desired fluorinated carboxamidrazone. However the reactions with 2-cyano-
5-fluoro pyridine carboxamidrazone and 2-cyano-3-fluoro pyridine carboxamidrazone with the acid chlo-
rides and acid in 1: 1.1 equivalent did not go to completion. Hence the 4-pentyl benzoyl chloride was
selected for the next set of reactions. Excess of reagent was used (2.5 equivalent of acid chloride to 1
equivalent of carboxamidrazone) to facilitate the reaction to go to completion and the desired fluorinated
2-pyridyl carboxamidrazone amide was obtained. The fluorinated carboxamidrazone amide compounds
are sent for anti tuberculosis screening at NIAID, US. The microbiology results are still pending.
The analytical data, namely, NMR spectra, IR spectra were found to be consistent with the proposed
structures. The NH bond was observed in the proton NMR spectrum in the region of 9 to 10 ppm
indicating the formation of an amide. The IR showed a broad peak in the range of 1665 − 1760 cm−1
representing the carbonyl group. The single peak in the region of -115 to -130 ppm on 19F NMR
confirmed the presence of fluorine atom. These compounds were characterised with melting points.
Table. 4.2 lists the fluorinated carboxamidrazone compounds synthesised along with its % yields and
melting points.
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Compound
number
Pyridyl R group Yield
(%)
Melting point
(◦C)
(162) 2-fluoro-4-
pyridyl
83 210 − 213.5
(163) 2-fluoro-4-
pyridyl
86 199.1 − 200.6
(164) 2-fluoro-4-
pyridyl
OH
72 200.1 − 203.5
(165) 3-fluoro-2-
pyridyl
79 207.2 − 208.8
(166) 5-fluoro-2-
pyridyl
76 209.1 − 211
Table 4.2: List of analogues of fluorinated carboxamidrazones.
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4.3.5 Purity
The fluorine substituted pyridine carboxamidrazones synthesised were clean and were used as it is for
next step. The crude linear carboxamidrazone amides synthesised were found to posses impurities and
the pure compound was isolated by recrystallisation.
4.3.6 Solubility
The fluorinated carboxamidrazone amides were readily soluble in most of the common polar and non-
polar solvents.
4.3.7 Microbiological results
The analogues of both the fluorinated carboxamidrazones and α-keto, β-hydroxy esters were sent to
the Infectious Disease Research Institute (IDRI, US) for screening against Mycobacterium tuberculosis
H37Rv strain. These compound libraries were subjected to MIC under aerobic conditions assay. The
assay was carried out on H37Rv strain to determine the MIC, IC50 and IC90 concentration for the com-
pounds. As discussed in 2.4.8 in chapter 2 the fluorinated carboxamidrazone analogues were subjected
to high throughput screening (HTS) process. This process involves two stages: in the first stage, assays
are carried out on H37Rv strain to determine the MIC, IC50 and IC90 concentration for the compounds.
The compounds which have MIC values of 32.47 µM or less are further taken to the second stage which
involves advanced anti mycobacterial susceptibility profiling (see 2.4.8) in chapter 2. The Table. 4.3
presents the first stage microbiological results obtained from IDRI. While the Table. 4.4 represents the
values of the control drug used in the testing.
Test Compounds
Compound number MIC (µM) IC50 (µM) IC90 (µM)
(162) 2.6 1.2 4.0
(163) >200 >200 >200
(164) >200 190 >200
Table 4.3: The first stage microbiological data summary of the fluorinated carboxamidrazone amides.
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Controlled Compound
Compound number MIC (µM) IC50 (µM) IC90 (µM)
Rifampicin 0.007 0.006 0.013
Table 4.4: Microbiological data for the Control drug used in the first stage analysis.
The compounds (162) and (164) were found to be active and hence they were taken to the second stage
of screening. The Table. 4.5 presents the data for MIC assays performed in aerobic conditions and
under low oxygen conditions. Both the compounds were found to have activity against Mycobacterium
tuberculosis H37Rv strain under aerobic and low oxygen condition.
Assays MIC under aerobic conditions MIC under low oxygen
Compound numbers (162) (164) (162) (164)
MIC (µM) 12 >200 3.4 11
IC50 (µM) 2 62 6.5 13
IC90 (µM) 12 >200 13 15
Table 4.5: The second stage MIC data summary of the fluorinated carboxamidrazone amides.
Both the compounds showed the bactericidal activity in the MBC assay. The minimum bactericidal
concentrations were found to be: 13 µM for compound (162) and 100 µM for compound (164). The
bactericidal action was found to be time dependent but not concentration dependent. The compound
(164) was found to be cytotoxic with the IC50 value of 83 µM, while both the compounds exhibited
intracellular activity against M. tuberculosis. The compounds (162) and (164) also showed activity
against M. tuberculosis resistant isolates RIF-R1 strain with the MIC values of 6.1 µM and 26 µM
respectively.
4.4 Summary and Conclusion
This study has explored the various possible ways for incorporation of fluorine and trifluoromethyl groups
on to the carboxamidrazone in an attempt to alter the penetration, and the subsequent metabolism of the
compound. Some activity was observed in two of the fluorinated compounds (162) and (164). The com-
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pound (162) i.e N-[(Z)-[amino-(2-fluoro-4-pyridyl)methylene]amino]-4-pentyl-benzamide exhibited very
significant activity. The related non fluorinated carboxamidrazone amide (N1-(4-Pentylbenzoyl)-pyridine-
4-carboxamidrazone) synthesised by Ren (2009) was noted to have a weak activity with the IC50 value
of 57.51 µM and the IC90 value of 80.82 µM. A significant improvement in the activity was observed
post fluorination. The IC50 value of 1.2µM, IC90 value of 4.0µM and the MIC of 2.6 µM was observed.
The possible improvement in the activity could be result of the increased cell permeability caused by
the fluorine. The microbiological data for the fluorine substituted 2-pyridyl carboxamidrazone amides
i.e. compounds (165) and (166) is in process. It would be very interesting to observe the data for these
compounds as they were the most active compounds of the Ren (2009) series.
The future work could possibly involve synthesis of analogues of fluorinated carboxamidrazone amide.
Also if an appropriate method is found, a direct trifluoromethylation can be performed on these com-
pounds to compare the activity of the compounds.
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4.5 Experimental
The chemicals and instrumentations used are the same as discussed in 3.5.
4.5.1 Preparation of pyridine(2-fluoro)-4-carboxamidrazone (167)
a
b
c
(1)
(2)
(167)
F
NH2
N
NH2
N
Figure 4.7: Pyridine(2-fluoro)-4-carboxamidrazone
4-cyano-2-fluoro pyridine (4.5 g, 36.88 mmol) was suspended in ethanol (13.5 mL) and to it hydrazine
monohydrate (9 mL) was added. This reaction mixture was stirred at room temperature for 14 days.
The excess of hydrazine was removed by rotary evaporation under reduced pressure at 50◦C and the
product was collected by filtration. The crude product was then washed three times with petrol ether 40
60◦C to give a yellowish compound. The crude product obtained was then recrystallised using ethanol.
Yield: 4.34 g, 86.5%.
Rf value [EtOAc:MeOH (2:1)]: 0.15.
1H NMR (250 MHz, d6-DMSO): 8.53 (d, 2H, J=6.3 Hz, a and b), 7.52 (d, 1H, J=6.3 Hz, c), 5.51 (bs,2H,
NH2(2)), 4.23 (bs, 2H, NH2(1)) ppm.
19F NMR: -67.58 (s, F) ppm.
4.5.2 Preparation of pyridine(5-fluoro)-2-carboxamidrazone (168)
a
b
c
(1)
(2)
(168)
F
NH2
N
NH2N
Figure 4.8: Pyridine(5-fluoro)-2-carboxamidrazone
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The procedure for the preparation of Pyridine(5-fluoro)-2-carboxamidrazone is same as for Pyridine(2-
fluoro)-4-carboxamidrazone.
Yield: 3.98 g,79.3 %.
Rf value [EtOAc:MeOH (2:1)]: 0.15.
1H NMR (250 MHz, d6-DMSO): 8.47 (m, 1H, a), 7.93 (m, 1H, b), 7.71 (td, 1H, J= 6.92, 1.8 Hz, c), 5.33
(bs, 2H, NH2(2)), 5.71 (bs,2H, NH2(1)) ppm.
19F NMR: -129.13 (s, F) ppm
4.5.3 Preparation of pyridine(3-fluoro)-2-carboxamidrazone (169)
a
b
c
(1)
(2)
(169)
NH2
N
NH2
F
N
Figure 4.9: Pyridine(3-fluoro)-2-carboxamidrazone
The procedure for the preparation of Pyridine(3-fluoro)-2-carboxamidrazone is same as for Pyridine(2-
fluoro)-4-carboxamidrazone.
Yield: 4.16 g, 82.9 %.
Rf value [EtOAc:MeOH (2:1)]: 0.15.
1H NMR (250 MHz, d6-DMSO): 8.53 (m,1H, a), 8.33 (td, 1H, J= 6.92, 1.8 Hz, c), 7.68 (td,1H, J=4.9, 1.2
Hz, b), 7.21 (s, 2H, NH2(2)), 5.37 (s,2H, NH2(1)) ppm.
19F NMR: -117.03 (s, F) ppm.
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4.5.4 General procedure for fluorinated carboxamidrazone amide synthesis from acid
chlorides
Heteroaryl fluorinated carboxamidrazone (1.0 g, 6.49 mmol) was suspended in an anhydrous THF (20
mL). To this solution Hu¨nig’s base (2 mL) was added, followed by acid chloride (1.1 eq). This reaction
mixture was stir overnight under argon at room temperature. This reaction mixture was added to sodium
bicarbonate solution (20 mL) and the product was collected by filtration. The crude product obtained
was then washed with water and dried under vacuum. The product obtained was pure and hence used
as it is.
4.5.5 General procedure for synthesis of fluorinated carboxamidrazone amide from
acids
N,N‘-carbonyl-di-imidazole (1.05 g, 6.49 mmol) and acid (6.49 mmol, 1 eq) was dissolved in THF (20
mL). To this reaction mixture appropriate fluorinated heteroaryl carboxamidrazone (1 g, 6.49 mmol) was
added and this reaction mixture was stir under argon at room temperature for overnight. This reaction
mixture was added to sodium bicarbonate solution (20 mL) and the product was collected by filtration.
The crude product obtained was then washed with water and dried under vacuum. The product obtained
was pure and hence used as it is.
N-[(Z)-[amino-(2-fluoro-4-pyridyl)methylene]amino]-4-pentyl-benzamide (162)
a
b
c
d
e
f
g
(
¦§
¨
©
¦
§
¦
ª
¦
1H NMR (250 MHz, d6-DMSO): 10.82 (s, 1H, -NH), 8.53 (d, 2H, J = 5.4 Hz, -b and c), 8.34 7.98
(overlapping m, 2H, -d and g), 7.87 (dd, 1H, J = 4.5, 1.6 Hz, -a), 7.34 (d, 2H, J = 8.3 Hz, -e and
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f), 6.74 (s, 2H, -NH2), 2.63 (t, 2H, J = 7.5 Hz, -CH2CH2(CH2 )2 CH3), 1.60 (dt, 1H, J = 14.9, 7.3 Hz,
-CH2CH2(CH2 )2 CH3), 1.35 − 1.27 (overlapping m, 4H, -CH2CH2(CH2 )2 CH3), 0.84 (t, 3H, J = 8.3, 5.4
Hz,J = 6.8 Hz, -CH2CH2(CH2 )2 CH3) ppm.
19F NMR: -67.58 (s, F) ppm.
IR (neat) ν:3885, 3851, 3730, 3648, 3587 (N-H), 3026 (Aromatic C-H), 2965 (Alkyl C-H), 2929 (Alkyl
C-H), 2555, 2361, 2213, 2021, 1973, 1772, 1748, 1710, 1681 (C-C in ring), 1654, 1627 (C=O), 1618,
1578, 1557, 1539, 1502, 1490, 1475, 1454, 1390, 1357, 1342, 1257, 1099 cm−1.
Melting point: 210 − 213.5◦C
Yield: 2.00 g, 83 %
N-[(Z)-[amino-(2-fluoro-4-pyridyl)methylene]amino]-4-hexyl-benzamide (163)
a
b
c
d
e
f
g
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1H NMR (250 MHz, d6-DMSO): 10.80 (s, 1H, -NH), 8.55 (d, 1H, J = 5.4 Hz, -c), 8.41 8.02 (overlapping
m, 2H, -a and b), 7.89 (dd, 2H, J = 4.5, 1.6 Hz, -d and g), 7.31 (d, 2H, J = 8.3 Hz, -e and f), 6.65 (s, 2H,
-NH2), 2.70 (t, 2H, J = 7.5 Hz, -CH2CH2(CH2 )3CH3), 1.64 (dd, 2H, J = 27.0, 20.5 Hz, -CH2CH2(CH2
)3CH3), 1.33 (dd, J = 11.4 Hz, 6H, -CH2CH2(CH2)3CH3), 0.84 (t, 3H, J = 6.7 Hz, -CH2CH2(CH2 )3CH3)
ppm.
19F NMR: -67.58 (s, F) ppm.
IR (neat) ν: 3356 (N-H), 3320 (N-H), 3150, 3025 (Aromatic C-H), 2948 (Alkyl C-H), 2917 (Alkyl C-H),
1705, 1645 (C=O), 1599, 1521, 1461, 1397, 1388, 1333, 1300, 1268 (C-N), 1222, 1190, 1140 cm−1.
Melting point: 199.1 − 200.6◦C
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Yield: 2.16 g, 86 %
N-[(Z)-[amino-(2-fluoro-4-pyridyl)methylene]amino]-3,5-ditert-butyl-2-hydroxy-benzamide (164)
a
b
c
d e
NH
°
± ±H
N
H
N
F
N
1H NMR (250 MHz, d6-DMSO): 11.51 (s, 1H, −OH), 10.03 (s, 1H, -NH), 8.41 (d, 2H, J = 5.4 Hz, -b
and c), 8.31 (complex m, 1H, d), 7.81 (dd, 1H, J = 4.5, 1.6 Hz, -a), 7.32 (d, 1H, J = 8.3 Hz, -e), 6.63 (s,
2H, -NH2), 1.42 (s, 9H, tert. butyl), 1.26 (s, 9H, tert. butyl) ppm.
19F NMR: -67.58 (s, F) ppm.
IR (neat) ν: 3441, 3333 (N-H), 3277 (N-H), 3035 (Aromatic C-H), 2919 (Alkyl C-H), 2853 (Alkyl C-H),
1636 (C=O), 1606, 1551, 1515, 1496, 1481, 1433, 1351, 1305, 1275 (C-N), 1244, 1175, 1102, 1068,
1020 cm−1.
Melting point: 200.1 − 203.5◦C
Yield: 2.04 g, 72 %
N-[(Z)-[amino-(5-fluoro-2-pyridyl)methylene]amino]-4-pentyl-benzamide (165)
a
b
c
d
g
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H
N
N
(165)
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1H NMR (250 MHz, d6-DMSO): 10.41 (s, 1H, -NH), 8.63 (complex m, 1H, -a), 8.04 (d, 1H, J = 8.2 Hz,
-b), 7.74 (ddd, 2H, J = 12.9, 9.6, 4.8 Hz, -d and g), 7.39 (ddd, 1H, J = 7.3, 4.9, 1.3 Hz, -c), 7.11 (d,
2H, J = 8.3 Hz, -e and f), 6.64 (s, 2H, -NH2), 2.68 (t, 2H, J = 7.5 Hz, -CH2CH2(CH2 )2 CH3), 1.82 1.54
(overlapping m, 2H, -CH2CH2(CH2 )2 CH3), 1.36 1.20 (overlapping m, 4H, -CH2CH2(CH2 )2 CH3), 0.83
(t, 3H, J = 6.8 Hz, -CH2CH2(CH2 )2 CH3) ppm.
19F NMR: -129.13 (s, F) ppm.
IR (neat) ν: 3341 (N-H), 3340 (N-H), 3303 (N-H), 3120, 3026 (Aromatic C-H), 2957 (Alkyl C-H), 1654
(C=O), 1608, 1581, 1558, 1475, 1443, 1392, 1463, 1416, 1291 (C-N), 1189 cm−1.
Melting point: 207.2 − 208.8◦C
Yield: 1.9 g, 79 %
N-[(Z)-[amino-(3-fluoro-2-pyridyl)methylene]amino]-4-pentyl-benzamide (166)
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1H NMR (250 MHz, d6-DMSO): 10.47 (s, 1H, -NH), 8.67 (m, 1H, -a), 8.01 (d, 2H, J = 8.2 Hz, -d and g),
7.84 (ddd, 1H, J = 12.9, 9.6, 4.8 Hz, -b), 7.42 (ddd, 1H, J = 7.3, 4.9, 1.3 Hz, -c), 7.21 (d, 2H, J = 8.3 Hz,
-e and f), 6.69 (s, 2H, -NH2), 2.60 (t, 2H, J = 7.5 Hz, -CH2CH2(CH2 )2 CH3), 1.85 1.44 (overlapping m,
2H, -CH2CH2(CH2 )2 CH3), 1.40 1.21 (overlapping m, 4H, -CH2CH2(CH2 )2 CH3), 0.85 (t, 3H, J = 6.8
Hz, -CH2CH2(CH2 )2 CH3) ppm.
19F NMR: -117.13 (s, F) ppm.
IR (neat) ν: 3356 (N-H), 3320 (N-H), 3252 (N-H), 3207, 3022 (Aromatic C-H), 2948 (Alkyl C-H), 1911,
1665 (C=O), 1634, 1547, 1470, 1438, 1393, 1247, 1170, 1057 , 1012, 1002 cm−1.
Melting point: 209.1 − 211◦C
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Yield: 1.83 g, 76 %
4.5.6 General procedure for trifluoromethylation of heteroaryl amidrazone compounds
using Langlois reagent
The required carboxamidrazone (0.5 g, 1.69 mmol, 1 eq) was dissolved in a solution of DMSO (7 mL)
and water (2.8 mL) along with 3 equivalents of sodium trifluromethanesulfinate (0.79 g, 5.067 mmol)
at 0◦C, followed by dropwise addition of 5 equivalents of tert-butylhydroperoxide (1.15 g, 8.45 mmol)
with vigorous stirring under argon. This reaction mixture was allowed to warm up to room temperature
and the progress of the reaction was monitored with an hourly TLC check until the reaction goes to
completion. The reaction mixture was then added to saturated NaHCO3 solution with rapid foaming.
The precipitate was collected by filtration and washed with water (three times, 15 mL). The obtained
was vacuum dried and stored.
4.5.7 General procedure for trifluoromethylation of heteroaryl amidrazone compounds
by photoredox catalysis method
A borosilicate tube was equipped with a small stirrer bar, iridium photocatalyst (Tris[2-(2,4-difluorophenyl)
pyridine]iridium(III), Ir(Fppy)3, 0.0076 g, 0.02 eq) and phosphate buffer (K2HPO4, 0.261 g, 3 eq) and
sealed with a rubber cork. This system was then degassed with alternate vacuum suction and argon
backfill (three times) before injecting the solvent anhydrous acetonitrile and required carboxamidrazone
amide (4-pyridyl-4-octylbenzoyl carboxamidrazone amide, 0.13 g, 0.5 mmol, 1 eq). The resulting reac-
tion mixture was again degassed with alternate vacuum suction and argon backfill (three times). To this
triflyl chloride (0.213 mL, 4 eq) was injected and the tube was placed approximately 2 cm apart from
the light bulb (in this case white light with the colour temperature of 6500 K and 1900 lumens output)
with very slow stirring (< 4000 rpm), to allow more light penetration through the solution, for 24 hours.
The reaction mixture was quenched with water (2 mL) and extracted with ethylacetate (two times) and
DCM (one time), and the combined organic layers were dried over magnesium sulphate and evaporated
under reduced pressure to give the desired product.
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4.5.8 General procedure for trifluoromethylation of heteroaryl amidrazone compounds
using the Togni reagent
4-cyano pyridine (0.3 mmol) was dissolved in anhydrous acetonitrile (2 mL) along with (0.6 mmol) of
Togni reagent. The entire system was degassed by alternate vacuum suction and argon backfill (three
times). This reaction mixture was stirred at 80◦C for 96 hours under argon. The reaction was monitored
by 19F NMR. The solvent was removed under reduced pressure and purified by column chromatogra-
phy(hexane/DCM 30:1).
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Chapter 5
Analogues of mycolic acids as potential
inhibitors of mycobacterial cell wall
synthesis
5.1 Introduction
The mycobacterial cell wall is unique in the sense that approximately 60% of the cell wall is constituted
of high molecular weight hydroxy fatty acids called mycolic acid (MA), a term coined by Anderson &
Chargaff (1929). In the cell wall the mycolic acid is covalently bound to the arabino-peptidogalactan
layer with intercation of free lipids (see Fig. 1.4). This complex structure is together referred to as
mycolyl-arabinogalactan-peptidoglycan (mAGP) complex. This is discussed in detail in the introduction
chapter (1.4). MA obtained fromM. tuberculosis occurs in three forms: α-MA, methoxy-MA and keto-MA
(see Fig. 1.5). The main function of MA is to provide integrity to the cell wall and form an extremely
robust and impermeable envelope with high resistance to host-derived and therapeutic anti-bacterial
agents.
The high degree of complexity in the structures of MA is attributed to its unique system as it employs
fatty acid synthase (FAS) type I and II for its synthesis. FAS II is of special interest as this synthase is
found exclusively in prokaryotic organisms and plants, but is absent in mammals. The detailed FAS I and
II pathways are discussed in 1, see Fig. 1.10. The high complexity of the mycolic acids suggests that
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many enzymes are involved in the bio-synthesis of this lipid. A detailed study of the this bio-synthesis
can enable the scientists to identify the key intermediates and the enzymes associated with them, thus
providing newer drug targets.
A detailed investigation was carried out by Takayama & Qureshi (1984) for Mycobacterium tuberculosis
H37Ra (Takayama & Qureshi (1984)) who identified several intermediates. One such key intermedi-
ate was (Z)-tetracos-5-enoic acid. The authors suggested that the pathway involved in synthesis of
α-mycolic acid in M. tuberculosis H37Ra involved desaturation of tetracosanoate to give (Z)-tetracos-
5-enoic acid. The authors proposed that this step might explain the anti tubercular activity of the drug
isoniazid (Takayama & Qureshi (1984), Winder (1982)), although an exact mechanism and the resis-
tance to isoniazid by certain mycobacteria remains to be completely understood.
Besra et al. (1993) first synthesised the intermediate (Z)-tetracos-5-enoic acid, an ordinary fatty acid,
an initial stage from where the bio-synthetic pathways diverge to form α-mycolates and oxygenated
mycolates. An experiment which involved the incorporation of a radioactive label on to the mycolic acids
inM. smegmatis confirmed its role in the bio-synthetic pathway of α-mycolic acid (Wheeler et al. (1993)).
In a separate study it was shown that the process of desaturation of stearate to form oleate is inhibited
by the cyclopropenyl analogue of the stearate (Fogerty et al. (1972), Jeffcoat & Pollard (1977)). With
this principle in mind the authors decided to synthesise the cyclopropene analogue of (Z)-tetracos-5-
enoate (methyl 4-(2-octadecylcyclopropen-1-yl)butanoate) as a potential inhibitor (Besra et al. (1993))
(see Fig. 5.1). The methyl 4-(2-octadecylcyclopropen-1-yl)butanoate was found to inhibit the mycolic
acid bio-synthesis in the M. smegmatis extract, possibly by inhibiting the desaturase enzyme.
(1) (2)
(Z)-tetracos-5-enoic acid Cyclopropene analogue of (Z)- tetracos-5-enoic acid 
(Methyl 4-(2-octadecylcyclopropen-1-yl)butanoate)
H3C(H2C)17 (CH2)3COOH H3C(H2C)17 (CH2)3CO2CH3
Figure 5.1: The key intermediate in mycolic acid pathway and its analogue
In this chapter, the concept of custom designed inhibitors is used. A set of long chain 2-hydroxy-3-
oxocarboxylic esters were synthesised. The possible mechanism of action proposed for these com-
pounds is the competitive direct uptake of the long alkyl chain esters in the FAS-II pathway instead of
the precursors from the FAS-I pathway, thus disrupting the mycolic acid bio-synthesis.
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5.2 Lead optimisation
]
2-hydroxy-3-oxocarboxylic esterphosphonate carbanion
(triethyl 2-phosphonopropionate)
Aldehyde/ Ketone
Gl. acetic acid, water, acetone in
the ratio of 7ml: 90ml: 300ml
KMnO4
α, β-unsaturated ester
NaH
R1
R3
R2
R2 R3
R3
R1O R2
O P
O
O
O
O O
O
O
OH
O
O
Scheme 5.1: A complete synthetic scheme for the proposed target compounds
R1 = ethyl or methyl groups
R2, R3 = long alkyl chains
R3
R2
R1O
OH
O
O
Figure 5.2: Generic structure of the proposed compounds
The synthesis of the 2-hydroxy-3-oxocarboxylic esters involves a two-step reaction sequence (see
Scheme. 5.1). The first step is the synthesis of alkenes i.e. α, β-unsaturated esters. The respec-
tive aldehyde and ketones were reacted with the phosphonate carbanions to predominantly produce
E-alkenes using HornerWadsworthEmmons modification to Wittig’s reaction (Wadsworth & Emmons
(1961), Wadsworth & Emmons (1965), Wadsworth (1977)). These compounds were then subjected to
direct oxidation by potassium permanganate under mildly acidic conditions to yield 2-alkyl-2-hydroxy-3-
oxocarboxylic esters (Crout & Rathbone (1989)). To synthesise a library of the target compound (see
Fig. 5.2), aldehydes and ketones were selected of varying chain lengths. Table. 5.1 lists the aldehyde
and ketones used for synthesis of the target compound.
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Table 5.1: Aldehyde and ketones used in synthesis of α, β-unsaturated esters
5.3 Results and Discussion
5.3.1 Synthesis of α, β-unsaturatedesters (alkene) by HornerWadsworthEmmonsmod-
ification to Wittig’s reaction
phosphonate car an on
tr eth phosphonoprop onate
eh e etone
nsat rate ester
a
¶
·
¶2
¶2¶·
¸
¸
¸
¹ ¸
¸
¸
¸
¸
Scheme 5.2: Scheme for synthesis of α, β-unsaturated esters (alkene) by HornerWadsworthEmmons
modification to Wittig’s reaction
The first step to synthesise the target compounds involved synthesis of α, β-unsaturated esters (alkene).
As described in the Scheme. 5.2, sodium hydride (60% in mineral oil) was dispersed in DME (dimethyl
ether), followed by drop wise addition of phosphonate carbanion (trimethyl phosphonoacetate, 1.1 eq),
taking care that the temperature did not rise above 35◦C by employing external cooling. It was observed
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that the reaction mixture turned frothy and vigorous evolution of hydrogen was noted. The reaction
mixture is stirred at room temperature for 30 mins, followed by drop wise addition of the ketone (6-
undecanone, 1.1 eq) maintaining the temperature below 35◦C. At this point it was observed that the
reaction mixture gelled and the stirring was obstructed hence additional solvent (DME) was added to
the reaction mixture to ensure smooth stirring. This reaction mixture was stirred at room temperature for
48 hours. The target α, β-unsaturated esters was obtained after an aqueous quenching and extractive
work up Wadsworth & Emmons (1965). In this reaction care was taken that all the glassware used were
oven-dried overnight and the reaction was carried out in dry conditions to avoid the contact of water or
moisture with sodium hydride. The TLC analysis of the crude product suggested the presence of both
alkene and ketone. A kugelrohr distillation apparatus was used for the purification. The individual proton
NMR data obtained for the fractions showed that the first three flasks contained the mixture of ketone
and alkene.
In an attempt to assist the reaction to go to the completion, the experiment was set up exactly the same
with only changing the temperature parameter. The reaction mixture was stirred at 50◦C for 48 hours.
The work up for the experiment was the same as mentioned earlier. The TLC analysis of the crude
product suggested that the reaction did not go to completion and instead a large amount of ketone was
observed. Thus the rise in temperature decreased the yield of alkene.
Another optimisation was lowering the quantity of the ketone. The sodium hydride (1 eq) was dispersed
in DME followed by addition of trimethyl phosphonoacetate (1.1 eq) with the temperature below 35◦C.
After stirring the reaction mixture at room temperature for 30 mins, the 6-undecanone was added (0.9
eq) and stirred at room temperature for 48 hours. The TLC of the crude product, obtained after the work
up, suggested the presence of alkene and trimethyl phosphonoacetate.
To validate the procedure of the reaction, an example from the literature was performed Wadsworth
& Emmons (1965). The experimental conditions for the new experiment were identical to the first ex-
periment and the ketone used was cyclohexanone. The crude material was purified using kugelrohr
distillation apparatus. The NMR data of the compound showed the pure product.
Hence for the next optimisation reaction using 6-undecanone was set up with the same quantities and
conditions as the first experiment, but with increased reaction time. The reaction mixture was stirred
for 7 days. Upon work up the crude product obtained was isolated using column chromatography.
The desired alkene was obtained. However for ease of separating the alkene from the ketone, an
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additional step was included in the work up. The bisulphite formation is a valuable chemoselective
process which is often used for protection and/or purification of aldehyde and cyclic ketones. Sodium
bisulphite when treated with aldehyde forms a sodium salt of the bisulphite adduct. These charged
adducts can be removed via precipitation (Caron (2011), Kjell et al. (1999)). The next reaction was set
up as usual and the crude product obtained was then stirred with freshly prepared sodium bisulphite
solution for 48 hours. The white precipitate formed was filtered off and the aqueous layer was then
extracted with ether. The organic layers collected were then evaporated under vacuum to give the
desired alkene and some impurities, which was then subjected to the column separation. Using the
same experimental conditions the aldehyde dodecanal was reacted to yield the respective alkene. The
ketones adamantanone, cyclododecanone and cyclopentadecanone required 72 hours as reaction time.
It was observed that the yields of the cyclododecanone and the cyclopentadecanone were significantly
lower compared to the smaller carbon chain ketones and aldehydes. A pattern was observed that as
the number of carbons increased in the compound the alkene yield decreased (see Table. 5.2).
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Compound
number
Aldehydes and Ke-
tones
Structure of alkenes Yield in
%
Number
of days
required for
reaction to
complete
(170) Dodecanal
O
O
28.3 3
(171) 6-Undecanone
O
O
24.7 7
(172) Cyclohexanone
O
O
60 overnight
(173) Adamantanone
O
O
98.7 6
(174) Cyclododecanone
O
O
12.53 7
(175) Cyclopentadecanone
O
O
3 7
Table 5.2: Summary of alkenes prepared along with their yields
5.3.2 Synthesis of long chain aldehydes using Swern oxidation
All the ketones and aldehyde used in this project were purchased commercially. The cyclised or open
chain aldehydes or ketones with the chain length above 15 carbons were not available commercially.
Hence an attempt was made to synthesise long chain aldehydes from long chain alcohols using Swern
oxidation, which can then be subjected to HornerWadsworthEmmons modification to Wittig’s reaction
(see Scheme. 5.3)
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Oxalyl chloride Dimethyl sulfoxide Alcohol
Alkoxy sulfonium ionAldehyde or ketone
Triethyl amine
OR S
+
O
H
H
R
H Cl
OHRS
+
Cl
Cl
O
Cl
O
S
O
+
+
Scheme 5.3: Scheme for synthesis of long chain aldehydes and ketones from primary alcohols using
Swern oxidation
This is a multi-step reaction sequence, where the oxalyl chloride and DMSO (dimethyl sulfoxide) are
reacted at a controlled temperature of -78◦C to give an intermediate product (sulfonium chloride) and
releasing carbon dioxide and carbon mono-oxide. This sulfonium chloride then reacts with alcohol (1-
docosanol) to yield alkoxysulfonium ion intermediate which in turn deprotonates in excess organic base
(triethyl amine) to give the corresponding aldehydes. The reaction mixture was stirred for one hour at
room temperature before it was quenched with water and the aqueous layer was extracted with DCM
three times. The organic extracts were then washed with 1M HCl. These washing were then dried over
anhydrous MgSO4, and evaporated under pressure to give desired product (Omura & Swern (1978)).
TLC analysis suggested formation of aldehyde, however the yield was low.
Hence to further optimise the reaction, another experiment was set up with a smaller alkyl chain alcohol
(1-octadecanol), the experimental conditions were same as stated earlier. The TLC and NMR analysis
of crude product shows a large amount of unreacted alcohol with traces of aldehyde. Hence in the
next experiment the procedure remained the same as mentioned except the reaction time, which was
increased to 3.5 hours maintaining the temperature at -70◦C. The crude product yielded large amounts
of unreacted alcohol. In the next set of experiments the quantities of the reagents were doubled ex-
cept for the alcohol (1-octadecanol) and the reaction time was 3.5 hours at -70◦C. After quenching the
reaction with water the aqueous layer was extracted with petrol ether (40-60◦C) and washed with 1M
HCl. The crude product obtained showed the presence of aldehyde. However, on the next day it was
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observed by TLC and NMR that the compound disintegrated and some impurities were observed. One
of the possibilities is that the aldehyde synthesised in the presence of moisture might have reacted to
give hemi-acetals or acetals.
Hence a scale up of the reaction was carried out in the next experiment and after a quick work up and
TLC check, half of the product was taken to the next step i.e. HWE reaction to prepare alkene. The
remaining half was dried thoroughly and stored in a freezer at 0◦C for analysis. The HWE reaction did
not progress after 72 hours and hence the reaction was stopped. In a similar way 1-docosanol was also
converted to aldehyde using Swern oxidation. In the next set of experiments, both the aldehydes were
prepared by Swern oxidation and after rapid work up were taken for HWE reactions. This reaction was
monitored by TLC, however the reaction did not go to completion, hence after 14 days the reaction was
stopped. Another set of experiment was set up with 1-octadecanol being converted to aldehyde and
then taken to HWE reaction, however instead of stirring the reaction mixture at room temperature, it was
heated up to 50-60◦C. The reaction was monitored by TLC, however as the reaction failed to progress
after 14 days, the reaction was stopped and traces of alkene were recovered along with a mixture of
aldehyde and possible acetal by-products. Hence this reaction was not taken further.
It was therefore concluded that though the aldehyde formation occurred, the HWE reaction does not
progress with large carbon chain compounds. It was also noted that the long chain aldehydes prepared
by Swern oxidation were unstable at room temperature and required to be stored in a cold place away
from moisture.
5.3.3 Synthesis of β-hydroxy esters by Reformatsky reaction
In an attempt to improve the yields of long carbon chain compounds a Reformatsky reaction was carried
out. This reaction converts α-haloesters and aldehydes or ketones to β-hydroxy esters in the presence
of zinc metal (see Fig. 5.4). These compounds can then be dehydrated to give α, β-unsaturated esters,
which can then be oxidised by potassium permanganate to give the target compound.
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Zinc foil Ethylbromo acetate O-zinc enolate Aldehyde or ketone
β-hydroxyester product
Intermediate
R2R1
R2
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··
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Scheme 5.4: Scheme for synthesis of β hydroxy esters by Reformatsky reaction
For this experiment, small pieces of zinc (1 equivalent) were added in the flask with anhydrous toluene,
followed by 20% of the required α-haloester i.e ethylbromo acetate (20% of 1 equivalent) added drop
wise in the flask. The remaining ethylbromo acetate was mixed with the ketone (cyclopentadecanone, 1
equivalent) along with the solvent (anhydrous toluene) and added to the mixture drop wise taking care
that the temperature did not rise above 30-40◦C. To avoid overheating external cooling was provided.
After the complete addition of ketone or aldehyde, the reaction mixture was heated at reflux for 18 hours.
This reaction mixture was then extracted with ethyl acetate. These layers were dried over magnesium
sulphate and evaporated under reduced pressure to give the required product (Shriner (1942)). It is es-
sential to maintain dry conditions throughout as moisture may cause decrease in yield. For the reaction
to progress the zinc surface should be clean, the oily coating of the by-product can stop the reaction. A
parallel reaction was set for cyclododecanone.
It was observed that the products obtained from the Reformatsky reaction did not improve the yield and
hence products from both the ketones, cyclopentadecanone and cyclododecanone, were not taken for
the next dehydration step. This reaction was validated by performing the experiment with a smaller car-
bon chain ketone like cyclohexanone. The experimental conditions remained same as mentioned in the
earlier experiment. It was observed that the yield of the product obtained form the cyclohexanone was
higher than products obtained from cyclopentadecanone and cyclododecanone. However on comparing
the yields of the cyclohexanone product from both the reactions, the HWE reation had a higher yield.
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Hence the yields of cyclopentadecanone and cyclododecanone were not optimised any further.
From the synthetic chemistry point of view, the Reformatsky reaction not only constitutes a method
for synthesis of β-hydroxy esters, but is also a valuable method for lengthening the carbon chain by
two carbon atoms. Due to the presence of carbethoxy group, it is possible to further lengthen the
chain through appropriate repetition of reaction sequence (Shriner (1942)). With this concept in mind,
a new experiment was set up with ethyl-2-bromo caprylate and dodecyl aldehyde, with exact conditions
as mentioned in the earlier reaction. However the reaction did not progress and large quantities of
aldehyde were recovered. Hence this reaction was not taken any further.
5.3.4 Synthesis of 2-alkyl-2-hydroxy-3-oxocarboxylic esters
2-hydroxy-3-oxocarboxylic esteraturated ester
l acetic acid ater aceton in
he ratio o l l l
º
»
2
¼
¼
2
»
Scheme 5.5: Scheme for synthesis of 2-alkyl-2-hydroxy-3-oxocarboxylic esters by direct oxidation
method by potassium permanganate
The α, β-unsaturated esters (alkene) prepared (see Scheme. 5.2) were oxidised using potassium
permanganate under mildly acidic conditions following the method of Crout & Rathbone (1989) (see
Scheme. 5.5). A solvent system was created by mixing glacial acetic acid, water, and acetone in the ra-
tio of 7: 90: 300. The ratio in which the solvents are mixed is of importance for the reaction to progress.
This solvent system was stirred along with the alkene (1eq) at -10◦C in an ice bath with ice and salt
(sodium chloride) mixture. To this reaction mixture solid KMnO4 (in excess of alkene) was added slowly
maintaining the temperature at -10◦C. After the complete addition of KMnO4, the reaction mixture was
allowed to stir at -10◦C for two hours. After the extractive work up with DCM, which upon evaporation
gave desired 2-hydroxy-3-oxocarboxylic esters (Crout & Rathbone (1989)). The oxidised alkene com-
pounds are sent for anti tuberculosis screening at NIAID, US. The microbiology results are still pending.
The table 5.3 lists the compounds synthesised.
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Compound
number
Structure of alkene Structure of final product Yield
(%)
(176)
O
O
O
O
C
H2
CH
½
O
OH
74.7
(177)
O
O
O H
OO
CH3
O
79.2
(178)
O
O
O
O
CH3
O
OH
87
(179)
O
O
O O
O
CH 3
OH
75.3
(180)
O
O
O
O
CH3
O
OH
30.2
(181)
O
O
OH
O
O
CH 3
O
49
Table 5.3: List of analogues of 2-alkyl-2-hydroxy-3-oxocarboxylic esters and 3,3-dialkyl-3-hydroxy-2-
oxocarboxylic ester.
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5.3.5 Attempted tertiary ketol rearrangement of 2-hydroxy-3-oxocarboxylic esters by
di-n-butyltin oxide catalyst method
Schloss et al. (1985), isolated an enzyme acetolactate synthase, which catalyzes the first step forma-
tion of α-keto-β-hydroxy isomers, in the synthesis of the branched-chain amino acids (valine, leucine,
and isoleucine). These intermediates undergo a tertiary ketol rearrangement to give β-keto-α-hydroxy
isomers in presence of the enzyme reductoisomerase. Crout & Rathbone (1987) demonstrated the ter-
tiary ketol rearrangement of α-keto-β-hydroxy compounds catalysed by di-n-butyltin oxide. The tertiary
ketol rearrangement provided an added advantage of ring expansion by one carbon atom with particular
examples (Crout & Rathbone (1987)). With this concept in mind, the tertiary ketol rearrangement was
attempted on the 3-hydroxy-2-oxocarboxylic ester.
A small scale reaction was carried out in a glass vessel. The 3-hydroxy-2-oxocarboxylic ester was stirred
in d8-toluene along with di-n-butyltin oxide (3 mol%). This tube was sealed and heated at a reflux at a
controlled temperature in a heating block. A periodic NMR data was collected to check progress of the
reaction. However as the reaction failed to progress, after two days the reaction was stopped. Another
reaction was carried out with the chemicals and the experimental conditions remained same, except the
reaction was allowed to stir for 7 days. However the reaction did not progress and hence the reaction
was not taken further.
3-hydroxy-¾¿oxocarboxyliÀ ÁÂÃÁr di-n-butyltin oxide 2-hydroxy-3-oxocarboxylic ester
R3
R2R1O
R1O
R2
R3
O
OHO
Sn
O
OH
O O
+
Scheme 5.6: Attempted scheme for synthesis of 2-alkyl-2-hydroxy-3-oxocarboxylic esters by catalytic
rearrangement method
5.3.6 Microbiological results
The 2-alkyl-2-hydroxy-3-oxocarboxylic esters were sent to the Infectious Disease Research Institute
(IDRI, US) for screening against Mycobacterium tuberculosis H37Rv strain. The Table. 5.4 presents the
results obtained from IDRI.
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Test Compounds
Compound number MIC (µM) IC50 (µM) IC90 (µM)
(178) >200 >200 >200
(176) 53 30 48
(177) >200 150 >200
(179) >200 >200 >200
(180) >200 >200 >200
(181) 200 150 180
Table 5.4: Table representing the first stage microbiological data for the 2-alkyl-2-hydroxy-3-
oxocarboxylic esters.
As discussed in 2.4.8 in chapter 2, since it was observed that one of the compound was found to posses
weak activity, the compound (176) was subjected to the high throughput screening (HTS) process (sec-
ond stage evaluation).
In the microbiological second stage evaluation, MIC assays were performed in aerobic conditions and
under low oxygen conditions and the compound was found to be active in both the assays (see Table.
5.5)
Assays MIC under aerobic conditions MIC under low oxygen
Compound number (176)
MIC (µM) 57 14
IC50 (µM) 32 28
IC90 (µM) 63 59
Table 5.5: The second stage MIC data summary of the 2-alkyl-2-hydroxy-3-oxocarboxylic esters.
The compound showed the bactericidal activity in the MBC assay. The minimum bactericidal concentra-
tions was found to be 13 µM and the bactericidal action was found to be concentration dependent but
not time dependent. The compound (176) was also found to be cytotoxic with the IC50 value of 16 µM,
and also exhibited intracellular activity against M. tuberculosis. The compound (176) was tested against
many M. tuberculosis resistant isolates and was found to be active (see Table.5.6)
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Compound number MIC (µM) Resistant Isolate
95 INH-R1
106 INH-R2
(176) 95 RIF-R1
99 RIF-R2
98 FQ-R1
Table 5.6: The second stage MIC data summary of the fluorinated carboxamidrazone amides.
5.4 Summary and Conclusion
This study has explored the concept of custom designed inhibitors, and a range of α, β-unsaturated
esters were prepared. The larger aldehydes and ketones proved problematic in preparation of the α,
β-unsaturated esters. The permanganate oxidation of the α, β-unsaturated esters worked well except
for the alkenes derived from the cyclic ketones having a ring size larger or equal to 12 carbons. With
this set of α, β-unsaturated esters (alkenes) the Bu2SnO catalysed tertiary ketol rearrangement was not
observed.
It was observed that one of the α-keto, β-hydroxy esters have shown a weak activity. The future work
might involve exploring various different ways to prepare stable long chain aldehydes and their subse-
quent conversion to α, β-unsaturated esters and oxidising it to derive the target compounds (α-keto,
β-hydroxy esters). Another interesting fact that can be observed is that the compounds containing cy-
clised ring structures do not show any activity. The possible reason might be the constraints imposed
on the rigid ring structure which make it difficult for the ligands to adapt to the binding site geometry of
the protein.
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5.5 Experimental
The chemicals and instrumentations used are the same as discussed in 3.5.
5.5.1 General preparation of α, β-unsaturated esters
NaH (60% in mineral oil, 0.88 g, 22 mmoles) was dispersed in 10 mL of DME and stirred under argon.
The reaction mixture was placed in an ice bath and the appropriate phosphonate (triethyl phosphono-
propionate or trimethyl phosphonoacetate) (25 mmoles) was added drop wise into the mixture ensuring
that the temperature remained below 35◦C. After the addition of phosphono acetate the reaction mixture
was allowed to stir at the room temperature for about 30 mins. The reaction mixture was again cooled to
10-15◦C and the respective aldehyde or ketone (25 mmoles) was added drop wise again maintaining the
temperature at 35◦C. Following the addition, the reaction mixture was allowed to stir at room tempera-
ture for 2 days or as was required. The reaction mixture was quenched with water (20 mL) and extracted
three times with DCM (15 mL). The organic layers collected were then evaporated under vacuum and
the crude product was collected. The crude product obtained was then stirred with freshly prepared sat.
sodium bisulphite solution for 48 hours. It was observed that a white precipitate was formed which was
filtered off and the aqueous layer was then extracted with ether. The organic layers collected were then
evaporated under vacuum to give the crude product, which was then subjected to column separation on
silica using 1% ether in petrol 40-60◦C as solvent system.
Ethyl (E)-2-methyltetradec-2-enoate (170)
a
b
c
d
e
f
g
h
i
Ä
Ä
1H NMR (CDCl3): 6.76 (m, 1H, J = 7.5, 1.4 Hz, a), 4.19 (q, J = 7.1 Hz, 2H, CH3CH2O-), 2.18 (s, 2H,
b), 1.83 (s, 3H, CH3), 1.65 (s, 3H, CH3CH2O-), 1.48 1.37 (overlapping m, 4H, c and k), 1.34 1.22
(overlapping m, 14H, d, e, f, g, h, i and j), 0.93 0.83 (t, 3H, J = 6.7 Hz, l) ppm.
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IR (KBr disc) ν: 2958 (Alkyl C-H), 2949 (Alkyl C-H), 1663 (C=O), 1626, 1565, 1541, 1504, 1463, 1435,
1240, 1163, 1112, 1062 cm−1.
Yield: 1.659 g, 24.7%.
Methyl 3-pentyloct-2-enoate (171)
a
a'
b
b'
c
c'
d
d'
e
e'
O
O
(171)
1H NMR (CDCl3): 5.63 (s, 1H, CH=C), 3.68 (s, 3H, -OCH3), 2.67 2.52 (overlapping m, 4H, a and a’),
2.16 (overlapping m, 4H, b and b’), 1.54 1.40 (overlapping m, 4H, c and c’), 1.31 (ddd, J = 9.8, 6.7,
2.8 Hz, 4H, d and d’), 0.90 (overlapping t, 6H, J = 6.7 Hz, e and e’) ppm.
IR (KBr disc) ν: 2946 (Alkyl C-H), 2925 (Alkyl C-H), 1636 (C=O), 1539, 1475, 1443, 1401, 1247, 1149
cm−1.
Yield: 1.602g, 28.3%.
Methyl 2-cyclohexylideneacetate (172)
a
b
c
d
e
O
O
(172)
1H NMR (CDCl3): 5.66 (s, 1H, CH=C), 3.78 (s, 3H, -OCH3), 2.37 2.23 (overlapping m, 4H, a and e),
1.64 1.44 (overlapping m, 4H, b and d), 1.35 (dtt, 2H, J=11.7, J=3.2, J=2.430, c) ppm.
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IR (KBr disc) ν: 2934 (Alkyl C-H), 2856 (Alkyl C-H), 1705, 1663 (C=O), 1445, 1420, 1338, 1310, 1220,
1117 cm−1.
Yield: 2.1 g, 60%.
Methyl 2-(2-adamantylidene)acetate (173)
a
b
c
d
e
f
g
h
i
Å
Å
1H NMR (CDCl3): 5.58 (s, 1H, CH=C), 3.67 (s, 3H, -OCH3), 2.43 (overlapping m, 4H, a and e), 2.10
1.73 (overlapping m, 6H, d, c and e), 1.51 − 1.45 (overlapping m, 10H, b, f, g, h and i) ppm.
IR (KBr disc) ν: 2913 (Alkyl C-H), 2844 (Alkyl C-H), 1647 (C=O), 1584, 1547, 1470, 1435, 1392, 1167
cm−1.
Yield: 5.095 g, 98.7%.
Methyl 2-cyclododecylideneacetate (174)
a b
c
d
e
f g
h
i
Æ
Æ
1H NMR (CDCl3): 5.74 (s, 1H, CH=C), 3.81 (s, 3H, -OCH3), 2.57 − 2.43 (overlapping m, 4H, a and k),
2.26 − 2.15 (ddd, 4H, J=13.646, J=8.060, J=3.820, b and j), 1.74 − 1.63 (overlapping m, 8H, c, d, h
and i), 1.58 − 1.46 (overlapping m, 6H, e, f and g) ppm.
263
IR (KBr disc) ν: 2928 (Alkyl C-H), 2855 (Alkyl C-H), 2671, 1713 (C=O), 1469, 1446, 1416, 1377, 1347,
1320, 1282, 1268, 1166, 1148, 1076, 1052, 1019 cm−1.
Yield: 0.747 g, 12.53%.
Methyl 2-cyclopentadecylideneacetate (175)
a
b
c
d e
f
g
h
i
Ç
Ç
1H NMR (CDCl3): 5.66 (s, 1H, CH=C), 3.67 (s, 3H, -OCH3), 2.65 − 2.53 (overlapping m, 4H, a and
n), 2.41 − 2.33 (overlapping m, 4H, b and m), 2.20 2.07 (overlapping m, 4H, c and l), 1.70 1.58
(overlapping m, 8H, d, e, j and k), 1.50 (dd, 2H, J = 13.8, 6.0 Hz, h), 1.45 1.21 (overlapping m, 6H, f,
g and i) ppm.
IR (KBr disc) ν: 2900 (Alkyl C-H), 2875 (Alkyl C-H), 1652 (C=O), 1607, 1579, 1547, 1475, 1447, 1419,
1338, 1282, 1156, 1039 cm−1.
Yield: 0.12 g, 3%.
5.5.2 General procedure for synthesis of aldehydes using Swern oxidation
Oxalyl chloride (3 mmoles) was stirred in anhydrous DCM (5 mL) at -78◦C under argon. To this solution
DMSO (6 mmoles) was added drop wise taking care that the temperature was maintained below -65◦C
and the reaction mixture was stirred vigorously for 20 mins. To this reaction mixture, a solution of
alcohol (2.1 mmol) in DCM (10 mL) was added drop wise maintaining the temperature below -65◦C.
This reaction mixture was then stirred for 1 hour, followed by the addition of triethylamine (12 mmoles).
The reaction mixture was stirred for one hour at room temperature before it was quenched with water
(20 mL) and stirred for 30 mins and the aqueous layer was extracted with DCM three times (15 mL).
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The organic extracts were then washed with 1M HCl (15 mL). These washing were then dried over
anhydrous MgSO4, and evaporated under pressure to give crude product.
Octadecanal (182)
a
b
c
d
e
f
g
h
i
È
1H NMR (CDCl3): 9.78 (s, 1H, O=C-H), 2.43 (overlapping m, 8H, a, b, c and d), 1.63 (overlapping m,
8H, e, f, g and h), 1.26 (overlapping m, 16H, i, j, k, l, m, n, o and p), 0.92 0.85 (t, 3H, J=7.000, q) ppm.
Yield: 0.37 g, 64%.
Docosanal (183)
a
b
c
d
e
f
g
h
i
É
1H NMR (CDCl3): 9.76 (s, 1H, O=C-H), 2.63 (overlapping m, 2H, a), 1.58 (overlapping m, 2H, b), 1.26
(overlapping m, 36H, c, d, e, f, g, h, i, j, k, l, m, n, o, p, q, r, s and t), 0.94 0.83 (t, 3H, J=7.000, u).
ppm.
Yield: 0.42 g, 73.6%.
5.5.3 General procedure for oxidation of α, β-unsaturated carboxylic esters
A solvent system was prepared by mixing glacial acetic acid, water, and acetone in the ratio of 2.33 mL:
30 mL: 100 mL and stirred in an ice bath with salt and ice mixture at -10◦C. To this solvent system alkene
(2.6 mmol) was added and stirred at -10◦C. To this reaction mixture solid KMnO4 (in excess of alkene 4.5
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mmol) was added slowly maintaining the temperature at -10◦C. After the complete addition of KMnO4,
the reaction mixture was allowed to stir at -10◦C for two hours. The reaction mixture was then filtered off
to remove the brown coloured manganese dioxide and the filtrate obtained was then evaporated under
reduced pressure to remove acetone. The remaining solvent was then extracted with DCM (15 mL)
three times and the organic layers were dried on magnesium sulphate, which upon evaporation gave
desired 2-hydroxy-3-oxocarboxylic esters or 3-hydroxy-2-oxocarboxylic esters
Ethyl 2-hydroxy-2-methyl-3-oxo-tetradecanoate (176)
a
b
c
d
e
f
g
h
i
ÊÊ
ËÌ
Í
ËÌ
Î
Ê
ÊÌ
1H NMR (CDCl3): 4.30 4.17 (q, 2H, J = 7.115, CH3CH2O-), 2.73 2.42 (complex m, 2H, a), 1.86
(complex m, 1H,OH), 1.61 (t, 3H, J = 7.1, CH3), 1.57 (t, 3H, J = 7.1, CH3CH2O-), 1.32 1.21 (overlapping
m, 18H, b, c, d, e, f, g, h, i and j), 0.90 0.83 (t, 3H, J = 6.7 Hz, k) ppm.
IR (neat) ν: 3045 (O-H), 2942 (Alkyl C-H), 2869 (Alkyl C-H), 1636 (C=O), 1446, 1427, 1389, 1324,
1283, 1267, 1131, 1092, 1047, 1019, 1010 cm−1.
Mass spectrum(APCI+) m/z: Found 301.2373 (M+H)+; calculated for C17H32O4 301.2300; 24.3 ppm.
Yield: 0.55g, 74.7%.
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Methyl 3-hydroxy-2-oxo-3-pentyl-octanoate (177)
a
a'
b
b'
c
c'
d
d'
e
e'
O
O
CH
Ï
O
OH
1H NMR (CDCl3): 9.74 (s, 1H, OH), 4.51 (s, 1H, -OCH3), 2.32 (overlapping m, 4H, a and a’), 1.89
(overlapping m, 4H, b and b’), 1.29 (overlapping m, 8H, c, c’, d and d’), 0.90 (overlapping t, 6H, J = 6.7
Hz, e and e’) ppm.
IR (neat) ν: 3044 (O-H), 2956 (Alkyl C-H), 2919 (Alkyl C-H), 1636 (C=O), 1496, 1479, 1462, 1412,
1390, 1283, 1247, 1149 cm−1.
Mass spectrum(APCI +) m/z: Found 258.1826 (M+H)+; calculated for C14H26O4 258.1831; 1.9 ppm.
Yield: 0.53g, 79.2%.
Methyl 2-(1-hydroxycyclohexyl)-2-oxo-acetate (178)
a
b
c
d
e
OH
O
O
CH
Ð
O
1H NMR (CDCl3): 9.72 (s, 1H, OH), 3.81 (s, 3H, -OCH3), 2.31 (overlapping m, 4H, a and e), 1.52
(overlapping m, 4H, b and d), 1.34 (dtt, 2H, J=11.706, J=3.180, J=2.430, c) ppm.
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IR (neat) ν: 3052 (O-H), 2946 (Alkyl C-H), 2925 (Alkyl C-H), 1624 (C=O), 1539, 1475, 1443, 1401,
1247, 1212, 1172, 1112, 1057, 1037, 1020, 1001 cm−1.
Mass spectrum(APCI +) m/z: Found 186.0886 (M+H)+; calculated for C9H14O4 186.0892; 3.2 ppm.
Yield: 1.47g, 87%.
Methyl 2-(2-hydroxy-2-adamantyl)-2-oxo-acetate (179)
a
b
cde
f g
h
i
Ñ
Ñ
Ñ
ÑÒ
1H NMR (CDCl3): 9.74 (s, 1H, OH), 3.71 (s, 3H, -OCH3), 2.31 (overlapping m, 4H, a and e), 1.84
(overlapping m, 6H, d, c and e), 1.40 (overlapping m, 10H, b, f, g, h and i) ppm.
IR (neat) ν: 3045 (O-H), 2956 (Alkyl C-H), 2919 (Alkyl C-H), 1631 (C=O), 1496, 1479, 1462, 1412,
1390, 1283, 1262, 1149, 1127, 1119, 1089, 1052, 1001 cm−1.
Mass spectrum(APCI+) m/z: Found 237.1124 (M−H)+; calculated for C13H18O4 238.1205; 34.0 ppm.
Yield: 3.41g, 75.3%.
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Methyl 2-(1-hydroxycyclododecyl)-2-oxo-acetate (180)
a b
c
d
e
f
g
h
i
Ó
ÓÔ
Ó
Ó
1H NMR (CDCl3): 9.76 (s, 1H, OH), 3.89 (s, 3H, -OCH3), 2.82 2.71 (overlapping m, 4H, a and k), 2.52
2.42 (overlapping m, 4H, b and j), 2.08 1.51 (overlapping m, 8H, c, d, h and i), 1.31 (overlapping d,
6H, J = 26.4 Hz, e and f), 0.87 (q, 2H, J = 6.1 Hz, g) ppm.
IR (neat) ν: 3100 (O-H), 2923 (Alkyl C-H), 2850 (Alkyl C-H), 1633 (C=O), 1611, 1539, 1314, 1298,
1248, 1183, 1145, 1109, 1075, 1048, 1011 cm−1.
Mass spectrum(APCI+) m/z: Found 271.1903 (M+H)+; calculated for C15H26O4 270.1831; 26.6 ppm.
Yield: 0.24g, 30.2%.
methyl 2-(1-hydroxycyclopentadecyl)-2-oxo-acetate (181)
a
b
c
d
e
f
g
h
i
Õ
Õ
Ö
Õ
Õ
1H NMR (CDCl3): 9.74 (s, 1H, OH), 3.62 (s, 3H, -OCH3), 2.54 − 2.47 (overlapping m, 4H, a and n),
2.37 − 2.28 (overlapping m, 4H, b and m), 2.12 (overlapping m, 4H, c and l), 1.64 (overlapping m, 8H,
d, e, j and k), 1.46 (dd, 2H, J = 13.8, 6.0 Hz, h), 1.32 (overlapping m, 6H, f, g and i) ppm.
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IR (neat) ν: 3060 (O-H), 2951 (Alkyl C-H), 2885 (Alkyl C-H), 2832, 1629 (C=O), 1482, 1460, 1438,
1428, 1396, 1372, 1314, 1291, 1244, 1169, 1149, 1112, 1100, 1069, 1046, 1008 cm−1.
Mass spectrum(APCI+) m/z: Found 312.2200 (M+H)+; calculated for C18H32O4 312.2300; 32.0 ppm.
Yield: 0.0387g, 10%.
5.5.4 General procedure used for Reformatsky reaction
In an oven dried flask, anhydrous toluene was added (10 mL). To this fine pieces of zinc metal sheet
were added (1 equivalent) followed by drop wise addition of 20% of the required ethylbromo acetate
(20% of 1 equivalent) maintaining the temperature below 35◦C using ice bath if required. The remaining
ethylbromo acetate was mixed with the ketone (1 equivalent) along with anhydrous toluene (20 mL) and
added drop wise again maintaining the temperature below 35◦C. After the complete addition of ketone
or aldehyde, the reaction mixture was heated at reflux for 18 hours. This reaction mixture was then
extracted with ethyl acetate (15 mL) three times. These layers were dried over magnesium sulphate and
evaporated under reduced pressure to give the desired product.
Ethyl 2-(1-hydroxycyclopentadecyl)acetate (184)
a
b
c
d
e
f
g
h
i×Ø
×
×
1H NMR (CDCl3): 4.20 (s,3H, -OCH2CH3), 2.43 (s, 1H, OH), 2.28 (complex m, 2H, o), 1.84 1.56
(overlapping m, 4H, a and n), 1.43 (overlapping m, 8H, b, c, m and l), 1.34 (m, 3H, -OCH2CH3), 1.28
(overlapping m, 16H, d, e, f, g, h, i, j and k) ppm.
Yield: 0.12g, 8.9%.
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Ethyl 2-(1-hydroxycyclohexyl)peroxyacetate (185)
a
b
c
d
e
(185)O
OH
O
f
1H NMR (CDCl3): 4.33 4.01 (complex m, 2H, -OCH2CH3), 2.45 (s, 1H, OH), 2.34 (complex m, 2H,
f), 1.73 1.55 (overlapping m, 4H, a and e), 1.48 1.37 (overlapping m, 4H, b and d), 1.32 (m, 3H,
-OCH2CH3), 1.26 (dtt, 2H, J=11.706, J=3.180, J=2.430, c) ppm.
Yield: 3.22g, 78%.
Ethyl 2-(1-hydroxycyclododecyl)acetate (186)
a b
c
d
e
f
g
h
i
Ù
ÙÚ
Ù
Û
1H NMR (CDCl3): 4.11 (complex m, 2H, -OCH2CH3), 2.47 (s, 1H, OH), 2.37 (complex m, 2H, l), 2.12
(overlapping m, 4H, a and k), 1.64 (overlapping m, 4H, b and j)), 1.46 (overlapping m, 8H, c, d, h and
i), 1.32 (m, 3H, -OCH2CH3), 1.25 (overlapping m, 6H, e, f and g) ppm.
Yield: 0.26g, 9.4%.
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5.5.5 General procedure for tertiary ketol rearrangement using di-n-butyltin oxide cat-
alyst
In an oven dried NMR glass tube, d8-toluene was added (0.8 mL). To this 3-hydroxy-2-oxocarboxylic
ester was added (0.33 mmoles) followed by di-n-butyltin oxide (3 mol%, 0.01g). This tube was then
sealed and heated at a controlled temperature in a heating block taking care that the toluene is just
refluxing. At regular intervals (4 hours) NMR data was collected to check the progress of reaction.
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